<nodes>
	<node>
		<Fname>
404: File Not Found ./hiv/custom403.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/custom403.html</Path>
		<FileBody>
			
		</FileBody>
	</node>
	<node>
		<Fname>
404: File Not Found ./hiv/custom404.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/custom404.html</Path>
		<FileBody>
			
		</FileBody>
	</node>
	<node>
		<Fname>
google3632a1c783ccb7e7.html ./hiv/google3632a1c783ccb7e7.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/google3632a1c783ccb7e7.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
UCSF Pulmonary, Critical Care, Allergy and Sleep Medicine ./hiv/index-pul.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/index-pul.html</Path>
		<FileBody>
			
			
			
			
			
			&lt;div class=&quot;container h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;row&quot;&gt;
			    &lt;div class=&quot;col&#45;sm&#45;12&quot;&gt;
			      &lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;darkblue panel&#45;&#45;inverse&quot;&gt;&lt;a class=&quot;h&#45;color&#45;&#45;white&quot; href=&quot;/about/news.html&quot;&gt;News &amp;amp; Highlights&lt;/a&gt;&lt;/h2&gt;
			
						
			&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;
			        &lt;a class=&quot;btn btn&#45;danger btn&#45;md&quot; href=&quot;/about/news.html&quot;&gt;&lt;strong&gt;View all news &amp; highlights &lt;/strong&gt;&amp;raquo;&lt;/a&gt;
			      &lt;/div&gt;
			
			    &lt;/div&gt;&lt;!&#45;&#45;end col&#45;sm&#45;12&#45;&#45;&gt;
			
			    
			  &lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;
			&lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;
			
			
			
			
			
			
			&lt;!&#45;&#45; Education &amp; Training
			================================================== &#45;&#45;&gt;
			&lt;div class=&quot;parallax parallax&#45;&#45;education&#45;bg h&#45;color&#45;&#45;white h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;container&quot;&gt;
			    &lt;div class=&quot;row text&#45;center&quot;&gt;
			      &lt;div&gt;
			        &lt;h1&gt;&lt;a href=&quot;/education/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;About&lt;/a&gt;&lt;/h1&gt;
			        &lt;p class=&quot;h&#45;spacing&#45;&#45;bottom&#45;25 lead&quot;&gt;The UCSF HIV/AIDS Division at San Francisco General Hospital is an internationally recognized global leader in HIV clinical care, research and education.&lt;/p&gt;
			        
			        &lt;p class=&quot;h&#45;spacing&#45;&#45;bottom&#45;25 lead&quot;&gt;As a &quot;standard&#45;setter&quot; for HIV care, we pioneer medical and scientific advances that influence HIV medicine globally. Our comprehensive care and treatment model (Positive Heath Program) has been widely adopted around the world. We conduct a wide array of educational activities including fellowships for clinical and research (NIH T32) training. We are committed to the training of the next generation of HIV medicine leaders. Our research portfolio is one of the largest in the Department of Medicine encompassing translational, epidemiologic, clinical and outcomes research domestically and internationally. To address the growing need to expand and improve efficiency and effectiveness of universal HIV treatment, we recently established an Implementation Science Core. &lt;/p&gt;
			        
			         &lt;p&gt;&lt;a class=&quot;btn btn&#45;danger&quot; href=&quot;/about/&quot;&gt;&lt;strong&gt;Learn More&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;/div&gt;
			
			     
			    &lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;
			
			    &lt;/div&gt;
			
			  &lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;
			&lt;/div&gt;&lt;!&#45;&#45;end parallax&#45;&#45;&gt;
			
			&lt;div class=&quot;h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;container&quot;&gt;
			    &lt;div class=&quot;row&quot;&gt;
			      &lt;div class=&quot;col&#45;sm&#45;5&quot;&gt;
			        &lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;darkblue panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;&gt;&lt;a href=&quot;/care/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;The Clinical Edge&lt;/a&gt;&lt;/h2&gt;
			        &lt;!&#45;&#45;div class=&quot;h&#45;spacing&#45;&#45;bottom&#45;5&quot;&gt;
			          &lt;a href=&quot;/care/&quot;&gt;&lt;img alt=&quot;Patient Care&quot; src=&quot;images/home&#45;patient&#45;care.jpg&quot; class=&quot;img&#45;responsive&quot;&gt;&lt;/a&gt;
			        &lt;/div&#45;&#45;&gt;      
			        &lt;p&gt;The Clinical Edge is a series of brief commentaries on topics of current interest in HIV care, prevention, and policy from the faculty of the UCSF HIV/AIDS Division at San Francisco General Hospital. It is sponsored by HIV InSite.&lt;/p&gt;
			
			&lt;p style=&quot;margin&#45;right:25px;&quot;&gt;The Division's faculty members have been at the forefront of HIV care and research for more than 30 years. Our practice at SFGH's Ward 86 is the first multidisciplinary outpatient clinic in the world dedicated to the care of patients with HIV/AIDS. 
			&lt;/p&gt;
			        &lt;p&gt;&lt;a class=&quot;btn btn&#45;danger&quot; href=&quot;/education/clinical_edge.html&quot;&gt;&lt;strong&gt;Learn More&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;/div&gt;
			      
			      &lt;div class=&quot;col&#45;sm&#45;1&quot;&gt;&amp;nbsp;&lt;/div&gt;
			
			      &lt;div class=&quot;col&#45;sm&#45;5&quot;&gt;
			        &lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;orange panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;&gt;&lt;a href=&quot;/education/recommendations.html&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Management Recommendations&lt;/a&gt;&lt;/h2&gt;
			        &lt;div class=&quot;h&#45;spacing&#45;&#45;bottom&#45;5&quot;&gt;
			          &lt;!&#45;&#45;a href=&quot;/research/&quot;&gt;&lt;img alt=&quot;Research&quot; src=&quot;images/home&#45;research.jpg&quot; class=&quot;img&#45;responsive&quot;&gt;&lt;/a&#45;&#45;&gt; 
			        &lt;/div&gt;   
			        &lt;p&gt;Ward 86 Medical Management Recommendations from the UCSF Positive Health Program HIV/AIDS Clinic (Ward 86) at San Francisco General Hospital is a series that offers clinical practice recommendations for management of HIV&#45;related conditions from the expert clinicians of the Positive Health Program at San Francisco General Hospital.&lt;/p&gt;
			        &lt;p&gt;&lt;a class=&quot;btn btn&#45;danger&quot; href=&quot;/education/recommendations.html&quot;&gt;&lt;strong&gt;Learn More&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;      
			      &lt;/div&gt;
			    &lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;
			  &lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;
			&lt;/div&gt;
			
			&lt;!&#45;&#45; Donations
			================================================== &#45;&#45;&gt;
			&lt;div class=&quot;bg&#45;fixed parallax&#45;&#45;giving&#45;bg&quot;&gt;
			  &lt;div class=&quot;container h&#45;padding&#45;&#45;topbot&#45;40&quot; &gt;
			    &lt;div class=&quot;row text&#45;center h&#45;color&#45;&#45;white&quot;&gt;
			      &lt;h1&gt;&lt;a href=&quot;/giving/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Giving &lt;/a&gt;&lt;/h1&gt;
			      &lt;p class=&quot;lead&quot;&gt;Donations play a vital role in sustaining our Mission.&lt;/p&gt;
			      &lt;p&gt;&lt;a class=&quot;btn btn&#45;success btn&#45;large&quot; href=&quot;https://makeagift.ucsf.edu/site/SPageServer?pagename=A1_API_CustomGivingForm&amp;Primary=Geriatrics&quot;&gt;&lt;strong&gt;Donate now&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt; 
			      &lt;p&gt;&lt;a href=&quot;/giving/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Learn more &amp;raquo;&lt;/a&gt;&lt;/p&gt; 
			    &lt;/div&gt;     
			  &lt;/div&gt;
			&lt;/div&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
UCSF Pulmonary, Critical Care, Allergy and Sleep Medicine ./hiv/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/index.html</Path>
		<FileBody>
			
			
			
			
			
			&lt;div class=&quot;container h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;row&quot;&gt;
			    &lt;div class=&quot;col&#45;sm&#45;8&quot;&gt;
			      &lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;darkblue panel&#45;&#45;inverse&quot;&gt;&lt;a class=&quot;h&#45;color&#45;&#45;white&quot; href=&quot;/about/news.html&quot;&gt;News &amp;amp; Highlights&lt;/a&gt;&lt;/h2&gt;
			
						
			&lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;
			        &lt;a class=&quot;btn btn&#45;danger btn&#45;md&quot; href=&quot;/about/news.html&quot;&gt;&lt;strong&gt;View all news &amp; highlights &lt;/strong&gt;&amp;raquo;&lt;/a&gt;
			      &lt;/div&gt;
			
			    &lt;/div&gt;&lt;!&#45;&#45;end col&#45;sm&#45;8&#45;&#45;&gt;
			
			    &lt;div class=&quot;col&#45;sm&#45;4 calendar&quot;&gt;
			      &lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;orange panel&#45;&#45;inverse&quot;&gt;&lt;a class=&quot;h&#45;color&#45;&#45;white&quot; href=&quot;/about/calendar.html&quot;&gt;Calendar&lt;/a&gt;&lt;/h2&gt;
						
			
			      &lt;div class=&quot;text&#45;right h&#45;border&#45;bottom&quot;&gt;&lt;a class=&quot;btn btn&#45;md btn&#45;danger&quot; href=&quot;/about/calendar.html&quot;&gt;&lt;strong&gt;View all events&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/div&gt;
			
			    &lt;/div&gt;&lt;!&#45;&#45;end col&#45;sm&#45;4&#45;&#45;&gt;
			
			  &lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;
			&lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;
			
			
			
			
			
			&lt;!&#45;&#45; Education &amp; Training
			================================================== &#45;&#45;&gt;
			&lt;div class=&quot;parallax parallax&#45;&#45;education&#45;bg h&#45;color&#45;&#45;white h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;container&quot;&gt;
			    &lt;div class=&quot;row text&#45;center&quot;&gt;
			      &lt;div&gt;
			        &lt;h1&gt;&lt;a href=&quot;/education/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;About&lt;/a&gt;&lt;/h1&gt;
			        &lt;p class=&quot;h&#45;spacing&#45;&#45;bottom&#45;25 lead&quot;&gt;As the largest Division in UC San Francisco’s Department of Medicine at Zuckerberg San Francisco General Hospital, the Division of HIV, Infectious Diseases (ID) and Global Medicine is a global leader in clinical care, research and education.&lt;/p&gt;
			
			        &lt;p class=&quot;h&#45;spacing&#45;&#45;bottom&#45;25 lead&quot;&gt;Its mission is to tend to all patients affected by infectious diseases, especially the vulnerable. Division members believe that ending the epidemics of devastating infectious diseases—such as HIV, malaria and tuberculosis—is achievable. The gains will yield more than health, including wellness, prosperity and social connectedness.&lt;/p&gt;
			
			         &lt;p&gt;&lt;a class=&quot;btn btn&#45;danger&quot; href=&quot;/about/&quot;&gt;&lt;strong&gt;Learn More&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;/div&gt;
			
			
			    &lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;
			
			    &lt;/div&gt;
			
			  &lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;
			&lt;/div&gt;&lt;!&#45;&#45;end parallax&#45;&#45;&gt;
			
			&lt;div class=&quot;h&#45;padding&#45;&#45;topbot&#45;40&quot;&gt;
			  &lt;div class=&quot;container&quot;&gt;
			    &lt;div class=&quot;row&quot;&gt;
			      &lt;div class=&quot;col&#45;sm&#45;5&quot;&gt;
			        &lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;darkblue panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;&gt;&lt;a href=&quot;/education/clinical_edge.html&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;The Clinical Edge&lt;/a&gt;&lt;/h2&gt;
			        &lt;!&#45;&#45;div class=&quot;h&#45;spacing&#45;&#45;bottom&#45;5&quot;&gt;
			          &lt;a href=&quot;/care/&quot;&gt;&lt;img alt=&quot;Patient Care&quot; src=&quot;images/home&#45;patient&#45;care.jpg&quot; class=&quot;img&#45;responsive&quot;&gt;&lt;/a&gt;
			        &lt;/div&#45;&#45;&gt;
			        &lt;p&gt;The Clinical Edge is a series of brief commentaries on topics of current interest in HIV care, prevention, and policy from the faculty of the UCSF HIV/AIDS Division at San Francisco General Hospital. It is sponsored by HIV InSite.&lt;/p&gt;
			
			&lt;p style=&quot;margin&#45;right:25px;&quot;&gt;The Division's faculty members have been at the forefront of HIV care and research for more than 30 years. Our practice at SFGH's Ward 86 is the first multidisciplinary outpatient clinic in the world dedicated to the care of patients with HIV/AIDS.
			&lt;/p&gt;
			        &lt;p&gt;&lt;a class=&quot;btn btn&#45;danger&quot; href=&quot;/education/clinical_edge.html&quot;&gt;&lt;strong&gt;Learn More&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;/div&gt;
			
			      &lt;div class=&quot;col&#45;sm&#45;1&quot;&gt;&amp;nbsp;&lt;/div&gt;
			
			      &lt;div class=&quot;col&#45;sm&#45;5&quot;&gt;
			        &lt;h2 class=&quot;h&#45;color&#45;&#45;bg&#45;orange panel&#45;&#45;inverse h&#45;spacing&#45;&#45;clear&quot;&gt;&lt;a href=&quot;/education/recommendations.html&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Management Recommendations&lt;/a&gt;&lt;/h2&gt;
			        &lt;div class=&quot;h&#45;spacing&#45;&#45;bottom&#45;5&quot;&gt;
			          &lt;!&#45;&#45;a href=&quot;/research/&quot;&gt;&lt;img alt=&quot;Research&quot; src=&quot;images/home&#45;research.jpg&quot; class=&quot;img&#45;responsive&quot;&gt;&lt;/a&#45;&#45;&gt;
			        &lt;/div&gt;
			        &lt;p&gt;Ward 86 Medical Management Recommendations from the UCSF Positive Health Program HIV/AIDS Clinic (Ward 86) at San Francisco General Hospital is a series that offers clinical practice recommendations for management of HIV&#45;related conditions from the expert clinicians of the Positive Health Program at San Francisco General Hospital.&lt;/p&gt;
			        &lt;p&gt;&lt;a class=&quot;btn btn&#45;danger&quot; href=&quot;/education/recommendations.html&quot;&gt;&lt;strong&gt;Learn More&lt;/strong&gt; &amp;raquo;&lt;/a&gt;&lt;/p&gt;
			      &lt;/div&gt;
			    &lt;/div&gt;&lt;!&#45;&#45;end row&#45;&#45;&gt;
			  &lt;/div&gt;&lt;!&#45;&#45;end container&#45;&#45;&gt;
			&lt;/div&gt;
			&lt;!&#45;&#45; Newsletter
			================================================== &#45;&#45;&gt;
			&lt;div class=&quot;parallax parallax&#45;&#45;education&#45;bg h&#45;color&#45;&#45;white h&#45;padding&#45;&#45;topbot&#45;40&quot;
			  &lt;div class=&quot;container&quot;&gt;
			    &lt;div class=&quot;text&#45;center&quot;&gt;
			      &lt;h1&gt;&lt;a href=&quot;/about/newsletter.html&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Newsletter&lt;/a&gt;&lt;/h1&gt;
			  &lt;p class=&quot;lead&quot;&gt;Want to keep up with all the latest news from the Division of HIV, ID and Global Medicine? Contact
			&lt;a href=&quot;mailto:hividgm@ucsf.edu?subject=Request%20to%20subscribe%20to%20newsletter&quot; style=&quot;color: #ffd700&quot;&gt;webmaster&lt;/a&gt; to subscribe to monthly newsletter.&lt;/a&gt;&lt;/h2&gt;
			&lt;p&gt;&lt;a href=&quot;/about/newsletter.html&quot; class=&quot;btn btn&#45;danger&quot;&gt;&lt;strong&gt;View archived newsletters &amp;raquo;&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt;
			&lt;/div&gt;&lt;/div&gt;
			    &lt;/div&gt;
			    &lt;!&#45;&#45;end row&#45;&#45;&gt;
			&lt;!&#45;&#45; Donations
			================================================== &#45;&#45;&gt;
			&lt;div class=&quot;bg&#45;fixed parallax&#45;&#45;giving&#45;bg&quot;&gt;
			  &lt;div class=&quot;container h&#45;padding&#45;&#45;topbot&#45;40&quot; &gt;
			    &lt;div class=&quot;row text&#45;center h&#45;color&#45;&#45;white&quot;&gt;
			      &lt;h1&gt;&lt;a href=&quot;/giving/&quot; class=&quot;h&#45;color&#45;&#45;white&quot;&gt;Giving&lt;/a&gt;&lt;/h1&gt;
			      &lt;p class=&quot;lead&quot;&gt;Now, more than ever, a world without HIV, malaria or tuberculosis is within reach. You are invited to join the UCSF Division of HIV, Infectious Diseases and Global Medicine in tackling medicine’s toughest and biggest problems with compassionate care, relentless research and generous guidance. You contributions can make this happen.&lt;/p&gt;
			
			&lt;p class=&quot;lead&quot; &quot;text&#45;center&quot;&gt;For more information on how you can help, please contact:&lt;p class=&quot;text&#45;center&quot;&gt;&lt;li&gt; &lt;a href=&quot;http://makeagift.ucsf.edu/HIVIDGM&quot;&gt; UCSF&lt;/a&gt;&lt;/li&gt;
			&lt;li&gt; &lt;a href=&quot;http://sfghf.org/&quot;&gt; SF Foundation&lt;/a&gt;&lt;br&gt;Under gift designation, type “Within Our Reach”&lt;/li&gt;  &lt;/p&gt;
			      &lt;p&gt;&lt;a href=&quot;/giving/&quot; class=&quot;btn btn&#45;danger&quot;&gt;&lt;strong&gt;Learn more &amp;raquo;&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt;
			    &lt;/div&gt;
			  &lt;/div&gt;
			&lt;/div&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
index.html~ ./hiv/index.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/index.html~</Path>
		<FileBody>
			
			
			
			&lt;div id=&quot;slideshow&quot;&gt;
			    &lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/homepage/home1.jpg&quot; class=&quot;active&quot; /&gt;
			    &lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/homepage/home2.jpg&quot; &gt;
			    &lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/homepage/home3.jpg&quot; &gt;
			&lt;/div&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			
			 &lt;div id=&quot;hometagVic&quot;&gt;&lt;/div&gt;
			&lt;div id=&quot;hometagtextVic&quot;&gt;Patient&#45;centered HIV Care, Research, Education and Public Service&lt;/div&gt;
			
						
			function slideSwitch() {
			    var $active = $('#slideshow IMG.active');
			
			    if ( $active.length == 0 ) $active = $('#slideshow IMG:last');
			    
			    if ( ! $active.next().length ) {
			        clearInterval( mySlideshow );
			        return;
			    }
			    
			    var $next = $active.next();
			
			    $active.addClass('last&#45;active');
			
			    $next.css({opacity: 0.0})
			        .addClass('active')
			        .animate({opacity: 1.0}, 1000, function() {
			            $active.removeClass('active last&#45;active');
			        });
			}
			
			$(function() {
			    var mySlideshow = setInterval( &quot;slideSwitch()&quot;, 5000 );
			});
			
						
			$items = 3;
			$start = $end = date('Y&#45;m&#45;d H:i:s');
			
			$news = find_recent_news_by_category($items, 18, $start, $end);
			
			if ($news) {
			    display_news($news);
			}
			
						
			$items = 3;
			$date = date('Y&#45;m&#45;d');
			
			$cal = find_recent_cal($items, '18', $date);
			if ($cal) {
			display_cal($cal);
			}
			
						include('/data/templates/new/bottom&#45;2008.php');
		</FileBody>
	</node>
	<node>
		<Fname>
Awards &amp; Recognition ./hiv/about/awards.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/about/awards.html</Path>
		<FileBody>
			
			&lt;ul&gt;
			&lt;li&gt;&lt;img class=&quot;imgLeft&quot; src=&quot;/sites/hiv.ucsf.edu/files/images/monica_award.jpg&quot;&gt;Dr. Monica Gandhi is the recipient of the 2011&#45;2012 Meg Newman Teaching Award.  Since Dr. Gandhi joined the HIV/AIDS Division in 2008, she has transformed the educational role of the division.  Dr. Gandhi created and chairs a divisional education committee which meets regularly to guide policy decisions, and reinvigorated the moribund HIV clinical fellowship, successfully obtaining a minority fellowship award for the Division from the Infectious Diseases Society of America HIV Medical Association.  She has also reinvigorated the HIV/AIDS Division medical student HIV clinical elective on the SFGH AIDS Consult Service and initiated a new outpatient medical resident HIV/AIDS elective.  She has authored chapters on HIV in women in two widely used textbooks on the clinical care of patients with HIV/AIDS as well as syllabi that are used at UCSF for teaching medical students, graduate students, medicine residents, and clinical fellows about HIV/AIDS. She also serves as a member of the UCSF Global Health Institute Education Committee and the UCSF Chancellor's Advisory Committee on Diversity and Education.  As evidence of her remarkable productivity as a teacher of HIV/AIDS clinical management, she this year received the UCSF AIDS Research Institute’s Sarlo Award for Excellence in Teaching. Dr. Meg Newman presented Dr. Gandhi with her award following HIV Grand Rounds at SFGH on Wednesday October 3rd, 2012.&lt;/li&gt;
			
			&lt;li&gt;&lt;img class=&quot;imgLeft&quot; src=&quot;/sites/hiv.ucsf.edu/files/images/franses1.jpg&quot;&gt;
			Ward 86 lead social worker, Karena Franses, MSW, LCSW was honored by the San Francisco Human Rights Commission with a 2012 Hero Award in a public ceremony at City Hall on May 24, 2012.  These prestigious awards recognize local “unsung heroes” for their outstanding contributions in the field of Human Rights Advocacy.  Karena was nominated for this award by a patient who described her as a &quot;Compassion Specialist and Advocate for persons living with HIV/AIDS.&quot;&lt;/li&gt;
			&lt;li&gt;&lt;img class=&quot;imgLeft&quot; src=&quot;/sites/hiv.ucsf.edu/files/images/geng2.jpg&quot;&gt;&lt;a href=&quot;/faculty/?key=dba7282c5b7cf48490744779c1ecdcb2&amp;amp;name=GENG%2CELVIN+H&quot;&gt;Dr. Elvin Geng&lt;/a&gt; is the recipient of a Hellman Award for his extraordinary research activities.&lt;/li&gt;
			&lt;/ul&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
calendar.html ./hiv/about/calendar.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/about/calendar.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Contact List ./hiv/about/contact_list.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/about/contact_list.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;To download a list of contacts for the HIV/AIDS division, please view this &lt;a href=&quot;/sites/hiv.ucsf.edu/files/docs/division_list_09_14.xlsx&quot;&gt;excel sheet document&lt;/a&gt;. &lt;/p&gt;
			
						
			
		</FileBody>
	</node>
	<node>
		<Fname>
History ./hiv/about/history.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/about/history.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;The UCSF Positive Health Program (PHP) at San Francisco General Hospital was founded in 1983 by three visionaries in AIDS treatment and research: oncologists &lt;a href=&quot;http://ari.ucsf.edu/science/scientists_volberding.aspx&quot;&gt;Paul Volberding, MD&lt;/a&gt; and &lt;a href=&quot;http://ari.ucsf.edu/science/scientists_abrams.aspx&quot;&gt;Donald Abrams MD&lt;/a&gt;, and the late Dr. Constance Wofsy, an infectious disease specialist.  It immediately became the center of care and treatment for the San Francisco AIDS epidemic throughout the 1980s.
			&lt;/p&gt;
			
			&lt;p&gt;&lt;b&gt;1981:&lt;/b&gt; First cases of HIV were seen and documented at the San Francisco General Hospital and Trauma Center (SFGH)&lt;/p&gt;
			&lt;p&gt;&lt;b&gt;1981:&lt;/b&gt; First&#45;ever AIDS research grant awarded. The American Cancer Society enables UCSF/SFGH researchers to study outbreaks of Kaposi Sarcoma (KS), an AIDS&#45;related skin cancer &lt;/p&gt;
			&lt;p&gt;&lt;b&gt;1983:&lt;/b&gt; Ward 86 AIDS Clinic opens January 1. First dedicated HIV/AIDS outpatientclinic in the world opened at SFGH by Paul Volberding, MD Donald Abrams, MD and Constance Wofsy, MD&lt;/p&gt;
			&lt;p&gt;&lt;b&gt;1983:&lt;/b&gt; Ward 5B, SFGH AIDS Unit opens July. First dedicated inpatient AIDS unit in the US &lt;/p&gt;
			&lt;p&gt;&lt;b&gt;1986:&lt;/b&gt;  The inpatient unit expands to accommodate the growing San Francisco epidemic&lt;/p&gt;
			&lt;p&gt;&lt;b&gt;1987:&lt;/b&gt;  AZT approved by the Federal Drug Administration. UCSF/SFGH researchers lead clinical trials of first medication approved for the treatment of HIV&lt;/p&gt;
			&lt;p&gt;&lt;b&gt;1990&#45;1995:&lt;/b&gt; AIDS deaths in San Francisco peak at 2,400 per year.  SFGH witnesses 10,000th AIDS death in 1993&lt;/p&gt;
			&lt;p&gt;&lt;b&gt;1996:&lt;/b&gt; Wide use of combination anti&#45;retroviral therapy in the US  changes HIV from fatal to chronic disease &lt;/p&gt;
			&lt;p&gt;&lt;b&gt;2002:&lt;/b&gt; UCSF/SFGH leaders helps design WHO guidelines to deploy antiretroviral therapy around the world    &lt;/p&gt;
			&lt;p&gt;&lt;b&gt;2010:&lt;/b&gt;  UCSF/SFGH&#45;based leaders establish first policy to treat all persons with HIV, regardless of CD4 count &lt;/p&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
About ./hiv/about/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/about/index.html</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/about2.jpg&quot; class=&quot;imgRight&quot; &gt;
			&lt;p class=&quot;introduction&quot;&gt;The UCSF HIV/AIDS Division at San Francisco General Hospital is an internationally recognized global leader in HIV clinical care, research and education.&lt;/p&gt;
			&lt;p&gt; As a &quot;standard&#45;setter&quot; for HIV care, we pioneer medical and scientific advances that influence HIV medicine globally.  Our comprehensive care and treatment model (Positive Heath Program) has been widely adopted around the world. We conduct a wide array of educational activities including fellowships for clinical and research (NIH T32) training. We are committed to the training of the next generation of HIV medicine leaders. Our research portfolio is one of the largest in the Department of Medicine encompassing translational, epidemiologic, clinical and outcomes research domestically and internationally. To address the growing need to expand and improve efficiency and effectiveness of universal HIV treatment, we recently established an Implementation Science Core.   &lt;/p&gt;
			
			&lt;p&gt;From its beginning as a county clinic with a staff of five, the HIV/AIDS Division has grown to encompass a network of specialty clinics, multiple research and clinical trials, an HIV education program, an international research program in East Africa and a vibrant community forum for clinicians and researchers. Our faculty serves in highly visible and influential positions in the World Health Organization, International AIDS Society, and HIV Medical Association, and frequent speakers at scientific meetings around the world.  Our program has a visible presence in the lay press and our faculty are frequent conveners at high level scientific events. UCSF has been ranked as the top AIDS program in the country by US News and World Report for several years.&lt;/p&gt;
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
News Archives ./hiv/about/news.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/about/news.html</Path>
		<FileBody>
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Newsletter ./hiv/about/newsletter.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/about/newsletter.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;Want to keep up with all the latest news from the Division of HIV, ID and Global Medicine? See our monthly newsletters below.
			&lt;/p&gt;
			&lt;h2&gt;2017&lt;/h2&gt;
			  &lt;ul&gt;&lt;li&gt; July&lt;/li&gt;
			  &lt;li&gt; August&lt;/li&gt;
			  &lt;li&gt; September&lt;/li&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Staff List ./hiv/about/staff_list.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/about/staff_list.html</Path>
		<FileBody>
			
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
						$file = file_get_contents(&quot;data/staff.txt&quot;);
			print $file;
						$file = file_get_contents(&quot;data/lab.txt&quot;);
			print $file;
						$file = file_get_contents(&quot;data/rea.txt&quot;);
			print $file;
						include('/data/templates/new/bottom&#45;2008.php');
			
			function draw_table($file) {
			    foreach ($file as $line) {
			
			
			    unset($eds);
			    unset($phn);
			    unset($fax);
			    unset($override);
			    unset($output);
			    $line = rtrim($line);
			    $hash = preg_split(&quot;/\|/&quot;, $line);
			#$start = microtime();
			#print &quot;Start: &quot; . microtime() . &quot;&lt;br&gt;&quot;;
			    $eds = eds_get_info_by_eid($hash[0]);
			#$end = microtime();
			
			#$s = preg_split(&quot;/ /&quot;, $start);
			#$e = preg_split(&quot;/ /&quot;, $end);
			
			#$diff = ($e[0] &#45; $s[0]) + ($e[1] &#45; $s[1]);
			#print &quot;End: &quot; . microtime() . &quot;&lt;br&gt;&quot;;
			#print &quot;Difference: $diff &lt;br&gt;&quot;;
			
			    $phn = db_get_phn('EMPLOYEE_ID', $hash[0], 'CMP1');
			    $fax = db_get_phn('EMPLOYEE_ID', $hash[0], 'FAX');
			
			    if (!$eds[ucsfeduworkingtitle] &amp;&amp; $eds[title]) {
				$output[title] = $eds[title];
			    } else {
				$output[title] = $eds[ucsfeduworkingtitle];
			    }
			
			    if (preg_match(&quot;/\d/&quot;, $phn[PHN_EXTENSION_NO])) {
				$ext = &quot; x$phn[PHN_EXTENSION_NO]&quot;;
			    } else {
				$ext = &quot;&quot;;
			    }
			
			    $output[phone] = &quot;($phn[PHN_AREA_CODE]) $phn[PHN_PREFIX]&#45;$phn[PHN_TELEPHONE_NO]$ext&quot;;
			
			    $output[firstname] = $eds[givenname];
			    $output[lastname] = $eds[sn];
			    $output[email] = $eds[mail];
			    $output[fax] = &quot;($fax[PHN_AREA_CODE]) $fax[PHN_PREFIX]&#45;$fax[PHN_TELEPHONE_NO]&quot;;
			
			    if ($hash[2]) {
				$overrides = preg_split(&quot;/\;/&quot;, $hash[2]);
				foreach ($overrides as $line) {
				    $line = rtrim($line);
				    $duo = preg_split(&quot;/=/&quot;, $line, 2);
				    $output[$duo[0]] = $duo[1];
				}
			    }
			
				print &lt;&lt;&lt;END
				    &lt;tr&gt;
				    &lt;td $even&gt;$output[firstname] $output[lastname]&lt;/td&gt;
				    &lt;td $even&gt;$output[title]&lt;/td&gt;
				    &lt;td $even&gt;&lt;a href=&quot;mailto:$output[email]&quot;&gt;$output[email]&lt;/a&gt;&lt;/span&gt;&lt;/td&gt;
				    &lt;td $even&gt;$output[phone]&lt;/span&gt;&lt;/td&gt;
				    &lt;td $even&gt;$output[fax]&lt;/span&gt;&lt;/td&gt;
				    
				    &lt;/tr&gt;
			
			END;
			
				if (!$even) {
				    $even = &quot;class='even'&quot;;
				} else {
				    $even = &quot;&quot;;
				}
			
			
			    }
			    
			}
						include('/data/templates/new/bottom&#45;2008.php');
		</FileBody>
	</node>
	<node>
		<Fname>
Strategic Plan ./hiv/about/strategic_plan.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/about/strategic_plan.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;We believe ending the HIV epidemic and restoring our world to AIDS&#45;free status is achievable. We commit to pursuing this vision with initiatives to prevent new HIV infections, identify acutely infected individuals and link them to care, develop a cure for HIV and deliver it to as many as possible, and to preserve maximum good health for all those in whom infection cannot be cured.&lt;/p&gt;
			
			&lt;p&gt;Our strategies integrate clinical care, research, education, international programs, health information technology, administration and public advocacy. On the clinical front, we will increase testing and linkage to care efforts, as well as improve engagement of patients who currently do not adequately adhere to care regimens. We will adapt and refine our care and treatment strategies for chronic disease management, as medical successes have created a welcome cohort of patients who have been living with HIV for twenty years or more. Cohesion of purpose and principle, born from the contributions of a wide cross&#45;section of professionals, make the clinical plan both a road map and lightning rod for progress.&lt;/p&gt;
			
			&lt;p&gt;We are decisively focused on eradicating HIV and AIDS. We will research strategies for novel and widespread HIV treatment; investigate how to optimally treat HIV co&#45;infections such as tuberculosis, malaria and hepatitis; and enhance understanding of how HIV affects aging patients. Our program has always attracted some of the brightest young minds in HIV, and we will need to nurture these individuals through sustained mentoring and resource support in order to succeed in addressing the incredibly challenging set of questions on our research agenda. Critical to our success will be the funding of new research programs in HIV Eradication and an International Center of Excellence in HIV, TB and malaria.&lt;/p&gt;
			
			&lt;p&gt;In education, we commit to rapid knowledge transfer and training of fellow providers and future generations of HIV clinicians so that evolving scientific and clinical algorithms are rapidly disseminated. We will champion better understanding of HIV by communities and patients through concerted efforts ranging from direct patient education to partnerships with community organizations.&lt;/p&gt;
			
			&lt;p&gt;We will establish an HIV/AIDS living museum – to our knowledge the first of its kind in the world. The story of HIV is inextricably linked to the history of San Francisco, and we can think of no better way to foster global educational outreach at the individual, civic and international levels than by creating a dynamic community academy, accessible to all through an interactive website, with a secretariat, museum and learning center housed in San Francisco.&lt;/p&gt;
			
			&lt;p&gt;Our international programs promote life&#45;saving universal access to ARTs and care by addressing critical staffing shortages in healthcare. We will expand mentoring of clinician trainers, local capacity building, and enhance analysis of efforts to innovate and refine effective methods in resource&#45;limited settings. We will facilitate our international colleagues’ firsthand observation of the structure and flow of our renowned care system through intensive training sessions at SFGH.&lt;/p&gt;
			
			&lt;p&gt;Our health information technology experts resolve to making electronic medical record access and literacy more commonplace among HIV&#45;patients in San Francisco’s public health system, as well as measure and document how the use of integrated health information technologies affect the overall quality of care for patients. We dedicate ourselves to a customer&#45;oriented administrative approach through recruiting, sustaining and mentoring professional talent; providing timely and accurate financial reporting, technological support, and other resources need to accomplish our vision; and refining systems through regular surveys and quality assurance evaluations.&lt;/p&gt;
			
			&lt;p&gt;All faculty and staff will be active catalysts for constructive cultural and legal change by advocating for the broad expansion of HIV testing and linkage to care, universal access to antiretroviral medicine, and combating stigma, discrimination and violence against people living with HIV/AIDS. The more we facilitate acceptance and support progress in these areas, the more quickly will the medical advancements we envision benefit all society.&lt;/p&gt;
			
			&lt;p&gt;
			To view the HIV/AIDS Division strategic plan, &lt;a href=&quot;strategic_plan.pdf&quot;&gt;click here&lt;/a&gt;.
			&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Strategic Plan ./hiv/about/strategic_plan.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/about/strategic_plan.html~</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;We believe ending the HIV epidemic and restoring our world to AIDS&#45;free status is achievable. We commit to pursuing this vision with initiatives to prevent new HIV infections, identify acutely infected individuals and link them to care, develop a cure for HIV and deliver it to as many as possible, and to preserve maximum good health for all those in whom infection cannot be cured.&lt;/p&gt;
			
			&lt;p&gt;Our strategies integrate clinical care, research, education, international programs, health information technology, administration and public advocacy. On the clinical front, we will increase testing and linkage to care efforts, as well as improve engagement of patients who currently do not adequately adhere to care regimens. We will adapt and refine our care and treatment strategies for chronic disease management, as medical successes have created a welcome cohort of patients who have been living with HIV for twenty years or more. Cohesion of purpose and principle, born from the contributions of a wide cross&#45;section of professionals, make the clinical plan both a road map and lightning rod for progress.&lt;/p&gt;
			
			&lt;p&gt;We are decisively focused on eradicating HIV and AIDS. We will research strategies for novel and widespread HIV treatment; investigate how to optimally treat HIV co&#45;infections such as tuberculosis, malaria and hepatitis; and enhance understanding of how HIV affects aging patients. Our program has always attracted some of the brightest young minds in HIV, and we will need to nurture these individuals through sustained mentoring and resource support in order to succeed in addressing the incredibly challenging set of questions on our research agenda. Critical to our success will be the funding of new research programs in HIV Eradication and an International Center of Excellence in HIV, TB and malaria.&lt;/p&gt;
			
			&lt;p&gt;In education, we commit to rapid knowledge transfer and training of fellow providers and future generations of HIV clinicians so that evolving scientific and clinical algorithms are rapidly disseminated. We will champion better understanding of HIV by communities and patients through concerted efforts ranging from direct patient education to partnerships with community organizations.&lt;/p&gt;
			
			&lt;p&gt;We will establish an HIV/AIDS living museum – to our knowledge the first of its kind in the world. The story of HIV is inextricably linked to the history of San Francisco, and we can think of no better way to foster global educational outreach at the individual, civic and international levels than by creating a dynamic community academy, accessible to all through an interactive website, with a secretariat, museum and learning center housed in San Francisco.&lt;/p&gt;
			
			&lt;p&gt;Our international programs promote life&#45;saving universal access to ARTs and care by addressing critical staffing shortages in healthcare. We will expand mentoring of clinician trainers, local capacity building, and enhance analysis of efforts to innovate and refine effective methods in resource&#45;limited settings. We will facilitate our international colleagues’ firsthand observation of the structure and flow of our renowned care system through intensive training sessions at SFGH.&lt;/p&gt;
			
			&lt;p&gt;Our health information technology experts resolve to making electronic medical record access and literacy more commonplace among HIV&#45;patients in San Francisco’s public health system, as well as measure and document how the use of integrated health information technologies affect the overall quality of care for patients. We dedicate ourselves to a customer&#45;oriented administrative approach through recruiting, sustaining and mentoring professional talent; providing timely and accurate financial reporting, technological support, and other resources need to accomplish our vision; and refining systems through regular surveys and quality assurance evaluations.&lt;/p&gt;
			
			&lt;p&gt;All faculty and staff will be active catalysts for constructive cultural and legal change by advocating for the broad expansion of HIV testing and linkage to care, universal access to antiretroviral medicine, and combating stigma, discrimination and violence against people living with HIV/AIDS. The more we facilitate acceptance and support progress in these areas, the more quickly will the medical advancements we envision benefit all society.&lt;/p&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Young Adult Clinic ./hiv/care/adolescent.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/adolescent.html</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/ward86logo.png&quot; height=&quot;140&quot; width=&quot;156&quot; align=&quot;right&quot;&gt;
			&lt;p class=&quot;introduction&quot;&gt;Young people living with HIV face unique challenges. With high rates of homelessness and substance use—compoundedby the usual hurdles of adolescent psychosocial development—HIV&#45;infected young adults can be exceptionally difficult to maintain in clinical programs. Recognizing the need for innovative care for this high&#45;risk group, the HIV Clinic at Ward 86 used youth peer consultants and focus groups to develop a Young Adult Clinic. &lt;/p&gt;
			
			&lt;p&gt;The Young Adult Clinic is designed to provide a clinic home for HIV&#45;infected young adults, and offers a comfortable clinic setting for care, social opportunities and facilitated group discussions. Our aim is to collaborate with young patients during this critical period of transition to ensure a smooth transition to adulthood.&lt;/p&gt;
			
			
			&lt;p&gt;For more information, contact Ted Ruel, MD at &lt;a href=&quot;mailto:RuelT@peds.ucsf.edu&quot;&gt;RuelT@peds.ucsf.edu&lt;/a&gt;.
			
					</FileBody>
	</node>
	<node>
		<Fname>
Golden Compass ./hiv/care/aging.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/aging.html</Path>
		<FileBody>
			
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/ward86logo.png&quot; height=&quot;140&quot; width=&quot;156&quot; align=&quot;right&quot;&gt;
			&lt;h3&gt;Helping People with HIV Navigate their Golden Years&lt;/h3&gt;
			&lt;br&gt;
			&lt;iframe width=&quot;560&quot; height=&quot;315&quot; src=&quot;https://www.youtube.com/embed/qlSEwtnhIHA&quot; frameborder=&quot;0&quot; allowfullscreen&gt;&lt;/iframe&gt;
			
			
			&lt;p class=&quot;introduction&quot;&gt;People with HIV are living longer, healthier lives in the era of antiretroviral treatment (ART). In San Francisco, over 60% of all people living with HIV are age 50 and older. Despite these successes, aging with HIV or later life diagnosis can bring new challenges. HIV can increase the risk of conditions like heart disease, osteoporosis (thin bones), memory problems and cancer. These and other aging&#45;related conditions may occur in HIV&#45;positive adults at younger ages than HIV&#45;negative adults. Older adults with HIV often face mental health issues like depression and may feel isolated from losing friends in the early days of the HIV/AIDS epidemic. &lt;/p&gt;
			
			&lt;p&gt;As a result, the HIV Clinic at Ward 86 launched Golden Compass in 2017. The program focuses on four “points” (related to compass directions) that serve the medical and psychosocial needs of people over 50 living with HIV. The program provides multidisciplinary medical care on&#45;site along with other comprehensive services, some of which are outlined below.&lt;/p&gt;
			
			&lt;p&gt;&lt;strong&gt;NORTH&lt;/strong&gt; — Heart and Mind: A cardiologist with expertise in HIV now sees patients at Ward 86 in a designated HIV Cardiology Clinic; Memory concerns are evaluated and a class to learn about brain and memory with some practical tips on improving memory is held regularly.&lt;/p&gt;
			
			&lt;p&gt;&lt;strong&gt;EAST&lt;/strong&gt; — Bones and Strength: Exercise classes for PLWH Age 50 or older are offered, focusing on preventing falls and supporting bone health.&lt;/p&gt;
			
			&lt;p&gt;&lt;strong&gt;WEST&lt;/strong&gt; — Dental, Hearing and Vision: Ward 86 helps link people to the appropriate screenings and services.&lt;/p&gt;
			
			&lt;p&gt;&lt;strong&gt;SOUTH&lt;/strong&gt; — Network and Navigation: A monthly support group provides an opportunity to come together, share experiences, and relieve loneliness.&lt;/p&gt;
			
			&lt;p&gt;For more information or to contribute to this initiative, contact &lt;a href=&quot;mailto:goldencompass@ucsf.edu&quot;&gt;goldencompass@ucsf.edu&lt;/a&gt; or (415) 206&#45;2473.&lt;/p&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Anal Dysplasia Clinic ./hiv/care/analdysplasia.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/analdysplasia.html</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/ward86logo.png&quot; height=&quot;140&quot; width=&quot;156&quot; align=&quot;right&quot;&gt;
			&lt;p&gt;
			Anal dysplasia is a pre&#45;cancerous condition that may lead to anal cancer. It is caused by the human papillomavirus (HPV). Anal dysplasia occurs in both men and women and is especially common among patients infected with HIV. This specialty clinic is held one afternoon a week on ward 86. We primarily provide anal cancer screening/prevention as well as treatment of anal and genital warts. Care includes a wide range of screening, diagnosis and treatment options, such as anal cytology, high&#45;resolution anoscopy (HRA), anal biopsy, electrocautery therapy and more.
			&lt;/p&gt;
			&lt;br&gt;
			&lt;br&gt;
			&lt;br&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Cardiology Clinic ./hiv/care/cardiology.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/cardiology.html</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/ward86logo.png&quot; height=&quot;140&quot; width=&quot;156&quot; align=&quot;right&quot;&gt;
			&lt;p&gt;
			A cardiologist with expertise in HIV will see patients at Ward 86 as part of the &lt;a href=&quot;/care/aging.html&quot;&gt;Golden Compass program&lt;/a&gt;.  This clinic cares for individuals with known cardiovascular disease and focuses on ways to reduce CV risk for all individuals.  As part of the clinic, individuals can be referred for additional cardiovascular testing as indicated in addition to other cardiovascular subspecialists including referrals for pacemakers, electrophysiology/devices, interventional cardiology, and CT/vascular surgery.  
			&lt;/p&gt;
			&lt;br&gt;
			&lt;br&gt;
			&lt;br&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Chest Clinic ./hiv/care/chest.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/chest.html</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/ward86logo.png&quot; height=&quot;140&quot; width=&quot;156&quot; align=&quot;right&quot;&gt;
			&lt;p class=&quot;introduction&quot;&gt;
			The lungs are a major target of HIV and lung diseases are frequent in people living with HIV. Historically, opportunistic pneumonias such as Pneumocystis pneumonia (PCP), bacterial pneumonia, and tuberculosis (TB) were the major pulmonary causes of illness and death. Currently, lung diseases such as chronic obstructive pulmonary disease (COPD; emphysema and chronic bronchitis), asthma, pulmonary fibrosis, and sleep apnea are prevalent. Established in 1995, the HIV/AIDS Chest Clinic is among the few clinics in the world exclusively dedicated to the diagnosis and management of pulmonary conditions for HIV&#45;infected individuals. The Chest Clinic is held on Friday afternoons from 1&#45;5pm and persons are scheduled after a referral from their primary care provider.&lt;/p&gt;
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/chestclinic.jpg&quot; height=&quot;180&quot; width=&quot;166&quot; align=&quot;left&quot;&gt;
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/chestclinic2.jpg&quot; height=&quot;430&quot; width=&quot;320&quot; align=&quot;right&quot;&gt;
			&lt;br&gt;
			&lt;br&gt;
			&lt;br&gt;
			&lt;br&gt;
			&lt;br&gt;
			&lt;br&gt;
			&lt;br&gt;
			&lt;h3&gt;Typical Referrals:&lt;/h3&gt;
			&lt;ul&gt;&lt;li&gt;Evaluation of unexplained shortness of breath, wheezing, cough, sputum production&lt;/li&gt;
			&lt;li&gt;Evaluation of abnormal findings on pulmonary testing (e.g., chest radiograph, chest computed tomograph scan, pulmonary function testing)&lt;/li&gt;
			&lt;li&gt;Facilitation of pulmonary diagnostic testing for suspected lung disease.&lt;/li&gt;
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Inpatient HIV Consultation ./hiv/care/consultation.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/consultation.html</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/ward86logo.png&quot; height=&quot;140&quot; width=&quot;156&quot; class=&quot;php&quot; align=&quot;right&quot;&gt;
			&lt;p&gt;
			Faculty from the Division of HIV, Infectious Diseases and Global Medicine provide HIV consultation services for patients hospitalized at ZSFG. Common consultation questions relate to antiretroviral medication initiation and management, diagnosis and treatment of opportunistic infections and HIV&#45;related malignancies, linkage to outpatient HIV care and services, and evaluation of new HIV diagnoses. The consult service works in close collaboration with our PHAST team to ensure proper linkage to outpatient HIV services. In line with the principles of the &lt;a href=&quot;https://www.gettingtozerosf.org/rapid&#45;standard&#45;operation&#45;procedure/&quot;&gt;RAPID program&lt;/a&gt;, we aim to start antiretroviral therapy on the same day of diagnosis.
			&lt;/p&gt;
			&lt;p&gt;
			Medical students, residents and fellows rotate on the inpatient consult service as an educational opportunity at UCSF.
			&lt;/p&gt;
			&lt;p&gt;
			The Division of HIV, Infectious Diseases, and Global Medicine Division endorses same&#45;day ART initiation in patients with HIV, regardless of degree of immunosuppression.
			&lt;/p&gt;&lt;p&gt;
			
			For more information, contact Monica Gandhi, MD at &lt;a href=&quot;mailto:Monica.Gandhi@ucsf.edu&quot;&gt;Monica.Gandhi@ucsf.edu&lt;/a&gt;
			&lt;/p&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
PHAST ./hiv/care/consultation.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/consultation.html~</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/php_logo.gif&quot; class=&quot;php&quot;&gt;
			&lt;p class=&quot;introduction&quot;&gt;
			
			The &lt;b&gt;Positive Health Access to Services and Treatment (PHAST)&lt;/b&gt; team is a
			rapid response team that has championed HIV testing and linkage to
			care across the SFGH campus since 2002.
			&lt;/p&gt;
			
			&lt;p&gt;
			Our mission is to meet the goals of the US National AIDS Strategy and CDC HIV Testing Guidelines by:
			&lt;ul&gt;
			
			&lt;li&gt; Identifying undiagnosed HIV infection in all patients who have contact with the SFGH system&lt;/li&gt;
			&lt;li&gt; Providing rapid linkage to care for individuals who are newly diagnosed or have barriers to engagement in care&lt;/li&gt;
			&lt;li&gt; Initiating antiretroviral therapy (ART) as soon as possible in all patients who are accepting of treatment&lt;/li&gt;
			&lt;li&gt; Supporting vulnerable patients by providing nursing care coordination and psychosocial stabilization throughout the linkage to care process&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/p&gt;
			&lt;p&gt;
			The PHAST team consists of a part.time registered nurse, part.time nurse practitioner and full.time social work associate. This team supports over 500 patients at risk for poor linkage to care and who are primarily persons of color with high rates of homelessness, mental illness and active substance use.  The average age of participants in PHAST is 39 and 11% are under the age of 25. At entry into the PHAST program, 21% of patients are taking ART. Within one year of participation in PHAST, 71% of patients are taking ART and 52% have undetectable HIV viral load. The lost.to.follow.up rate for PHAST patients is &amp;lt;10%.
			&lt;/P&gt;
			&lt;p&gt;
			&lt;b&gt;Key components&lt;/b&gt; of the PHAST model include:
			&lt;ul&gt;
			&lt;li&gt; Interdisciplinary skill set that includes nursing, social work, and bridging to primary care&lt;/li&gt;
			&lt;li&gt; A single team that tracks patients from initial HIV diagnosis through successful linkage to care&lt;/li&gt;
			&lt;li&gt; Rapid response to new HIV diagnoses that assists clinicians with disclosure of positive results and supports patients with counseling, education, partner services and self.disclosure to family and friends&lt;/li&gt;
			&lt;li&gt; Expedited clinic intake (within 1.4 days from initial diagnosis and first medical appointment within 10 days) with a focus on identifying barriers to successful linkage to care&lt;/li&gt;
			&lt;li&gt; Initial medical stabilization and careful matching to a primary care provider&lt;/li&gt;
			&lt;li&gt; Psychosocial stabilization: benefits, housing, mental health, addiction referrals&lt;/li&gt;
			&lt;li&gt; Intensive HIV education and orientation and mentoring on navigating the health care system&lt;/li&gt;
			&lt;li&gt; Appointment tracking: reminders and follow up on missed appointments&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/p&gt;
			&lt;p&gt;
			
			
			For more information, contact Diane Jones, RN at &lt;a href=&quot;mailto:djones@php.ucsf.edu&quot;&gt;djones@php.ucsf.edu&lt;/a&gt;
			&lt;/p&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Hepatitis Co-Infection Clinic ./hiv/care/hepc.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/hepc.html</Path>
		<FileBody>
			&lt;br&gt;
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/ward86logo.png&quot; height=&quot;140&quot; width=&quot;156&quot; class=&quot;php&quot; align=&quot;right&quot;&gt;
			&lt;p class=&quot;introduction&quot;&gt; Hepatitis C virus (HCV) affects 30% of patients at the HIV Clinic at Ward 86. Although it is a leading cause of illness and death in HIV infection, HCV can be cured with proper treatment. New medications with oral regimens, few side effects and short durations (8&#45;12 weeks) offer the promise of improved cure rates.&lt;/p&gt;
			
			&lt;p&gt;To increase access to HCV care and cure, the UCSF Division of HIV, Infectious Diseases and Global Medicine has developed a primary care&#45;based model for HCV care and treatment that includes a treatment protocol and additional resources available at &lt;a href=&quot;http://bayareaaetc.org/resources/&quot; target=&quot;_blank&quot;&gt;sfaetc.ucsf.edu&lt;/a&gt;. We are also helping to lead a “Getting to Zero” program for eradicating Hepatitis C infection across the city:&lt;a href=&quot;https://endhepcsf.org/&quot; target=&quot;_blank&quot;&gt; End Hep C SF.&lt;/a&gt;&lt;/p&gt;
			
			&lt;p&gt;All HIV patients in our clinic are tested for HCV annually and those who test positive are offered on&#45;site treatment to achieve cure, support groups and education. During the short duration of treatment, the patient is supported by a clinic pharmacist, specialty nurse, and socialworkers as needed.  &lt;/p&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Patient Care ./hiv/care/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/index.html</Path>
		<FileBody>
			
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/ward86logo.png&quot; height=&quot;140&quot; width=&quot;156&quot; style=&quot;float:right;margin&#45;top:&#45;62px;&quot;&gt;
			
			&lt;p class=&quot;introduction&quot;&gt;A proud partner of the San Francisco Department of Public Health (SFDPH), the HIV Clinic at Ward 86 (formerly Positive Health Program) provides inter&#45;professional, life&#45;sustaining services, including primary medical care, HIV specialty care (e.g., hepatitis, psychiatry, dermatology, cardiology, pulmonology, gynecology, geriatrics, addiction medicine, anal dysplasia, and nutrition), urgent care, mental health and substance use counseling, clinical pharmacy services, social work services and case management. We also provide inpatient HIV and Infectious Diseases consultations at Zuckerberg San Francisco General Hospital (ZSFG).
			&lt;/p&gt;&lt;!&#45;&#45;img src=&quot;/sites/hiv.ucsf.edu/files/images/clinic1.jp&quot; &#45;&#45;&gt;
			
			
			&lt;div style=&quot;width:420px;height:350px;background:#eee;padding:5px 10px;margin:10px;&quot;&gt;
			&lt;h3&gt;&lt;a href=&quot;https://vimeo.com/64675894&quot; target=&quot;_blank&quot;&gt;Welcome to Ward 86&lt;/a&gt;&lt;/h3&gt;
			&lt;iframe src=&quot;http://player.vimeo.com/video/64675894&quot; width=&quot;399&quot; height=&quot;266&quot; style=&quot;border: 1px solid #ccc;padding:5px;&quot; frameborder=&quot;0&quot; webkitAllowFullScreen mozallowfullscreen allowFullScreen&gt;&lt;/iframe&gt;
			&lt;/div&gt;
			
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Patient Care ./hiv/care/index.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/index.html~</Path>
		<FileBody>
			
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/php_logo.gif&quot; class=&quot;php&quot;&gt;
			
			&lt;p class=&quot;introduction&quot;&gt;A proud partner of the San Francisco Department of Public Health, the Positive Health Program (HIV/AIDS Clinic) at Ward 86 provides interprofessional, life&#45;sustaining services including primary medical care, HIV specialty care [hepatitis treatment, psychiatry, dermatology, pulmonology, gynecology, and nutrition], urgent care, mental health and substance abuse support, clinical pharmacy services, social work services, and case management.  Our physicians also provide inpatient AIDS consultation services at San Francisco General Hospital. 
			&lt;/p&gt;&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/clinic1.jpg&quot; &gt;
			
			
			&lt;div style=&quot;width:312px;height:230px;float:right;background:#eee;padding:5px 10px;margin:20px;&quot;&gt;
			&lt;h3&gt;&lt;a href=&quot;https://vimeo.com/64675894&quot; target=&quot;_blank&quot;&gt;Welcome to Ward 86&lt;/a&gt;&lt;/h3&gt;
			&lt;iframe src=&quot;http://player.vimeo.com/video/64675894&quot; width=&quot;299&quot; height=&quot;166&quot; style=&quot;border: 1px solid #ccc;padding:5px;&quot; frameborder=&quot;0&quot; webkitAllowFullScreen mozallowfullscreen allowFullScreen&gt;&lt;/iframe&gt;
			&lt;/div&gt;
			
			&lt;p&gt;Our patient&#45;centered medical home model includes:&lt;/p&gt;
			
			&lt;ul&gt;&lt;li&gt;Rapid new patient evaluation and appointments 
			&lt;/li&gt;&lt;li&gt;Electronic health records with a patient portal
			&lt;/li&gt;&lt;li&gt;On&#45;site education, support group and treatment for  hepatitis C infection
			&lt;/li&gt;&lt;li&gt;Specific and culturally sensitive programs dedicated to the health of HIV&#45;infected women, African&#45;Americans, Latinos and adolescents
			&lt;/li&gt;&lt;li&gt;Examination of the effects of HIV on aging
			&lt;/li&gt;&lt;/ul&gt;
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Patient Care ./hiv/care/index_old.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/index_old.html</Path>
		<FileBody>
			
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/php_logo.gif&quot; class=&quot;php&quot;&gt;
			
			&lt;p class=&quot;introduction&quot;&gt;PHP provides integrated, life&#45;sustaining services that include medical primary care, mental health assistance and comprehensive support to promote healthy living for our clients. 
			&lt;/p&gt;
			&lt;p&gt;Approximately 1 of every 5 HIV+ patients in San Francisco receive care here. Of these patients, 37% are co&#45;infected with Hepatitis C, 20% are female and 7% speak Spanish only. In addition to urgent and primary care, our dedicated case management professionals complement medical care by maintaining ongoing communication with patients and facilitating access to appropriate city agencies and services including shelter, domestic abuse, and health insurance. &lt;/p&gt;
			
			&lt;p&gt;Some of our ongoing, specialized programs that &quot;treat the whole patient&quot; include:&lt;/p&gt;
			&lt;ul&gt;&lt;li&gt;Hepatitis C co&#45;infection support group
			&lt;/li&gt;&lt;li&gt;Dedicated women&#45;only clinic
			&lt;/li&gt;&lt;li&gt;Fuzeon Users support group
			&lt;/li&gt;&lt;li&gt;Onsite psychiatry referral
			&lt;/li&gt;&lt;li&gt;Onsite substance abuse counseling
			&lt;/li&gt;&lt;li&gt;Smoking cessation and other healthy lifestyle programs 
			&lt;/li&gt;&lt;/ul&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Infectious Diseases Clinic ./hiv/care/infectiousdiseases.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/infectiousdiseases.html</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/ward86logo.png&quot; height=&quot;140&quot; width=&quot;156&quot; align=&quot;right&quot;&gt;
			&lt;p class=&quot;introduction&quot;&gt;The Infectious Diseases (ID) Clinic at Zuckerberg San Francisco General Hospital (ZSFG) treats the full array of infectious disease conditions occurring in individuals with and without HIV. These include cardiac conditions (including endocarditis and infections of implanted cardiac devices), pulmonary conditions (including viral, bacterial and fungal respiratory infections), hepatic, abdominal and gastrointestinal infections (including Clostridium difficile), post&#45;surgical infections (including skin/soft tissue infections, and infections of prosthetic implants), osteomyelitis, complex urinary and sinus infections, fever of unknown origin, zoonotic illnesses, and clinical syndromes in returning travelers.&lt;/p&gt;
			
			&lt;p&gt;The ID Clinic sees outpatients cared for both at Ward86 and throughout the CHN system, as well as patients recently hospitalized and in need of further follow up. They also provide clinic consultations on HIV, Hepatitis C, and Zika virus for patients cared for by CHN providers.&lt;/p&gt;
			
			&lt;p&gt;The ID Clinic can be contacted via the ZSFG e&#45;referral system, or by calling (415) 206&#45;7926.&lt;/p&gt;
			
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Latino Clinic ./hiv/care/latino.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/latino.html</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/ward86logo.png&quot; height=&quot;140&quot; width=&quot;156&quot; align=&quot;right&quot;&gt;
			&lt;p class=&quot;introduction&quot;&gt;Roughly 500 patients who are Hispanic receive care at the HIV Clinic at Ward 86, and over a third of these are monolingual Spanish or have limited English skills. At a weekly HIV clinic for Spanish&#45;speaking patients (on Wednesday afternoons), we provide a welcoming environment with culturally and linguistically appropriate services, including:&lt;/p&gt;
			
			&lt;ul&gt;&lt;li&gt;HIV primary care
			&lt;/li&gt;&lt;li&gt;Mental health services
			&lt;/li&gt;&lt;li&gt;Social support services, including housing and immigration assistance
			&lt;/li&gt;&lt;li&gt;Care coordination with community case managers
			&lt;/li&gt;&lt;li&gt;Health education and literacy
			&lt;/li&gt;&lt;/ul&gt;
			&lt;p&gt;More intensive case management services—including linkage to patient navigator assistance—are providedto Latino Clinic patients identified as particularly vulnerable or high risk, including those with a new diagnosis of HIV, newly engaged in care, CD4 cell counts of &lt; 200 cells/mm3 and/or active opportunistic infections. These patients are followed in our SALUD cohort (Securing Access for Latinos who are Underserved or Disabled).&lt;/p&gt;
			
			&lt;p&gt;For more information, contact Jenessa Bayda, MSW at &lt;a href=&quot;mailto:jenessa.bayda@ucsf.edu&quot;&gt;jenessa.bayda@ucsf.edu&lt;/a&gt; or call 415&#45;206&#45;2429.&lt;/p&gt;
			
			&lt;p&gt;See the Spanish translation of this page &lt;a href=&quot;/care/latino_spanish.html&quot;&gt;here&lt;/a&gt;.&lt;/p&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
La Clinica Latina ./hiv/care/latino_spanish.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/latino_spanish.html</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/php_logo.gif&quot; class=&quot;php&quot;&gt;
			&lt;p class=&quot;introduction&quot;&gt;Alrededor de 500 pacientes de la Clínica de VIH/SIDA del Hospital General de San Francisco son hispanos, y más de un tercio de ellos sólo hablan español o un inglés limitado. En nuestra Clínica semanal de VIH/SIDA enfocada principalmente en pacientes de habla hispana, ofrecemos un ambiente cultural y linguísticamente apropiado, donde proveemos los siguientes servicios:&lt;/p&gt;
			
			&lt;ul&gt;&lt;li&gt;Servicios médicos primarios para el tratamiento del VIH/SIDA
			&lt;/li&gt;&lt;li&gt;Servicios de salud mental, y consejería
			&lt;/li&gt;&lt;li&gt;Servicios sociales de ayuda, incluyendo vivienda, alimentación, finanzas y asistencia  legal migratoria
			&lt;/li&gt;&lt;li&gt;Coordinación de servicios con otros trabajadores de casos en la comunidad
			&lt;/li&gt;&lt;li&gt;Educación en conceptos y lenguaje sobre temas  relacionados a la salud
			&lt;/li&gt;&lt;/ul&gt;
			&lt;p&gt;Otros servicios más intensivos, incluyendo la asistencia en la conexión a otros colaboradores y trabajadores sociales en la comunidad, se ofrecen en la Clínica a aquellos pacientes que han sido identificados como más vulnerables, o de alto riesgo: pacientes con un diagnóstico reciente, aquellos que están comenzando su tratamiento, o que tienen un recuento de CD4 &lt; 200 y/o una infección oportunista activa. Estos pacientes son seguidos con especial atención por nuestra clínica SALUD.&lt;/p&gt;
			
			&lt;p&gt;Para mayor información, puede contactar a Hernán Ludueña Segre, MFTi  a la siguiente dirección de correo electrónico: &lt;a href=&quot;mailto:hsegre@php.ucsf.edu&quot;&gt;hsegre@php.ucsf.edu&lt;/a&gt; o por teléfono al (415) 206&#45;2429. Muchas gracias..&lt;/p&gt; 
			
			&lt;p&gt;Recursos en español sobre el VIH/SIDA:&lt;/p&gt;
			
			&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.cdc.gov/hiv/spanish/topics/basic/index.htm&quot;&gt;http://www.cdc.gov/hiv/spanish/topics/basic/index.htm&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;http://www.thebody.com/espanol.html?ic=3001&quot;&gt;http://www.thebody.com/espanol.html?ic=3001&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;http://www.latinoaids.org/esp/abc_hiv.php&quot;&gt;http://www.latinoaids.org/esp/abc_hiv.php&lt;/a&gt;
			&lt;/li&gt;&lt;/ul&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Clinic Location ./hiv/care/locations.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/locations.html</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/ward86logo.png&quot; height=&quot;140&quot; width=&quot;156&quot; align=&quot;right&quot; style=&quot;margin:&#45;50px 0px&quot;&gt;
			
			&lt;p class=&quot;introduction&quot;&gt;Ward 86 is located on the main campus of ZuckerbergSan Francisco General Hospital at the corner of Potrero Avenue and 22nd Street in San Francisco’s Mission District. The clinic is on the 6th Floor of Building 80.&lt;/p&gt;
			
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/cliniclocation3.jpg&quot; height=&quot;270&quot; width=&quot;456&quot; class=&quot;imgRight&quot; style=&quot;margin:&#45;10px 0px&quot;&gt;
			&lt;h4&gt;Address:&lt;/h4&gt;
			&lt;blockquote&gt;
			995 Potrero Avenue&lt;br /&gt;
			Ward 86, Zuckerberg San Francisco General Hospital&lt;br /&gt;
			San Francisco, CA  94110&lt;br /&gt;
			&lt;br /&gt;
			Download &lt;a href=&quot;/sites/hiv.ucsf.edu/files/docs/map.pdf&quot;&gt;campus map&lt;/a&gt; and/or see &lt;a href=&quot;http://maps.google.com/maps?q=995+Potrero+Avenue,+San+Francisco,+CA&amp;hl=en&amp;sll=37.0625,&#45;95.677068&amp;sspn=61.582079,79.277344&amp;oq=995+Potrero+Avenue&amp;hnear=995+Potrero+Ave,+San+Francisco,+California+94110&amp;t=m&amp;z=17&quot; target=&quot;blank&quot;&gt;Google map&lt;/a&gt;.
			&lt;/blockquote&gt;
			&lt;br&gt;
			&lt;h4&gt;Hours:&lt;/h4&gt;
			&lt;blockquote&gt;
			Monday, Tuesday, Thursday, Friday – 8a.m.&#45;5p.m., closed 12:00&#45;12:45p.m. &lt;br /&gt;
			Wednesday – 9a.m.&#45;5p.m., closed 12:00&#45;12:45p.m. &lt;br /&gt;
			&lt;br&gt;
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/cliniclocation2.jpg&quot; height=&quot;270&quot; width=&quot;456&quot; class=&quot;imgRight&quot; style=&quot;margin:&#45;10px 0px&quot;&gt;
			&lt;i&gt;Note:  The clinic opens at 1 p.m. on the first Friday of every month.&lt;/i&gt;&lt;br /&gt;
			Drop&#45;in medical care available from 10 a.m.&#45;5 p.m. daily in addition to appointments with primary care providers, social workers and RNs.&lt;br /&gt;
			
			&lt;p&gt;Weekend and holiday urgent care is located in the Adult Urgent Care Center on Ward 81, in the first floor of Building 80. &lt;br/&gt;
			Hours are Monday through Friday: 8&#45;9 p. m. Weekends and holidays: 8 a.m&#45;8 p.m. If you have a life&#45;threatening emergency, please call 911.&lt;/p&gt;
			&lt;/blockquote&gt;
			
			
			&lt;br&gt;
			&lt;h4&gt;Phone:&lt;/h4&gt;
			&lt;blockquote&gt;
			Main number of Ward 86: (415) 206&#45;2400&lt;br /&gt;
			Appointments:  (415) 206&#45;2403&lt;br /&gt;
			Eligibility:  (415) 206&#45;3154&lt;br /&gt;
			Fax: (415) 502&#45;4777
			&lt;/blockquote&gt;
			&lt;br&gt;
			&lt;br&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Psychiatry and Case Management ./hiv/care/mentalhealth.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/mentalhealth.html</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/ward86logo.png&quot; height=&quot;140&quot; width=&quot;156&quot; align=&quot;right&quot;&gt;
			&lt;br&gt;
			&lt;h3&gt;Mental Health Services:&lt;/h3&gt;
			&lt;p&gt;Ward 86 provides daily, on&#45;site mental health services through a team and collaborative approach. Social Workers provide mental health assessment and referrals while also provide individual counseling. Alliance Health Project psychiatrists provide psychiatry clinics at Ward 86 with seven half&#45;day sessions per week, including both morning and afternoon clinics based on client needs. These psychiatrists provide ongoing medication monitoring, assessment and referral to PHP primary medical providers, social work staff, Ward 86 partners, or other outside community based agencies as appropriate.
			
			&lt;h3&gt;Case Management Services:&lt;/h3&gt;
			&lt;p&gt;Ward 86 provides daily, on&#45;site case management services through a team and collaborative approach. A medical social work model of case management is employed on&#45;site at Ward 86 by licensed social workers to all clients. In addition, culturally specific community case management services are available to clients who need additional stabilization through three Center of Excellences (Women’s CoE, Black Health CoE and CCHAMP CoE) that are based at Ward 86. Some of these community case management services are also available off&#45;site with our collaborative partners, Alliance Health Project, San Francisco AIDS Foundation and Catholic Charities. Finally, another layer of nursing case management is available for those clients with the greatest medical needs. All services are available during normal operating hours at each of the sites.
			
			&lt;h3&gt;Substance Use Services:&lt;/h3&gt;
			&lt;p&gt;Ward 86 provides substance use services through a team and collaborative approach. Ward 86 Social Work staff can provide initial screening and referrals to in&#45;house services provided by The Stimulant Treatment Outpatient Program (STOP) and the SFAF/Stonewall Project. Stonewall Project provides integrated substance abuse and mental health counseling and access to support groups to clients who use cocaine or methamphetamine. STOP has particular expertise with patients with severe psychotic and medical conditions that complicate the management of their HIV disease. STOP works closely with Ward 86 nurses, social workers, primary care providers, and AHP psychiatrists and case managers using an integrated practice model.
			
					</FileBody>
	</node>
	<node>
		<Fname>
For Patients ./hiv/care/patients.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/patients.html</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/php_logo.gif&quot; class=&quot;php&quot;&gt;
			&lt;p class=&quot;introduction&quot;&gt;Content goes here.
			&lt;/p&gt;
			&lt;p&gt;Second paragraph.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Bay Area Perinatal AIDS Center (BAPAC) ./hiv/care/perinatal-old.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/perinatal-old.html</Path>
		<FileBody>
			
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/bapac_logo2.jpg&quot; class=&quot;imgLeft&quot; style=&quot;border:none;&quot;&gt;
			&lt;p class=&quot;introduction&quot;&gt;Healthy Women, Healthy Babies, Healthy Families.&lt;/p&gt;
			
			&lt;p&gt;&lt;b&gt;BAPAC's Mission:&lt;/b&gt; 
			BAPAC provides comprehensive preconception counseling and prenatal care to women and families infected and affected by HIV.&lt;/p&gt;
			
			&lt;p&gt; Committed to leadership in perinatal HIV care, BAPAC also offers consultations and education to medical providers worldwide. Part of UCSF&#45;Positive Health Program, BAPAC is a multi&#45;disciplinary team tailoring medical and psychosocial services to the specific needs of each woman and her family before, during and after pregnancy. 
			&lt;/p&gt;
			&lt;h2&gt;For Women&lt;/h2&gt;
			&lt;iframe class=&quot;image&quot; src=&quot;http://player.vimeo.com/video/51461711&quot; width=&quot;500&quot; height=&quot;281&quot; frameborder=&quot;&quot; webkitAllowFullScreen mozallowfullscreen allowFullScreen&gt;&lt;/iframe&gt;
			&lt;br /&gt;
			
			&lt;p&gt;Larger video can be seen &lt;a href=&quot;https://vimeo.com/51461711&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			
			&lt;h2&gt;For Men&lt;/h2&gt;
			
			&lt;iframe class=&quot;image&quot; src=&quot;http://player.vimeo.com/video/54624505&quot; width=&quot;500&quot; height=&quot;281&quot; frameborder=&quot;0&quot; webkitAllowFullScreen mozallowfullscreen allowFullScreen&gt;&lt;/iframe&gt;
			&lt;p&gt;Larger video can be seen &lt;a href=&quot;https://vimeo.com/54624505&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
perinatal.html ./hiv/care/perinatal.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/perinatal.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
PHAST ./hiv/care/phast.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/phast.html</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/ward86logo.png&quot; height=&quot;140&quot; width=&quot;156&quot; class=&quot;php&quot; align=&quot;right&quot;&gt;
			&lt;p class=&quot;introduction&quot;&gt;
			
			The Positive Health Access to Services and Treatment (PHAST) team is a rapid response team that has championed HIV testing and linkage to care across the ZSFG campus since 2002.
			&lt;/p&gt;
			
			&lt;p&gt;
			Our mission is to meet the goals of the US National AIDS Strategy and CDC HIV Testing Guidelines by:
			&lt;ul&gt;
			
			&lt;li&gt; Identifying undiagnosed HIV infection in all patients who have contact with the SFDPH system&lt;/li&gt;
			&lt;li&gt; Providing rapid linkage to care for individuals who are newly diagnosed or have barriers to engagement in care&lt;/li&gt;
			&lt;li&gt; Initiating antiretroviral therapy (ART) as soon as possible (same day as diagnosis, if possible) in all patients who are accepting of treatment&lt;/li&gt;
			&lt;li&gt; Supporting vulnerable patients by providing nursing care coordination and psychosocial stabilization throughout the linkage to care process&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/p&gt;
			&lt;p&gt;
			The PHAST team consists of a registered nurse, nurse practitioner and social work associate. This team supports over 500 patients at risk forpoor linkage to care. Patientsare primarily persons of color with high rates of homelessness, mental illness and active substance use. The average age of participants in PHAST is 39 and 11% are under the age of 25. At entry into the PHAST program, 21% of patients are taking ART. Within one year of participation in PHAST, 71% of patients are taking ART and a majority of participants have undetectable HIV viral load. The lost.to.follow.up rate for PHAST patients is &lt;10%.
			&lt;/P&gt;
			&lt;p&gt;
			&lt;b&gt;Key components&lt;/b&gt; of the PHAST model include:
			&lt;ul&gt;
			&lt;li&gt; Interdisciplinary skill set that includes nursing, social work, and bridging to primary care&lt;/li&gt;
			&lt;li&gt; A single team that tracks patients from initial HIV diagnosis through successful linkage to care&lt;/li&gt;
			&lt;li&gt; Rapid response to new HIV diagnoses that assists clinicians with disclosure of positive results and supports patients with counseling, education, partner services and self.disclosure to family and friends&lt;/li&gt;
			&lt;li&gt; Initiation of ART on the same day of diagnosis when possible (the “RAPID program”)&lt;/li&gt;
			&lt;li&gt; Expedited clinic intake (within 1.4 days from initial diagnosis and first medical appointment within 10 days) with a focus on identifying barriers to successful linkage to care&lt;/li&gt;
			&lt;li&gt; Initial medical stabilization and careful matching to a primary care provider&lt;/li&gt;
			&lt;li&gt; Psychosocial stabilization: benefits, housing, mental health, addiction referrals&lt;/li&gt;
			&lt;li&gt; Intensive HIV education and orientation and mentoring on navigating the health care system&lt;/li&gt;
			&lt;li&gt; Appointment tracking: reminders and follow up on missed appointments&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/p&gt;
			&lt;p&gt;
			
			
			For more information, contact Clarissa Ospina&#45;Norvell at &lt;a href=&quot;mailto:Clarissa.ospina&#45;norvell@ucsf.edu&quot;&gt;Clarissa.ospina&#45;norvell@ucsf.edu&lt;/a&gt;.
			&lt;/p&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
PHAST ./hiv/care/phast.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/phast.html~</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/php_logo.gif&quot; class=&quot;php&quot;&gt;
			&lt;p class=&quot;introduction&quot;&gt;
			
			The &lt;b&gt;Positive Health Access to Services and Treatment (PHAST)&lt;/b&gt; team is a
			rapid response team that has championed HIV testing and linkage to
			care across the SFGH campus since 2002.
			&lt;/p&gt;
			
			&lt;p&gt;
			Our mission is to meet the goals of the US National AIDS Strategy and CDC HIV Testing Guidelines by:
			&lt;ul&gt;
			
			&lt;li&gt; Identifying undiagnosed HIV infection in all patients who have contact with the SFGH system&lt;/li&gt;
			&lt;li&gt; Providing rapid linkage to care for individuals who are newly diagnosed or have barriers to engagement in care&lt;/li&gt;
			&lt;li&gt; Initiating antiretroviral therapy (ART) as soon as possible in all patients who are accepting of treatment&lt;/li&gt;
			&lt;li&gt; Supporting vulnerable patients by providing nursing care coordination and psychosocial stabilization throughout the linkage to care process&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/p&gt;
			&lt;p&gt;
			The PHAST team consists of a part.time registered nurse, part.time nurse practitioner and full.time social work associate. This team supports over 500 patients at risk for poor linkage to care and who are primarily persons of color with high rates of homelessness, mental illness and active substance use.  The average age of participants in PHAST is 39 and 11% are under the age of 25. At entry into the PHAST program, 21% of patients are taking ART. Within one year of participation in PHAST, 71% of patients are taking ART and 52% have undetectable HIV viral load. The lost.to.follow.up rate for PHAST patients is &amp;lt;10%.
			&lt;/P&gt;
			&lt;b&gt;Key components&lt;/b&gt; of the PHAST model include:
			&lt;ul&gt;
			&lt;li&gt; Interdisciplinary skill set that includes nursing, social work, and bridging to primary care&lt;/li&gt;
			&lt;li&gt; A single team that tracks patients from initial HIV diagnosis through successful linkage to care&lt;/li&gt;
			&lt;li&gt; Rapid response to new HIV diagnoses that assists clinicians with disclosure of positive results and supports patients with counseling, education, partner services and self.disclosure to family and friends&lt;/li&gt;
			&lt;li&gt; Expedited clinic intake (within 1.4 days from initial diagnosis and first medical appointment within 10 days) with a focus on identifying barriers to successful linkage to care&lt;/li&gt;
			&lt;li&gt; Initial medical stabilization and careful matching to a primary care provider&lt;/li&gt;
			&lt;li&gt; Psychosocial stabilization: benefits, housing, mental health, addiction referrals&lt;/li&gt;
			&lt;li&gt; Intensive HIV education and orientation and mentoring on navigating the health care system&lt;/li&gt;
			&lt;li&gt; Appointment tracking: reminders and follow up on missed appointments&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/p&gt;
			&lt;p&gt;
			
			
			For more information, contact Diane Jones, RN at &lt;a href=&quot;mailto:djones@php.ucsf.edu&quot;&gt;djones@php.ucsf.edu&lt;/a&gt;
			&lt;/p&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
PrEP Clinic ./hiv/care/prep.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/prep.html</Path>
		<FileBody>
			
			 &lt;iframe width=&quot;400&quot; height=&quot;215&quot; src=&quot;https://www.youtube.com/embed/&#45;Xx92whZS0o&quot; frameborder=&quot;0&quot; allowfullscreen class=&quot;image&quot; style=&quot;margin&#45;left:100px;margin&#45;bottom:20px;&quot;&gt;&lt;/iframe&gt;
			
			&lt;p class=&quot;introduction&quot;&gt;Pre&#45;Exposure Prophylaxis (PrEP) is an HIV prevention tool for HIV&#45;negative people. Individuals at risk of HIV infection can take a daily pill that can reduce HIV risk by more than 90%. Safe and effective, a combination of tenofovir disoproxil fumarate and emtricitabine (called Truvada®) was approved for PrEP in 2012.These medications are available at Ward 86 with a focus on men who have sex with men, women at risk for HIV, transgender individuals, and people who inject drugs. The Ward 86 PrEP Clinic offers PrEP navigation and clinical care services as part of a comprehensive sexual health program.&lt;/p&gt;
			
			&lt;p&gt;Individuals interested in PrEP may call 415&#45;206&#45;2453 to schedule an appointment. Alternatively, drop in to Ward 86 from 10am&#45;5pm Monday&#45;Friday (closed from 12&#45;12:45pm). &lt;/p&gt;
			
			&lt;p&gt;The PrEP Clinic at Ward 86 helps people access PrEP through the following services:
			&lt;ul&gt;&lt;li&gt;Support to start PrEP and follow&#45;up with primary care clinic (or linkage to a primary care if needed)
			&lt;/li&gt;&lt;li&gt;Option to stay at Ward 86 as a primary care medical home when on PrEP
			&lt;/li&gt;&lt;li&gt;PrEP counseling and navigation services
			&lt;/li&gt;&lt;li&gt;Help accessing PrEP medications
			&lt;/li&gt;&lt;li&gt;Sexual health services including STD screening, treatment and condoms
			 &lt;/li&gt;&lt;/ul&gt;
			
			&lt;p&gt;For more information about the Ward 86 PrEP Clinic and for help in accessing PrEP, contact the San Francisco Health Network PrEP Coordinator at 415&#45;206&#45;2453 or &lt;a href=&quot;mailto:miranda.nordell@sfdph.org&quot;&gt;miranda.nordell@sfdph.org&lt;/a&gt;.&lt;/p&gt;
			
			&lt;h3&gt;Provider Consultation:&lt;/h3&gt;
			&lt;p&gt;We also provide consultation and training for local health care providers and partners on PrEP. The &lt;a href=&quot;/sites/hiv.ucsf.edu/files/docs/sfhn_prep&#45;guide_june2016.pdf&quot;&gt;San Francisco Health Network PrEP Guidelines&lt;/a&gt; provide local clinical guidelines and resources for health care providers. For more information, contact Miranda Nordell, at 415&#45;206&#45;2453 or &lt;a href=&quot;mailto:miranda.nordell@sfdph.org&quot;&gt; miranda.nordell@sfdph.org&lt;/a&gt;&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
HIV Primary Care Clinic ./hiv/care/primary.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/primary.html</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/ward86logo.png&quot; height=&quot;140&quot; width=&quot;156&quot; style=&quot;float:right;margin&#45;top:&#45;82px; margin&#45;left:5px;&quot;&gt;
			&lt;br /&gt;
			
			&lt;p class=&quot;introduction&quot;&gt; &lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/clinic2.jpg&quot; class=&quot;imgRight&quot;&gt;Established in 1983 as one of the first dedicated HIV clinics in the United States, the HIV Clinic at Ward 86 is located on the Zuckerberg San Francisco General Hospital campus. Currently providing care for roughly 2,600 HIV&#45;infected individuals in San Francisco, the HIV Clinic at Ward 86 offers comprehensive medical services, including:&lt;/p&gt;
			
			&lt;iframe src=&quot;https://player.vimeo.com/video/64675848&quot; width=&quot;540&quot; height=&quot;298&quot; frameborder=&quot;0&quot; webkitallowfullscreen mozallowfullscreen allowfullscreen&gt;&lt;/iframe&gt;
			
			&lt;/p&gt;
			&lt;p&gt;
			&lt;ul&gt;&lt;li&gt;Primary medical care
			&lt;/li&gt;&lt;li&gt;HIV specialty care
			&lt;/li&gt;&lt;li&gt;Drop&#45;in medical services (“Urgent Care”)
			&lt;/li&gt;&lt;li&gt;Hepatitis C evaluation and curative treatment
			&lt;/li&gt;&lt;li&gt;Rapid new HIV patient evaluation and initiation of antiretroviral therapy (ART) on the day of diagnosis (“RAPID” initiative)
			&lt;/li&gt;&lt;li&gt;Comprehensive “panel” management—includes a physician (MD), nurse practitioner (NP), nurse, social worker, pharmacist, and case manager—for all patients
			&lt;/li&gt;&lt;li&gt;Pre&#45;exposure prophylaxis (PrEP) for at&#45;risk individuals (who are HIV negative)
			&lt;/li&gt;&lt;li&gt;HIV Chest Clinic for pulmonary diseases
			&lt;/li&gt;&lt;li&gt;HIV Dermatology Clinic for skin conditions
			&lt;/li&gt;&lt;li&gt;Anal dysplasia services
			&lt;/li&gt;&lt;li&gt;Psychiatry and mental health services
			&lt;/li&gt;&lt;li&gt;Transgender services
			&lt;/li&gt;&lt;li&gt;Infectious Disease Clinic
			&lt;/li&gt;&lt;li&gt;Substance use evaluation and treatment
			&lt;/li&gt;&lt;li&gt;Clinical pharmacy services, including medication evaluation and adherence support and smoking cessation services
			&lt;/li&gt;&lt;li&gt;Nursing care coordination and case management
			&lt;/li&gt;&lt;li&gt;Linkage to HIV care and help with getting to appointments
			&lt;/li&gt;&lt;li&gt;Specialized services for African&#45;Americans, women, adolescents and Latinos living with HIV
			&lt;/li&gt;&lt;li&gt;Golden Compass, a comprehensive care program for HIV&#45;positive patients over 50 years of age
			&lt;/li&gt;&lt;/ul&gt;
			
			&lt;p&gt;The HIV Clinic at Ward 86 has an electronic medical record with a patient portal, allowing patients to have secure internet&#45;based access to medical records and health information.&lt;/p&gt;
			
			
			&lt;p&gt;In 2010, the HIV Clinic at Ward 86 became the first clinic in the world to recommend &lt;a href=&quot;http://www.nytimes.com/2010/04/04/us/04sftreatment.html?_r=1 &quot; target=&quot;_blank&quot;&gt;Universal Antiretroviral Treatment&lt;/a&gt; regardless of CD4 count.  The clinic policy states, “All patients, regardless of CD4 count, will be evaluated for initiation of antiretroviral therapy (ART)” and that “...all patients should be offered ART unless there is a reason to defer therapy.” A copy of this policy and FAQ sheet can be downloaded &lt;a href=&quot;/sites/hiv.ucsf.edu/files/docs/art_initguide.pdf&quot;&gt;here&lt;/a&gt;. Currently, over 90% of Ward 86 patients are prescribed ART and over 80% of those have an undetectable HIV viral load.&lt;/p&gt;
			
			&lt;p&gt;In addition, the HIV Clinic at Ward 86 has formal &lt;a href=&quot;/sites/hiv.ucsf.edu/files/docs/hiv_monitoring_guideline.pdf&quot;&gt;HIV monitoring guidelines&lt;/a&gt; that provide recommendations on routine laboratory monitoring for HIV related issues.&lt;/p&gt;
			&lt;p&gt;The HIV Clinic at Ward 86 is a proud partner of the San Francisco Department of Public Health. Funding comes from the City and County of San Francisco and the Ryan White Care Act with additional support from the San Francisco General Hospital Foundation and private donations.&lt;/p&gt;
			
			
			&lt;br&gt;
			&lt;br&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Substance Use Services ./hiv/care/substance_use.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/substance_use.html</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/ward86logo.png&quot; height=&quot;140&quot; width=&quot;156&quot; align=&quot;right&quot;&gt;
			&lt;p class=&quot;introduction&quot;&gt;Many of the patients receiving care on Ward 86 struggle with unhealthy substance use along the spectrum from risky use to addiction. Substance use services at Ward 86 are based on the principles of harm reduction. Harm reduction is a public health philosophy, which promotes methods of reducing the physical, social, emotional, and economic harms associated with drug and alcohol use and other harmful behaviors on individuals and their community. Harm reduction methods and treatment goals are free of judgment or blame and directly involve the client in setting their own goals.&lt;/p&gt;
			
			
			&lt;ul&gt;
			&lt;li&gt;&lt;b&gt;Counseling &amp; Social Work&lt;/b&gt;
			&lt;ul&gt;
			&lt;li&gt;
			Licensed social workers are available for one&#45;on&#45;one counseling and case management designed to meet individual needs. As appropriate, referrals to on&#45;site or community&#45;based substance use and mental health services are also made. Please contact Helen Lin, LCSW at (415) 206&#45;2425 for further information.
			&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;http://psych.ucsf.edu/sfgh.aspx?id=472&quot; target=&quot;_blank&quot;&gt;Stimulant Treatment Outpatient Program (STOP) &lt;/a&gt;
			&lt;ul&gt;
			&lt;li&gt;
			STOP provides primary care integrated substance use counseling for Ward 86 patients with cocaine, methamphetamine or other substance use disorders. STOP staff helps patients clarify their needs and goals using motivational interventions, and guides them in behavior change, i.e. harm reduction, cessation of use, or relapse prevention.  A STOP staff member is available to meet with patients on Ward 86. Please contact Valerie Gruber, PhD at (415) 206&#45;3943 for more information.
			&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;http://www.stonewallsf.org/ &quot; target=&quot;_blank&quot;&gt;Stonewall Project&lt;/a&gt; &lt;ul&gt;&lt;li&gt;
			The Stonewall Project is a harm reduction program serving all San Francisco residents, especially men who have sex with men, who are seeking help with substanceuse. Substance use counselors specialize in working with clients who use speed, cocaine, crack, heroin, and other drugs that can lead to risky sexual behavior. Clients are not required to be sober. A Stonewall staff member is available to meet clients on Ward 86. Please contact Michael Siever, PhD at (415) 487&#45;3101 for more information.
			&lt;/li&gt;&lt;/ul&gt;
			&lt;/li&gt;&lt;li&gt;&lt;b&gt;Beehive Program&lt;/b&gt;&lt;ul&gt;&lt;li&gt;
			The Beehive Program provides office&#45;based opioid treatment (OBOT) and counseling at the Ward 86 for patients with opioid use disorders. Qualified providers may prescribe buprenorphine to patients seeking treatment for heroin or pain pill addiction. In addition, patients stably maintained on methadone at an opioid treatment program (OTP) may be eligible to transfer to an office&#45;based methadone satellite program. Patients are seen on Ward 86 for monitoring and counseling and receive methadone or buprenorphine dispensing at a community pharmacy. Please ask your primary care provider for a referral or contact Paula Lum, MD, MPH, at (415) 476&#45;4082 ext. 411 for moreinformation.
			&lt;/li&gt;&lt;/ul&gt;
			
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;http://psych.ucsf.edu/sfgh.aspx?id=472&quot; target=&quot;_blank&quot;&gt;Opiate Treatment Outpatient Program (OTOP)&lt;/a&gt;&lt;ul&gt;&lt;li&gt;
				The Opiate Treatment Outpatient Program (OTOP) is a publicly&#45;funded methadone program for the treatment of opioid use disorder at Ward 93 on theZSFG campus.
				Ward 86 patients may be referred or self&#45;refer to OTOP for methadone treatment and counseling. Other available services include on&#45;site HIV primary care by a Ward 86 physician, pharmacotherapies for alcohol and tobacco use disorders, and directly&#45;observed therapy (DOT) services for HIV, HCV, and psychiatric medication adherence support. Please contact (415) 206&#45;8412 for more information.&lt;/li&gt;&lt;/ul&gt;
			&lt;/li&gt;&lt;/ul&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Women's Clinic ./hiv/care/womens.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/womens.html</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/ward86logo.png&quot; height=&quot;140&quot; width=&quot;156&quot; align=&quot;right&quot;&gt;
			&lt;p class=&quot;introduction&quot;&gt;At the HIV/AIDS Clinic, we recognize the special medical and social needs of women and families in our community who are infected with and affected by HIV. We offer programs and services designed exclusively for women, including dedicated clinic hours for our female and transgender patients. &lt;/p&gt;
			&lt;iframe src=&quot;https://player.vimeo.com/video/64675266&quot; align=&quot;right&quot; width=&quot;360&quot; height=&quot;260&quot; frameborder=&quot;0&quot; webkitallowfullscreen mozallowfullscreen allowfullscreen&gt;&lt;/iframe&gt;
			
			&lt;h3&gt;Women's Clinic&lt;/h3&gt;
			&lt;p&gt;At the HIV Clinic at Ward 86, we recognize the special medical and social needs of women and families affected by HIV. We offer programs and services designed for women, including dedicated clinic hours for female and transgender (male to female) patients.The providers of the HIV Clinic at Ward 86 hold weekly clinic hours for female patients, which includes primary care, gynecologic care, community case management, and mental health and substance use services. We encourage female patients to visit during these hours to socialize and eat complimentary food in the waiting room. Women’s Clinic is held on Thursday mornings. If you would like to schedule your medical appointments during these hours, please contact the front desk at (415) 206&#45;2400. &lt;/p&gt;
			
			
			&lt;h3&gt;HIVE&lt;/h3&gt;
			&lt;p&gt;If you are pregnant, considering becoming pregnant, or generally concerned about HIV and reproductive health, you may be interested in the services of the HIVE program (formerly BAPAC—Bay Area Perinatal AIDS Center), which provides comprehensive preconception counseling, prenatal care and perinatal care for women and their families. Click &lt;a href=&quot;https://www.hiveonline.org/&quot; target=&quot;_blank&quot;&gt;here&lt;/a&gt; to learn more about HIVE.&lt;/p&gt;
			
			
			&lt;h3&gt;Family Service Network&lt;/h3&gt;
			&lt;p&gt;The Family Service Network (FSN) is a network of community&#45;based organizations in San Francisco. FSN provides comprehensive, coordinated and family&#45;centered care to HIV&#45;infected women of color, children and youth and their affected families. Contact Chris Harris for more information at (415) 206&#45;2436. &lt;/p&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Contact ./hiv/care/perinatal/contact.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/perinatal/contact.html</Path>
		<FileBody>
			
			&lt;p&gt;Monday&#45;Friday&lt;/p&gt;
			&lt;blockquote&gt;
			                Phone: 415&#45;206&#45;8919&lt;br&gt;
			                Fax: 415&#45;206&#45;3626&lt;/blockquote&gt;
			                &lt;p&gt;After hours and on weekends:&lt;/p&gt;
			&lt;blockquote&gt;
			                Page San Francisco General Hospital Reproductive Infectious Disease Fellow:&lt;br&gt;
							415&#45;443&#45;8726
							&lt;/blockquote&gt;
							&lt;p&gt;Office Address:&lt;/p&gt;
			             &lt;blockquote&gt;
			                &lt;/strong&gt;BAPAC&lt;br&gt;
			                San Francisco General Hospital&lt;br&gt;
			                1001 Potrero Avenue, 6D&#45;33&lt;br&gt;
			                San Francisco, CA 94110&lt;/blockquote&gt;
			        &lt;p&gt;Email:&lt;/p&gt;
			        &lt;blockquote&gt;
			        		&lt;a href=&quot;mailto:Shannon.Weber@ucsf.edu&quot;&gt;Shannon.Weber@ucsf.edu&lt;/a&gt;
			        &lt;/blockquote&gt;
			              
			            
			&lt;h3&gt;Other Telephone Resources&lt;/h3&gt;
			              &lt;p&gt;&lt;b&gt;Hotlines: Nationwide&lt;/b&gt;&lt;/p&gt;
			              &lt;ul&gt;&lt;li&gt;National HIV/AIDS hotline: (800) 342&#45;2437 
			                (English)
			                &lt;/li&gt;&lt;li&gt;National HIV/AIDS hotline: (800) 344&#45;7423 
			                (Espa&amp;ntilde;ol)
			                &lt;/li&gt;&lt;li&gt;National HIV Treatment hotline: (800) 
			                822&#45;7422&lt;br&gt;
			                M&#45;F 9&#45;5, Sa 10&#45;4 Pacific Time. Answers to your treatment questions.
			                &lt;/li&gt;&lt;li&gt;Project Inform (800) 822&#45;7422.&lt;br&gt;
			                Information about HIV and testing for HIV. Phone call will not 
			                show on your phone record.&lt;/p&gt;
			                  &lt;/li&gt;&lt;/ul&gt;
			                  
			              &lt;p &gt;&lt;b&gt;Hotlines: California&lt;/b&gt;&lt;/p&gt;
			             &lt;ul&gt;&lt;li&gt;California AIDS hotline: (800) 367&#45;2437&lt;br&gt;
			                Provides referrals to AIDS hotlines in your area or states outside 
			                of California&lt;/p&gt;
			                  &lt;/li&gt;&lt;/ul&gt;
			                  
			              &lt;p &gt;&lt;b&gt;Hotlines: San Francisco&lt;/b&gt;&lt;/p&gt;
			            &lt;ul&gt;&lt;li&gt;Child Abuse Hotline/Talkline: (415) 
			                441&#45;KIDS
			                &lt;/li&gt;&lt;li&gt;Rape Hotline: (415) 647&#45;Rape
			                &lt;/li&gt;&lt;li&gt;Suicide Prevention: (415) 781&#45;0500
			                &lt;/li&gt;&lt;li&gt;San Francisco AIDS HIV nightline: 
			                (415) 434&#45;AIDS&lt;br&gt;
			                5pm&#45;5am 7 nights/week, emotional support.
			                &lt;/li&gt;&lt;li&gt;Access (provides mental health referrals): 
			                (888) 246&#45;3333 &lt;/p&gt;
			                  &lt;/li&gt;&lt;/ul&gt;
			                  
			              &lt;p &gt;&lt;b&gt;HIV Testing: San Francisco&lt;/b&gt;&lt;/p&gt;
			          &lt;ul&gt;&lt;li&gt;AIDS Health Project (415) 502&#45;8378
			                &lt;/li&gt;&lt;li&gt;City Clinic (415) 864&#45;8100
			                &lt;/li&gt;&lt;li&gt;Planned Parenthood (415) 441&#45;7858
			                  &lt;/li&gt;&lt;/ul&gt;
			                &lt;p&gt;&lt;b&gt;HIV Respite Care and Support&lt;/b&gt;&lt;/p&gt;
			             &lt;ul&gt;&lt;li&gt;Family Support Services (415) 861&#45;4284&lt;br&gt;
			                Respite care for San Francisco caregivers.
			                 &lt;/li&gt;&lt;/ul&gt;
			              &lt;p&gt;&lt;b&gt; Provider Telephone Support&lt;/b&gt;&lt;/p&gt;
			               &lt;ul&gt;&lt;li&gt;Perinatal Hotline (888) 448&#45;8765&lt;br&gt;
			                National Perinatal HIV Consultation and Referral Service. 24 hour advice regarding management of 			HIV&#45;positive pregnant women and HIV&#45;exposed infants.
			                &lt;/li&gt;&lt;li&gt;Warmline (800) 933&#45;3413&lt;br&gt;
			                National HIV telephone consultation service. Hours: Monday&#45;Friday 
			                6am&#45;5pm Pacific Time.
			                &lt;/li&gt;&lt;li&gt;PEPline (888) 448&#45;4911&lt;br&gt;
			                National Clinicians' Post&#45;exposure Prophylaxis Hotline. 24 hour 
			                advice regarding management of healthcare worker HIV exposure.&lt;/p&gt;
			                &lt;/li&gt;&lt;/ul&gt;
			                
			              &lt;p &gt;&lt;b&gt;Banked Human Milk&lt;/b&gt;&lt;/p&gt;
			              &lt;ul&gt;&lt;li&gt;Mother's Milk Bank, San Jose (408) 
			                998&#45;4550&lt;br&gt;
			                &lt;a href=&quot;http://www.sanjosemilkbank.com&quot; target=&quot;_blank&quot;&gt;www.sanjosemilkbank.com/&lt;/a&gt;&lt;/p&gt;
			              &lt;/li&gt;&lt;/ul&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Donate ./hiv/care/perinatal/donate.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/perinatal/donate.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;BAPAC is largely funded by charitable donations and sponsored grants.&lt;/p&gt;
			            &lt;p&gt;You may donate to BAPAC through the &lt;a href=&quot;https://sfghf.org/support&#45;us/donate/&quot; target=&quot;_blank&quot;&gt;SFGH Foundation&lt;/a&gt;. When completing the donate form, please enter “BAPAC” under OPTIONAL GIFT INFORMATION to assure the donation is routed to our program. Thank you in advance for your generosity!&lt;/p&gt;
			            &lt;p&gt;Many of our mothers need infant clothing and basic baby care items. If you would like to donate, please contact Shannon Weber by email: &lt;a href=&quot;mailto:shannon.weber@ucsf.edu&quot;&gt;shannon.weber@ucsf.edu&lt;/a&gt;.&lt;/p&gt;
			            &lt;h3&gt;BAPAC Items For Sale&lt;/h3&gt;
			            &lt;ul&gt;&lt;li&gt;Blank all occasion note cards with artwork by BAPAC children.&lt;br /&gt;&lt;i&gt;
						Price: $20.00 for set of 12 assorted 4x5 note cards.&lt;/i&gt;&lt;/li&gt;
			           &lt;li&gt;Long&#45;sleeved or short&#45;sleeved shirts and tanks with BAPAC logo, 
			            assorted colors &amp; styles &lt;br /&gt;&lt;i&gt;
			            Price: $15.00 for tank or short sleeves. $20.00 for long sleeves.&lt;/i&gt;&lt;/li&gt;&lt;/ul&gt;
			            &lt;p&gt;To purchase, contact George Louis by 
			            email: &lt;a href=&quot;mailto:george.louis@ucsf.eduu&quot;&gt;george.louis@ucsf.edu&lt;/a&gt;.&lt;/p&gt;
			            &lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Donate ./hiv/care/perinatal/donate.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/perinatal/donate.html~</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;BAPAC is largely funded by charitable donations and sponsored grants.&lt;/p&gt;
			            &lt;p&gt;If you would like to make a tax deductible contribution to BAPAC you may donate online at the &lt;a href=&quot;http://sfghfoundation.net/giving.html&quot; target=&quot;_blank&quot;&gt;SFGH website&lt;/a&gt;. Please specify Bay Area Perinatal AIDS Center when asked for your preference on the donation information form.&lt;/p&gt;
			            &lt;p&gt;Many of our mothers need infant clothing and basic baby care items. If you would like to donate, please contact Shannon Weber by email: &lt;a href=&quot;mailto:sweber@nccc.ucsf.edu&quot;&gt;sweber@nccc.ucsf.edu&lt;/a&gt;.&lt;/p&gt;
			            &lt;h3&gt;BAPAC Items For Sale&lt;/h3&gt;
			            &lt;ul&gt;&lt;li&gt;Blank all occasion note cards with artwork by BAPAC children.&lt;br /&gt;&lt;i&gt;
						Price: $20.00 for set of 12 assorted 4x5 note cards.&lt;/i&gt;&lt;/li&gt;
			           &lt;li&gt;Long&#45;sleeved or short&#45;sleeved shirts and tanks with BAPAC logo, 
			            assorted colors &amp; styles &lt;br /&gt;&lt;i&gt;
			            Price: $15.00 for tank or short sleeves. $20.00 for long sleeves.&lt;/i&gt;&lt;/li&gt;&lt;/ul&gt;
			            &lt;p&gt;To purchase, contact George Lous by 
			            email: &lt;a href=&quot;mailto:louisg@obgyn.ucsf.edu&quot;&gt;louisg@obgyn.ucsf.edu&lt;/a&gt;.&lt;/p&gt;
			            &lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Information ./hiv/care/perinatal/info.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/perinatal/info.html</Path>
		<FileBody>
			
			
			              &lt;h3&gt;If you are a woman who is HIV positive:&lt;/h3&gt;
			              &lt;p &gt;We are here to help.&lt;/p&gt;
			              &lt;p &gt;If you are thinking about becoming 
			                pregnant, we can help you get ready for pregnancy so that you 
			                and your baby can be as healthy as possible and to reduce the 
			                risk of transmission of HIV to your child. We can also discuss 
			                ways for you to become pregnant while reducing the chance of passing 
			                HIV to your partner if he is not infected with HIV.&lt;/p&gt;
			              &lt;p &gt;If you are pregnant now, get health 
			                care for yourself as soon as you know you are pregnant. You can 
			                likely reduce your chance of passing HIV to your baby to less 
			                than 1% by getting health care early in your pregnancy and taking 
			                your antiretroviral medication faithfully. &lt;/p&gt;
			              &lt;p &gt;Your health care team can help you 
			                to stay in the best health so that you can be with your child 
			                as he or she grows up.&lt;/p&gt;
			              &lt;p  &gt;Check out our &lt;a href=&quot;/care/perinatal/links.html&quot;&gt;web 
			                links&lt;/a&gt;. There is a lot of information there for you and your 
			                family. &lt;/p&gt;
			              &lt;p  &gt;If you need to talk with someone, 
			                there is someone who cares. Call one of the hotline numbers in 
			                our &lt;a href=&quot;/care/perinatal/contact.html&quot;&gt;Contacts&lt;/a&gt; section.&lt;/p&gt;
			              &lt;h3&gt;If your partner is HIV positive 
			                and you are HIV negative: &lt;/h3&gt;
			              &lt;p  &gt;We can talk with you about safer ways 
			                to conceive a baby.&lt;/p&gt;
			              &lt;p  &gt;Please look at the &lt;a href=&quot;/care/perinatal/links.html&quot;&gt;links 
			                for patients&lt;/a&gt; so that you can learn about HIV.&lt;/p&gt;
			             
			             
			              &lt;h3&gt;If you are a health care provider:&lt;/h3&gt;
			              &lt;p  &gt;Call the Perinatal Hotline 888&#45;448&#45;8765  for expert clinical consultation 					24/7. &lt;/p&gt;
			              &lt;p  &gt;We are happy to consult with you by phone or e&#45;mail, co&#45;manage patient care, or assume care of patients you refer to us.&lt;/p&gt;
			              &lt;p  &gt;Current USPHS task force recommendations 
			                for the health care of HIV positive pregnant women and their exposed 
			                infants are available at the HIV/AIDS Treatment Information service 
			                website &lt;a target=&quot;_blank&quot; href=&quot;http://www.aidsinfo.nih.gov/&quot;&gt;www.aidsinfo.nih.gov&lt;/a&gt;&lt;/p&gt;
			              &lt;p  &gt;Also please see other useful resources 
			                in our &lt;a href=&quot;/care/perinatal/links.html&quot;&gt;links&lt;/a&gt; section.&lt;/p&gt;
			                
			                
			                
			                
			                
			              &lt;h3&gt;If you are a social worker:&lt;/h3&gt;
			              &lt;p  &gt;Be sure to look at our &lt;a href=&quot;/care/perinatal/links.html&quot;&gt;social 
			                services web links&lt;/a&gt;.&lt;/p&gt;
			              &lt;p  &gt;The BAPAC social worker is also available 
			                to acquaint you with support services for clients with HIV.&amp;nbsp; Send 
			                her an e&#45;mail or give her a call.&lt;/p&gt;
			                &lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Links ./hiv/care/perinatal/links.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/perinatal/links.html</Path>
		<FileBody>
			
			            &lt;h3&gt;For Providers&lt;/h3&gt;
			        
			            &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hiv.ucsf.edu&quot;&gt;hiv.ucsf.edu&lt;/a&gt;&lt;br&gt;
			              The Positive Health Program, a division of University of California 
			              San Francisco's Department of Medicine is BAPAC's parent organization. 
			              Many useful HIV&#45;related resources are available through this site, 
			              including cutting&#45;edge research information and lectures as provided 
			              by expert providers and researchers of the PHP.&lt;/p&gt;
			            &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.amfar.org&quot;&gt;www.amfar.org&lt;/a&gt;&lt;br&gt;
			              American Foundation for AIDS Research maintains information regarding 
			              HIV/AIDS clinical trials. Links available for global trials. &lt;/p&gt;
			            &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.cdc.gov/&quot;&gt;www.cdc.gov&lt;/a&gt;&lt;br&gt;
			              Centers for Disease Control and Prevention provides comprehensive 
			              infectious disease information. HIV/AIDS resources include basic 
			              science information, treatment guidelines, policy, epidemiology, 
			              research, fact sheets, and links. &lt;/p&gt;
			            &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.aidsinfo.nih.gov/&quot;&gt;www.aidsinfo.nih.gov&lt;/a&gt;&lt;br&gt;
			              HIV/AIDS Treatment Information Service (ATIS) provides access to 
			              federally approved HIV/AIDS treatment guidelines. Adult &amp;amp; Adolescent, 
			              Pediatric, Perinatal, Opportunistic Infections, Occupational and 
			              Non&#45;Occupational Exposure and others are updated regularly. Format 
			              for handhelds available. Also has links to other federal health 
			              and infectious disease web sites. &lt;/p&gt;
			            &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.hopkins&#45;aids.edu/&quot;&gt;www.hopkins&#45;aids.edu&lt;/a&gt;&lt;br&gt;
			              Johns Hopkins AIDS Service provides access to publications, expert 
			              opinion, clinical guidelines, HIV epidemiology, links to other sites.&lt;/p&gt;
			            &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.thebodypro.com/&quot;&gt;www.thebodypro.com&lt;/a&gt;&lt;br&gt;
			              Information for healthcare professionals sponsored by The Body, 
			              provides access to expert opinion, clinical trials information, 
			              treatment library, conference coverage, and more. &lt;/p&gt;
			            &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.unaids.org/&quot;&gt;www.unaids.org&lt;/a&gt;&lt;br&gt;
			              United Nations provides a global perspective, providing press releases, 
			              fact sheets, epidemiological information, and publications. Also 
			              available in Spanish, French, and Russian. &lt;/p&gt;
			            &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.hivandhepatitis.com/&quot;&gt;www.hivandhepatitis.com&lt;/a&gt;&lt;br&gt;
			              Information about HIV, hepatitis, and HIV/Hepatitis co&#45;infection. 
			              Access to expert opinion, treatment information, guidelines, and 
			              research. Updated often.&lt;/p&gt;
			            &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/&quot;&gt;http://hivinsite.ucsf.edu&lt;/a&gt;&lt;br&gt;
			              Comprehensive coverage of current HIV/AIDS knowledge including policy, 
			              treatment, research, and prevention from a United States and global 
			              perspective. Some information suitable for patient use.&lt;/p&gt;
			            &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.ivf.com&quot;&gt;www.ivf.com&lt;/a&gt;&lt;br&gt;
			              Georgia Reproductive Specialists provides detailed information regarding 
			              male and female fertility issues and treatments.&lt;br&gt;
			            &lt;/p&gt;
			            &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.who.int/&quot;&gt;www.who.int&lt;/a&gt;&lt;br&gt;
			              See HIV Infection section for HIV information and treatment from 
			              an international perspective.&lt;/p&gt;
			            &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://womenchildrenhiv.org/&quot;&gt;http://womenchildrenhiv.org&lt;/a&gt;&lt;br&gt;
			              Resources on the prevention and treatment of HIV infection in women and children targeted at health workers, program managers, and policy makers in resource&#45;poor settings....The Women, Children, and HIV Web site is the result of a collaboration between the François&#45;Xavier Bagnoud (FXB) Center at the University of Medicine and Dentistry of New Jersey (UMDNJ) and the Center for HIV Information (CHI) at the University of California San Francisco. &lt;/p&gt;  
			              
			              
			            &lt;p  &gt;&lt;b&gt;Rapid HIV Testing for Labor and Delivery&lt;/b&gt;:&lt;/p&gt;
			            &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.sfaetc.ucsf.edu/resources/rtdl_resource_manual/&quot;&gt;http://www.sfaetc.ucsf.edu/resources/rtdl_resource_manual/&lt;/a&gt;&lt;br&gt;
			Online resource manual provided by San Francisco AIDS Education and Training Center to support implementation of rapid HIV testing for hospital labor and delivery units contains sample protocols, forms, infomation about testing kits. &lt;/p&gt; 
			            &lt;a name=&quot;patients&quot;&gt;&lt;/a&gt; &lt;div align=&quot;center&quot;&gt;&lt;img width=&quot;450&quot; height=&quot;2&quot; border=&quot;0&quot; alt=&quot;&quot; src=&quot;images/bar.gif&quot;&gt;&lt;/div&gt;
			            &lt;h3&gt;For Patients&lt;/h3&gt;
			            
			
			            &lt;p  &gt;&lt;b&gt;Family Violence&lt;/b&gt;:&lt;/p&gt;
			            
			              
			            &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.futureswithoutviolence.org/&quot;&gt;http://www.futureswithoutviolence.org/&lt;/a&gt;&lt;br&gt;
			              Information and resources related to family violence.&lt;/p&gt;
			            &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.ndvh.org/&quot;&gt;www.ndvh.org&lt;/a&gt;&lt;br&gt;
			              Resources and help for victims, survivors, and perpetrators of family 
			              violence&lt;/p&gt;
			            &lt;p  &gt;&lt;b&gt;General information&lt;/b&gt;:&lt;/p&gt;
			            &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.thebody.com/&quot;&gt;www.thebody.com&lt;/a&gt;
			              Comprehensive HIV information, access to expert opinion, interactive 
			              forums, designed specifically for patients. Also in Spanish.&lt;/p&gt;
			            &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.projectinform.com/&quot;&gt;www.projectinform.com&lt;/a&gt;&lt;br&gt;Information, 
			              Inspiration and Advocacy for People Living with HIV/AIDS&quot;. 
			              General HIV information, including special section devoted to dealing 
			              with new diagnosis of HIV. Sponsors hotline and hotline training, 
			              publications available by mail and on&#45;line. Information available 
			              in Spanish.&lt;/p&gt;
			             &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.thewellproject.org/&quot;&gt;www.thewellproject.org&lt;/a&gt;&lt;br&gt;
			              The Well Project's mission is to change the course of this HIV/AIDS pandemic through a unique and comprehensive focus on women. In order to reach this goal, we are always working to develop new resources to educate, nurture, and support the community of HIV+ women, their caregivers, and their health care providers.&lt;/p&gt;
			            &lt;p  &gt;&lt;b&gt;Pediatric HIV and hepatitis:&lt;/b&gt;&lt;/p&gt;
			            &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.pkids.org/&quot;&gt;www.pkids.org&lt;/a&gt; 
			              &lt;br&gt;
			              Parents of Kids with Infectious Diseases' site for families who 
			              have a child with HIV/AIDS, hepatitis, and other infectious diseases. 
			              Provides information and opportunity to ask expert opinion. Also 
			              in Spanish and Russian.&lt;/p&gt;
			            &lt;p  &gt;&lt;b&gt;Preconception:&lt;/b&gt;&lt;/p&gt;
			            &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.fertilityplus.org/&quot;&gt;www.fertilityplus.org&lt;/a&gt;&lt;br&gt;
			              &quot;By patients, for patients&quot;, general information regarding 
			              trying to conceive, including explanations of commonly performed 
			              tests. Not specifically for couples affected by HIV, but does give 
			              detailed instructions for &quot;at&#45;home insemination&quot;, a technique 
			              useful for couples with HIV positive woman and HIV negative male 
			              partner.&lt;/p&gt;
			            &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.ucsfivf.org/&quot;&gt;www.ucsfivf.org&lt;/a&gt;&lt;br&gt;
			              University of California San Francisco's web site for infertility 
			              and assisted reproductive techniques such as IVF, IUI. Includes 
			              links to other infertility web sites for patients and professionals.&lt;/p&gt;
			            &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.spermbankdirectory.com&quot;&gt;www.spermbankdirectory.com&lt;/a&gt;&lt;br&gt;
			              National directory of sperm banks for the United States. Some sperm 
			              banks provide international services. &lt;/p&gt;
			            &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.thespermbankofca.org&quot;&gt;www.thespermbankofca.org&lt;/a&gt;&lt;br&gt;
			              Non&#45;profit California agency, non&#45;judgmental services available 
			              nationally and internationally. Web site contains information regarding 
			              the process of using donor sperm and provides answers to many frequently 
			              asked questions. &lt;/p&gt;
			            &lt;p  &gt;&lt;b&gt;Adoption&lt;/b&gt;&lt;/p&gt;
			            &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.adoptionconnection.org&quot;&gt;www.adoptionconnection.org&lt;/a&gt;&lt;br&gt;
			            San Francisco&#45;based adoption agency provides services for adoptive parents and birth parents. This agency is experienced with HIV&#45;infected birth mothers and with HIV&#45;affected parents who wish to adopt.  &lt;/p&gt;
			            &lt;p  &gt;&lt;b&gt;Human Milk Bank&lt;/b&gt;&lt;/p&gt;
			            &lt;p  &gt;&lt;a target=&quot;_blank&quot; href=&quot;http://www.sanjosemilkbank.com/&quot;&gt;www.sanjosemilkbank.com/&lt;/a&gt;&lt;br&gt;
			            Agency provides human human milk from screened donors, based in San Jose, California.&lt;/p&gt;
			            &lt;a name=&quot;social&quot;&gt;&lt;/a&gt; &lt;div align=&quot;center&quot;&gt;&lt;img width=&quot;450&quot; height=&quot;2&quot; border=&quot;0&quot; alt=&quot;&quot; src=&quot;images/bar.gif&quot;&gt;&lt;/div&gt;
			            
			            &lt;h3&gt;Social Services &#45; for Patients &amp;amp; Providers&lt;/h3&gt;
			            
			            &lt;p  &gt;&lt;b&gt;Resources&lt;/b&gt;&lt;/p&gt;
			            &lt;p  &gt; &lt;a href=&quot;http://www.sfhsa.org&quot;  &gt;San Francisco Health and Human Services Agency&lt;/a&gt; provides a range of benefits and services to pregnant women and families.&amp;nbsp; Contact agencies directly for eligibility requirements.
			            &lt;/p&gt;&lt;ul type=&quot;disc&quot;  &gt;
			              &lt;li&gt;WIC &amp;ndash; nutritional      education and food support for pregnant women and children up to 5yrs old.&lt;/li&gt;
			              &lt;li&gt;MediCal &amp;ndash; including full scope coverage and      restricted services for pregnancy &lt;/li&gt;
			              &lt;li&gt;Foodstamps&lt;/li&gt;
			              &lt;li&gt;Calworks&lt;/li&gt;
			            &lt;/ul&gt;&lt;p&gt;&lt;/p&gt;
			            &lt;p  &gt;AIDS Drug Assistance Program &lt;br&gt;
			              Fully funded coverage of HIV medicines for low&#45;income people without MediCal or with limited coverage.&lt;br&gt;
			  &lt;a href=&quot;http://www.phsb.com/patient&quot;&gt;www.phsb.com/patient&lt;/a&gt;&lt;/p&gt;
			            &lt;p  &gt;Project Open Hand&lt;br&gt;
			              Foodbank and meal services for people with financial and medical need.&lt;br&gt;
			  &lt;a href=&quot;http://www.projectopenhand.com/&quot;&gt;www.projectopenhand.com/&lt;/a&gt;&lt;/p&gt;
			            &lt;p  &gt;AIDS Emergency Fund&lt;br&gt;
			              Emergency grants for individuals with disabling HIV.&lt;br&gt;
			  &lt;a href=&quot;http://www.aidsemergencyfund.org/&quot;&gt;http://www.aidsemergencyfund.org/&lt;/a&gt; &lt;/p&gt;
			            &lt;p  &gt;&lt;b&gt;Information and Support Services&lt;/b&gt;&lt;/p&gt;
			            &lt;p  &gt;&lt;em&gt;HIV/AIDS&lt;/em&gt;&lt;/p&gt;
			            &lt;p  &gt;WORLD &amp;ndash; Women Organized to Respond to Life Threatening Illnesses&lt;br&gt;
			              Peer support, education and advocacy for women with HIV.&amp;nbsp; WORLD puts on an annual women’s retreat focused on peer support and relaxation, and produces and distributes a monthly newsletter.&lt;br&gt;
			  &lt;a href=&quot;http://www.womenhiv.org&quot;&gt;www.womenhiv.org&lt;/a&gt;&lt;/p&gt;
			            &lt;p  &gt;Project Inform &lt;br&gt;
			              Up to date treatment information and advocacy for patients with HIV.&amp;nbsp; Has a special section with information and support for people with new diagnosis.&lt;br&gt;
			  &lt;a href=&quot;http://www.projinf.org&quot;&gt;www.projinf.org&lt;/a&gt;&lt;/p&gt;
			            &lt;p  &gt;San Francisco AIDS Foundation&lt;br&gt;
			              Community based services for people living with HIV.&amp;nbsp; Services include a statewide information and support hotline support for patients and providers, support groups, benefits counseling, housing subsidies.&amp;nbsp; &lt;br&gt;
			  &lt;a href=&quot;http://www.sfaf.org&quot;&gt;www.sfaf.org&lt;/a&gt;&lt;/p&gt;
			            &lt;p  &gt;Catholic Charities&lt;br&gt;
			              Support services and programs people of all faiths including children’s programs, housing assistance, meals on wheels and refugee and immigration assistance.&amp;nbsp; Catholic Charities’ Rita da Cascia is a community center and family housing site with case management, therapy and support groups for women and families affected by HIV.&amp;nbsp; &lt;br&gt;
			  &lt;a href=&quot;http://www.cccyo.org&quot;&gt;www.cccyo.org&lt;/a&gt;&lt;/p&gt;
			            &lt;p  &gt;Asian Pacific Islander Wellness Center&lt;br&gt;
			              HIV testing, information, support and case management services for Asian and Pacific Islander communities.&lt;br&gt;
			  &lt;a href=&quot;http://www.apiwellness.org&quot;&gt;www.apiwellness.org&lt;/a&gt;&lt;/p&gt;
			            &lt;p  &gt;Instituto Familiar de la Raza&lt;br&gt;
			              Mental health services in English and Spanish for the Latino community.&amp;nbsp; Special program, Mano a Mano, for people living with HIV.&lt;br&gt;
			              (415) 229&#45;0500&lt;/p&gt;
			            &lt;p  &gt;&lt;em&gt;Pregnancy and Parenting&lt;/em&gt;&lt;/p&gt;
			            &lt;p  &gt;&lt;a href=&quot;http://www.homelessprenatal.org&quot;&gt;www.homelessprenatal.org&lt;/a&gt; &lt;br&gt;
			              Continuum of care and support services for low income or homeless pregnant and parenting women including drop&#45;in center, housing advocacy, employment training, parenting classes, support groups and emergency resources.&lt;/p&gt;
			            &lt;p  &gt;&lt;a href=&quot;http://www.talklineforparents.org&quot;&gt;www.talklineforparents.org&lt;/a&gt; &lt;br&gt;
			              Early intervention services designed to reduce parental stress, enhance parenting skills, and provide ongoing support to families. Services include drop&#45;in center, respite childcare and 24 hour talkline (415) 441&#45;KIDS.&lt;/p&gt;
			            &lt;p  &gt;&lt;a href=&quot;http://www.childrenscouncil.org&quot;&gt;www.childrenscouncil.org&lt;/a&gt; &lt;br&gt;
			              Childcare resource and referral.&lt;/p&gt;
			            &lt;p  &gt;&lt;a href=&quot;http://www.fsasf.org&quot;&gt;http://www.fsasf.org&lt;/a&gt; &lt;br&gt;
			              Mental health and support services for children and families.&amp;nbsp; Services include child and family mental health assessment and treatment, teen pregnancy and parenting educational and support services, childcare and school readiness programs for children at risk. &lt;/p&gt;
			            &lt;p  &gt;&lt;a href=&quot;http://www.apasfgh.org&quot;&gt;www.apasfgh.org&lt;/a&gt; &lt;br&gt;
			              Community and in&#45;home services providing family support to Asian and Pacific Islander children and families with focus on preventing child abuse and domestic violence.&amp;nbsp; &lt;/p&gt;
			            &lt;p  &gt;&lt;em&gt;Domestic Violence&lt;/em&gt;&lt;/p&gt;
			            &lt;p  &gt;National Domestic Violence Hotline&lt;br&gt;
			                &lt;a href=&quot;http://www.ndvh.org&quot;&gt;www.ndvh.org&lt;/a&gt;&lt;br&gt;
			              (800) 799&#45;SAFE (7233)&lt;/p&gt;
			            &lt;p  &gt;WOMAN Inc&lt;br&gt;
			              Hotline with shelter referral and legal advocacy for battered women in San Francisco.&lt;br&gt;
			  &lt;a href=&quot;http://www.womaninc.org&quot;&gt;www.womaninc.org&lt;/a&gt;&lt;/p&gt;
			            &lt;p  &gt;La Casa de Las Madres&lt;br&gt;
			              Emergency shelter and support services for battered women, all services in English and Spanish.&lt;br&gt;
			  &lt;a href=&quot;http://www.lacasa.org&quot;&gt;www.lacasa.org&lt;/a&gt;&lt;/p&gt;
			            &lt;p  &gt;Community United Against Violence (CUAV)&lt;br&gt;
			              Support services and advocacy for victims of violence with a focus on the lesbian, gay, bisexual and transgender communities.&lt;br&gt;
			  &lt;a href=&quot;http://www.cuav.org&quot;&gt;www.cuav.org&lt;/a&gt;&lt;/p&gt;
			            &lt;p  &gt;Family Violence Prevention Fund&lt;br&gt;
			              Information and support for victims of violence and service providers.&lt;br&gt;
			  &lt;a href=&quot;http://www.endabuse.org&quot;&gt;www.endabuse.org&lt;/a&gt;&lt;/p&gt;
			            &lt;p  &gt;LEAP&lt;br&gt;
			              Information for providers including safety planning, violence screening, and mandatory reporting guidelines.&lt;br&gt;
			  &lt;a href=&quot;http://www.leapsf.org&quot;&gt;www.leapsf.org&lt;/a&gt;&lt;/p&gt;
			            
			            &lt;p  &gt;&lt;em&gt;Housing and Homeless Services&lt;/em&gt;&lt;/p&gt;
			            &lt;p  &gt;Compass Community Services/Connecting Point&lt;br&gt;
			              Family shelter referral.&lt;br&gt;
			  &lt;a href=&quot;http://www.compass&#45;sf.org/&quot;&gt;www.compass&#45;sf.org/&lt;/a&gt;&lt;/p&gt;
			            &lt;p  &gt;Hamilton Family Center&lt;br&gt;
			              Emergency food, shelter and support services for families.&lt;br&gt;
			  &lt;a href=&quot;http://www.hamiltonfamilycenter.org&quot;&gt;www.hamiltonfamilycenter.org&lt;/a&gt;&lt;/p&gt;
			          
			            &lt;p  &gt;&lt;em&gt;Legal and Advocacy Services&lt;/em&gt;&lt;/p&gt;
			            &lt;p  &gt;Positive Resource Center&lt;br&gt;
			              Benefits advocacy for people living with HIV.&lt;br&gt;
			  &lt;a href=&quot;http://www.positiveresource.org&quot;&gt;www.positiveresource.org&lt;/a&gt;&lt;/p&gt;
			            &lt;p  &gt;Legal Services for Children&lt;br&gt;
			              Legal advocacy and representation for children and youth.&amp;nbsp; Includes permanency planning and guardianship services for parents with terminal illness. &lt;br&gt;
			  &lt;a href=&quot;http://www.lsc&#45;sf.org&quot;&gt;www.lsc&#45;sf.org&lt;/a&gt;&lt;/p&gt;
			            &lt;p  &gt;AIDS Legal Referral Panel&lt;br&gt;
			              Legal advice and referral for people living with HIV.&lt;br&gt;
			  &lt;a href=&quot;http://www.alrp.org&quot;&gt;www.alrp.org&lt;/a&gt;&lt;/p&gt;
			            &lt;p  &gt;Volunteer Legal Services&lt;br&gt;
			              Pro&#45;bono and sliding scale legal services.&lt;br&gt;
			  &lt;a href=&quot;http://www.sfbar.org&quot;&gt;www.sfbar.org&lt;/a&gt;&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
In the News ./hiv/care/perinatal/news.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/perinatal/news.html</Path>
		<FileBody>
			
						
			&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.kqed.org/a/forum/R201404170900&quot; target=&quot;_blank&quot;&gt;HIV Drug Divides Gay Community&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;
			
			&lt;h3&gt;HIV+ Men wanting children&lt;/h3&gt;
			&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.blogtalkradio.com/dawnmarmorstein/2014/04/10/expanding&#45;reproductive&#45;health&#45;options&#45;for&#45;hiv&#45;affected&#45;individuals&#45;its&#45;time&quot; target=&quot;_blank&quot;&gt;Expanding Reproductive Health Options for HIV&#45;Affected Individuals: It’s Time&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;li&gt;&lt;a href=&quot;http://www.washingtonpost.com/national/health&#45;science/as&#45;mixed&#45;status&#45;hiv&#45;couples&#45;weigh&#45;risks&#45;more&#45;choose&#45;to&#45;conceive&#45;the&#45;old&#45;fashioned&#45;way/2014/04/24/8c8b11a4&#45;b9d4&#45;11e3&#45;96ae&#45;f2c36d2b1245_story.html&quot; target=&quot;_blank&quot;&gt;Mixed&#45;Status HIV Couples Weigh Risks&lt;/a&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/news_docs/sfchron_2013.02.07.pdf&quot;&gt;BAPAC SF Chronicle 2013.02.07 (PDF)&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;/care/perinatal/news_docs/calreport2013.02.15.pdf&quot;&gt;BAPAC California Report 2013.02.15 (PDF)&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;/care/perinatal/news_docs/calreport2013.02.15.mp3&quot;&gt;BAPAC California Report 2013.02.15 (MP3)&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;BAPAC KCBS radio HIV Dads &lt;a href=&quot;/care/perinatal/news_docs/kcbs_hiv_dads&#45;1_2013.01.27.mp3&quot;&gt;#1 (MP3)&lt;/a&gt; &amp; &lt;a href=&quot;/care/perinatal/news_docs/kcbs_hiv_dads&#45;2_2013.01.27.mp3&quot;&gt;#2 (MP3)&lt;/a&gt; 2013.01.27&lt;/a&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;http://www.blogtalkradio.com/dawnmarmorstein/2013/11/16/family&#45;building&#45;and&#45;fertility&#45;options&#45;for&#45;those&#45;living&#45;with&#45;hiv&#45;1&quot; target=&quot;new&quot;&gt;Family&#45;Building and Fertility Options for Those Living with HIV&lt;/a&gt;
			&lt;/li&gt;
			
			&lt;/ul&gt;
			
			&lt;h3&gt;Pre&#45;Exposure Prophylaxis (PrEP)&lt;/h3&gt;
			&lt;ul&gt;
			
			&lt;li&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=tnikU90thCY&amp;list=UUZy7Ay5S1ZC0VrUPnVTUIPw&quot; target=&quot;_blank&quot;&gt;Dr. Bob Grant on what we know and need to know about transgender women and PrEP, 10/12/14&lt;/a&gt;&lt;/li&gt;&lt;li&gt;
			 
			&lt;li&gt;&lt;a href=&quot;http://www.theatlantic.com/health/archive/2014/10/getting&#45;pregnant&#45;when&#45;one&#45;partner&#45;has&#45;hiv/380951/?single_page=true&quot; target=&quot;_blank&quot;&gt;The Atlantic, ‘Getting Pregnant When One Partner Has HIV’, 10/12/14&lt;/a&gt;&lt;/li&gt;&lt;li&gt;
			
			&lt;li&gt;&lt;a href=&quot;http://betablog.org/prep&#45;safe&#45;pregnant&#45;women&#45;hiv&#45;positive&#45;partners/&quot; target=&quot;_blank&quot;&gt;Is PrEP Safe for Pregnant Women with HIV&#45;positive Partners?, 10/02/14&lt;/a&gt;&lt;/li&gt;&lt;li&gt;
			
			&lt;a href=&quot;http://myprepexperience.blogspot.com/2014/09/audio&#45;magnetic&#45;love&#45;and&#45;making&#45;healthy.html&quot; target=&quot;_blank&quot;&gt;My PrEP Experience Blog, 09/30/14&lt;/a&gt;&lt;/li&gt;&lt;li&gt;
			 
			&lt;a href=&quot;https://www.youtube.com/watch?v=mQx4DaN4EXc&amp;feature=em&#45;upload_owner&quot; target=&quot;_blank&quot;&gt;PrEP, Dr. Lealah Pollock and Carolina, 09/30/14, in Spanish&lt;/a&gt;&lt;/li&gt;&lt;li&gt;
			 
			&lt;a href=&quot;http://altijdwat.incontxt.nl/seizoenen/2014/afleveringen/30&#45;09&#45;2014/fragmenten/reportage&#45;prep&quot; target=&quot;_blank&quot;&gt;PrEP, NCRV Dutch Public Television, 09/30/14, in Dutch&lt;/a&gt;&lt;/li&gt;&lt;li&gt;
			 
			&lt;a href=&quot;http://www.bbc.co.uk/programmes/p0275yw7&quot; target=&quot;_blank&quot;&gt;BBC World Service, Would an HIV&#45;preventing Drug Change Your World?’, 09/30/14&lt;/a&gt;&lt;/li&gt;&lt;li&gt;
			 
			&lt;a href=&quot;http://www.avac.org/event/prep&#45;me&#45;please&quot; target=&quot;_blank&quot;&gt;PrEP Me, Please: Understand PrEP's Role in Women's Health &amp; Safer Conception, 09/23/14&lt;/a&gt;&lt;/li&gt;&lt;li&gt;
			&lt;li&gt;&lt;a href=&quot;http://content.sphere.com/articles/positive&#45;news&#45;for&#45;hiv&#45;positive&#45;parents/&quot; target=&quot;_blank&quot;&gt;Positive News for HIV&#45;Positive Parents&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;
			
			&lt;a href=&quot;http://www.ebar.com/news/article.php?sec=news&amp;article=70039&quot; target=&quot;_blank&quot;&gt;Bay Area Reporter 09/25/14:  Supervisor Campos seeks funds for PrEP access&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;
			 
			&lt;a href=&quot;http://www.huffingtonpost.com/shannon&#45;weber/embracing&#45;the&#45;reproductive&#45;rights&#45;of&#45;hiv&#45;affected&#45;couples_b_5774512.html&quot; target=&quot;_blank&quot;&gt;Huffington Post 09/19/214, Embracing the Reproductive Rights of HIV&#45;affected Couples: It's Time&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;
			
			&lt;a href=&quot;https://www.youtube.com/watch?v=GzaiNZXO28g&amp;feature=youtu.be&quot; target=&quot;_blank&quot;&gt;ABC7 News 09/18/14, San Francisco City Hall PrEP Rally&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;
			
			&lt;a href=&quot;http://tinyurl.com/lh9br7u&quot; target=&quot;_blank&quot;&gt;KCSB5 and KCBS Radio News 09/18/14, San Francisco City Hall PrEP Rally&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;
			
			&lt;a href=&quot;http://youtu.be/i35o020KZDI&quot; target=&quot;_blank&quot;&gt;San Francisco City Hall PrEP Rally, 09/18/14&lt;/a&gt;
			&lt;/li&gt;
			
			
			&lt;li&gt;&lt;a href=&quot;http://betablog.org/woman&#45;centered&#45;hiv&#45;prevention/&quot; target=&quot;_blank&quot;&gt;PrEPared to Fight: A Woman&#45;Centered Approach to HIV Prevention&lt;/a&gt;&lt;/li&gt;
			
			&lt;li&gt;&lt;a href=&quot;https://nwhn.org/newsletter/node/1666&quot; target=&quot;_blank&quot;&gt;PrEP&#45;ception: Using PrEP to reduce HIV transmission risk during conception&lt;/a&gt;&lt;/li&gt;
			
			&lt;li&gt;&lt;a href=&quot;http://www.nytimes.com/2013/12/31/health/a&#45;resisted&#45;pill&#45;to&#45;prevent&#45;hiv.html?_r=1&amp;&quot;&gt;Pre&#45;Exposure Prophylaxis (PrEP)&lt;/a&gt;&lt;/li&gt;
			
			&lt;li&gt;&lt;a href=&quot;http://www.avac.org/ht/display/EventDetails/i/52104/TPL/MatDetails/pid/351#&quot; target=&quot;new&quot;&gt;PrEP&#45;ception: Sero&#45;Discordant Couples Using PrEP to Reduce HIV Transmission Risk during Pregnancy&lt;/a&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/news_docs/npr_truvada_2012.07.17.pdf&quot;&gt;NPR 2012.07.17 Deciding On Truvada:  Who Should Take HIV Prevention Pill (PDF)&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;/care/perinatal/news_docs/npr_truvada_2012.07.17.mp3&quot;&gt;NPR 2012.07.17 Deciding On Truvada:  Who Should Take HIV Prevention Pill (MP3)&lt;/a&gt;
			&lt;/li&gt;&lt;/ul&gt;
			
			&lt;h3&gt;Curing of HIV&#45;Positive Child&lt;/h3&gt;
			&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;/sites/hiv.ucsf.edu/files/images/kqed_2013.03.04.pdf&quot;&gt;BAPAC KQED Curing of HIV&#45;Positive Child (PDF)&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;/sites/hiv.ucsf.edu/files/images/kqed_2013.03.04.mp3&quot;&gt;BAPAC KQED Curing of HIV&#45;Positive Child (MP3)&lt;/a&gt;
			&lt;/li&gt;&lt;/ul&gt;
			
			&lt;h3&gt;BAPAC Honored&lt;/h3&gt;
			&lt;ul&gt;&lt;li&gt;
			&lt;/li&gt;&lt;li&gt;San Francisco General Hospital Foundation honors BAPAC&lt;br /&gt;&lt;iframe src=&quot;http://player.vimeo.com/video/61575986&quot; width=&quot;500&quot; height=&quot;281&quot; frameborder=&quot;0&quot; webkitAllowFullScreen mozallowfullscreen allowFullScreen&gt;&lt;/iframe&gt; 
			&lt;/li&gt;
			&lt;/ul&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
In the News ./hiv/care/perinatal/news.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/perinatal/news.html~</Path>
		<FileBody>
			
						
			&lt;h3&gt;HIV+ Men wanting children&lt;/h3&gt;
			&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;/care/perinatal/news_docs/sfchron_2013.02.07.pdf&quot;&gt;BAPAC SF Chronicle 2013.02.07 (PDF)&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;/care/perinatal/news_docs/calreport2013.02.15.pdf&quot;&gt;BAPAC California Report 2013.02.15 (PDF)&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;/care/perinatal/news_docs/calreport2013.02.15.mp3&quot;&gt;BAPAC California Report 2013.02.15 (MP3)&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;BAPAC KCBS radio HIV Dads &lt;a href=&quot;/care/perinatal/news_docs/kcbs_hiv_dads&#45;1_2013.01.27.mp3&quot;&gt;#1 (MP3)&lt;/a&gt; &amp; &lt;a href=&quot;/care/perinatal/news_docs/kcbs_hiv_dads&#45;2_2013.01.27.mp3&quot;&gt;#2 (MP3)&lt;/a&gt; 2013.01.27&lt;/a&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;http://www.blogtalkradio.com/dawnmarmorstein/2013/11/16/family&#45;building&#45;and&#45;fertility&#45;options&#45;for&#45;those&#45;living&#45;with&#45;hiv&#45;1&quot; target=&quot;new&quot;&gt;Family&#45;Building and Fertility Options for Those Living with HIV&lt;/a&gt;
			&lt;/li&gt;
			
			&lt;/ul&gt;
			
			&lt;h3&gt;Pre&#45;Exposure Prophylaxis (PrEP)&lt;/h3&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;http://www.nytimes.com/2013/12/31/health/a&#45;resisted&#45;pill&#45;to&#45;prevent&#45;hiv.html?_r=1&amp;&quot;&gt;Pre&#45;Exposure Prophylaxis (PrEP)&lt;/a&gt;&lt;/li&gt;
			
			&lt;li&gt;&lt;a href=&quot;http://www.avac.org/ht/display/EventDetails/i/52104/TPL/MatDetails/pid/351#&quot; target=&quot;new&quot;&gt;PrEP&#45;ception: Sero&#45;Discordant Couples Using PrEP to Reduce HIV Transmission Risk during Pregnancy&lt;/a&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/news_docs/npr_truvada_2012.07.17.pdf&quot;&gt;NPR 2012.07.17 Deciding On Truvada:  Who Should Take HIV Prevention Pill (PDF)&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;/care/perinatal/news_docs/npr_truvada_2012.07.17.mp3&quot;&gt;NPR 2012.07.17 Deciding On Truvada:  Who Should Take HIV Prevention Pill (MP3)&lt;/a&gt;
			&lt;/li&gt;&lt;/ul&gt;
			
			&lt;h3&gt;Curing of HIV&#45;Positive Child&lt;/h3&gt;
			&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;/sites/hiv.ucsf.edu/files/images/kqed_2013.03.04.pdf&quot;&gt;BAPAC KQED Curing of HIV&#45;Positive Child (PDF)&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;/sites/hiv.ucsf.edu/files/images/kqed_2013.03.04.mp3&quot;&gt;BAPAC KQED Curing of HIV&#45;Positive Child (MP3)&lt;/a&gt;
			&lt;/li&gt;&lt;/ul&gt;
			
			&lt;h3&gt;BAPAC Honored&lt;/h3&gt;
			&lt;ul&gt;&lt;li&gt;
			&lt;/li&gt;&lt;li&gt;San Francisco General Hospital Foundation honors BAPAC&lt;br /&gt;&lt;iframe src=&quot;http://player.vimeo.com/video/61575986&quot; width=&quot;500&quot; height=&quot;281&quot; frameborder=&quot;0&quot; webkitAllowFullScreen mozallowfullscreen allowFullScreen&gt;&lt;/iframe&gt; 
			&lt;/li&gt;
			&lt;/ul&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
PRO Men (Positive Reproductive Outcomes for HIV+ Men) ./hiv/care/perinatal/pro_men.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/perinatal/pro_men.html</Path>
		<FileBody>
			
			
			&lt;h4&gt;Materials&lt;/h4&gt;
			
			&lt;ul&gt;
				
			
						
				&lt;li&gt;&lt;a href=&quot;pro_men/pro_men_newsletter_042013.pdf&quot; target=&quot;_blank&quot;&gt;PRO Men First Year Report&lt;/a&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;pro_men/promen_2nd.pdf&quot; target=&quot;_blank&quot;&gt;PRO Men Second Year Report&lt;/a&gt;&lt;/li&gt;
			
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/resources.html&quot;&gt;Resources for Patients&lt;/a&gt;&lt;/li&gt;
			
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/pro_men/safer_conception_hiv&#45;pos_male_hiv&#45;neg_female_12&#45;4&#45;2013.pdf&quot; target=&quot;new&quot;&gt;Safer Conception for HIV+ Male with HIV&#45; Female (PDF)&lt;/a&gt;
			&lt;/li&gt;
			
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/pro_men/conception&#45;male&#45;female&#45;spanish.pdf&quot;&gt;Concepción más segura para el hombre VIH positive con la mujer VIH negativa (PDF)&lt;/a&gt;
			&lt;/li&gt;
			
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/pro_men/safer_conception_hiv&#45;neg_female_hiv&#45;pos_male_12&#45;4&#45;2013.pdf&quot; target=&quot;new&quot;&gt;Safer Conception for HIV&#45; Female with HIV+ Male (PDF)&lt;/a&gt;
			&lt;/li&gt;
			&lt;/li&gt;
			
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/pro_men/female&#45;male&#45;spanish.pdf&quot;&gt;Concepción más segura para la mujer VIH negativa con el hombre VIH positivo (PDF)&lt;/a&gt;
			
			
			
			&lt;li&gt;&lt;a href=&quot;/sites/hiv.ucsf.edu/files/docs/guide_for_hiv_pos_men.pdf&quot; target=&quot;new&quot;&gt;Preventing pregnancy and HIV: A Guide for HIV&#45;Positive Men (PDF)&lt;/a&gt; &lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/pro_men/web&#45;prevpreg&#45;span.pdf&quot;&gt;Una guía para el hombre VIH Positivo (PDF)&lt;/a&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/pro_men/is_prep_right_for_me_2013&#45;12&#45;11.pdf&quot; target=&quot;new&quot;&gt;Is PrEP Right for Me?  A primer for HIV&#45;negative women (PDF)&lt;/a&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/pro_men/web&#45;prep&#45;hiv&#45;wom&#45;span.pdf&quot;&gt;¿Es la PrEP para mí? (PDF)&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;
			
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/resources.html&quot;&gt;Resources for Providers&lt;/a&gt;
			&lt;/li&gt;
			
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/pro_men/preconception_care_template_hiv&#45;neg_females.doc&quot;&gt;Preconception Care Template for HIV&#45;Negative Females (DOC)&lt;/a&gt; 
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/forproviders/decision&#45;tree&#45;menwomen&#45;06.20.pdf&quot;&gt;Decision Tree for Sexually Active Men and Women (PDF)&lt;/a&gt; 
			&lt;/li&gt;
			&lt;/ul&gt;
			
			
			&lt;/ul&gt;
			
			&lt;h4&gt;Media Coverage&lt;/h4&gt;
			
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;http://positively&#45;negative.squarespace.com/buy&#45;the&#45;book/&quot; target=&quot;_blank&quot;&gt;Positively Negative: Love, Pregnancy, and Science's Surprising Victory Over HIV, by Heather Boerner&lt;/a&gt;&lt;/li&gt;
			
			&lt;li&gt;&lt;a href=&quot;http://fusion.net/video/35740/truvada&#45;increasingly&#45;used&#45;by&#45;women&#45;to&#45;have&#45;children&#45;with&#45;hiv&#45;positive&#45;partners/&quot; target=&quot;_blank&quot;&gt;Poppy &amp; Ted Morgan tell their story to Fusion TV about using PrEP to conceive an HIV&#45;free child, 12/23/14&lt;/a&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;http://www.sfweekly.com/sanfrancisco/aids&#45;hiv&#45;prep&#45;truvada&#45;lgbt/Content?oid=3299283&quot;target=&quot;_blank&quot;&gt;Viral Panic: Fear Has Been Useful in the Fight Against AIDS, Until It Wasn't, SF Weekly 12/16/14&lt;/a&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;http://www.cnn.com/2014/12/01/health/world&#45;aids&#45;day&#45;hiv&#45;family/index.html?iref=allsearch&quot; target=&quot;_blank&quot;&gt;“Building a Family While Living with HIV, CNN Health, 12/01/14”&lt;/a&gt;&lt;/li&gt;
			
			&lt;li&gt;&lt;a href=&quot;http://www.takepart.com/article/2014/12/01/women&#45;and&#45;truvada&quot; target=&quot;_blank&quot;&gt;PrEP, Truvada and Women 12/01/14&lt;/a&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=tnikU90thCY&amp;list=UUZy7Ay5S1ZC0VrUPnVTUIPw&quot; target=&quot;_blank&quot;&gt;Dr. Bob Grant on what we know and need to know about transgender women and PrEP, 10/12/14&lt;/a&gt;&lt;/li&gt;&lt;li&gt;
			 
			&lt;li&gt;&lt;a href=&quot;http://www.theatlantic.com/health/archive/2014/10/getting&#45;pregnant&#45;when&#45;one&#45;partner&#45;has&#45;hiv/380951/?single_page=true&quot; target=&quot;_blank&quot;&gt;The Atlantic, ‘Getting Pregnant When One Partner Has HIV’, 10/12/14&lt;/a&gt;&lt;/li&gt;&lt;li&gt;
			
			&lt;li&gt;&lt;a href=&quot;http://betablog.org/prep&#45;safe&#45;pregnant&#45;women&#45;hiv&#45;positive&#45;partners/&quot; target=&quot;_blank&quot;&gt;Is PrEP Safe for Pregnant Women with HIV&#45;positive Partners?, 10/02/14&lt;/a&gt;&lt;/li&gt;&lt;li&gt;
			
			&lt;a href=&quot;http://myprepexperience.blogspot.com/2014/09/audio&#45;magnetic&#45;love&#45;and&#45;making&#45;healthy.html&quot; target=&quot;_blank&quot;&gt;My PrEP Experience Blog, 09/30/14&lt;/a&gt;&lt;/li&gt;&lt;li&gt;
			 
			&lt;a href=&quot;https://www.youtube.com/watch?v=mQx4DaN4EXc&amp;feature=em&#45;upload_owner&quot; target=&quot;_blank&quot;&gt;PrEP, Dr. Lealah Pollock and Carolina, 09/30/14, in Spanish&lt;/a&gt;&lt;/li&gt;&lt;li&gt;
			 
			&lt;a href=&quot;http://altijdwat.incontxt.nl/seizoenen/2014/afleveringen/30&#45;09&#45;2014/fragmenten/reportage&#45;prep&quot; target=&quot;_blank&quot;&gt;PrEP, NCRV Dutch Public Television, 09/30/14, in Dutch&lt;/a&gt;&lt;/li&gt;&lt;li&gt;
			 
			&lt;a href=&quot;http://www.bbc.co.uk/programmes/p0275yw7&quot; target=&quot;_blank&quot;&gt;BBC World Service, ‘Would an HIV&#45;preventing Drug Change Your World?’, 09/30/14&lt;/a&gt;&lt;/li&gt;&lt;li&gt;
			 
			&lt;a href=&quot;http://www.avac.org/event/prep&#45;me&#45;please&quot; target=&quot;_blank&quot;&gt;PrEP Me, Please: Understand PrEP's Role in Women's Health &amp; Safer Conception, 09/23/14&lt;/a&gt;&lt;/li&gt;&lt;li&gt;
			
			
			&lt;li&gt;&lt;a href=&quot;http://content.sphere.com/articles/positive&#45;news&#45;for&#45;hiv&#45;positive&#45;parents/&quot; target=&quot;_blank&quot;&gt;Positive News for HIV&#45;Positive Parents&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;
			
			&lt;a href=&quot;http://www.ebar.com/news/article.php?sec=news&amp;article=70039&quot; target=&quot;_blank&quot;&gt;Bay Area Reporter 09/25/14:  Supervisor Campos seeks funds for PrEP access&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;
			 
			&lt;a href=&quot;http://www.huffingtonpost.com/shannon&#45;weber/embracing&#45;the&#45;reproductive&#45;rights&#45;of&#45;hiv&#45;affected&#45;couples_b_5774512.html&quot; target=&quot;_blank&quot;&gt;Huffington Post 09/19/214, Embracing the Reproductive Rights of HIV&#45;affected Couples: It's Time&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;
			
			&lt;a href=&quot;https://www.youtube.com/watch?v=GzaiNZXO28g&amp;feature=youtu.be&quot; target=&quot;_blank&quot;&gt;ABC7 News 09/18/14, San Francisco City Hall PrEP Rally&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;
			
			&lt;a href=&quot;http://tinyurl.com/lh9br7u&quot; target=&quot;_blank&quot;&gt;KCSB5 and KCBS Radio News 09/18/14, San Francisco City Hall PrEP Rally&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;
			
			&lt;a href=&quot;http://youtu.be/i35o020KZDI&quot; target=&quot;_blank&quot;&gt;San Francisco City Hall PrEP Rally, 09/18/14&lt;/a&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;http://betablog.org/woman&#45;centered&#45;hiv&#45;prevention/&quot; target=&quot;_blank&quot;&gt;PrEPared to Fight: A Woman&#45;Centered Approach to HIV Prevention&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;https://nwhn.org/newsletter/node/1666&quot;&gt;PrEP&#45;ception: Using PrEP to reduce HIV transmission risk during conception&lt;/a&gt;
			       &lt;/li&gt;&lt;li&gt;&lt;a href=&quot;http://www.blogtalkradio.com/dawnmarmorstein/2014/04/10/expanding&#45;reproductive&#45;health&#45;options&#45;for&#45;hiv&#45;affected&#45;individuals&#45;its&#45;time&quot; target=&quot;_blank&quot;&gt;Expanding Reproductive Health Options for HIV&#45;Affected Individuals:  It’s Time&lt;/a&gt;
			       
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;http://www.kqed.org/a/forum/R201404170900&quot; target=&quot;_blank&quot;&gt;HIV Drug Divides Gay Community&lt;/a&gt;
			      &lt;/li&gt;&lt;li&gt;&lt;a href=&quot;http://www.washingtonpost.com/national/health&#45;science/as&#45;mixed&#45;status&#45;hiv&#45;couples&#45;weigh&#45;risks&#45;more&#45;choose&#45;to&#45;conceive&#45;the&#45;old&#45;fashioned&#45;way/2014/04/24/8c8b11a4&#45;b9d4&#45;11e3&#45;96ae&#45;f2c36d2b1245_story.html&quot; target=&quot;_blank&quot;&gt;Mixed&#45;Status HIV Couples Weigh Risks&lt;/a&gt;
			
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;http://www.thebodypro.com/content/73944/pro&#45;men&#45;a&#45;bay&#45;area&#45;program&#45;providing&#45;reproductive&#45;.html&quot; target=&quot;_blank&quot;&gt;PRO Men: A Bay Area Program Providing Reproductive Health Support for HIV&#45;Positive Men&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/news_docs/croi_2013.pdf&quot;&gt;HIV&#45;Positive Straight Men Alone No More, CROI 2013 Update (PDF)&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/news_docs/sfchron_2013.02.07.pdf&quot;&gt;BAPAC SF Chronicle 2013.02.07 (PDF)&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;/care/perinatal/news_docs/calreport2013.02.15.pdf&quot;&gt;BAPAC California Report 2013.02.15 (PDF)&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;/care/perinatal/news_docs/calreport2013.02.15.mp3&quot;&gt;BAPAC California Report 2013.02.15 (MP3)&lt;/a&gt;
			&lt;/li&gt;
			
			&lt;li&gt;BAPAC KCBS radio HIV Dads &lt;a href=&quot;/care/perinatal/news_docs/kcbs_hiv_dads&#45;1_2013.01.27.mp3&quot;&gt;#1 (MP3)&lt;/a&gt; &amp; &lt;a href=&quot;/care/perinatal/news_docs/kcbs_hiv_dads&#45;2_2013.01.27.mp3&quot;&gt;#2 (MP3)&lt;/a&gt; 2013.01.27&lt;/a&gt;
			&lt;/li&gt;
			
			&lt;li&gt;&lt;a href=&quot;http://www.blogtalkradio.com/dawnmarmorstein/2013/11/16/family&#45;building&#45;and&#45;fertility&#45;options&#45;for&#45;those&#45;living&#45;with&#45;hiv&#45;1&quot; target=&quot;new&quot;&gt;Family&#45;Building and Fertility Options for Those Living with HIV&lt;/a&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;http://blogs.babycenter.com/mom_stories/my&#45;husband&#45;has&#45;hiv&#45;we&#45;had&#45;a&#45;baby&#45;no&#45;were&#45;not&#45;crazy/&quot; target=&quot;new&quot;&gt;HIV&#45;Different Couples&lt;/a&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;http://www.avac.org/event/prep&#45;ception&#45;sero&#45;discordant&#45;couples&#45;using&#45;prep&#45;reduce&#45;hiv&#45;transmission&#45;risk&#45;during&#45;pregnancy&quot; target=&quot;new&quot;&gt;PrEP&#45;ception:  Sero&#45;Discordant Couples Using PrEP to Reduce HIV Transmission Risk during Pregnancy&lt;/a&gt;
			&lt;/li&gt;
			
			
			&lt;/ul&gt;
			&lt;h4&gt;Patient Videos&lt;/h4&gt;
			
			
			&lt;h5&gt;PRO Men Adherence English&lt;/h5&gt;
			
			&lt;iframe src=&quot;//player.vimeo.com/video/85200690&quot; width=&quot;500&quot; height=&quot;281&quot; frameborder=&quot;0&quot; webkitallowfullscreen mozallowfullscreen allowfullscreen&gt;&lt;/iframe&gt; &lt;p&gt;
			Larger video can be seen &lt;a href=&quot;https://vimeo.com/85200690&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			
			&lt;h5&gt;PRO Men Adherence Spanish&lt;/h5&gt;
			&lt;iframe src=&quot;//player.vimeo.com/video/85201209&quot; width=&quot;500&quot; height=&quot;281&quot; frameborder=&quot;0&quot; webkitallowfullscreen mozallowfullscreen allowfullscreen&gt;&lt;/iframe&gt; &lt;p&gt;
			Larger video can be seen &lt;a href=&quot;http://vimeo.com/85201209&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			
			&lt;h5&gt;PRO Men Disclosure&lt;/h5&gt;
			&lt;iframe src=&quot;//player.vimeo.com/video/85201701&quot; width=&quot;500&quot; height=&quot;281&quot; frameborder=&quot;0&quot; webkitallowfullscreen mozallowfullscreen allowfullscreen&gt;&lt;/iframe&gt; &lt;p&gt;
			Larger video can be seen &lt;a href=&quot;http://vimeo.com/85201701&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			
			&lt;h5&gt;Timed Intercourse (HIV&#45;Positive Male)&lt;/h5&gt;
			&lt;iframe src=&quot;http://player.vimeo.com/video/54624505&quot; width=&quot;500&quot; height=&quot;281&quot; frameborder=&quot;0&quot; webkitAllowFullScreen mozallowfullscreen allowFullScreen&gt;&lt;/iframe&gt;&lt;br /&gt;
			&lt;p&gt;Larger video can be seen &lt;a href=&quot;http://vimeo.com/54624505&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			
			&lt;h5&gt;Timed Intercourse (HIV&#45;Negative Female)&lt;/h5&gt;
			
			&lt;iframe class=&quot;image&quot; src=&quot;http://player.vimeo.com/video/52362150&quot; width=&quot;500&quot; height=&quot;240&quot; frameborder=&quot;0&quot; webkitAllowFullScreen mozallowfullscreen allowFullScreen&gt;&lt;/iframe&gt;
			
			&lt;p&gt;Larger video can be seen &lt;a href=&quot;http://vimeo.com/52362150&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			
			&lt;h5&gt;Additional Videos&lt;/h5&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;http://youtu.be/cX4q3xw3UcU&quot; target=&quot;_blank&quot;&gt;Drs. Pooja Mittal and Robert Grant on the PrEP Essentials Pocket Card&lt;/a&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=AinuQPYuQ8Q&amp;list=UUZy7Ay5S1ZC0VrUPnVTUIPw&quot; target=&quot;_blank&quot;&gt;Bay Area Perinatal AIDS Center: Safer Conception Options for HIV+ male/HIV&#45; female couples&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=wOANjpfThp4&quot; target=&quot;_blank&quot;&gt;Dr. Nelly Mugo on PrEP for Women&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;http://youtu.be/dIPq7ALHqUU?list=UUZy7Ay5S1ZC0VrUPnVTUIPw&quot; target=&quot;_blank&quot;&gt;AVAC's Deidre Grant &amp; Mitchell Warren on PrEP for Women&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=&#45;3wvpnWAUN8&quot; target=&quot;_blank&quot;&gt;AVAC's Kevin Fisher &amp; Julie Patterson on PrEP for Women&lt;/a&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;http://youtu.be/vi6Ww0QG8UA&quot; target=&quot;_blank&quot;&gt;SisterLove’s Dazon Dixon Diallo on How Our Language Impacts PrEP for Women&lt;/a&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;http://youtu.be/DEOQpUBHld4&quot; target=&quot;_blank&quot;&gt;Judy Auerbach on PrEP and Women’s Perception of Risk&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
PRO Men (Positive Reproductive Outcomes for HIV+ Men) ./hiv/care/perinatal/pro_men.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/perinatal/pro_men.html~</Path>
		<FileBody>
			
			
			&lt;h4&gt;Materials&lt;/h4&gt;
			
			&lt;ul&gt;
				&lt;li&gt;&lt;a href=&quot;pro_men/pro_men_support_group_poster_flyer_2014.pdf&quot; target=&quot;_blank&quot;&gt;PRO Men Support Group Poster Flyer (PDF)&lt;/a&gt;&lt;/li&gt;
			
						
				&lt;li&gt;&lt;a href=&quot;pro_men/pro_men_newsletter_042013.pdf&quot; target=&quot;_blank&quot;&gt;PRO Men First Year Report&lt;/a&gt;&lt;/li&gt;
			
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/resources.html&quot;&gt;Resources for Patients&lt;/a&gt;&lt;/li&gt;
			
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/pro_men/safer_conception_hiv&#45;pos_male_hiv&#45;neg_female_12&#45;4&#45;2013.pdf&quot; target=&quot;new&quot;&gt;Safer Conception for HIV+ Male with HIV&#45; Female (PDF)&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;/care/perinatal/pro_men/safer_conception_hiv&#45;neg_female_hiv&#45;pos_male_12&#45;4&#45;2013.pdf&quot; target=&quot;new&quot;&gt;Safer Conception for HIV&#45; Female with HIV+ Male (PDF)&lt;/a&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/survey_woman_man.docx&quot;&gt;Survey of HIV&#45;negative women with an HIV&#45;positive man&lt;/a&gt;
			&lt;/li&gt;
			
			&lt;li&gt;&lt;a href=&quot;/sites/hiv.ucsf.edu/files/docs/guide_for_hiv_pos_men.pdf&quot; target=&quot;new&quot;&gt;Preventing pregnancy and HIV: A Guide for HIV&#45;Positive Men&lt;/a&gt; &lt;img src=&quot;images/pdf.gif&quot;&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/pro_men/is_prep_right_for_me_2013&#45;12&#45;11.pdf&quot; target=&quot;new&quot;&gt;Is PrEP Right for Me?  A primer for HIV&#45;negative women&lt;/a&gt;
			 (PDF)&lt;/li&gt;
			&lt;/ul&gt;
			
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/resources.html&quot;&gt;Resources for Providers&lt;/a&gt;
			&lt;/li&gt;
			
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/pro_men/preconception_care_template_hiv&#45;neg_females.doc&quot;&gt;Preconception Care Template for HIV&#45;Negative Females&lt;/a&gt; (DOC)
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/forproviders/decision_tree_women_2013.doc&quot;&gt;Decision Tree for Sexually Active Men and Women&lt;/a&gt; (DOC)
			&lt;/li&gt;
			&lt;/ul&gt;
			
			
			&lt;/ul&gt;
			
			&lt;h4&gt;Media Coverage&lt;/h4&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/news_docs/croi_2013.pdf&quot;&gt;HIV&#45;Positive Straight Men Alone No More, CROI 2013 Update (PDF)&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/news_docs/sfchron_2013.02.07.pdf&quot;&gt;BAPAC SF Chronicle 2013.02.07 (PDF)&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;/care/perinatal/news_docs/calreport2013.02.15.pdf&quot;&gt;BAPAC California Report 2013.02.15 (PDF)&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;/care/perinatal/news_docs/calreport2013.02.15.mp3&quot;&gt;BAPAC California Report 2013.02.15 (MP3)&lt;/a&gt;
			&lt;/li&gt;
			
			&lt;li&gt;BAPAC KCBS radio HIV Dads &lt;a href=&quot;/care/perinatal/news_docs/kcbs_hiv_dads&#45;1_2013.01.27.mp3&quot;&gt;#1 (MP3)&lt;/a&gt; &amp; &lt;a href=&quot;/care/perinatal/news_docs/kcbs_hiv_dads&#45;2_2013.01.27.mp3&quot;&gt;#2 (MP3)&lt;/a&gt; 2013.01.27&lt;/a&gt;
			&lt;/li&gt;
			
			&lt;li&gt;&lt;a href=&quot;http://www.blogtalkradio.com/dawnmarmorstein/2013/11/16/family&#45;building&#45;and&#45;fertility&#45;options&#45;for&#45;those&#45;living&#45;with&#45;hiv&#45;1&quot; target=&quot;new&quot;&gt;Family&#45;Building and Fertility Options for Those Living with HIV&lt;/a&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;http://blogs.babycenter.com/mom_stories/my&#45;husband&#45;has&#45;hiv&#45;we&#45;had&#45;a&#45;baby&#45;no&#45;were&#45;not&#45;crazy/&quot; target=&quot;new&quot;&gt;HIV&#45;Different Couples&lt;/a&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;http://www.avac.org/ht/display/EventDetails/i/52104/TPL/MatDetails/pid/351#&quot; target=&quot;new&quot;&gt;PrEP&#45;ception:  Sero&#45;Discordant Couples Using PrEP to Reduce HIV Transmission Risk during Pregnancy&lt;/a&gt;
			&lt;/li&gt;
			&lt;/ul&gt;
			&lt;h4&gt;Patient Videos&lt;/h4&gt;
			
			
			&lt;h5&gt;PRO Men Adherence English&lt;/h5&gt;
			
			&lt;iframe src=&quot;//player.vimeo.com/video/85200690&quot; width=&quot;500&quot; height=&quot;281&quot; frameborder=&quot;0&quot; webkitallowfullscreen mozallowfullscreen allowfullscreen&gt;&lt;/iframe&gt; &lt;p&gt;
			Larger video can be seen &lt;a href=&quot;https://vimeo.com/85200690&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			
			&lt;h5&gt;PRO Men Adherence Spanish&lt;/h5&gt;
			&lt;iframe src=&quot;//player.vimeo.com/video/85201209&quot; width=&quot;500&quot; height=&quot;281&quot; frameborder=&quot;0&quot; webkitallowfullscreen mozallowfullscreen allowfullscreen&gt;&lt;/iframe&gt; &lt;p&gt;
			Larger video can be seen &lt;a href=&quot;http://vimeo.com/85201209&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			
			&lt;h5&gt;PRO Men Disclosure&lt;/h5&gt;
			&lt;iframe src=&quot;//player.vimeo.com/video/85201701&quot; width=&quot;500&quot; height=&quot;281&quot; frameborder=&quot;0&quot; webkitallowfullscreen mozallowfullscreen allowfullscreen&gt;&lt;/iframe&gt; &lt;p&gt;
			Larger video can be seen &lt;a href=&quot;http://vimeo.com/85201701&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			
			&lt;h5&gt;Timed Intercourse (HIV&#45;Positive Male)&lt;/h5&gt;
			&lt;iframe src=&quot;http://player.vimeo.com/video/54624505&quot; width=&quot;500&quot; height=&quot;281&quot; frameborder=&quot;0&quot; webkitAllowFullScreen mozallowfullscreen allowFullScreen&gt;&lt;/iframe&gt;&lt;br /&gt;
			&lt;p&gt;Larger video can be seen &lt;a href=&quot;http://vimeo.com/54624505&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			
			&lt;h5&gt;Timed Intercourse (HIV&#45;Negative Female)&lt;/h5&gt;
			
			&lt;iframe class=&quot;image&quot; src=&quot;http://player.vimeo.com/video/52362150&quot; width=&quot;500&quot; height=&quot;240&quot; frameborder=&quot;0&quot; webkitAllowFullScreen mozallowfullscreen allowFullScreen&gt;&lt;/iframe&gt;
			
			&lt;p&gt;Larger video can be seen &lt;a href=&quot;http://vimeo.com/52362150&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Resources ./hiv/care/perinatal/resources.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/perinatal/resources.html</Path>
		<FileBody>
			
			&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;/care/perinatal/forproviders/web&#45;prep&#45;providers&#45;2015.02.18.pdf&quot;&gt;Bay Area PrEP Providers Directory, 2015.02.18&lt;/a&gt;&lt;img src=&quot;images/pdf.gif&quot;&gt;
			&lt;/li&gt;&lt;/ul&gt;
			
			
			&lt;h3&gt;For Providers&lt;/h3&gt;
			&lt;ul&gt;
				&lt;li&gt;&lt;a href=&quot;forproviders/antep_list.docx&quot;&gt;Antepartum Care Template&lt;/a&gt; &lt;img src=&quot;images/word_icon.gif&quot;&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;forproviders/pregcare.doc&quot;&gt;BAPAC HIV pregnancy care&lt;/a&gt; &lt;img src=&quot;images/word_icon.gif&quot;&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;forproviders/decision&#45;tree&#45;menwomen&#45;06.20.pdf&quot;&gt;Decision Tree for Sexually Active Men and Women&lt;/a&gt; &lt;img src=&quot;images/pdf.gif&quot;&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;forproviders/hiv&#45;exposed_infant_worksheet_matin_6&#45;2013.pdf&quot;&gt;HIV&#45;exposed infant management&lt;/a&gt; &lt;img src=&quot;images/pdf.gif&quot;&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;/care/perinatal/handouts/web&#45;antepartum.pdf&quot;&gt;MD Orders Maternal Antepartum BAPAC&lt;/a&gt;&lt;img src=&quot;images/pdf.gif&quot;&gt;
				&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;/care/perinatal/handouts/web&#45;intrapartum.pdf&quot;&gt;MD Orders Maternal Intrapartum BAPAC&lt;/a&gt;&lt;img src=&quot;images/pdf.gif&quot;&gt;
				&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;/care/perinatal/handouts/web&#45;postpartum.pdf&quot;&gt;MD Orders Maternal Postpartum BAPAC&lt;/a&gt;&lt;img src=&quot;images/pdf.gif&quot;&gt;
			&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;forproviders/PerinatalHIVMgmtChecklist.doc&quot;&gt;Perinatal HIV Management Checklist&lt;/a&gt; &lt;img src=&quot;images/word_icon.gif&quot;&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;forproviders/preconception_template_female_positive_2012.10.26.doc&quot;&gt;Preconception for HIV Positive Females&lt;/a&gt; &lt;img src=&quot;images/word_icon.gif&quot;&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;/care/perinatal/pro_men/preconception_care_template_hiv&#45;neg_females.doc&quot;&gt;Preconception Care Template for HIV&#45;Negative Females&lt;/a&gt; &lt;img src=&quot;images/word_icon.gif&quot;&gt;&lt;/li&gt;
					&lt;li&gt;&lt;a href=&quot;/care/perinatal/handouts/web&#45;sfgh&#45;fhc&#45;prep&#45;essentials&#45;2015.01.28.pdf&quot;&gt;SFGH Family Health Center PrEP Essentials Pocket Card&lt;/a&gt;&lt;img src=&quot;images/pdf.gif&quot;&gt;&lt;/li&gt;
				
			&lt;/ul&gt;
			
			            
			&lt;h3&gt;For Patients&lt;/h3&gt;
			&lt;ul&gt;
			
			&lt;li&gt;&lt;a href=&quot;forpatients/bapac_prenatal_care_info_english_2012.10.28.doc&quot;&gt;BAPAC Prenatal Care Patient Info&lt;/a&gt; &lt;img src=&quot;images/word_icon.gif&quot;&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;forpatients/BAPACprenatalcareptinfo_Spanish.doc&quot;&gt;BAPAC Prenatal Care Patient Info Spanish&lt;/a&gt; &lt;img src=&quot;images/word_icon.gif&quot;&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/forpatients/breastfeeding&#45;waldron.pdf&quot;&gt;“Breastfeeding for HIV+ Mothers in the US”&lt;/a&gt; &lt;img src=&quot;images/pdf.gif&quot;&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;forpatients/bondingwoutbfeeding.pdf&quot;&gt;Bonding With Baby Without Breastfeeding&lt;/a&gt; &lt;img src=&quot;images/pdf.gif&quot;&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/pro_men/safer_conception_hiv&#45;neg_female_hiv&#45;pos_male_12&#45;4&#45;2013.pdf&quot;&gt;Safer Conception for HIV&#45; Female with HIV+ Male&lt;/a&gt; &lt;img src=&quot;images/pdf.gif&quot;/&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/pro_men/conception&#45;male&#45;female&#45;spanish.pdf&quot;&gt;Concepción más segura para el hombre VIH positive con la mujer VIH negativa &lt;/a&gt;&lt;img src=&quot;images/pdf.gif&quot;/&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/pro_men/safer_conception_hiv&#45;pos_male_hiv&#45;neg_female_12&#45;4&#45;2013.pdf&quot;&gt;Safer Conception for HIV+ Male with HIV&#45; Female&lt;/a&gt; &lt;img src=&quot;images/pdf.gif&quot;/&gt;&lt;/li&gt;
			
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/pro_men/female&#45;male&#45;spanish.pdf&quot;&gt;Concepción más segura para la mujer VIH negativa con el hombre VIH positivo &lt;/a&gt;&lt;img src=&quot;images/pdf.gif&quot;/&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;forpatients/HomeinseminationforHIVfemalediscordantcouple.pdf&quot;&gt;Home insemination for HIV+ female discordant couple&lt;/a&gt; &lt;img src=&quot;images/pdf.gif&quot;&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;forpatients/homeinsemination_hiv_femaledisc_es.pdf&quot; target=&quot;new&quot;&gt;Home insemination for HIV+ female discordant couple&lt;/a&gt; (Spanish) &lt;img src=&quot;images/pdf.gif&quot;&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/pro_men/is_prep_right_for_me_2013&#45;12&#45;11.pdf&quot; target=&quot;new&quot;&gt;Is PrEP Right for Me?: A primer for women considering options to prevent HIV&lt;/a&gt; &lt;img src=&quot;images/pdf.gif&quot;/&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/pro_men/prep_spanish.pdf&quot;&gt;¿Es la PrEP para mí?&lt;/a&gt;&lt;img src=&quot;images/pdf.gif&quot;&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;forpatients/preparing_healthy_pregnancy_2012.doc&quot;&gt;Preparing for a Healthy Pregnancy&lt;/a&gt; &lt;img src=&quot;images/word_icon.gif&quot;&gt;
			&lt;/li&gt;
			
			&lt;li&gt;&lt;a href=&quot;/sites/hiv.ucsf.edu/files/docs/guide_for_hiv_pos_men.pdf&quot; target=&quot;new&quot;&gt;Preventing pregnancy and HIV: A Guide for HIV&#45;Positive Men&lt;/a&gt; &lt;img src=&quot;images/pdf.gif&quot;&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/care/perinatal/pro_men/preg_pos_men_spanish.pdf&quot;&gt;Una guía para el hombre VIH Positivo&lt;/a&gt;&lt;img src=&quot;images/pdf.gif&quot;&gt;&lt;/li&gt;
			&lt;/ul&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Services ./hiv/care/perinatal/services.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/perinatal/services.html</Path>
		<FileBody>
			
			&lt;ul&gt;&lt;li&gt;Preconception counseling for women and concordant/discordant couples, including infertility evaluation
			&lt;/li&gt;&lt;li&gt;Prenatal and postpartum care, including:
			&lt;ul&gt;&lt;li&gt;Outpatient and inpatient high&#45;risk obstetrics in conjunction with SFGH Women's Health Center and UCSF Department of OB/GYN
			&lt;/li&gt;&lt;li&gt;Psychiatry
			&lt;/li&gt;&lt;li&gt;Genetic counseling and testing
			&lt;/li&gt;&lt;li&gt;Nutrition and health education
			&lt;/li&gt;&lt;li&gt;HIV testing for infant(s) and family members
			&lt;/li&gt;&lt;li&gt;Level III Labor and Delivery, Intensive&#45;Care Nursery, and Well&#45;Baby Nursery&lt;/li&gt;&lt;/ul&gt;
			&lt;/li&gt;&lt;li&gt;Full&#45;service gynecologic care including:
			&lt;ul&gt;&lt;li&gt;Colposcopy
			&lt;/li&gt;&lt;li&gt;Contraceptive counseling
			&lt;/li&gt;&lt;li&gt;Outpatient/Inpatient surgery&lt;/li&gt;&lt;/ul&gt;
			&lt;/li&gt;&lt;li&gt;Consultation for providers and patients
			&lt;ul&gt;&lt;li&gt;Twenty&#45;four hour a day coverage&lt;/li&gt;&lt;/ul&gt;
			&lt;/li&gt;&lt;li&gt;Intensive case management, counseling, and social services for clients and their families, including assessment and referral for:
			&lt;ul&gt;&lt;li&gt;Mental health treatment
			&lt;/li&gt;&lt;li&gt;Alcohol/drug treatment including methadone
			&lt;/li&gt;&lt;li&gt;Smoking cessation
			&lt;/li&gt;&lt;li&gt; Housing and transportation
			&lt;/li&gt;&lt;li&gt;Legal services
			&lt;/li&gt;&lt;li&gt;ADAP, Medi&#45;Cal, financial benefits (SSI, TANF, GA)
			&lt;/li&gt;&lt;li&gt;Parenting support and child&#45;care&lt;/li&gt;&lt;/ul&gt;
			&lt;/li&gt;&lt;li&gt;Education
			&lt;ul&gt;&lt;li&gt;In&#45;service trainings on perinatal HIV&lt;/li&gt;&lt;/ul&gt;
			&lt;/li&gt;&lt;li&gt;Access to clinical research
			&lt;/li&gt;&lt;li&gt;Primary Care referral for infected and uninfected family members
			&lt;/li&gt;&lt;/ul&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
BAPAC Team ./hiv/care/perinatal/team.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/perinatal/team.html</Path>
		<FileBody>
			
							&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/deb_cohan2.jpg&quot; class=&quot;image&quot;/&gt;
				Deborah Cohan, MD, MPH; Medical Director&lt;br /&gt;
				
					&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/web&#45;hahn&#45;headshot.jpg&quot; class=&quot;image&quot;/&gt;
				&lt;a href=&quot;mailto:monica.hahn@ucsf.edu&quot;&gt;Monica Hahn, MD&lt;/a&gt;, Lead Clinician&lt;br /&gt;
				
				
					&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/web&#45;harter&#45;headshot.jpg&quot; class=&quot;image&quot;/&gt;
				&lt;a href=&quot;mailto:kristin.harter@sfdph.org&quot;&gt;Kristin Harter&lt;/a&gt;, Pharm.D., Clinical Pharmacist&lt;br /&gt;
				
				
				&lt;img src=&quot;images/george_louis.jpg&quot; class=&quot;image&quot;/&gt;
				&lt;a href=&quot;mailto:George.Louis@ucsf.edu&quot;&gt;George Louis&lt;/a&gt;, Administrative Assistant&lt;br /&gt;
				
				
				
				
				
				
				
				
				
				
				&lt;img src=&quot;images/rebecca_shwartz.jpg&quot; class=&quot;image&quot;/&gt;
				&lt;a href=&quot;mailto:rebecca.schwartz@ucsf.edu&quot;&gt;Rebecca Schwartz&lt;/a&gt;, ACSW; Clinical Social Worker&lt;br&gt;
				
				&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/web&#45;watson&#45;headshot.jpg&quot; class=&quot;image&quot;/&gt;
				Caroline Watson, Social Justice and Reproductive Health Intern&lt;br /&gt;
				
				&lt;img src=&quot;images/shannon_weber.jpg&quot; class=&quot;image&quot;/&gt;
				&lt;a href=&quot;mailto:shannon.weber@ucsf.edu&quot;&gt;Shannon Weber&lt;/a&gt;, MSW; BAPAC Coordinator&lt;br&gt;
				
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
BAPAC Team ./hiv/care/perinatal/team.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/perinatal/team.html~</Path>
		<FileBody>
			
							&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/deb_cohan2.jpg&quot; class=&quot;image&quot;/&gt;
				Deborah Cohan, MD, MPH; Medical Director&lt;br /&gt;
				
				&lt;img src=&quot;images/michelle_khan.jpg&quot; class=&quot;image&quot;/&gt;
				&lt;a href=&quot;mailto:KhanM@globalhealth.ucsf.edu&quot;&gt;Michelle Khan&lt;/a&gt;, MD, MPH; Clinical Fellow&lt;br /&gt;
				
				&lt;img src=&quot;images/george_louis.jpg&quot; class=&quot;image&quot;/&gt;
				&lt;a href=&quot;mailto:louisg@obgyn.ucsf.edu&quot;&gt;George Louis&lt;/a&gt;, MSc&lt;br /&gt;
				
				&lt;img src=&quot;images/ian_mcnicholl.jpg&quot; class=&quot;image&quot;/&gt;
				&lt;a href=&quot;mailto:imcnicholl@php.ucsf.edu&quot;&gt;Ian McNicholl&lt;/a&gt;, Pharm.D, FCCP, BCPS, Pharmacist&lt;br /&gt;
				
				&lt;img src=&quot;images/susan_doula.jpg&quot; class=&quot;image&quot;/&gt;
				Susan Nourse, Doula&lt;br&gt;
				
				&lt;img src=&quot;images/lauren_poole.jpg&quot; class=&quot;image&quot;/&gt;
				&lt;a href=&quot;mailto:lpoole@php.ucsf.edu&quot;&gt;Lauren Poole&lt;/a&gt;, MS, FNP; Family Nurse Practitioner&lt;br&gt;
				
				&lt;img src=&quot;images/rebecca_shwartz.jpg&quot; class=&quot;image&quot;/&gt;
				&lt;a href=&quot;mailto:rschwartz@php.ucsf.edu&quot;&gt;Rebecca Schwartz&lt;/a&gt;, ACSW; Clinical Social Worker&lt;br&gt;
				
				&lt;img src=&quot;images/janell_tryon_doula.jpg&quot; class=&quot;image&quot;/&gt;
				Janell Tryon, Doula&lt;br&gt;
				
				&lt;img src=&quot;images/shannon_weber.jpg&quot; class=&quot;image&quot;/&gt;
				&lt;a href=&quot;mailto: sweber@nccc.ucsf.edu&quot;&gt;Shannon Weber&lt;/a&gt;, MSW; BAPAC Coordinator&lt;br&gt;
				
				&lt;img src=&quot;images/emily_wolfe.jpg&quot; class=&quot;image&quot;/&gt;
				&lt;a href=&quot;mailto:WolfeRoubatise@sfghpeds.ucsf.edu&quot;&gt;Emily Wolfe&#45;Roubatis&lt;/a&gt;, Research Assistant
			
					</FileBody>
	</node>
	<node>
		<Fname>
Video Resources ./hiv/care/perinatal/videores.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/perinatal/videores.html</Path>
		<FileBody>
			
			&lt;h2&gt;For Women&lt;/h2&gt;
			&lt;iframe class=&quot;image&quot; src=&quot;http://player.vimeo.com/video/51461711&quot; width=&quot;500&quot; height=&quot;281&quot; frameborder=&quot;&quot; webkitAllowFullScreen mozallowfullscreen allowFullScreen&gt;&lt;/iframe&gt;
			&lt;p&gt;Larger video can be seen &lt;a href=&quot;https://vimeo.com/51461711&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			&lt;br /&gt;
			
			
			
			&lt;h5&gt;Other Videos&lt;/h5&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=tnikU90thCY&amp;list=UUZy7Ay5S1ZC0VrUPnVTUIPw&quot; target=&quot;_blank&quot;&gt;Dr. Bob Grant on Transgender women and pre&#45;exposure prophylaxis 10/12/14&lt;/a&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=glyOKRBbWGY&quot; target=&quot;_blank&quot;&gt;Renee Heffron:  For Providers &#45; HIV &amp; Hormonal Contraception&lt;/a&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=L&#45;29HeVC51A&quot; target=&quot;_blank&quot;&gt;Renee Heffron:  For Consumers &#45; HIV &amp; Hormonal Contraception&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;
			
			&lt;h2&gt;For Men&lt;/h2&gt;
			
			&lt;iframe class=&quot;image&quot; src=&quot;http://player.vimeo.com/video/54624505&quot; width=&quot;500&quot; height=&quot;281&quot; frameborder=&quot;0&quot; webkitAllowFullScreen mozallowfullscreen allowFullScreen&gt;&lt;/iframe&gt;
			&lt;p&gt;Larger video can be seen &lt;a href=&quot;https://vimeo.com/54624505&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			
			&lt;h2&gt;PRO Men Adherence English&lt;/h2&gt;
			
			&lt;iframe src=&quot;//player.vimeo.com/video/85200690&quot; width=&quot;500&quot; height=&quot;281&quot; frameborder=&quot;0&quot; webkitallowfullscreen mozallowfullscreen allowfullscreen&gt;&lt;/iframe&gt; &lt;p&gt;
			Larger video can be seen &lt;a href=&quot;https://vimeo.com/85200690&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			
			&lt;h2&gt;PRO Men Adherence Spanish&lt;/h2&gt;
			&lt;iframe src=&quot;//player.vimeo.com/video/85201209&quot; width=&quot;500&quot; height=&quot;281&quot; frameborder=&quot;0&quot; webkitallowfullscreen mozallowfullscreen allowfullscreen&gt;&lt;/iframe&gt; &lt;p&gt;
			Larger video can be seen &lt;a href=&quot;http://vimeo.com/85201209&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			
			&lt;h2&gt;PRO Men Disclosure&lt;/h2&gt;
			&lt;iframe src=&quot;//player.vimeo.com/video/85201701&quot; width=&quot;500&quot; height=&quot;281&quot; frameborder=&quot;0&quot; webkitallowfullscreen mozallowfullscreen allowfullscreen&gt;&lt;/iframe&gt; &lt;p&gt;
			Larger video can be seen &lt;a href=&quot;http://vimeo.com/85201701&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			
			
			&lt;h2&gt;Timed Intercourse (HIV Negative Female)&lt;/h2&gt;
			
			&lt;iframe class=&quot;image&quot; src=&quot;http://player.vimeo.com/video/52362150&quot; width=&quot;500&quot; height=&quot;240&quot; frameborder=&quot;0&quot; webkitAllowFullScreen mozallowfullscreen allowFullScreen&gt;&lt;/iframe&gt;
			
			&lt;p&gt;Larger video can be seen &lt;a href=&quot;http://vimeo.com/52362150&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			
			&lt;h2&gt;Timed Intercourse (HIV Positive Female)&lt;/h2&gt;
			
			&lt;iframe class=&quot;image&quot; src=&quot;http://player.vimeo.com/video/52362149&quot; width=&quot;500&quot; height=&quot;240&quot; frameborder=&quot;0&quot; webkitAllowFullScreen mozallowfullscreen allowFullScreen&gt;&lt;/iframe&gt;
			
			&lt;p&gt;Larger video can be seen &lt;a href=&quot;http://vimeo.com/52362149&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			
			&lt;h2&gt;Additional Videos&lt;/h2&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;http://youtu.be/cX4q3xw3UcU&quot; target=&quot;_blank&quot;&gt;Drs. Pooja Mittal and Robert Grant on the PrEP Essentials Pocket Card&lt;/a&gt;&lt;/li&gt;
			
			&lt;li&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=AinuQPYuQ8Q&amp;list=UUZy7Ay5S1ZC0VrUPnVTUIPw&quot; target=&quot;_blank&quot;&gt;Bay Area Perinatal AIDS Center: Safer Conception Options for HIV+ male/HIV&#45; female couples&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=wOANjpfThp4&quot; target=&quot;_blank&quot;&gt;Dr. Nelly Mugo on PrEP for Women&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;http://youtu.be/dIPq7ALHqUU?list=UUZy7Ay5S1ZC0VrUPnVTUIPw&quot; target=&quot;_blank&quot;&gt;AVAC's Deidre Grant &amp; Mitchell Warren on PrEP for Women&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=&#45;3wvpnWAUN8&quot; target=&quot;_blank&quot;&gt;AVAC's Kevin Fisher &amp; Julie Patterson on PrEP for Women&lt;/a&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;http://youtu.be/vi6Ww0QG8UA&quot; target=&quot;_blank&quot;&gt;SisterLove’s Dazon Dixon Diallo on How Our Language Impacts PrEP for Women&lt;/a&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;http://youtu.be/DEOQpUBHld4&quot; target=&quot;_blank&quot;&gt;Judy Auerbach on PrEP and Women’s Perception of Risk&lt;/a&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;http://youtu.be/QST&#45;G3WOKQY&quot; target=&quot;_blank&quot;&gt;Dr. Rana Chakraborty on the Impact of the Mississippi Baby Case&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Video Resources ./hiv/care/perinatal/videores.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/care/perinatal/videores.html~</Path>
		<FileBody>
			
			&lt;h2&gt;For Women&lt;/h2&gt;
			&lt;iframe class=&quot;image&quot; src=&quot;http://player.vimeo.com/video/51461711&quot; width=&quot;500&quot; height=&quot;281&quot; frameborder=&quot;&quot; webkitAllowFullScreen mozallowfullscreen allowFullScreen&gt;&lt;/iframe&gt;
			&lt;br /&gt;
			
			&lt;p&gt;Larger video can be seen &lt;a href=&quot;https://vimeo.com/51461711&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			
			&lt;h2&gt;For Men&lt;/h2&gt;
			
			&lt;iframe class=&quot;image&quot; src=&quot;http://player.vimeo.com/video/54624505&quot; width=&quot;500&quot; height=&quot;281&quot; frameborder=&quot;0&quot; webkitAllowFullScreen mozallowfullscreen allowFullScreen&gt;&lt;/iframe&gt;
			&lt;p&gt;Larger video can be seen &lt;a href=&quot;https://vimeo.com/54624505&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			
			&lt;iframe src=&quot;//player.vimeo.com/video/85200690&quot; width=&quot;500&quot; height=&quot;281&quot; frameborder=&quot;0&quot; webkitallowfullscreen mozallowfullscreen allowfullscreen&gt;&lt;/iframe&gt; &lt;p&gt;
			Larger video can be seen &lt;a href=&quot;https://vimeo.com/85200690&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			
			
			&lt;iframe src=&quot;//player.vimeo.com/video/85201209&quot; width=&quot;500&quot; height=&quot;281&quot; frameborder=&quot;0&quot; webkitallowfullscreen mozallowfullscreen allowfullscreen&gt;&lt;/iframe&gt; &lt;p&gt;
			Larger video can be seen &lt;a href=&quot;http://vimeo.com/85201209&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			
			&lt;iframe src=&quot;//player.vimeo.com/video/85201701&quot; width=&quot;500&quot; height=&quot;281&quot; frameborder=&quot;0&quot; webkitallowfullscreen mozallowfullscreen allowfullscreen&gt;&lt;/iframe&gt; &lt;p&gt;
			Larger video can be seen &lt;a href=&quot;http://vimeo.com/85201701&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			
			
			&lt;h2&gt;Timed Intercourse (HIV Negative Female)&lt;/h2&gt;
			
			&lt;iframe class=&quot;image&quot; src=&quot;http://player.vimeo.com/video/52362150&quot; width=&quot;500&quot; height=&quot;240&quot; frameborder=&quot;0&quot; webkitAllowFullScreen mozallowfullscreen allowFullScreen&gt;&lt;/iframe&gt;
			
			&lt;p&gt;Larger video can be seen &lt;a href=&quot;http://vimeo.com/52362150&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			
			&lt;h2&gt;Timed Intercourse (HIV Positive Female)&lt;/h2&gt;
			
			&lt;iframe class=&quot;image&quot; src=&quot;http://player.vimeo.com/video/52362149&quot; width=&quot;500&quot; height=&quot;240&quot; frameborder=&quot;0&quot; webkitAllowFullScreen mozallowfullscreen allowFullScreen&gt;&lt;/iframe&gt;
			
			&lt;p&gt;Larger video can be seen &lt;a href=&quot;http://vimeo.com/52362149&quot;&gt;HERE&lt;/a&gt;&lt;/p&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Community ./hiv/community/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/community/index.html</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/comm_1.jpg&quot; class=&quot;imgRight&quot; &gt;
			&lt;p class=&quot;introduction&quot;&gt;The Positive Health Program collaborates with multiple providers of services and information to the San Francisco community.  A partial list of our key partners follows.  
			&lt;/p&gt;
			&lt;br clear=all&gt;
			&lt;p&gt;
			&lt;h3&gt;Bay Area Perinatal AIDS Center (BAPAC)&lt;/h3
			&lt;p&gt;
			The Bay Area Perinatal AIDS Center is a key PHP partner, led by Dr. Deborah Cohan. BAPAC provides comprehensive preconception counseling and prenatal care to women and families infected and affected by HIV. Services include prenatal and postpartum care; preconception counseling for women, concordant and discordant couples, including infertility evaluation; full&#45;service gynecological care; intensive case management and social services for clients and their families; access to clinical research; consultation for providers and patients; and in&#45;service trainings on perinatal HIV.
			&lt;/p&gt;
			&lt;p&gt;Please visit &lt;a href=&quot;http://php.ucsf.edu/bapac/index.aspx&quot;&gt;their website&lt;/a&gt; or call (415) 206&#45;8919 for more information.
			&lt;/p&gt;
			
			
			&lt;h3&gt;Family Service Network&lt;/h3&gt;
			&lt;p&gt;The Family Service Network (FSN) is a network of community based organizations throughout San Francisco.  FSN provides comprehensive, coordinated, family&#45;centered care to HIV&#45;infected women of color, children and youth and their affected families.  Member organizations include Walden House, Rita da Cascia Program and Larkin Street Youth Center, among others.  Contact Stephanie Leroux for more information at (415) 476&#45;4082 ext.121.
			&lt;/p&gt;
			
			&lt;h3&gt;The Positive Health Access to Services
			and Treatment (PHAST)&lt;/h3&gt;
			&lt;p&gt;The PHAST program at San Francisco General Hospital emergency focuses on quickly and correctly diagnosing and refering to PHP, those patients emitted to emergency who are in need of specialized HIV/AIDS care.  PHAST is staffed by Positive Health Program professionals and focuses specifically on HIV positive people of color, those with significant psychiatric disease, and those with substance use problems.
			For more information please contact Diane Jones at
			(415) 206&#45;2458 or &lt;a href=&quot;mailto:jfriend@php.ucsf.edu&quot;&gt;djones@php.ucsf.edu&lt;/a&gt;.
			&lt;/p&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Community ./hiv/community/index.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/community/index.html~</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;The Positive Health Program collaborates with multiple providers of services and information to the San Francisco community.  A partial list of our key partners follows.  
			&lt;/p&gt;
			&lt;h3&gt;Bay Area Perinatal AIDS Center (BAPAC)&lt;/h3
			&lt;p&gt;
			The Bay Area Perinatal AIDS Center is a key PHP partner, led by Dr. Deborah Cohan. BAPAC provides comprehensive preconception counseling and prenatal care to women and families infected and affected by HIV. Services include prenatal and postpartum care; preconception counseling for women, concordant and discordant couples, including infertility evaluation; full&#45;service gynecological care; intensive case management and social services for clients and their families; access to clinical research; consultation for providers and patients; and in&#45;service trainings on perinatal HIV.
			&lt;/p&gt;
			&lt;p&gt;Please visit &lt;a href=&quot;http://php.ucsf.edu/bapac/index.aspx&quot;&gt;their website&lt;/a&gt; or call (415) 206&#45;8919 for more information.
			&lt;/p&gt;
			
			
			&lt;h3&gt;Family Service Network&lt;/h3&gt;
			&lt;p&gt;The Family Service Network (FSN) is a network of community based organizations throughout San Francisco.  FSN provides comprehensive, coordinated, family&#45;centered care to HIV&#45;infected women of color, children and youth and their affected families.  Member organizations include Walden House, Rita da Cascia Program and Larkin Street Youth Center, among others.  Contact Stephanie Leroux for more information at (415) 476&#45;4082 ext.121.
			&lt;/p&gt;
			
			&lt;h3&gt;The Positive Health Access to Services
			and Treatment (PHAST)&lt;/h3&gt;&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/comm_1.jpg&quot; class=&quot;imgRight&quot; &gt;
			&lt;p&gt;The PHAST program at San Francisco General Hospital emergency focuses on quickly and correctly diagnosing and refering to PHP, those patients emitted to emergency who are in need of specialized HIV/AIDS care.  PHAST is staffed by Positive Health Program professionals and focuses specifically on HIV positive people of color, those with significant psychiatric disease, and those with substance use problems.
			For more information please contact Diane Jones at
			(415) 206&#45;2458 or &lt;a href=&quot;mailto:jfriend@php.ucsf.edu&quot;&gt;djones@php.ucsf.edu&lt;/a&gt;.
			&lt;/p&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Community Partners ./hiv/community/partners.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/community/partners.html</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/comm_2.jpg&quot; class=&quot;imgRight&quot; &gt;
			&lt;p class=&quot;introduction&quot;&gt;Content goes here.
			&lt;/p&gt;
			&lt;p&gt;Second paragraph.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Volunteering ./hiv/community/volunteering.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/community/volunteering.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;Content goes here.
			&lt;/p&gt;
			&lt;p&gt;Second paragraph.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
UCSF Primary Care Addiction Medicine Fellowship ./hiv/education/addiction-fellowship.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/education/addiction-fellowship.html</Path>
		<FileBody>
			
			
			&lt;p&gt;Welcome to UCSF’s Primary Care Addiction Medicine Fellowship. If you have questions after viewing this page, please don’t hesitate to contact &lt;a href=&quot;mailto:stephen.may@ucsf.edu&quot; target=&quot;_blank&quot;&gt;Stephen May&lt;/a&gt; (Program Coordinator) or &lt;a href=&quot;mailto:paula.lum@ucsf.edu&quot;&gt;Dr. Paula Lum&lt;/a&gt; (Program Director) for more information.&lt;/p&gt;
			&lt;h3&gt;Program Description&lt;/h3&gt;
			&lt;p&gt;The UCSF Primary Care Addiction Medicine Fellowship prepares primary care physicians to become leaders in the care of persons with substance use disorders in the safety net communities of San Francisco. Through a combination of direct patient care, clinical teaching, experiential learning, and scientific inquiry embedded in public sector health care delivery systems, this one&#45;year clinically&#45;focused ambulatory training program combines the resources of the UCSF School of Medicine and the San Francisco Department of Public Health (SFDPH) to offer fellows outstanding opportunities to obtain and demonstrate competence in patient care and the diagnosis, management, and treatment of the spectrum of unhealthy substance use and addiction.&lt;/p&gt;
			
			&lt;p&gt;Fellows, all of whom have completed another primary care residency, will receive training in the knowledge and skills essential for the scope of practice of Addiction Medicine and to develop an identity as an addiction medicine physician. Clinical rotations include community&#45;based outpatient and residential treatment and hospital&#45;based inpatient consultation. Core rotations and continuity clinics emphasize patient&#45;centered communication and the integration of primary care, addiction medicine services, and harm reduction practice and policies for patients with health disparities from urban, low&#45;income, and stigmatized populations. Fellows also select or design electives with their program mentors to either complement their skills and experiences or further develop specific areas of expertise. All trainees will complete an addiction&#45;related mentored scholarly project, either through direct participation in research or by undertaking medical education or clinical practice quality improvement projects that make use of scientific methods.&lt;/p&gt;
			
			&lt;p&gt;The training experiences of fellows are tailored to their individual interests and guided by interprofessional and interdisciplinary program faculty, ten of whom are board&#45;certified in addiction medicine. Program faculty have established relationships with teaching sites that currently include:&lt;/p&gt;
			
			&lt;ol&gt;&lt;li&gt;Public hospital&#45;based ambulatory addiction, primary care, and inpatient services at San Francisco General Hospital
			&lt;/li&gt;&lt;li&gt;A wide range of community&#45;based primary care, case management, sobering, respite, chronic pain, and addiction pharmacotherapy programs sponsored by the San Francisco Department of Public Health
			&lt;/li&gt;&lt;li&gt;Local, non&#45;profit community organizations that provide integrated primary medical care and mental health services, as well as detoxification, residential and outpatient addiction treatment to low&#45;income, uninsured and under&#45;insured, and marginalized people in San Francisco.
			&lt;/li&gt;&lt;/ol&gt;
			
			
			&lt;p&gt;&lt;strong&gt;Sponsoring Institution:&lt;/strong&gt;    University of California San Francisco&lt;br /&gt;
			&lt;strong&gt;Length of Training: &lt;/strong&gt;          One year&lt;br /&gt;
			
			&lt;strong&gt;Total ABAM Foundation Approved Positions:&lt;/strong&gt;      2&lt;br /&gt;
			&lt;strong&gt;Program Director:&lt;/strong&gt;
			&lt;br /&gt;Paula J. Lum, MD, MPH, FASAM&lt;br /&gt;
			Division of HIV, ID and Global Medicine &lt;br /&gt;San Francisco General Hospital&lt;br /&gt; 995 Potrero Avenue, Building 80, Ward 84&lt;br /&gt;
			San Francisco, CA 94110
			&lt;br /&gt;email: &lt;a href=&quot;mailto:paula.lum@ucsf.edu&quot;&gt;paula.lum@ucsf.edu&lt;/a&gt;&lt;br /&gt;
			
			
			
			&lt;/p&gt;
			
			&lt;h3&gt;Eligibility&lt;/h3&gt;
			
			&lt;p&gt;Applicants currently must be board certified or board eligible in Internal Medicine or Family Medicine.  Additionally, applicants must be graduates of, or in the final year of an ACGME accredited clinical residency program.  We are particularly interested in applications from highly&#45;qualified physicians that are underrepresented in medicine. Applications are reviewed on a “rolling basis” prior to the start of the fellowship, which typically begins July 1st.  A full California medical license is required before starting the fellowship.  Possession of a DEA physician waiver or X&#45;license for buprenorphine prescribing is highly encouraged. &lt;/p&gt;
			
			&lt;h3&gt;How to Apply&lt;/h3&gt;
			
			&lt;p&gt;The application process is simple.  We request:&lt;/p&gt;
			
			&lt;ul&gt;&lt;li&gt;A completed &lt;a href=&quot;/sites/hiv.ucsf.edu/files/docs/adm_fellowship_rev2.pdf&quot; target=&quot;_blank&quot;&gt;Application Form&lt;/a&gt;
			&lt;/li&gt;&lt;li&gt;Your current CV
			&lt;/li&gt;&lt;li&gt;A one to two page personal statement describing your interest in primary care addiction medicine and your career goals upon fellowship completion.
			&lt;/li&gt;&lt;li&gt;Three letters of recommendation (LoR): Please use this &lt;a href=&quot;/sites/hiv.ucsf.edu/files/docs/request_form.pdf&quot; target=&quot;_blank&quot;&gt;Reference Request Form&lt;/a&gt; to request your letters of recommendation.
			 &lt;/li&gt;&lt;/ul&gt;
			&lt;p&gt;Please e&#45;mail your CV and Personal Statement to the Fellowship Program Coordinator. Letters of recommendation should be sent directly via e&#45;mail or by mail to:&lt;/p&gt;
			
			&lt;p&gt;Stephen May, Primary Care Addiction Medicine Fellowship Program Coordinator &lt;br /&gt;
			Division of HIV, Infectious Diseases and Global Medicine &lt;br /&gt;
			San Francisco General Hospital &lt;br /&gt;
			Box 0874 &lt;br /&gt;
			University of California, San Francisco &lt;br /&gt;
			San Francisco, CA. 94143&#45;0874 &lt;br /&gt;
			Tel: 415&#45;476&#45;4082 Ext. 138 &lt;br /&gt;
			Fax: 415&#45;502&#45;8662 &lt;br /&gt;
			Email: &lt;a href=&quot;mailto:Stephen.may@ucsf.edu&quot;&gt;stephen.may@ucsf.edu&lt;/a&gt;&lt;/p&gt;
			
			&lt;p&gt;&lt;strong&gt;Deadline:&lt;/strong&gt;&lt;br /&gt;
			We are now accepting applications for the 2018&#45;19 Fellowship.  Applications are reviewed on a rolling basis.  Please submit your application materials no later than &lt;b&gt;January 1st, 2018.&lt;/b&gt;&lt;/p&gt;
			
			&lt;p&gt;&lt;strong&gt;Interviews:&lt;/strong&gt;&lt;br /&gt;
			After a complete application has been received, the Program Director and Selection Committee will review your application and make a decision to offer an interview.  Prospective candidates will meet with the Fellowship Program Director and with faculty member(s) with similar clinical or scholarly interests.  Interviews provide an opportunity to ask questions and learn more about the curriculum and training program.  For a July 1st start date, successful applicants will be notified no later than &lt;b&gt;February 28th, 2018.&lt;/b&gt;&lt;/p&gt;
			
			&lt;p&gt;If you are a physician with a demonstrated commitment to a career integrating evidence&#45;based addiction medicine into the primary care of the urban underserved, we hope you will consider applying to join us.&lt;/p&gt;
			
			&lt;p&gt;Warm regards,&lt;/p&gt;
			
			&lt;p&gt;Paula J. Lum, MD MPH     &lt;br /&gt;
			Program Director          &lt;br /&gt;  &lt;br /&gt;
			
			Stephen May &lt;br /&gt;
			Program Coordinator &lt;br /&gt;
			
			&lt;/p&gt;
			
			
			
			
			
			
			
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Conferences ./hiv/education/c2.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/education/c2.html</Path>
		<FileBody>
			
			&lt;h3&gt;2012 International AIDS Conference, Washington DC, USA&lt;/h3&gt;
			&lt;p style=&quot;margin&#45;top:&#45;10px;&quot;&gt;July 22&#45;27, 2012, Walter E. Washington Convention Center&lt;/p&gt;
			
			&lt;p&gt;AIDS 2012, the 29th Annual International AIDS conference, will bring together leading scientists, public health experts, policy&#45;makers and the HIV&#45;affected community to translate recent momentous scientific advances into action that will address means to end the epidemic, within the current context of significant global economic challenges. The Conference will have a positive impact on the HIV and AIDS response globally, and in the United States and Washington, DC, in particular.  The theme of the conference “Turning the Tide Together” reflects the general sense of optimism around advances in HIV prevention and treatment that can ultimately end the epidemic.
			
			&lt;/p&gt;
			
			&lt;p&gt;The UCSF Positive Health Program&#45;HIV/AIDS Division at SFGH, along with other UCSF divisions, will participate actively with multiple oral and poster presentations at the conference. The conference will be co&#45;chaired by IAS President Dr. Elly Katabira as International Chair, and HIV/AIDS Division Chief Dr. Diane Havlir as the U.S. Co&#45;Chair.   See the full &lt;a href=&quot;http://www.aids2012.org&quot;&gt;conference and registration info here&lt;/a&gt; for the AIDS 2012 conference, go to &lt;/p&gt;
			
			
			&lt;p&gt;For 24 years, PHP has produced the UCSF Medical Management of AIDS conference in San Francisco providing focused, topical HIV clinical education and updates for providers who attend from around the world.&lt;/p&gt;
			
			&lt;p&gt;Topics emphasized include antiretroviral initiation, treatment as prevention, and antiretroviral treatment of highly experienced patients. The course recruits experts in end&#45;organ complications of HIV/AIDS to deliver lectures on bone, cardiovascular, neurological, renal, dermatological, and pulmonary sequalae of infection and treatment. HIV in women, including reproductive issues, will be explored through a lecture and workshop format.  HIV and aging will be emphasized, as will new treatments and paradigms of treating hepatitis C in HIV&#45;infected individuals.  The management and incidence of sexually transmitted diseases (STDs) in HIV&#45;infected patients will be discussed in an engaging case&#45;based format, as will HIV in special populations, such as transgendered individuals and those with addiction disorders.   &lt;/p&gt;
			
			&lt;p&gt;This symposium is presented by the Division of HIV/AIDS – San Francisco General Hospital, Department of Medicine, UCSF, and enrolled and provided CME credits for approximately 250 participants.  &lt;/p&gt;
			
			&lt;p&gt;The conference is chaired by Division Chief and Professor Dr. Diane Havlir and Professor Emeritus Dr. Meg Newman of the Division of HIV/AIDS.  &lt;/p&gt;
			
			&lt;p&gt;See the &lt;a href=&quot;https://www.cme.ucsf.edu/cme/CourseDetail.aspx?coursenumber=MDM13K02&quot;&gt;full schedule and registration information here&lt;/a&gt; for the Medical Management of HIV/AIDS Conference. &lt;/p&gt;
			&lt;p&gt;To see what UCSF researchers, faculty and experts are saying about the conference, check out &lt;a href=&quot;http://aids2012.ucsf.edu/&quot;&gt;our blog&lt;/a&gt;.&lt;/p&gt;
			
			&lt;h3&gt;2012 International AIDS Conference, Washington DC, USA&lt;/h3&gt;
			&lt;p style=&quot;margin&#45;top:&#45;10px;&quot;&gt;July 22&#45;27, 2012, Walter E. Washington Convention Center&lt;/p&gt;
			
			
			&lt;p&gt;An historic development from the conference is the creation of the “Washington DC Declaration,” which seeks to build broad support for bringing an end the AIDS epidemic.  The DC declaration calls for:&lt;/p&gt;
			&lt;ul&gt;&lt;li&gt;An increase in targeted new investments;
			&lt;/li&gt;&lt;li&gt;Evidence&#45;based HIV prevention, treatment and care in accord with the human rights of those at greatest risk and in greatest need;
			&lt;/li&gt;&lt;li&gt;An end to stigma, discrimination, legal sanctions and human rights abuses against those living with and at risk for HIV;
			&lt;/li&gt;&lt;li&gt;Marked increases in HIV testing, counseling and linkages to services;
			&lt;/li&gt;&lt;li&gt;Treatment for all pregnant and nursing women living with HIV and an end to peri&#45;natal transmission;
			&lt;/li&gt;&lt;li&gt;Expanded access to antiretroviral treatment for all in need;
			&lt;/li&gt;&lt;li&gt;Identification, diagnosis and treatment of tuberculosis (TB);
			&lt;/li&gt;&lt;li&gt;Accelerated research on new tools for HIV prevention, treatment, vaccines and a cure;
			&lt;/li&gt;&lt;li&gt;Mobilization and meaningful involvement of affected communities.
			&lt;/li&gt;&lt;/ul&gt;
			
			&lt;p&gt;Everyone is urged to read and sign the DC Declaration at &lt;a href=&quot;http://www.dcdeclaration.org&quot;&gt;www.dcdeclaration.org&lt;/a&gt; or &lt;a href=&quot; http://www.2endaids.org&quot;&gt;www.2endaids.org&lt;/a&gt; , where the full text is available in English, Spanish, French, Portuguese, German, Russian, Chinese, Arabic, Swahili, Japanese, Hindi and Thai.&lt;/p&gt;
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Conferences ./hiv/education/c2.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/education/c2.html~</Path>
		<FileBody>
			
			&lt;h3&gt;Medical Management of HIV/AIDS Conference, San Francisco, CA, USA&lt;/h3&gt;
			&lt;p style=&quot;margin&#45;top:&#45;10px;&quot;&gt;December 6&#45;8, 2012, Westin San Francisco Market Street&lt;/p&gt;
			
			&lt;p&gt;For 24 years, PHP has produced the UCSF Medical Management of AIDS conference in San Francisco providing focused, topical HIV clinical education and updates for providers who attend from around the world.&lt;/p&gt;
			
			&lt;p&gt;Topics emphasized include antiretroviral initiation, treatment as prevention, and antiretroviral treatment of highly experienced patients. The course recruits experts in end&#45;organ complications of HIV/AIDS to deliver lectures on bone, cardiovascular, neurological, renal, dermatological, and pulmonary sequalae of infection and treatment. HIV in women, including reproductive issues, will be explored through a lecture and workshop format.  HIV and aging will be emphasized, as will new treatments and paradigms of treating hepatitis C in HIV&#45;infected individuals.  The management and incidence of sexually transmitted diseases (STDs) in HIV&#45;infected patients will be discussed in an engaging case&#45;based format, as will HIV in special populations, such as transgendered individuals and those with addiction disorders.   &lt;/p&gt;
			
			&lt;p&gt;This symposium is presented by the Division of HIV/AIDS – San Francisco General Hospital, Department of Medicine, UCSF, and enrolled and provided CME credits for approximately 250 participants.  &lt;/p&gt;
			
			&lt;p&gt;The conference is chaired by Division Chief and Professor Dr. Diane Havlir and Professor Emeritus Dr. Meg Newman of the Division of HIV/AIDS.  &lt;/p&gt;
			
			&lt;p&gt;See the &lt;a href=&quot;https://www.cme.ucsf.edu/cme/CourseDetail.aspx?coursenumber=MDM13K02&quot;&gt;full schedule and registration information here&lt;/a&gt; for the Medical Management of HIV/AIDS Conference. &lt;/p&gt;
			&lt;p&gt;To see what UCSF researchers, faculty and experts are saying about the conference, check out &lt;a href=&quot;http://aids2012.ucsf.edu/&quot;&gt;our blog&lt;/a&gt;.&lt;/p&gt;
			
			&lt;h3&gt;2012 International AIDS Conference, Washington DC, USA&lt;/h3&gt;
			&lt;p style=&quot;margin&#45;top:&#45;10px;&quot;&gt;July 22&#45;27, 2012, Walter E. Washington Convention Center&lt;/p&gt;
			
			&lt;p&gt;AIDS 2012, the 29th Annual International AIDS conference, will bring together leading scientists, public health experts, policy&#45;makers and the HIV&#45;affected community to translate recent momentous scientific advances into action that will address means to end the epidemic, within the current context of significant global economic challenges. The Conference will have a positive impact on the HIV and AIDS response globally, and in the United States and Washington, DC, in particular.  The theme of the conference “Turning the Tide Together” reflects the general sense of optimism around advances in HIV prevention and treatment that can ultimately end the epidemic.
			
			&lt;/p&gt;
			
			&lt;p&gt;The UCSF Positive Health Program&#45;HIV/AIDS Division at SFGH, along with other UCSF divisions, will participate actively with multiple oral and poster presentations at the conference. The conference will be co&#45;chaired by IAS President Dr. Elly Katabira as International Chair, and HIV/AIDS Division Chief Dr. Diane Havlir as the U.S. Co&#45;Chair.   See the full &lt;a href=&quot;http://www.aids2012.org&quot;&gt;conference and registration info here&lt;/a&gt; for the AIDS 2012 conference, go to &lt;/p&gt;
			
			&lt;p&gt;An historic development from the conference is the creation of the “Washington DC Declaration,” which seeks to build broad support for bringing an end the AIDS epidemic.  The DC declaration calls for:&lt;/p&gt;
			&lt;ul&gt;&lt;li&gt;An increase in targeted new investments;
			&lt;/li&gt;&lt;li&gt;Evidence&#45;based HIV prevention, treatment and care in accord with the human rights of those at greatest risk and in greatest need;
			&lt;/li&gt;&lt;li&gt;An end to stigma, discrimination, legal sanctions and human rights abuses against those living with and at risk for HIV;
			&lt;/li&gt;&lt;li&gt;Marked increases in HIV testing, counseling and linkages to services;
			&lt;/li&gt;&lt;li&gt;Treatment for all pregnant and nursing women living with HIV and an end to peri&#45;natal transmission;
			&lt;/li&gt;&lt;li&gt;Expanded access to antiretroviral treatment for all in need;
			&lt;/li&gt;&lt;li&gt;Identification, diagnosis and treatment of tuberculosis (TB);
			&lt;/li&gt;&lt;li&gt;Accelerated research on new tools for HIV prevention, treatment, vaccines and a cure;
			&lt;/li&gt;&lt;li&gt;Mobilization and meaningful involvement of affected communities.
			&lt;/li&gt;&lt;/ul&gt;
			
			&lt;p&gt;Everyone is urged to read and sign the DC Declaration at &lt;a href=&quot;http://www.dcdeclaration.org&quot;&gt;www.dcdeclaration.org&lt;/a&gt; or &lt;a href=&quot; http://www.2endaids.org&quot;&gt;www.2endaids.org&lt;/a&gt; , where the full text is available in English, Spanish, French, Portuguese, German, Russian, Chinese, Arabic, Swahili, Japanese, Hindi and Thai.&lt;/p&gt;
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
The Clinical Edge ./hiv/education/clinical_edge.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/education/clinical_edge.html</Path>
		<FileBody>
			
			
			&lt;p class=&quot;introduction&quot;&gt;The Clinical Edge is a series of brief commentaries on topics of current interest in HIV care, prevention, and policy from the faculty of the UCSF HIV/AIDS Division at San Francisco General Hospital. It is sponsored by &lt;a href=&quot;http://hivinsite.com/&quot; target=_&quot;blank&quot;&gt;HIV InSite&lt;/a&gt;.&lt;/p&gt;
			
			&lt;p&gt;The Division's faculty members have been at the forefront of HIV care and research for more than 30 years. Our practice at SFGH's Ward 86 is the first multidisciplinary outpatient clinic in the world dedicated to the care of patients with HIV/AIDS.&lt;/p&gt;
			
			&lt;p&gt;Please be advised that the authors' views are their own and are not intended to provide medical advice for specific patients.&lt;/p&gt;
			
			&lt;h3 style=&quot;margin&#45;bottom:0px;&quot;&gt;&lt;a href=&quot;http://hivinsite.ucsf.edu/InSite?page=md&#45;expert&#45;spinelli&quot; target=&quot;_blank&quot;&gt;Undetectable Equals Untransmittable&lt;/a&gt;&lt;/h3&gt;
			January 2018
			&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/matthew.spinelli&quot; target=&quot;_blank&quot;&gt;Drs. Matthew Spinelli&lt;/a&gt; and &lt;a href=&quot;http://profiles.ucsf.edu/monica.gandhi&quot; target=&quot;_blank&quot;&gt;Monica Gandhi&lt;/a&gt; examine the evidence that persons living with HIV who have undetectable viral loads on effective antiretroviral treatment have effectively no risk of passing the virus to an uninfected partner.&lt;/p&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Community Education ./hiv/education/community.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/education/community.html</Path>
		<FileBody>
			
			
			&lt;p class=&quot;introduction&quot;&gt;The UCSF HIV/AIDS Division at San Francisco General Hospital has hosted a number of community education events throughout the years to update the public on new advances or policy changes in HIV management.   &lt;/p&gt;
			
			&lt;p&gt; As part of the Division’s attempts to further educate the public on the enormous advances in HIV management and policy over the past five years, we will organize a course for the community through &lt;a href=&quot;http://ucsfcme.com/minimedicalschool/&quot;&gt;UCSF’s “Mini Medical School for the Public” program&lt;/a&gt; in winter of 2012. For more details on the course, please contact the HIV/AIDS Division’s Education Director, Monica Gandhi MD at  &lt;a href=&quot;mailto:monica.gandhi@ucsf.edu&quot;&gt;monica.gandhi@ucsf.edu&lt;/a&gt;.   &lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Conferences ./hiv/education/conferences.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/education/conferences.html</Path>
		<FileBody>
			
			&lt;h3 style=&quot;margin&#45;bottom:0px;&quot;&gt;Medical Management of HIV/AIDS and Hepatitis Conference&lt;/h2&gt;
			San Francisco, CA, USA
			&lt;br /&gt;&lt;br /&gt;&lt;p class=&quot;introduction&quot;&gt;Each year, PHP produces the UCSF Medical Management of HIV/AIDS and Hepatitis, a 3&#45;day continuing medical education (CME) conference held in San Francisco. The conference provides focused, topical education and updates on HIV and viral hepatitis for  clinicians who attend from around the world. Lectures and workshops are presented by leading clinicians and researchers in the field. &lt;/p&gt;
			
			&lt;p&gt;Each year’s topics reflect recent advances and discoveries and are geared at a range of HIV providers, from novice to advanced. HIV topics highlighted at this past year’s conference include HIV prevention, preexposure prophylaxis (PrEP), antiretroviral management, and reproductive health. Presentations on hepatitis C and B emphasized new treatment options for coinfected patients. A focus on end organ diseases (cardiovascular, dermatologic, bone, endocrine), other infections (STDs, HPV), and primary care management of HIV patients was woven throughout the course.&lt;/p&gt;
			
			&lt;p&gt;This symposium is presented by the Division of HIV/AIDS, San Francisco General Hospital, Department of Medicine, UCSF, and enrolls and provides CME credits for approximately 300 participants. It is chaired by Division Chief and Professor Dr. Diane Havlir, Associate Professor Emeritus Dr. Meg Newman, and Associate Professor Dr. Annie Luekemeyer, all of the Division of HIV/AIDS.&lt;/p&gt;
			
			&lt;p&gt;See the &lt;a href=&quot;http://www.ucsfcme.com/2016/MDM16K02/info.html&quot; target=&quot;_blank&quot;&gt;schedule and registration information&lt;/a&gt; for the 2015 Medical Management of HIV/AIDS Conference.&lt;/p&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Conferences ./hiv/education/conferences.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/education/conferences.html~</Path>
		<FileBody>
			
			&lt;h3&gt;2012 International AIDS Conference, Washington DC, USA&lt;/h3&gt;
			
			&lt;p style=&quot;margin&#45;top:&#45;10px;&quot;&gt;July 22&#45;27, 2012, Walter E. Washington Convention Center&lt;/p&gt;
			
			
			&lt;p&gt;AIDS 2012, the 29th Annual International AIDS conference, will bring together leading scientists, public health experts, policy&#45;makers and the HIV&#45;affected community to translate recent momentous scientific advances into action that will address means to end the epidemic, within the current context of significant global economic challenges. The Conference will have a positive impact on the HIV and AIDS response globally, and in the United States and Washington, DC, in particular. The theme of the conference .Turning the Tide Together. reflects the general sense of optimism around advances in HIV prevention and treatment that can ultimately end the epidemic. &lt;/p&gt;
			
			&lt;p&gt;
			The UCSF Positive Health Program&#45;HIV/AIDS Division at SFGH, along with other UCSF divisions, will participate actively with multiple oral and poster presentations at the conference. The conference will be co&#45;chaired by IAS President Dr. Elly Katabira as International Chair, and HIV/AIDS Division Chief Dr. Diane Havlir as the U.S. Co&#45;Chair. See the full &lt;a href=&quot;http://www.aids2012.org&quot;&gt;conference and registration info here&lt;/a&gt; for the AIDS 2012 conference.
			&lt;/p&gt;
			&lt;p&gt;
			
			An historic development from the conference is the creation of the
			&lt;a href=&quot;http://www.2endaids.org/&quot;&gt;Washington DC Declaration&lt;/a&gt; which seeks to build broad support for
			bringing an end the AIDS epidemic. The DC declaration calls for:
			
			&lt;ul&gt;
			&lt;li&gt; An increase in targeted new investments; 
			&lt;li&gt; Evidence&#45;based HIV prevention, treatment and care in accord with the human rights of those at greatest risk and in greatest need; 
			&lt;li&gt; An end to stigma, discrimination, legal sanctions and human rights abuses against those living with and at risk for HIV; 
			&lt;li&gt; Marked increases in HIV testing, counseling and linkages to services; 
			&lt;li&gt; Treatment for all pregnant and nursing women living with HIV and an end to peri&#45;natal transmission; 
			&lt;li&gt; Expanded access to antiretroviral treatment for all in need; 
			&lt;li&gt; Identification, diagnosis and treatment of tuberculosis (TB); 
			&lt;li&gt; Accelerated research on new tools for HIV prevention, treatment, vaccines and a cure; 
			&lt;li&gt; Mobilization and meaningful involvement of affected communities. 
			&lt;/ul&gt;
			&lt;/p&gt;
			
			&lt;p&gt;Everyone is urged to read and sign the DC Declaration at &lt;a href=&quot;http://www.dcdeclaration.org&quot;&gt;www.dcdeclaration.org&lt;/a&gt; or &lt;a href=&quot; http://www.2endaids.org&quot;&gt;www.2endaids.org&lt;/a&gt; , where the full text is available in English, Spanish, French, Portuguese, German, Russian, Chinese, Arabic, Swahili, Japanese, Hindi and Thai.&lt;/p&gt;
			&lt;p&gt;To see what UCSF researchers, faculty and experts are saying about the conference, check out &lt;a href=&quot;http://aids2012.ucsf.edu/&quot;&gt;our blog&lt;/a&gt;.&lt;/p&gt;
			
			&lt;p&gt;For 24 years, PHP has produced the UCSF Medical Management of AIDS conference in San Francisco providing focused, topical HIV clinical education and updates for providers who attend from around the world.&lt;/p&gt;
			
			&lt;p&gt;Topics emphasized include antiretroviral initiation, treatment as prevention, and antiretroviral treatment of highly experienced patients. The course recruits experts in end&#45;organ complications of HIV/AIDS to deliver lectures on bone, cardiovascular, neurological, renal, dermatological, and pulmonary sequalae of infection and treatment. HIV in women, including reproductive issues, will be explored through a lecture and workshop format.  HIV and aging will be emphasized, as will new treatments and paradigms of treating hepatitis C in HIV&#45;infected individuals.  The management and incidence of sexually transmitted diseases (STDs) in HIV&#45;infected patients will be discussed in an engaging case&#45;based format, as will HIV in special populations, such as transgendered individuals and those with addiction disorders.   &lt;/p&gt;
			
			&lt;p&gt;This symposium is presented by the Division of HIV/AIDS – San Francisco General Hospital, Department of Medicine, UCSF, and enrolled and provided CME credits for approximately 250 participants.  &lt;/p&gt;
			
			&lt;p&gt;The conference is chaired by Division Chief and Professor Dr. Diane Havlir and Professor Emeritus Dr. Meg Newman of the Division of HIV/AIDS.  &lt;/p&gt;
			
			&lt;p&gt;See the &lt;a href=&quot;https://www.cme.ucsf.edu/cme/CourseDetail.aspx?coursenumber=MDM13K02&quot;&gt;full schedule and registration information here&lt;/a&gt; for the Medical Management of HIV/AIDS Conference. &lt;/p&gt;
			&lt;p&gt;To see what UCSF researchers, faculty and experts are saying about the conference, check out &lt;a href=&quot;http://aids2012.ucsf.edu/&quot;&gt;our blog&lt;/a&gt;.&lt;/p&gt;
			
			&lt;h3&gt;2012 International AIDS Conference, Washington DC, USA&lt;/h3&gt;
			&lt;p style=&quot;margin&#45;top:&#45;10px;&quot;&gt;July 22&#45;27, 2012, Walter E. Washington Convention Center&lt;/p&gt;
			
			&lt;p&gt;AIDS 2012, the 29th Annual International AIDS conference, will bring together leading scientists, public health experts, policy&#45;makers and the HIV&#45;affected community to translate recent momentous scientific advances into action that will address means to end the epidemic, within the current context of significant global economic challenges. The Conference will have a positive impact on the HIV and AIDS response globally, and in the United States and Washington, DC, in particular.  The theme of the conference &quot;Turning the Tide Together&quot; reflects the general sense of optimism around advances in HIV prevention and treatment that can ultimately end the epidemic.
			
			&lt;/p&gt;
			
			&lt;p&gt;The UCSF Positive Health Program&#45;HIV/AIDS Division at SFGH, along with other UCSF divisions, will participate actively with multiple oral and poster presentations at the conference. The conference will be co&#45;chaired by IAS President Dr. Elly Katabira as International Chair, and HIV/AIDS Division Chief Dr. Diane Havlir as the U.S. Co&#45;Chair.   See the full &lt;a href=&quot;http://www.aids2012.org&quot;&gt;conference and registration info here&lt;/a&gt; for the AIDS 2012 conference.&lt;/p&gt;
			
			
			&lt;p&gt;Everyone is urged to read and sign the DC Declaration at &lt;a href=&quot;http://www.dcdeclaration.org&quot;&gt;www.dcdeclaration.org&lt;/a&gt; or &lt;a href=&quot; http://www.2endaids.org&quot;&gt;www.2endaids.org&lt;/a&gt; , where the full text is available in English, Spanish, French, Portuguese, German, Russian, Chinese, Arabic, Swahili, Japanese, Hindi and Thai.&lt;/p&gt;
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Nursing, Pharmacy and Medical Assistant Education ./hiv/education/educators.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/education/educators.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;Since the beginning of the HIV epidemic in San Francisco, UCSF nurses and nurse practitioners have been leaders in the care and management of persons living with HIV and AIDS.  &lt;/p&gt;
			
			&lt;p&gt;Through a collaboration with the &lt;a href=&quot;http://nursing.ucsf.edu/&quot;&gt;UCSF School of Nursing&lt;/a&gt; and supported by a federal training grant in association with the Positive Health Practice, students in the Master's Entry Program in Nursing (MEPN) and Clinical Nurse Specialist (CNS) Program can gain clinical experience in HIV primary and specialty care at Ward 86, the HIV Clinic at San Francisco General Hospital.  For more details on the HIV training programs for nurse practitioner students, please contact Suzan Stringari&#45;Murray NP at  &lt;a href=&quot;mailto:suzan.stringari&#45;murray@nursing.ucsf.edu&quot;&gt;suzan.stringari&#45;murray@nursing.ucsf.edu&lt;/a&gt;.   For more details on the UCSF HIV CNS Program at Ward 86, please contact Carol Dawson RN PhD at &lt;a href=&quot;Carol.dawson&#45;rose@nursing.ucsf.edu&quot; target=&quot;blank&quot;&gt;Carol.dawson&#45;rose@nursing.ucsf.edu&lt;/a&gt;. Additional information about UCSF’s prestigious International Center for HIV/AIDS Research and Clinical Training in Nursing can be found on the &lt;a href=&quot;http://nursing.ucsf.edu/international&#45;center&#45;hivaids&#45;research&#45;and&#45;clinical&#45;training&#45;nursing&quot; target=&quot;_blank&quot;&gt;School of Nursing website&lt;/a&gt;.&lt;/p&gt;
			
			&lt;p&gt;Students in the registered nurse (RN) program at the &lt;a href=&quot;http://www.usfca.edu/nursing/&quot; target=&quot;_blank&quot;&gt;University of San Francisco&lt;/a&gt; as well as students in various medical assistant programs from around the Bay Area receive valuable experience through on&#45;site and hands&#45;on training programs on Ward 86.  For more details on the RN training program, as well as the phlebotomy and medical assistant training programs at Ward 86, please contact Roland Zepf MS, RN, ACRN at &lt;a href=&quot;mailto:rzepf@php.ucsf.edu&quot;&gt;rzepf@php.ucsf.edu&lt;/a&gt;.&lt;/p&gt; 
			
			&lt;p&gt;Clinical pharmacy services within the HIV/AIDS Division are directed by Ian McNicholl PharmD, Associate Professor in the &lt;a href=&quot;http://pharmacy.ucsf.edu/&quot; target=&quot;_blank&quot;&gt;School of Pharmacy at UCSF&lt;/a&gt;.  Clinical pharmacists provide extensive counseling to HIV&#45;infected patients in the Positive Health Practice on medication adherence, smoking cessation, drug&#45;drug interactions and use of concomitant medications.  The Positive Health Practice also offers an intensive opportunity for postgraduate year 1 (PGY1) pharmacy residents and 4th year pharmacy students to actively participate and undergo training in the comprehensive health care of HIV&#45;positive patients on Ward 86. In addition, Clinical Pharmacy is responsible for updating the HIV InSite ARV Drug Interactions database, providing drug consults, participating in HIV and aging polypharmacy research, and providing continuing medical education from SFGH HIV/AIDS Grand Rounds to presentations at major national Infectious Diseases meetings.  For more details on pharmacy education at the Positive Health Practice, please contact Dr. McNicholl at &lt;a href=&quot;mailto:imcnicholl@php.ucsf.edu&quot;&gt;imcnicholl@php.ucsf.edu&lt;/a&gt;.&lt;/p&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Nursing, Pharmacy and Medical Assistant Education ./hiv/education/educators.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/education/educators.html~</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;Since the beginning of the HIV epidemic in San Francisco, UCSF nurses and nurse practitioners have been leaders in the care and management of persons living with HIV and AIDS.  &lt;/p&gt;
			
			&lt;p&gt;Through a collaboration with the &lt;a href=&quot;http://nursing.ucsf.edu/&quot;&gt;UCSF School of Nursing&lt;/a&gt; and supported by a federal training grant in association with the Positive Health Practice, students in the Master's Entry Program in Nursing (MEPN) and Clinical Nurse Specialist (CNS) Program can gain clinical experience in HIV primary and specialty care at Ward 86, the HIV Clinic at San Francisco General Hospital.  For more details on the HIV training programs for nurse practitioner students, please contact Suzan Stringari&#45;Murray NP at  &lt;a href=&quot;mailto:suzan.stringari&#45;murray@nursing.ucsf.edu&quot;&gt;suzan.stringari&#45;murray@nursing.ucsf.edu&lt;/a&gt;.   For more details on the UCSF HIV CNS Program at Ward 86, please contact Carol Dawson RN PhD at &lt;a href=&quot;Carol.dawson&#45;rose@nursing.ucsf.edu&quot; target=&quot;blank&quot;&gt;Carol.dawson&#45;rose@nursing.ucsf.edu&lt;/a&gt;. Additional information about UCSF’s prestigious International Center for HIV/AIDS Research and Clinical Training in Nursing can be found on the &lt;a href=&quot;http://nursing.ucsf.edu/international&#45;center&#45;hivaids&#45;research&#45;and&#45;clinical&#45;training&#45;nursing&quot; target=&quot;_blank&quot;School of Nursing website&lt;/a&gt;.&lt;/p&gt;
			
			&lt;p&gt;Students in the registered nurse (RN) program at the &lt;a href=&quot;http://www.usfca.edu/nursing/&quot; target=&quot;_blank&quot;&gt;University of San Francisco&lt;/a&gt; as well as students in various medical assistant programs from around the Bay Area receive valuable experience through on&#45;site and hands&#45;on training programs on Ward 86.  For more details on the RN training program, as well as the phlebotomy and medical assistant training programs at Ward 86, please contact Roland Zepf MS, RN, ACRN at &lt;a href=&quot;mailto:rzepf@php.ucsf.edu&quot;&gt;rzepf@php.ucsf.edu&lt;/a&gt;.&lt;/p&gt; 
			
			&lt;p&gt;Clinical pharmacy services within the HIV/AIDS Division are directed by Ian McNicholl PharmD, Associate Professor in the &lt;a href=&quot;http://pharmacy.ucsf.edu/&quot; target=&quot;_blank&quot;&gt;School of Pharmacy at UCSF&lt;/a&gt;.  Clinical pharmacists provide extensive counseling to HIV&#45;infected patients in the Positive Health Practice on medication adherence, smoking cessation, drug&#45;drug interactions and use of concomitant medications.  The Positive Health Practice also offers an intensive opportunity for postgraduate year 1 (PGY1) pharmacy residents and 4th year pharmacy students to actively participate and undergo training in the comprehensive health care of HIV&#45;positive patients on Ward 86. In addition, Clinical Pharmacy is responsible for updating the HIV InSite ARV Drug Interactions database, providing drug consults, participating in HIV and aging polypharmacy research, and providing continuing medical education from SFGH HIV/AIDS Grand Rounds to presentations at major national Infectious Diseases meetings.  For more details on pharmacy education at the Positive Health Practice, please contact Dr. McNicholl at &lt;a href=&quot;mailto:imcnicholl@php.ucsf.edu&quot;&gt;imcnicholl@php.ucsf.edu&lt;/a&gt;.&lt;/p&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
HIV Clinical Fellowship ./hiv/education/fellowship.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/education/fellowship.html</Path>
		<FileBody>
			&lt;div style=&quot;float:right;width:128px;margin&#45;left:15px;&quot;&gt;
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/edu_2.jpg&quot; class=&quot;image&quot;&gt;
			&lt;p class=&quot;caption&quot;&gt;Dr. Meg Newman, former Director of the Education Program, and Dr. Royce Lin, Fellowship graduate.&lt;/p&gt;
			&lt;/div&gt;
			
			&lt;p class=introduction&gt;To address the very real and imminent  &lt;a
			href=&quot;http://www.ucsf.edu/news/2011/12/11065/coming&#45;dearth&#45;doctors&#45;who&#45;specialize&#45;hiv&#45;aids&quot;&gt;workforce
			shortage&lt;/a&gt; of HIV providers in the United States, the HIV/AIDS Division at SFGH offers a one&#45;year intensive, applied medical training program in HIV clinical care.&lt;/p&gt;
			&lt;p&gt;
			Initiated in 2004, this competitive one&#45;year HIV clinical fellowship leverages the teaching skills and expertise of our forty full&#45;time and affiliated faculty in HIV primary care and sub&#45;specialty care to train fellows in the clinical care of HIV&#45;infected adults. Fellows rotate through a variety of primary care and specialty care clinics at SFGH, as well as the HIV inpatient consult service, gaining experience in managing complications and comorbidities of HIV. Fellows are trained in management of antiretroviral therapy, opportunistic infections, and viral hepatitis; other areas of focus include HIV&#45;related dermatologic, pulmonary, psychiatric, neurologic, metabolic, and cardiovascular comorbidities.
			&lt;/p&gt; 
			
			
			&lt;div style=&quot;float:right;width:128px;&quot;&gt;
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/sombredero.jpg&quot; class=&quot;image&quot;&gt;
			&lt;p class=&quot;caption&quot;&gt;Alisson Sombredero, MD&lt;/p&gt;
			&lt;/div&gt;
			
			&lt;p&gt; 
			
			The &lt;strong&gt;UCSF HIV Clinical Scholar's Fellowship&lt;/strong&gt; is distinct from traditional academic training programs in Infectious Diseases, and can be completed in just one year. We emphasize the training of front&#45;line clinicians who will become leaders in their chosen field within HIV medicine. Graduates of our fellowship provide HIV expertise, care, and leadership in a variety of community settings. 
			
			 &lt;/p&gt; &lt;p&gt;
			
			The 2016&#45;2017 HIV clinical fellow is funded by the &lt;a href=&quot;https://www.hivma.org/HIVMA_Clinical_Fellowship.aspx&quot; target=&quot;_blank&quot;&gt;HIV Medical Association (HIVMA)'s Clinical Fellowship&lt;/a&gt;, and our fellowship currently is restricted to those eligible for the HIVMA program. The HIVMA Clinical Fellowship is intended to train HIV clinicians who are committed to caring for underserved minority HIV&#45;infected patients. 
			&lt;/p&gt; &lt;p&gt;
			For more information, please contact Stephen May at &lt;a href=&quot;mailto:smay@php.ucsf.edu&quot;&gt;smay@php.ucsf.edu&lt;/a&gt; (or Susa Coffey, MD, at &lt;a href=&quot;mailto:scoffey@php.ucsf.edu&quot;&gt;scoffey@php.ucsf.edu&lt;/a&gt;).
			
			&lt;/p&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
HIV Clinical Fellowship ./hiv/education/fellowship.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/education/fellowship.html~</Path>
		<FileBody>
			&lt;div style=&quot;float:right;width:128px;&quot;&gt;
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/edu_2.jpg&quot; class=&quot;image&quot;&gt;
			&lt;p class=&quot;caption&quot;&gt;Dr. Meg Newman, former Director of the Education Program, and Dr. Royce Lin, Fellowship graduate.&lt;/p&gt;
			&lt;/div&gt;
			
			&lt;p class=introduction&gt;To address the very real and imminent &lt;a
			href=&quot;http://www.ucsf.edu/news/2011/12/11065/coming&#45;dearth&#45;doctors&#45;who&#45;specialize&#45;hiv&#45;aids&quot;&gt;workforce
			shortage&lt;/a&gt; of HIV providers in the United States, the HIV/AIDS Division at SFGH has created a one&#45;year intensive, applied medical training program in HIV management.&lt;/p&gt;
			&lt;p&gt;
			Initiated in 2004, this competitive HIV clinical fellowship leverages the teaching skills and expertise of our forty full&#45;time and affiliated faculty in HIV primary care and sub&#45;specialty care to train a fellow in the infectious, malignant, dermatologic, psychiatric, neurologic, renal, cardiovascular metabolic and endocrinologic complications of HIV. The fellow rotates through a variety of primary care and specialty care clinics at SFGH, as well as the HIV inpatient consult service for approximately half of the year.
			&lt;/p&gt; 
			&lt;div style=&quot;float:right;width:128px;&quot;&gt;
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/sombredero.jpg&quot; class=&quot;image&quot;&gt;
			&lt;p class=&quot;caption&quot;&gt;Alisson Sombredero, MD&lt;/p&gt;
			&lt;/div&gt;
			
			&lt;p&gt;
			
			Distinct from traditional academic training programs in Infectious Diseases, the &lt;strong&gt;UCSF HIV Clinical Scholar's Fellowship&lt;/stonrg&gt; can be completed in just one year. We ultimately emphasize the training of front&#45;line clinicians who will become leaders in their chosen field within HIV medicine. The HIV/AIDS Division has graduated five fellows, all providing HIV expertise, care and leadership in a variety of community settings, from its full&#45;time clinical fellowship program, in addition to training multiple other Infectious Diseases fellows on a part&#45;time basis through the years. The 2012&#45;13 HIV clinical fellow at SFGH was Alisson Sombredero MD, a recipient of the HIV Medical Association (HIVMA)'s prestigious Minority Clinical Fellowship Scholarship.
			&lt;/p&gt; &lt;p&gt; 
			
			The 2013&#45;2014 HIV clinical fellow (Michael Martinez MD) is also funded
			through HIVMA's Minority fellowship program. Due to lack of funds, the
			HIV clinical fellowship at SFGH is currently restricted to those
			eligible for the &lt;a href=&quot;http://www.hivma.org/Minority_Clinical_Fellowship.aspx&quot;&gt;Minority Clinical Fellowship Scholarship&lt;/a&gt;, but the
			Division continues to actively seek funds from a generous donor
			willing to sponsor this important training opportunity in order to
			expand its scope.
			
			 &lt;/p&gt; &lt;p&gt;
			
			For more information, contact Steve May at &lt;a href=&quot;mailto:smay@php.ucsf.edu&quot;&gt;smay@php.ucsf.edu&lt;/a&gt; (or
			Monica Gandhi, MD at &lt;a href=&quot;mailto:Monica.Gandhi@ucsf.edu&quot;&gt;Monica.Gandhi@ucsf.edu&lt;/a&gt;)
			
			&lt;/p&gt; &lt;p&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
HIV Clinical Fellowship ./hiv/education/fellowship_old.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/education/fellowship_old.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;To address the very real and imminent &lt;a href=&quot;http://www.ucsf.edu/news/2011/12/11065/coming&#45;dearth&#45;doctors&#45;who&#45;specialize&#45;hiv&#45;aids&quot;&gt;workforce shortage&lt;/a&gt; of HIV providers in the United States, the HIV/AIDS Division at SFGH has created a one&#45;year intensive, applied medical training program in HIV management.  &lt;/p&gt;
			
			&lt;p&gt;Initiated in 2004, this competitive HIV clinical fellowship leverages the teaching skills and expertise of our forty full&#45;time and affiliated faculty in HIV primary care and sub&#45;specialty care to train a fellow in the infectious, malignant, dermatologic, psychiatric, neurologic, renal, cardiovascular metabolic and endocrinologic complications of HIV.  The fellow rotates through a variety of primary care and specialty care clinics at SFGH, as well as the HIV inpatient consult service for approximately half of the year.     &lt;/p&gt;
			
			&lt;p&gt;Distinct from traditional academic training programs in Infectious Diseases, the &lt;b&gt;UCSF HIV Clinical Scholar’s Fellowship&lt;/b&gt; can be completed in just one year.  We ultimately emphasize the training of front&#45;line clinicians who will become leaders in their chosen field within HIV medicine.   The HIV/AIDS Division has graduated four fellows, all providing HIV expertise, care and leadership in a variety of community settings, from its full&#45;time clinical fellowship program, in addition to training multiple other Infectious Diseases fellows on a part&#45;time basis through the years. The current 2012&#45;13 HIV clinical fellow at SFGH is Alisson Sombredero MD, a recipient of the HIV Medical Association (HIVMA)’s prestigious  &lt;a href=&quot;http://www.hivma.org/Minority_Clinical_Fellowship.aspx&quot;&gt;Minority Clinical Fellowship Scholarship&lt;/a&gt;.  &lt;/p&gt;
			
			&lt;h3&gt;Former HIV Clinical Scholars&lt;/h3&gt;
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/loftus.jpg&quot; class=&quot;imgLeft&quot;&gt;
			&lt;p&gt;Dr. Loftus completed his B.A. at Yale University and M.D. and internal medicine residency at UCSF.  He applied to the HIV Clinical Scholars program because he saw in the faculty a “shared passion to save lives and prioritize advocacy.” After completing the fellowship, Dr. Loftus established an HIV specialty practice at Davies Medical Center.  He is now in private practice for a large HIV&#45;infected population at the Eisenhower Health Center in Palm Springs, California, continuing to work on education and advocacy efforts to supplement the HIV workforce.&lt;/p&gt;
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/lin.jpg&quot; class=&quot;imgLeft&quot;&gt;
			&lt;p&gt;Dr. Lin completed his B.A. at Harvard University, M.D. at Yale, and internal medicine residency at UCSF, Dr. Lin applied for the HIV Clinical Scholars program because “it was the only program that offered training with the most experienced and recognized faculty of HIV clinical practitioners in the world.” Dr. Lin was formerly co&#45;director of ASPIRE (AIDS Services – Prevention, Intervention, Research, and Education), an international program providing training to clinicians throughout Africa.  He now serves impoverished HIV&#45;infected patients full&#45;time in a San Francisco&#45;based community health center (Tom Waddell Health Center).&lt;/p&gt;
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/wong.jpg&quot; class=&quot;imgLeft&quot;&gt;
			&lt;p&gt;Dr. Wong went to Brown University for her B.A. and M.D. degrees and completed an internal medicine residency at UCSF.  She now provides HIV primary care to underserved communities in Northern California – including Asians and non&#45;English speaking immigrants&#45; and serves as the medical director for a foundation focusing on expansion of HIV services in China.  &lt;/p&gt;
			
			
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/grieco.jpg&quot; class=&quot;imgLeft&quot;&gt;
			&lt;p&gt;Dr. Grieco received her undergraduate degree from Wittenberg University and then spent a year working with battered and homeless women through AmeriCorps.  She earned a Doctor of Osteopathy from the University of New England College of Osteopathic Medicine, and completed a residency in Family Practice at St. Joseph Medical Center.  She came to the UCSF HIV Clinical Scholars Fellowship seeking “concentrated training in HIV medicine, not just in treatment regimens and resistance testing, but in prevention and psychosocial factors”. Dr. Grieco is currently enrolled in a fellowship in addiction medicine at Yale University, after which she plans to enter a community&#45;based practice serving those dually diagnosed with HIV and addiction.&lt;/p&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
HIV Grand Rounds ./hiv/education/grandrounds.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/education/grandrounds.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;The Division’s weekly HIV/AIDS Grand Rounds is a continuing medical education (CME)&#45;accredited educational event targeted to HIV providers from San Francisco General Hospital, affiliated Community Health Network clinics, local hospital based HIV clinics and HIV private practices in the Bay area. We are accredited through the University of California, San Francisco Office of CME (ACCME Provider number 0000302). &lt;/p&gt; 
			
			&lt;p&gt;Weekly lectures and discussions provide participants with the latest clinical, diagnostic, research and treatment information regarding the pathogenesis and management of HIV disease. As a Center of Excellence for HIV/AIDS care in the Bay Area and a top tier academic institution, the HIV Division is uniquely positioned to host this rigorous, state&#45;of&#45;the&#45;art Grand Rounds series focused on HIV issues relevant to current practice. 
			
			&lt;/p&gt; 
			
			&lt;p&gt;Speakers include HIV Division faculty as well as other invited physicians, researchers and HIV care providers. Lectures are an engaging blend of clinical case conferences, report&#45;backs from important HIV meetings, updates on current HIV research, and subspecialty reviews of the optimal management of particular aspects of HIV disease. 
			
			&lt;/p&gt;
			
			&lt;p&gt;Selected lectures are taped and webcast on the leading HIV education and news website, &lt;a href=&quot;www.hivinsite.org&quot; target=&quot;_blank&quot;&gt;HIVInsite&lt;/a&gt;.&lt;/p&gt;
			
			
			&lt;p&gt;Please see &lt;a href=&quot;/about/calendar.html&quot;&gt;our calendar&lt;/a&gt; for our current Grand Rounds schedule.&lt;/p&gt;
			
			&lt;p&gt;For more information please contact  James Hunger at (415) 476&#45;4082 ext. 424 or at &lt;a href=&quot;mailto:james.hunger@ucsf.edu&quot;&gt;james.hunger@ucsf.edu&lt;/a&gt;. &lt;/p&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
HIV Grand Rounds ./hiv/education/grandrounds.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/education/grandrounds.html~</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;The Division’s weekly HIV/AIDS Grand Rounds is a continuing medical education (CME)&#45;accredited educational event targeted to HIV providers from San Francisco General Hospital, affiliated Community Health Network clinics, local hospital based HIV clinics and HIV private practices in the Bay area. We are accredited through the University of California, San Francisco Office of CME (ACCME Provider number 0000302). &lt;/p&gt; 
			
			&lt;p&gt;Weekly lectures and discussions provide participants with the latest clinical, diagnostic, research and treatment information regarding the pathogenesis and management of HIV disease. As a Center of Excellence for HIV/AIDS care in the Bay Area and a top tier academic institution, the HIV Division is uniquely positioned to host this rigorous, state&#45;of&#45;the&#45;art Grand Rounds series focused on HIV issues relevant to current practice. 
			
			&lt;/p&gt; 
			
			&lt;p&gt;Speakers include HIV Division faculty as well as other invited physicians, researchers and HIV care providers. Lectures are an engaging blend of clinical case conferences, report&#45;backs from important HIV meetings, updates on current HIV research, and subspecialty reviews of the optimal management of particular aspects of HIV disease. 
			
			&lt;/p&gt;
			
			&lt;p&gt;Selected lectures are taped and webcast on the leading HIV education and news website, &lt;a href=&quot;www.hivinsite.org&quot; target=&quot;_blank&quot;&gt;HIVInsite&lt;/a&gt;.&lt;/p&gt;
			
			
			&lt;p&gt;Please see our calendar for our current &lt;a href=&quot;/about/calendar.html&quot;&gt;Grand Rounds schedule&lt;/a&gt;.&lt;/p&gt;
			
			&lt;p&gt;For more information please contact Elena Jensen at (415) 476&#45;4082 ext. 123 or at &lt;a href=&quot;mailto:jensene@php.ucsf.edu&quot;&gt;jensene@php.ucsf.edu&lt;/a&gt;. &lt;/p&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Education ./hiv/education/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/education/index.html</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/edu_1.jpg&quot; class=&quot;imgRight&quot; style=&quot;margin&#45;bottom:10px;&quot;&gt;
			&lt;p class=&quot;introduction&quot;&gt;We are committed to educating fellow HIV providers, junior faculty, postdoctoral scholars, residents, students, patients and the community at large.  &lt;/p&gt;
			&lt;p&gt;We host a one&#45;year HIV clinical fellowship program for internists committed to providing HIV care to underserved populations. The fellowship offers advanced physician training in inpatient and outpatient settings, with intensive mentoring by our faculty clinicians. We also offer a one&#45;year Primary Care Addiction Medicine fellowship program.  The fellowship trains primary care physicians to become leaders in the care, diagnosis, management, and treatment of persons from urban, low&#45;income, and stigmatized populations along the spectrum of unhealthy substance use and addiction. We organize HIV electives for UCSF residents and students, and host visiting scholars from the U.S. and abroad. Our weekly Grand Rounds lectures are open to the public and feature clinical case conferences and conference report&#45;backs; select sessions are webcast on HIVInsite (hivinsite.ucsf.edu). Our annual Medical Management of AIDS conference, taught by expert clinicians, draws regional, national and international health care professionals (cme.ucsf.edu). We also provide short&#45;term intensive training for medical professionals and students; training delegations to date include China, Côte d’Ivoire, Egypt, Uganda and Tanzania.&lt;/p&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Education ./hiv/education/index_old.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/education/index_old.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;To help educate fellow providers, junior faculty, students, patients, and the community at large, the UCSF Positive Health Program at San Francisco General Hospital offers several educational programs dedicated to practical health care training. 
			&lt;/p&gt;
			&lt;p&gt;As the Program's reputation has grown, so have requests from clinicians and researchers for curricula and seminars tailored specifically to their needs. In response, PHP education offerings continue to evolve. Today we provide a variety of opportunities for onsite training with our faculty and clinicians for weeks or for years. We also host symposia and seminars designed for diverse participants, locally and globally. &lt;/p&gt;
			
			&lt;p&gt;PHP is dedicated to the ongoing refinement and extension of its education programs and to reaching the broadest and most diverse audiences. In so doing, PHP seeks to enable others to advance their own missions of excellence in research and care.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
HIV InSite ./hiv/education/insite.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/education/insite.html</Path>
		<FileBody>
			
			
			&lt;p class=&quot;introduction&quot;&gt;The HIV InSite website provides comprehensive, up&#45;to&#45;date information on HIV/AIDS treatment, prevention, and policy from UCSF and is edited by Dr. Susa Coffey, faculty within the HIV/AIDS Division at SFGH. &lt;/p&gt;
			
			&lt;p&gt;Visited by more than a million viewers annually and updated daily, this website provides a living document of HIV clinical and research findings.  A particularly helpful and visited feature of the website includes the interactive database called the “Antiretroviral (ARV) Drug Interactions Database” to help clinicians identify key drug&#45;drug interactions between ARVs and other medications or supplements.  Other popular features include the comprehensive “ARV Profiles for Clinicians” and the daily digest of up&#45;to&#45;date research and policy findings in HIV medicine.   For more details, please go to &lt;a href=&quot;http://hivinsite.com/InSite&quot;&gt;HIV InSite website&lt;/a&gt;. &lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Medical Student &amp; Resident Education ./hiv/education/medical.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/education/medical.html</Path>
		<FileBody>
			
			
			
			&lt;h3&gt;Medical Student Education&lt;/h3&gt;  The UCSF HIV/AIDS Division at San Francisco General Hospital (SFGH) participates in educational initiatives at UCSF at all levels of medical student training.  The Education Director of the HIV/AIDS Division, Dr. Monica Gandhi, co&#45;directs the international and public health small group sections of the Infection, Immunity and Inflammation course for second year medical students at UCSF, with an emphasis on HIV global epidemiology.  The Division participates in the 1st and 2nd year medical student elective entitled the “Student AIDS Forum” to deliver introductory lectures on HIV epidemiology and management to interested students. 
			
			&lt;/p&gt; 
			
			&lt;p&gt;The HIV/AIDS Division also organizes MED 140.13 (Care of the Patient with AIDS), a clinical elective for 3rd and 4th year UCSF and visiting medical students in HIV medicine.  Students rotate through the HIV/AIDS Consult Service at San Francisco General  Hospital, which supplies HIV expertise and consultation to inpatient providers on a variety of services (e.g. Medicine, Surgery, Family Practice, Obstetrics/Gynecology, etc.), as well as support and education to patients and their families.   Highly focused on student learning, this elective provides an opportunity for students interested in learning HIV medicine to participate actively in the consultation and management of HIV&#45;infected patients at SFGH.  For more information on the medical student elective, visit the &lt;a href=&quot;http://medschool.ucsf.edu/curriculum/clinical/electives/specialty.aspx&quot;&gt;School of Medicine site&lt;/a&gt;. &lt;/p&gt; 
			
			&lt;h3&gt;Resident Education&lt;/h3&gt;
			&lt;p&gt;The HIV/AIDS Division at SFGH provides a variety of educational experiences for UCSF medical residents, as well as visiting residents from national and international training programs.  The faculty in the HIV Division provide a series of lectures for the UCSF medical residents as part of their outpatient and inpatient core curriculum training.  HIV Division faculty attend on the medical wards at SFGH approximately 10 months of the year, providing intensive inpatient teaching on HIV medicine for students and residents rotating through the wards.  Finally, the HIV/AIDS Division directs 2H&#45;HIV, the HIV clinical elective for interns and residents in the UCSF Medical Residency program for housestaff interested in obtaining specialty training in HIV medicine.  Open also to visiting residents, this elective provides mostly outpatient training in our large, public outpatient HIV clinic (“Ward 86”) at SFGH, along with outpatient experiences at the HIV Clinic at the UCSF&#45;Parnassus campus and a variety of San Francisco Public Health&#45;funded community clinics throughout San Francisco.  For more details on the resident elective in HIV medicine, visit the &lt;a href=&quot;http://medicine.ucsf.edu/education/residency/program&quot;&gt;School of Medicine site&lt;/a&gt;.&lt;/p&gt; 
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Pharmacy Students ./hiv/education/pharmacy.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/education/pharmacy.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;Content goes here.
			&lt;/p&gt;
			&lt;p&gt;Second paragraph.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Phlebotomy Students ./hiv/education/phlebotomy.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/education/phlebotomy.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;Content goes here.
			&lt;/p&gt;
			&lt;p&gt;Second paragraph.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Ward 86 Management Recommendations ./hiv/education/recommendations-old.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/education/recommendations-old.html</Path>
		<FileBody>
			
			
			&lt;h3&gt;Medical Management Recommendations from the UCSF Positive Health Program HIV/AIDS Clinic (Ward 86) at San Francisco General Hospital.&lt;/h3&gt;
						&lt;p class=&quot;introduction&quot; target=&quot;_blank&quot;&gt;This series offers clinical practice recommendations for management of HIV&#45;related conditions from the expert clinicians of the Positive Health Program at San Francisco General Hospital. &lt;a href=&quot;http://hivinsite.ucsf.edu/InSite?page=md&#45;ward86&#45;intro&quot; target=&quot;_blank&quot;&gt;Learn more&lt;/a&gt;.&lt;/p&gt;&lt;p class=&quot;expertinfo&quot;&gt;Editor:  &lt;a href=&quot;http://hiv.ucsf.edu/faculty/?key=24077331&amp;amp;name=JACOBSON%2CMARK+A&quot; target=&quot;OffSite&quot;&gt;Mark Jacobson, MD&lt;/a&gt;&lt;/p&gt;&lt;p class=&quot;expertinfo&quot; style=&quot;margin&#45;top:&#45;20px;&quot; target=&quot;_blank&quot;&gt;Coeditors:  &lt;a href=&quot;http://hiv.ucsf.edu/faculty/?key=21543343&amp;amp;name=COFFEY%2CSUSAN+C&quot; target=&quot;OffSite&quot;&gt;Susa Coffey, MD&lt;/a&gt;; &lt;a href=&quot;http://hiv.ucsf.edu/faculty/?key=25009820&amp;amp;name=HAVLIR%2CDIANE+V&quot; target=&quot;OffSite&quot;&gt;Diane Havlir, MD&lt;/a&gt;; &lt;a href=&quot;http://hiv.ucsf.edu/faculty/?key=26353656&amp;amp;name=GANDHI%2CMONICA&quot; target=&quot;OffSite&quot;&gt;Monica Gandhi, MD&lt;/a&gt;&lt;/p&gt; 
						
						&lt;ul&gt;			
						
			
			
			&lt;ul&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;InSite?doc=md&#45;ward86&#45;osteoporosis&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Osteoporosis&lt;/a&gt;&lt;/b&gt;&lt;br&gt;October 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;InSite?doc=md&#45;ward86&#45;hepatitis&#45;c&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;HIV/HCV Coinfection&lt;/a&gt;&lt;/b&gt;&lt;br&gt;July 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;InSite?doc=md&#45;ward86&#45;drug&#45;drug&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;ARV Drug Interactions&lt;/a&gt;&lt;/b&gt;&lt;br&gt;March 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;InSite?doc=md&#45;ward86&#45;preventive&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Preventive Management&lt;/a&gt;&lt;/b&gt;&lt;br&gt;October 2015&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;InSite?doc=md&#45;ward86&#45;pruritus&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Pruritus&lt;/a&gt;&lt;/b&gt;&lt;br&gt;October 2015&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;InSite?doc=md&#45;ward86&#45;testosterone&#45;replacement&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Testosterone Replacement&lt;/a&gt;&lt;/b&gt;&lt;br&gt;May 2015&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;InSite?doc=md&#45;ward86&#45;odynophagia&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Odynophagia and Dysphagia&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated July 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;InSite?doc=md&#45;ward86&#45;cns&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Central Nervous System Disease&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated July 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;InSite?doc=md&#45;ward86&#45;diarrhea&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Diarrhea&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated July 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;InSite?doc=md&#45;ward86&#45;methamphetamine&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Methamphetamine Use&lt;/a&gt;&lt;/b&gt;&lt;br&gt;January 2015&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;InSite?doc=md&#45;ward86&#45;neuropathy&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Distal Symmetrical Polyneuropathy&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated May 2015&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;InSite?doc=md&#45;ward86&#45;hyperlipidemia&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Hyperlipidemia&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated April 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;InSite?doc=md&#45;ward86&#45;cmv&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Cytomegalovirus Disease&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated April 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;InSite?doc=md&#45;ward86&#45;pneumocystis&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Pneumocystis Pneumonia&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated April 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;InSite?doc=md&#45;ward86&#45;neutropenia&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Neutropenia&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated April 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;InSite?doc=md&#45;ward86&#45;cryptococcosis&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Cryptococcal Infection&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated April 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;InSite?doc=md&#45;ward86&#45;bacterial&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Community&#45;Acquired Pneumonia and Skin/Soft Tissue Infections&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated April 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;InSite?doc=md&#45;ward86&#45;dmac&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Disseminated Mycobacterium avium Complex Infection &lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated April 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;InSite?doc=md&#45;ward86&#45;iris&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Immune Reconstitution Inflammatory Syndrome (IRIS)&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated April 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;InSite?doc=md&#45;ward86&#45;tb&#45;diagnosis&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Tuberculosis and Latent M. tuberculosis Infection (Diagnosis)&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated May 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;InSite?doc=md&#45;ward86&#45;tb&#45;treatment&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Tuberculosis and Latent M. tuberculosis Infection (Treatment)&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated July 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;InSite?doc=md&#45;ward86&#45;art&#45;oi&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Initiating Antiretroviral Therapy in Hospitalized Patients&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated April 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;InSite?doc=md&#45;ward86&#45;syphilis&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Syphilis&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated April 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;InSite?doc=md&#45;ward86&#45;neurosyphilis&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Neurosyphilis&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated April 2016&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Ward 86 Management Recommendations ./hiv/education/recommendations.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/education/recommendations.html</Path>
		<FileBody>
			
			
			&lt;h3&gt;Medical Management Recommendations from the UCSF Positive Health Program HIV/AIDS Clinic (Ward 86) at San Francisco General Hospital.&lt;/h3&gt;
						&lt;p class=&quot;introduction&quot; target=&quot;_blank&quot;&gt;This series offers clinical practice recommendations for management of HIV&#45;related conditions from the expert clinicians of the Positive Health Program at San Francisco General Hospital. &lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?page=md&#45;ward86&#45;intro&quot; target=&quot;_blank&quot;&gt;Learn more&lt;/a&gt;.&lt;/p&gt;&lt;p class=&quot;expertinfo&quot;&gt;Editor:  &lt;a href=&quot;http://hiv.ucsf.edu/faculty/?key=24077331&amp;amp;name=JACOBSON%2CMARK+A&quot; target=&quot;OffSite&quot;&gt;Mark Jacobson, MD&lt;/a&gt;&lt;/p&gt;&lt;p class=&quot;expertinfo&quot; style=&quot;margin&#45;top:&#45;20px;&quot; target=&quot;_blank&quot;&gt;Coeditors:  &lt;a href=&quot;http://hiv.ucsf.edu/faculty/?key=21543343&amp;amp;name=COFFEY%2CSUSAN+C&quot; target=&quot;OffSite&quot;&gt;Susa Coffey, MD&lt;/a&gt;; &lt;a href=&quot;http://hiv.ucsf.edu/faculty/?key=25009820&amp;amp;name=HAVLIR%2CDIANE+V&quot; target=&quot;OffSite&quot;&gt;Diane Havlir, MD&lt;/a&gt;; &lt;a href=&quot;http://hiv.ucsf.edu/faculty/?key=26353656&amp;amp;name=GANDHI%2CMONICA&quot; target=&quot;OffSite&quot;&gt;Monica Gandhi, MD&lt;/a&gt;&lt;/p&gt; 
						
						&lt;ul&gt;			
			
			
			
			&lt;ul&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?doc=md&#45;ward86&#45;osteoporosis&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Osteoporosis&lt;/a&gt;&lt;/b&gt;&lt;br&gt;October 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?doc=md&#45;ward86&#45;hepatitis&#45;c&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;HIV/HCV Coinfection&lt;/a&gt;&lt;/b&gt;&lt;br&gt;July 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?doc=md&#45;ward86&#45;drug&#45;drug&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;ARV Drug Interactions&lt;/a&gt;&lt;/b&gt;&lt;br&gt;March 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?doc=md&#45;ward86&#45;preventive&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Preventive Management&lt;/a&gt;&lt;/b&gt;&lt;br&gt;October 2015&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?doc=md&#45;ward86&#45;pruritus&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Pruritus&lt;/a&gt;&lt;/b&gt;&lt;br&gt;October 2015&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?doc=md&#45;ward86&#45;testosterone&#45;replacement&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Testosterone Replacement&lt;/a&gt;&lt;/b&gt;&lt;br&gt;May 2015&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?doc=md&#45;ward86&#45;odynophagia&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Odynophagia and Dysphagia&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated July 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?doc=md&#45;ward86&#45;cns&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Central Nervous System Disease&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated July 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?doc=md&#45;ward86&#45;diarrhea&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Diarrhea&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated July 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?doc=md&#45;ward86&#45;methamphetamine&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Methamphetamine Use&lt;/a&gt;&lt;/b&gt;&lt;br&gt;January 2015&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?doc=md&#45;ward86&#45;neuropathy&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Distal Symmetrical Polyneuropathy&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated May 2015&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?doc=md&#45;ward86&#45;hyperlipidemia&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Hyperlipidemia&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated April 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?doc=md&#45;ward86&#45;cmv&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Cytomegalovirus Disease&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated April 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?doc=md&#45;ward86&#45;pneumocystis&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Pneumocystis Pneumonia&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated April 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?doc=md&#45;ward86&#45;neutropenia&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Neutropenia&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated April 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?doc=md&#45;ward86&#45;cryptococcosis&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Cryptococcal Infection&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated April 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?doc=md&#45;ward86&#45;bacterial&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Community&#45;Acquired Pneumonia and Skin/Soft Tissue Infections&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated April 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?doc=md&#45;ward86&#45;dmac&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Disseminated Mycobacterium avium Complex Infection &lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated April 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?doc=md&#45;ward86&#45;iris&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Immune Reconstitution Inflammatory Syndrome (IRIS)&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated April 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?doc=md&#45;ward86&#45;tb&#45;diagnosis&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Tuberculosis and Latent M. tuberculosis Infection (Diagnosis)&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated May 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?doc=md&#45;ward86&#45;tb&#45;treatment&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Tuberculosis and Latent M. tuberculosis Infection (Treatment)&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated July 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?doc=md&#45;ward86&#45;art&#45;oi&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Initiating Antiretroviral Therapy in Hospitalized Patients&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated April 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?doc=md&#45;ward86&#45;syphilis&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Syphilis&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated April 2016&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a target=&quot;_blank&quot; href=&quot;http://hivinsite.ucsf.edu/InSite?doc=md&#45;ward86&#45;neurosyphilis&amp;amp;page=md&#45;ward86&#45;index&quot;&gt;Neurosyphilis&lt;/a&gt;&lt;/b&gt;&lt;br&gt;Updated April 2016&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Ward 86 Management Recommendations ./hiv/education/recommendations.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/education/recommendations.html~</Path>
		<FileBody>
			
			
			&lt;h3&gt;Medical Management Recommendations from the UCSF Positive Health Program HIV/AIDS Clinic (Ward 86) at San Francisco General Hospital.&lt;/h3&gt;
						&lt;p class=&quot;introduction&quot; target=&quot;_blank&quot;&gt;This series offers clinical practice recommendations for management of HIV&#45;related conditions from the expert clinicians of the Positive Health Program at San Francisco General Hospital. &lt;a href=&quot;http://hivinsite.ucsf.edu/InSite?page=md&#45;ward86&#45;intro&quot; target=&quot;_blank&quot;&gt;Learn more&lt;/a&gt;.&lt;/p&gt;&lt;p class=&quot;expertinfo&quot;&gt;Editor:  &lt;a href=&quot;http://hiv.ucsf.edu/faculty/?key=24077331&amp;amp;name=JACOBSON%2CMARK+A&quot; target=&quot;OffSite&quot;&gt;Mark Jacobson, MD&lt;/a&gt;&lt;/p&gt;&lt;p class=&quot;expertinfo&quot; style=&quot;margin&#45;top:&#45;20px;&quot; target=&quot;_blank&quot;&gt;Coeditors:  &lt;a href=&quot;http://hiv.ucsf.edu/faculty/?key=21543343&amp;amp;name=COFFEY%2CSUSAN+C&quot; target=&quot;OffSite&quot;&gt;Susa Coffey, MD&lt;/a&gt;; &lt;a href=&quot;http://hiv.ucsf.edu/faculty/?key=25009820&amp;amp;name=HAVLIR%2CDIANE+V&quot; target=&quot;OffSite&quot;&gt;Diane Havlir, MD&lt;/a&gt;; &lt;a href=&quot;http://hiv.ucsf.edu/faculty/?key=26353656&amp;amp;name=GANDHI%2CMONICA&quot; target=&quot;OffSite&quot;&gt;Monica Gandhi, MD&lt;/a&gt;&lt;/p&gt; 
						
						&lt;ul&gt;			
									
			
			&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;http://hivinsite.org/InSite?doc=md&#45;ward86&#45;methamphetamine&amp;amp;page=md&#45;ward86&#45;index&quot; target=&quot;_blank&quot;&gt;Methamphetamine Use&lt;/a&gt;&lt;/b&gt;&lt;br&gt;January 2015&lt;/p&gt;&lt;/li&gt;
			&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;http://hivinsite.org/InSite?doc=md&#45;ward86&#45;neuropathy&amp;amp;page=md&#45;ward86&#45;index&quot; target=&quot;_blank&quot;&gt;Distal Symmetrical Polyneuropathy&lt;/a&gt;&lt;/b&gt;&lt;br&gt;December 2014&lt;/p&gt;&lt;/li&gt;
			&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;http://hivinsite.org/InSite?doc=md&#45;ward86&#45;hyperlipidemia&amp;amp;page=md&#45;ward86&#45;index&quot; target=&quot;_blank&quot;&gt;Hyperlipidemia&lt;/a&gt;&lt;/b&gt;&lt;br&gt;December 2014&lt;/p&gt;&lt;/li&gt;
			&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;http://hivinsite.org/InSite?doc=md&#45;ward86&#45;cmv&amp;amp;page=md&#45;ward86&#45;index&quot; target=&quot;_blank&quot;&gt;Cytomegalovirus Disease&lt;/a&gt;&lt;/b&gt;&lt;br&gt;October 2014&lt;/p&gt;&lt;/li&gt;
			&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;http://hivinsite.org/InSite?doc=md&#45;ward86&#45;pneumocystis&amp;amp;page=md&#45;ward86&#45;index&quot; target=&quot;_blank&quot;&gt;Pneumocystis Pneumonia&lt;/a&gt;&lt;/b&gt;&lt;br&gt;October 2014&lt;/p&gt;&lt;/li&gt;
			&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;http://hivinsite.org/InSite?doc=md&#45;ward86&#45;neutropenia&amp;amp;page=md&#45;ward86&#45;index&quot; target=&quot;_blank&quot;&gt;Neutropenia&lt;/a&gt;&lt;/b&gt;&lt;br&gt;October 2014&lt;/p&gt;&lt;/li&gt;
			&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;http://hivinsite.org/InSite?doc=md&#45;ward86&#45;cryptococcosis&amp;amp;page=md&#45;ward86&#45;index&quot; target=&quot;_blank&quot;&gt;Cryptococcal Infection&lt;/a&gt;&lt;/b&gt;&lt;br&gt;October 2014&lt;/p&gt;&lt;/li&gt;
			&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;http://hivinsite.org/InSite?doc=md&#45;ward86&#45;bacterial&amp;amp;page=md&#45;ward86&#45;index&quot; target=&quot;_blank&quot;&gt;Community&#45;Acquired Pneumonia and Skin/Soft Tissue Infections&lt;/a&gt;&lt;/b&gt;&lt;br&gt;October 2014&lt;/p&gt;&lt;/li&gt;
			&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;http://hivinsite.org/InSite?doc=md&#45;ward86&#45;dmac&amp;amp;page=md&#45;ward86&#45;index&quot; target=&quot;_blank&quot;&gt;Disseminated Mycobacterium avium Complex Infection &lt;/a&gt;&lt;/b&gt;&lt;br&gt;October 2014&lt;/p&gt;&lt;/li&gt;
			&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;http://hivinsite.org/InSite?doc=md&#45;ward86&#45;iris&amp;amp;page=md&#45;ward86&#45;index&quot; target=&quot;_blank&quot;&gt;Immune Reconstitution Inflammatory Syndrome (IRIS)&lt;/a&gt;&lt;/b&gt;&lt;br&gt;October 2014&lt;/p&gt;&lt;/li&gt;
			&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;http://hivinsite.org/InSite?doc=md&#45;ward86&#45;tb&#45;diagnosis&amp;amp;page=md&#45;ward86&#45;index&quot; target=&quot;_blank&quot;&gt;Tuberculosis and Latent M. tuberculosis Infection (Diagnosis)&lt;/a&gt;&lt;/b&gt;&lt;br&gt;September 2014&lt;/p&gt;&lt;/li&gt;
			&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;http://hivinsite.org/InSite?doc=md&#45;ward86&#45;tb&#45;treatment&amp;amp;page=md&#45;ward86&#45;index&quot; target=&quot;_blank&quot;&gt;Tuberculosis and Latent M. tuberculosis Infection (Treatment)&lt;/a&gt;&lt;/b&gt;&lt;br&gt;September 2014&lt;/p&gt;&lt;/li&gt;
			&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;http://hivinsite.org/InSite?doc=md&#45;ward86&#45;art&#45;oi&amp;amp;page=md&#45;ward86&#45;index&quot; target=&quot;_blank&quot;&gt;Initiating Antiretroviral Therapy in Hospitalized Patients&lt;/a&gt;&lt;/b&gt;&lt;br&gt;September 2014&lt;/p&gt;&lt;/li&gt;
			&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;http://hivinsite.org/InSite?doc=md&#45;ward86&#45;syphilis&amp;amp;page=md&#45;ward86&#45;index&quot; target=&quot;_blank&quot;&gt;Syphilis&lt;/a&gt;&lt;/b&gt;&lt;br&gt;September 2014&lt;/p&gt;&lt;/li&gt;
			&lt;li&gt;&lt;p&gt;&lt;b&gt;&lt;a href=&quot;http://hivinsite.org/InSite?doc=md&#45;ward86&#45;neurosyphilis&amp;amp;page=md&#45;ward86&#45;index&quot; target=&quot;_blank&quot;&gt;Neurosyphilis&lt;/a&gt;&lt;/b&gt;&lt;br&gt;September 2014&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Faculty Profiles ./hiv/faculty/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/faculty/index.html</Path>
		<FileBody>
			
		</FileBody>
	</node>
	<node>
		<Fname>
Dining By Design ./hiv/giving/diningbydesign.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/giving/diningbydesign.html</Path>
		<FileBody>
			
			
			&lt;p class=&quot;introduction&quot;&gt;For more than ten years, the Positive Health Program has been the primary beneficiary of DINING BY DESIGN San Francisco, produced by &lt;a href=&quot;http://diffasf.org/&quot; target=&quot;_blank&quot;&gt;DIFFA&lt;/a&gt;.* &lt;/p&gt;
			
			&lt;p&gt;This elegant fundraiser is held every November in downtown San Francisco. Renowned professional designers, architects and artists create stunningly creative dinner tables for an unparalleled dining experience, and a wonderful silent auction is a highlight of the gala event. To learn more about corporate and individual sponsorship, contributions for the auction, and more, contact Marc Vincent at DIFFA San Francisco Committee or call (415) 513&#45;7084.&lt;/p&gt;
			
			&lt;p&gt;&lt;i&gt;*&lt;a href=&quot;http://diffasf.org/&quot; target=&quot;_blank&quot;&gt;The Design Industries Foundation Fighting AIDS (DIFFA)&lt;/a&gt; is one of the oldest and largest funders of HIV/AIDS service and education programs in the U.S. Since its founding in 1984, DIFFA has mobilized the immense resources of the design communities to provide over $35 million to hundreds of AIDS organizations nationwide.  &lt;/i&gt;&lt;/p&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Giving - Within Our Reach ./hiv/giving/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/giving/index.html</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/ribbon.jpg&quot; style=&quot;float:left;margin&#45;top:&#45;10px;&quot;&gt;
			&lt;p class=&quot;introduction&quot;&gt;&lt;i&gt;Campaign for the Future.&lt;/i&gt;&lt;/p&gt;
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/within_reach.jpg&quot; class=&quot;imgRight&quot;&gt;
			&lt;p&gt;As we enter our fourth decade of managing HIV and AIDS, we are on the verge of critical milestones in treatment and prevention.&lt;/p&gt;
			 
			&lt;p&gt;In 30 years, we turned HIV infection from a death sentence into a treatable chronic condition.&lt;/p&gt; 
			 
			&lt;p&gt;Today, we believe more than ever that a world without HIV and AIDS is Within Our Reach.  Join us in bringing that future closer.  Some examples of how you can help:&lt;/p&gt;
			&lt;ul&gt;&lt;li&gt;&lt;b&gt;Financial:&lt;/b&gt;   $10 provides patients three round&#45;trip bus fares to the clinic. $25 provides four months of nutritional support for 4 HIV infected pregnant women in Uganda.  $50 gives a patient a night of safe, indoor lodging managed by our staff.  $100 helps us respond to four hours of incoming calls from patients in need.
			&lt;/li&gt;&lt;li&gt;&lt;b&gt;Advocacy:&lt;/b&gt;  Education materials are available online.  Download them free of charge and use them to help build a world free of stigma or shame towards HIV. 
			&lt;/li&gt;&lt;/ul&gt;
			
			&lt;p&gt;Please visit the &lt;a href=&quot;http://sfghf.org/&quot; target=&quot;_blank&quot;&gt;San Francisco General Hospital Foundation website&lt;/a&gt; to make a gift. Please type &quot;Within Our Reach&quot; in the Gift Designation so your donation will come directly to the Positive Health Program to help us end HIV/AIDS.&lt;/p&gt;
			
			&lt;p&gt;For specific questions regarding your donation, please contact Olivia Herbert at (415) 476&#45;9878 or &lt;a href=&quot;mailto:oherbert@support.ucsf.edu&quot;&gt;oherbert@support.ucsf.edu&lt;/a&gt;.&lt;/p&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Volunteer ./hiv/giving/volunteer.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/giving/volunteer.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt; Donations, gifts, volunteers and pro bono work make a critical difference in our work in San Francisco and around the world. &lt;/p&gt;
			
			&lt;p&gt;By supporting our efforts through donations, volunteering and participation in our fundraising events, you help make a difference in the lives of HIV positive people everywhere. &lt;/p&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
$custom[entity] Search ./hiv/news/search.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/news/search.html</Path>
		<FileBody>
			/* &lt;![CDATA[ */
			
			#ucsfheadercontainer {
			  width: 100%;
			  background&#45;color: #000000;
			}
			td{
			    border:hidden;
			padding:1px;
			}
			
			
			/* ]]&gt; */
						  (function() {
			    var cx = '$custom[key]';
			    var gcse = document.createElement('script');
			    gcse.type = 'text/javascript';
			    gcse.async = true;
			    gcse.src = 'https://cse.google.com/cse.js?cx=' + cx;
			    var s = document.getElementsByTagName('script')[0];
			    s.parentNode.insertBefore(gcse, s);
			  })();
					</FileBody>
	</node>
	<node>
		<Fname>
Options &amp; Scope ./hiv/research/#options.html#
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/#options.html#</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/php_logo.gif&quot; class=&quot;php&quot;&gt;&lt;br clear=all&gt;
			
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/options.jpg&quot; class=&quot;imgRight&quot;&gt;
			&lt;h3&gt;The OPTIONS Project&lt;/h3&gt;
			
			&lt;p&gt; is a multi&#45;study research program at UCSF. Our goal is to learn as much as possible about early HIV infection and to better understand how HIV is being transmitted now. OPTIONS is one of the largest studies of its kind in the world.&lt;/p&gt;
			
			&lt;p&gt;We offer studies for persons with recent HIV infection whether or not participants want to start treatment immediately. Key research questions include assessing the frequency with which drug resistant HIV is being transmitted, factors that may enhance or decrease HIV infectivity, and advancing our understanding of early immune responses in controlling HIV infection. For participants in long&#45;term follow&#45;up, OPTIONS is also part of an overall effort at UCSF and other institutions, the Martin Delaney Collaboratory: Towards an HIV&#45;1 Cure program.  This effort is studying how HIV persists in persons on effective treatment, and is aimed at identifying ways to cure HIV in the future. &lt;/p&gt;
			
			
			&lt;p&gt;OPTIONS also follows people who have been at high risk of getting HIV infected but remain HIV negative.  This work is aimed at understanding what genetic  and immune factors may protect against getting HIV infection.&lt;/p&gt;
			
			
			&lt;h5&gt;Areas of Current Focus&lt;/h5&gt;
			
			OPTIONS has been working with early HIV infection since 1996.  We have recently expanded our research, and are currently enrolling men who have sex with men who are HIV&#45;negative or untested, as we study mechanisms that may protect people from getting HIV. &lt;/p&gt;
			 
			
			&lt;h5&gt;Key Publications&lt;/h5&gt;
			
			&lt;ol&gt;&lt;li&gt;
			Josefsson L, Eriksson S, Sinclair E, Ho T, Killian M, Epling L, Shao W, Lewis 
			B, Bacchetti P, Loeb L, Custer J, Poole L, Hecht FM, Palmer S. Hematopoietic
			Precursor Cells Isolated From Patients on Long&#45;term Suppressive HIV Therapy Did
			Not Contain HIV&#45;1 DNA. J Infect Dis. 2012 Jul;206(1):28&#45;34. Epub 2012 Apr 25.
			PubMed PMID: 22536001.
			
			&lt;/li&gt;&lt;li&gt;Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, Poole L, Loeb L,
			Pilcher CD, Grant RM, Deeks SG, Hecht FM. Transmitted drug resistance in persons 
			with acute/early HIV&#45;1 in San Francisco, 2002&#45;2009. PLoS One. 2010 Dec
			10;5(12):e15510. PubMed PMID: 21170322; PubMed Central PMCID: PMC3000814.
			
			
			&lt;/li&gt;&lt;li&gt;Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Diaz RS, Kallas EG, Janini LM, Liegler T, Pilcher CD, Grant RM, Cortes R, Deeks SG, Hecht FM. Differential Persistence of Transmitted HIV&#45;1 Drug Resistance Mutation Classes. J Infect Dis. 2011,203:1174&#45;1181..
			
			&lt;/li&gt;&lt;li&gt;Hecht FM, Wellman R, Busch MP, Pilcher CD, Norris PJ, Margolick JB, Collier AC, Little SJ, Markowitz M, Routy JP, Holte S. Identifying the early post&#45;HIV antibody seroconversion period. J Infect Dis. 2011;204:526&#45;33 .
			
			&lt;/li&gt;&lt;li&gt;Hecht FM, Hartogensis W, Bragg L, Bacchetti P, Atchison R, Grant R, Barbour J,
			Deeks SG. HIV RNA level in early infection is predicted by viral load in the
			transmission source. AIDS. 2010 Apr 24;24(7):941&#45;5. PubMed PMID: 20168202; PubMed
			Central PMCID: PMC2887742.
			&lt;/li&gt;&lt;/ol&gt;
			
			 
			&lt;p&gt;
			For more information, contact Options Project staff at 415&#45;502&#45;8100, or email us at &lt;a href=&quot;mailto:options@php.ucsf.edu&quot;&gt;options@php.ucsf.edu&lt;/a&gt;, or visit us at &lt;a href&quot;http://labs.ucsf.edu/options/&quot; target=&quot;_blank&quot;&gt;http://labs.ucsf.edu/options/&lt;/a&gt;.&lt;/p&gt;
			&lt;/li&gt;&lt;li&gt;Hsue PY, Ordovas K, Lee T, Reddy G, Gotway M, Schnell A, Ho JE, Selby V, Madden E, Martin JN, Deeks SG, Ganz P, Waters DD. Carotid intima&#45;media thickness among human immunodeficiency virus&#45;infected patients without coronary calcium. Am J Cardiol. 2012 Mar 1; 109(5):742&#45;7.
			&lt;/li&gt;&lt;/ol&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
The Scope Study ./hiv/research/#s2.html#
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/#s2.html#</Path>
		<FileBody>
			
			
			&lt;h3&gt;The Scope Study&lt;/h3&gt;
			 &lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/scope.jpg&quot; class=&quot;imgRight&quot;&gt;
			&lt;p&gt;The SCOPE study is an ongoing pathogenesis oriented cohort of over 1500 HIV infected and uninfected persons. Our overall goal is to provide a platform for linking the basic laboratory with the clinic. This type of work!!EditedContent!!which is generally referred to as !!EditedContent!!translational research!!EditedContent!!is often difficult to perform, as basic scientists rarely have the requisite expertise to do clinical research and clinicians often lack the expertise to perform laboratory&#45;based research. The tremendous advances that routinely occur in the laboratory are hence rarely transferred to patient care. To address these concerns, our group has assembled a large cohort of well characterized HIV&#45;infected and uninfected persons of diverse demographic and clinical backgrounds. An extensive biologic specimen repository and clinical data&#45;base have been assembled. These resources are routinely shared with collaboration investigators at UCSF and elsewhere.&lt;/p&gt;
			 
			&lt;p&gt;In the same spirit of insuring that scientific discoveries lead to therapies for patients, the SCOPE cohort has been constructed to support early clinical testing of novel ideas. We have performed several !!EditedContent!!first&#45;in&#45;human!!EditedContent!! studies of such approaches, often working closely with the San Francisco community to make sure the study is both relevant and safe. Along these lines, the SCOPE team is now supporting several studies aimed at reducing HIV&#45;associated inflammation during therapy. We are also supporting small clinical trials aimed at reducing the size of the reservoir. Our long&#45;term aim is to help find a cure for HIV infection.&lt;/p&gt;
			 
			&lt;p&gt;The field sites for SCOPE are the HIV/AIDS clinic of the San Francisco General Hospital (SFGH) and the San Francisco Veterans Affairs Medical Center (SFVAMC). As a cohort conceived in the contemporary treatment era, SCOPE is designed as a dynamic cohort to allow recruitment based upon the interests of the collaborating scientists. For example, a concerted effort was made by the study directors to respond to the growing interest in those rare individuals who are able to control HIV replication in the absence of any therapy (!!EditedContent!!elite!!EditedContent!! controllers).  We are also enriching our study for those individuals who fail to exhibit robust CD4+ T cell reconstitution despite otherwise effective therapy.  Finally, HIV&#45;uninfected !!EditedContent!!healthy!!EditedContent!! subjects have also been enrolled in SCOPE as a valuable comparator to the HIV&#45;infected individuals.&lt;/p&gt;
			 
			&lt;p&gt;Subjects enrolled in SCOPE are seen every 4 months for a confidential questionnaire regarding medications, symptoms, quality of life, and high risk behaviors.  Blood is  collected at every visit.  SCOPE participants are also asked to participate in additional studies assessing the impact of HIV infection on cardiovascular, kidney, neurologic and gastrointestinal function.&lt;/p&gt;
			 
			&lt;p&gt;The SCOPE cohort is directed by Drs. Steven Deeks, Jeffrey Martin, Hiroyou Hatano, Peter Hunt, Priscilla Hsue and Harry Lampiris.&lt;/p&gt;
			 
			&lt;p&gt;For questions or to inquire about enrollment, please call the SCOPE staff at (415) 476&#45;4082 x 140.&lt;/p&gt;
			 
			&lt;h5&gt;Recent Papers&lt;/h5&gt;
			 
			&lt;ol&gt;&lt;li&gt;Deeks SG, McCune JM. Can HIV be cured with stem cell therapy? Nat Biotechnol. 2010 Aug; 28(8):807&#45;10.
			 
			&lt;/li&gt;&lt;li&gt;Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010 Jul 3; 376(9734):49&#45;62.
			 
			&lt;/li&gt;&lt;li&gt;Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, Lampiris H, Hunt PW, Palmer S, McCune JM, Martin JN, Busch MP, Shacklett BL, Deeks SG. A randomized, controlled trial of raltegravir intensification in antiretroviral&#45;treated, HIV&#45;infected patients with a suboptimal CD4+ T cell response. J Infect Dis. 2011 Apr 1; 203(7):960&#45;8.
			 
			&lt;/li&gt;&lt;li&gt;Kulkarni S, Savan R, Qi Y, Gao X, Yuki Y, Bass SE, Martin MP, Hunt P, Deeks SG, Telenti A, Pereyra F, Goldstein D, Wolinsky S, Walker B, Young HA, Carrington M. Differential microRNA regulation of HLA&#45;C expression and its association with HIV control. Nature. 2011 Apr 28; 472(7344):495&#45;8.
			 
			&lt;/li&gt;&lt;li&gt;Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, Tracy RP, Corey L, Deeks SG. Valganciclovir reduces T cell activation in HIV&#45;infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis. 2011 May 15; 203(10):1474&#45;83.
			 
			&lt;/li&gt;&lt;li&gt;Hsue PY, Ordovas K, Lee T, Reddy G, Gotway M, Schnell A, Ho JE, Selby V, Madden E, Martin JN, Deeks SG, Ganz P, Waters DD. Carotid intima&#45;media thickness among human immunodeficiency virus&#45;infected patients without coronary calcium. Am J Cardiol. 2012 Mar 1; 109(5):742&#45;7.
			&lt;/li&gt;&lt;/ol&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
The Scope Study ./hiv/research/#scope.html#
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/#scope.html#</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/php_logo.gif&quot; class=&quot;php&quot;&gt;&lt;br clear=all&gt;
			
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/options.jpg&quot; class=&quot;imgRight&quot;&gt;
			&lt;h3&gt;The OPTIONS Project&lt;/h3&gt;
			
			&lt;p&gt; is a multi&#45;study research program at UCSF. Our goal is to learn as much as possible about early HIV infection and to better understand how HIV is being transmitted now. OPTIONS is one of the largest studies of its kind in the world.&lt;/p&gt;
			
			&lt;p&gt;We offer studies for persons with recent HIV infection whether or not participants want to start treatment immediately. Key research questions include assessing the frequency with which drug resistant HIV is being transmitted, factors that may enhance or decrease HIV infectivity, and advancing our understanding of early immune responses in controlling HIV infection. For participants in long&#45;term follow&#45;up, OPTIONS is also part of an overall effort at UCSF and other institutions, the Martin Delaney Collaboratory: Towards an HIV&#45;1 Cure program.  This effort is studying how HIV persists in persons on effective treatment, and is aimed at identifying ways to cure HIV in the future. &lt;/p&gt;
			
			
			&lt;p&gt;OPTIONS also follows people who have been at high risk of getting HIV infected but remain HIV negative.  This work is aimed at understanding what genetic  and immune factors may protect against getting HIV infection.&lt;/p&gt;
			
			
			&lt;h5&gt;Areas of Current Focus&lt;/h5&gt;
			
			OPTIONS has been working with early HIV infection since 1996.  We have recently expanded our research, and are currently enrolling men who have sex with men who are HIV&#45;negative or untested, as we study mechanisms that may protect people from getting HIV. &lt;/p&gt;
			 
			
			&lt;h5&gt;Key Publications&lt;/h5&gt;
			
			&lt;ol&gt;&lt;li&gt;
			Josefsson L, Eriksson S, Sinclair E, Ho T, Killian M, Epling L, Shao W, Lewis 
			B, Bacchetti P, Loeb L, Custer J, Poole L, Hecht FM, Palmer S. Hematopoietic
			Precursor Cells Isolated From Patients on Long&#45;term Suppressive HIV Therapy Did
			Not Contain HIV&#45;1 DNA. J Infect Dis. 2012 Jul;206(1):28&#45;34. Epub 2012 Apr 25.
			PubMed PMID: 22536001.
			
			&lt;/li&gt;&lt;li&gt;Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, Poole L, Loeb L,
			Pilcher CD, Grant RM, Deeks SG, Hecht FM. Transmitted drug resistance in persons 
			with acute/early HIV&#45;1 in San Francisco, 2002&#45;2009. PLoS One. 2010 Dec
			10;5(12):e15510. PubMed PMID: 21170322; PubMed Central PMCID: PMC3000814.
			
			
			&lt;/li&gt;&lt;li&gt;Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Diaz RS, Kallas EG, Janini LM, Liegler T, Pilcher CD, Grant RM, Cortes R, Deeks SG, Hecht FM. Differential Persistence of Transmitted HIV&#45;1 Drug Resistance Mutation Classes. J Infect Dis. 2011,203:1174&#45;1181..
			
			&lt;/li&gt;&lt;li&gt;Hecht FM, Wellman R, Busch MP, Pilcher CD, Norris PJ, Margolick JB, Collier AC, Little SJ, Markowitz M, Routy JP, Holte S. Identifying the early post&#45;HIV antibody seroconversion period. J Infect Dis. 2011;204:526&#45;33 .
			
			&lt;/li&gt;&lt;li&gt;Hecht FM, Hartogensis W, Bragg L, Bacchetti P, Atchison R, Grant R, Barbour J,
			Deeks SG. HIV RNA level in early infection is predicted by viral load in the
			transmission source. AIDS. 2010 Apr 24;24(7):941&#45;5. PubMed PMID: 20168202; PubMed
			Central PMCID: PMC2887742.
			&lt;/li&gt;&lt;/ol&gt;
			
			 
			&lt;p&gt;
			For more information, contact Options Project staff at 415&#45;502&#45;8100, or email us at &lt;a href=&quot;mailto:options@php.ucsf.edu&quot;&gt;options@php.ucsf.edu&lt;/a&gt;, or visit us at &lt;a href&quot;http://labs.ucsf.edu/options/&quot; target=&quot;_blank&quot;&gt;http://labs.ucsf.edu/options/&lt;/a&gt;.&lt;/p&gt;
			
			&lt;h3&gt;The Scope Study&lt;/h3&gt;
			 &lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/scope.jpg&quot; class=&quot;imgRight&quot;&gt;
			&lt;p&gt;The SCOPE study is an ongoing pathogenesis oriented cohort of over 1500 HIV infected and uninfected persons. Our overall goal is to provide a platform for linking the basic laboratory with the clinic. This type of work!!EditedContent!!which is generally referred to as !!EditedContent!!translational research!!EditedContent!!is often difficult to perform, as basic scientists rarely have the requisite expertise to do clinical research and clinicians often lack the expertise to perform laboratory&#45;based research. The tremendous advances that routinely occur in the laboratory are hence rarely transferred to patient care. To address these concerns, our group has assembled a large cohort of well characterized HIV&#45;infected and uninfected persons of diverse demographic and clinical backgrounds. An extensive biologic specimen repository and clinical data&#45;base have been assembled. These resources are routinely shared with collaboration investigators at UCSF and elsewhere.&lt;/p&gt;
			 
			&lt;p&gt;In the same spirit of insuring that scientific discoveries lead to therapies for patients, the SCOPE cohort has been constructed to support early clinical testing of novel ideas. We have performed several !!EditedContent!!first&#45;in&#45;human!!EditedContent!! studies of such approaches, often working closely with the San Francisco community to make sure the study is both relevant and safe. Along these lines, the SCOPE team is now supporting several studies aimed at reducing HIV&#45;associated inflammation during therapy. We are also supporting small clinical trials aimed at reducing the size of the reservoir. Our long&#45;term aim is to help find a cure for HIV infection.&lt;/p&gt;
			 
			&lt;p&gt;The field sites for SCOPE are the HIV/AIDS clinic of the San Francisco General Hospital (SFGH) and the San Francisco Veterans Affairs Medical Center (SFVAMC). As a cohort conceived in the contemporary treatment era, SCOPE is designed as a dynamic cohort to allow recruitment based upon the interests of the collaborating scientists. For example, a concerted effort was made by the study directors to respond to the growing interest in those rare individuals who are able to control HIV replication in the absence of any therapy (!!EditedContent!!elite!!EditedContent!! controllers).  We are also enriching our study for those individuals who fail to exhibit robust CD4+ T cell reconstitution despite otherwise effective therapy.  Finally, HIV&#45;uninfected !!EditedContent!!healthy!!EditedContent!! subjects have also been enrolled in SCOPE as a valuable comparator to the HIV&#45;infected individuals.&lt;/p&gt;
			 
			&lt;p&gt;Subjects enrolled in SCOPE are seen every 4 months for a confidential questionnaire regarding medications, symptoms, quality of life, and high risk behaviors.  Blood is  collected at every visit.  SCOPE participants are also asked to participate in additional studies assessing the impact of HIV infection on cardiovascular, kidney, neurologic and gastrointestinal function.&lt;/p&gt;
			 
			&lt;p&gt;The SCOPE cohort is directed by Drs. Steven Deeks, Jeffrey Martin, Hiroyou Hatano, Peter Hunt, Priscilla Hsue and Harry Lampiris.&lt;/p&gt;
			 
			&lt;p&gt;For questions or to inquire about enrollment, please call the SCOPE staff at (415) 476&#45;4082 x 140.&lt;/p&gt;
			 
			&lt;h5&gt;Recent Papers&lt;/h5&gt;
			 
			&lt;ol&gt;&lt;li&gt;Deeks SG, McCune JM. Can HIV be cured with stem cell therapy? Nat Biotechnol. 2010 Aug; 28(8):807&#45;10.
			 
			&lt;/li&gt;&lt;li&gt;Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010 Jul 3; 376(9734):49&#45;62.
			 
			&lt;/li&gt;&lt;li&gt;Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, Lampiris H, Hunt PW, Palmer S, McCune JM, Martin JN, Busch MP, Shacklett BL, Deeks SG. A randomized, controlled trial of raltegravir intensification in antiretroviral&#45;treated, HIV&#45;infected patients with a suboptimal CD4+ T cell response. J Infect Dis. 2011 Apr 1; 203(7):960&#45;8.
			 
			&lt;/li&gt;&lt;li&gt;Kulkarni S, Savan R, Qi Y, Gao X, Yuki Y, Bass SE, Martin MP, Hunt P, Deeks SG, Telenti A, Pereyra F, Goldstein D, Wolinsky S, Walker B, Young HA, Carrington M. Differential microRNA regulation of HLA&#45;C expression and its association with HIV control. Nature. 2011 Apr 28; 472(7344):495&#45;8.
			 
			&lt;/li&gt;&lt;li&gt;Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, Tracy RP, Corey L, Deeks SG. Valganciclovir reduces T cell activation in HIV&#45;infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis. 2011 May 15; 203(10):1474&#45;83.
			 
			&lt;/li&gt;&lt;li&gt;Hsue PY, Ordovas K, Lee T, Reddy G, Gotway M, Schnell A, Ho JE, Selby V, Madden E, Martin JN, Deeks SG, Ganz P, Waters DD. Carotid intima&#45;media thickness among human immunodeficiency virus&#45;infected patients without coronary calcium. Am J Cardiol. 2012 Mar 1; 109(5):742&#45;7.
			&lt;/li&gt;&lt;/ol&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Adult AIDS Clinical Trials Group (ACTG) ./hiv/research/actg.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/actg.html</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/tubes.jpg&quot; class=&quot;imgRight&quot;&gt;
			&lt;p class=&quot;introduction&quot;&gt;The UCSF Adult AIDS Clinical Trials Group (ACTG) at San Francisco General Hospital conducts clinical trials evaluating the optimal management of HIV and associated complications, strategies for HIV eradication, and treatment of viral hepatitis and tuberculosis. As part of the NIH&#45;funded multicenter ACTG clinical trials network, this clinical trials unit has access to a broad menu of cutting edge studies and conducts research addressing health issues of key importance to the San Francisco population.
			&lt;/p&gt;
			
			&lt;h3&gt;Areas of Current Focus&lt;/h3&gt;
			&lt;ul&gt;&lt;li&gt;Innovative antiretroviral approaches to minimize long term toxicity  for HIV treatment naïve and treatment experienced patients
			&lt;/li&gt;&lt;li&gt;Strategies to control HIV related inflammation, reduce the HIV reservoir and ultimately eradicate HIV. 
			&lt;/li&gt;&lt;li&gt;Development of shorter, more potent and less toxic HCV therapies using the rapidly expanding field of HCV direct acting agents (DAA’s)  in both  HIV&#45;HCV coinfected and HCV monoinfected patients. 
			&lt;/li&gt;&lt;li&gt;Improved tuberculosis diagnosis and treatment of active and latent tuberculosis infeciton
			&lt;/li&gt;&lt;/ul&gt;
			&lt;h3&gt;Recent publications&lt;/h3&gt;
			
			&lt;ol&gt;&lt;li&gt;Havlir, D.V., et al., Timing of antiretroviral therapy for HIV&#45;1 infection and tuberculosis. The New England journal of medicine, 2011. 365(16): p. 1482&#45;91.
			&lt;/li&gt;&lt;li&gt;Geng, E.H., et al., The effect of AIDS Clinical Trials Group Protocol 5164 on the time from Pneumocystis jirovecii pneumonia diagnosis to antiretroviral initiation in routine clinical practice: a case study of diffusion, dissemination, and implementation. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011. 53(10): p. 1008&#45;14.
			&lt;/li&gt;&lt;li&gt;Haubrich, R.H., et al., Initial viral decay to assess the relative antiretroviral potency of protease inhibitor&#45;sparing, nonnucleoside reverse transcriptase inhibitor&#45;sparing, and nucleoside reverse transcriptase inhibitor&#45;sparing regimens for first&#45;line therapy of HIV infection. AIDS, 2011. 25(18): p. 2269&#45;78.
			&lt;/li&gt;&lt;li&gt;Hogan, C.M., et al., The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV&#45;1&#45;infected individuals. The Journal of infectious diseases, 2012. 205(1): p. 87&#45;96.
			&lt;/li&gt;&lt;li&gt;Connick, E., et al., Augmented HIV&#45;specific interferon&#45;gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection. Journal of acquired immune deficiency syndromes, 2011. 58(1): p. 1&#45;8.
			&lt;/li&gt;&lt;li&gt;Robertson, K., et al., A multinational study of neurological performance in antiretroviral therapy&#45;naive HIV&#45;1&#45;infected persons in diverse resource&#45;constrained settings. Journal of neurovirology, 2011. 17(5): p. 438&#45;47.
			&lt;/li&gt;&lt;/ol&gt;
			
			&lt;p&gt;Download a list of &lt;a href=&quot;/sites/hiv.ucsf.edu/files/docs/open_studies_08_2015.pdf&quot;&gt;open enrolling studies&lt;/a&gt;.&lt;/p&gt;
			
			&lt;p&gt;For more information on currently enrolling studies, contact our outreach coordinator Stephen May (415) 476&#45;4082 ext 358, &lt;a href=&quot;mailto:smay@php.ucsf.edu&quot;&gt;smay@php.ucsf.edu&lt;/a&gt;) or our ACTG study coordinator Jay Dwyer (415) 476&#45;4082 ext. 353, &lt;a href=&quot;mailto:jdwyer@php.ucsf.edu&quot;&gt;jdwyer@php.ucsf.edu&lt;/a&gt;).&lt;/p&gt;
			
			
			&lt;p&gt;For more information on the ACTG clinical trials network, please visit &lt;a href=&quot;http://www.actgnetwork.org&quot;&gt;http://www.actgnetwork.org&lt;/a&gt;.&lt;/p&gt; 
			
			
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Adult AIDS Clinical Trials Group (ACTG) ./hiv/research/actg.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/actg.html~</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/tubes.jpg&quot; class=&quot;imgRight&quot;&gt;
			&lt;p class=&quot;introduction&quot;&gt;The UCSF Adult AIDS Clinical Trials Group (ACTG) at San Francisco General Hospital conducts clinical trials evaluating the optimal management of HIV and associated complications, strategies for HIV eradication, and treatment of viral hepatitis and tuberculosis. As part of the NIH&#45;funded multicenter ACTG clinical trials network, this clinical trials unit has access to a broad menu of cutting edge studies and conducts research addressing health issues of key importance to the San Francisco population.
			&lt;/p&gt;
			
			&lt;h3&gt;Areas of Current Focus&lt;/h3&gt;
			&lt;ul&gt;&lt;li&gt;Innovative antiretroviral approaches to minimize long term toxicity  for HIV treatment naïve and treatment experienced patients
			&lt;/li&gt;&lt;li&gt;Strategies to control HIV related inflammation, reduce the HIV reservoir and ultimately eradicate HIV. 
			&lt;/li&gt;&lt;li&gt;Development of shorter, more potent and less toxic HCV therapies using the rapidly expanding field of HCV direct acting agents (DAA’s)  in both  HIV&#45;HCV coinfected and HCV monoinfected patients. 
			&lt;/li&gt;&lt;li&gt;Improved tuberculosis diagnosis and treatment of active and latent tuberculosis infeciton
			&lt;/li&gt;&lt;/ul&gt;
			&lt;h3&gt;Recent publications&lt;/h3&gt;
			
			&lt;ol&gt;&lt;li&gt;Havlir, D.V., et al., Timing of antiretroviral therapy for HIV&#45;1 infection and tuberculosis. The New England journal of medicine, 2011. 365(16): p. 1482&#45;91.
			&lt;/li&gt;&lt;li&gt;Geng, E.H., et al., The effect of AIDS Clinical Trials Group Protocol 5164 on the time from Pneumocystis jirovecii pneumonia diagnosis to antiretroviral initiation in routine clinical practice: a case study of diffusion, dissemination, and implementation. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011. 53(10): p. 1008&#45;14.
			&lt;/li&gt;&lt;li&gt;Haubrich, R.H., et al., Initial viral decay to assess the relative antiretroviral potency of protease inhibitor&#45;sparing, nonnucleoside reverse transcriptase inhibitor&#45;sparing, and nucleoside reverse transcriptase inhibitor&#45;sparing regimens for first&#45;line therapy of HIV infection. AIDS, 2011. 25(18): p. 2269&#45;78.
			&lt;/li&gt;&lt;li&gt;Hogan, C.M., et al., The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV&#45;1&#45;infected individuals. The Journal of infectious diseases, 2012. 205(1): p. 87&#45;96.
			&lt;/li&gt;&lt;li&gt;Connick, E., et al., Augmented HIV&#45;specific interferon&#45;gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection. Journal of acquired immune deficiency syndromes, 2011. 58(1): p. 1&#45;8.
			&lt;/li&gt;&lt;li&gt;Robertson, K., et al., A multinational study of neurological performance in antiretroviral therapy&#45;naive HIV&#45;1&#45;infected persons in diverse resource&#45;constrained settings. Journal of neurovirology, 2011. 17(5): p. 438&#45;47.
			&lt;/li&gt;&lt;/ol&gt;
			
			&lt;p&gt;Download a list of &lt;a href=&quot;https://hero.som.ucsf.edu/Docs/open_adult_studies.pdf&quot;&gt;open enrolling studies&lt;/a&gt;.&lt;/p&gt;
			
			&lt;p&gt;For more information on currently enrolling studies, contact our outreach coordinator Jacque Clark (415) 476&#45;4082 ext 352, &lt;a href=&quot;clarkj@php.ucsf.edu&quot;&gt;clarkj@php.ucsf.edu&lt;/a&gt;)  or our ACTG study coordinator Jay Dwyer (415) 476&#45;4082 ext. 350, &lt;a href=&quot;mailto:jdwyer@php.ucsf.edu&quot;&gt;jdwyer@php.ucsf.edu&lt;/a&gt;). &lt;/p&gt;
			
			&lt;p&gt;For more information on the ACTG clinical trials network, please visit &lt;a href=&quot;http://www.actgnetwork.org&quot;&gt;http://www.actgnetwork.org&lt;/a&gt;.&lt;/p&gt; 
			
			
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
druguser_mtgs.html ./hiv/research/druguser_mtgs.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/druguser_mtgs.html</Path>
		<FileBody>
			
			&lt;table&gt;
			&lt;tr&gt;&lt;th&gt;
			Date
			&lt;/th&gt;
			&lt;th&gt;Speaker
			&lt;/th&gt;
			&lt;th&gt;Talk
			&lt;/th&gt;
			&lt;/tr&gt;
			
			
			&lt;tr&gt;&lt;td&gt;	2/28/13	&lt;/td&gt;&lt;td&gt;	Claudia Diaz Mooney, MD, Chief Resident, UCSF/SFGH Family and Community Medicine	&lt;/td&gt;&lt;td&gt;	Teaching resident physicians about substance use in pregnancy	&lt;/td&gt;&lt;/tr&gt;
			&lt;tr&gt;&lt;td class=&quot;other&quot;&gt;	11/29/12	&lt;/td&gt;&lt;td class=&quot;other&quot;&gt;	Phillip Coffin, MD, 
			MIA Director of Substance Use Research HIV Prevention Section,
			San Francisco Department of Public Health
			Assistant Clinical Professor, 
			Division of HIV/AIDS University of California, San Francisco
				&lt;/td&gt;&lt;td class=&quot;other&quot;&gt;	How can we evaluate naloxone prescription in the DPH clinic system?	&lt;/td&gt;&lt;/tr&gt;
			&lt;tr&gt;&lt;td&gt;	10/25/13	&lt;/td&gt;&lt;td&gt;	Alice Gleghorn, Ph.D.
			Community Programs Privacy Officer and
			County Alcohol and Drug Administrator
			San Francisco Department of Public Health Community Behavioral Health Services
			&lt;/td&gt;&lt;td&gt;	NIDA 2012 Community Epidemiology Work Group (CEWG) report on recent drug trends in the Bay Area 	&lt;/td&gt;&lt;/tr&gt;
			&lt;tr&gt;&lt;td class=&quot;other&quot;&gt;	9/20/12	&lt;/td&gt;&lt;td class=&quot;other&quot;&gt;	Howard Newville, Ph.D.
			Clinical Psychology Fellow
			UCSF, Dept. of Psychiatry
			&lt;/td&gt;&lt;td class=&quot;other&quot;&gt;	The Information&#45;Motivation&#45;Behavior Skills model of HAART adherence in HIV&#45;positive substance users	&lt;/td&gt;&lt;/tr&gt;
			&lt;tr&gt;&lt;td&gt;	6/21/12	&lt;/td&gt;&lt;td&gt;	Pamela DeCarlo
			Project Director, 
			UFO Presents!
			&lt;/td&gt;&lt;td&gt;	Trends in hepatitis C risk among young adult injectors: an informal needs assessment from across the US	&lt;/td&gt;&lt;/tr&gt;
			&lt;tr&gt;&lt;td class=&quot;other&quot;&gt;	5/17/12	&lt;/td&gt;&lt;td class=&quot;other&quot;&gt;	Eliza Wheeler
			DOPE Project Manager
			Harm Reduction Coalition
			&quot;&lt;/td&gt;&lt;td class=&quot;other&quot;&gt;	Take&#45;home naloxone for opioid overdose prevention: Strategies to reduce prescription opioid and heroin overdose deaths	&lt;/td&gt;&lt;/tr&gt;
			&lt;tr&gt;&lt;td&gt;	4/19/12	&lt;/td&gt;&lt;td&gt;	Sarah CM Roberts, DrPH
			Public Health Social Scientist
			Bixby Center for Global Reproductive Health, UCSF
				&lt;/td&gt;&lt;td&gt;	Women's perspectives on screening for drug use in prenatal care	&lt;/td&gt;&lt;/tr&gt;
			&lt;tr&gt;&lt;td class=&quot;other&quot;&gt;	2/16/12	&lt;/td&gt;&lt;td class=&quot;other&quot;&gt;	Dr. Sarah G Mars 
			Honorary Research Fellow
			Faculty of Public Health and Policy
			London School of Hygiene and Tropical Medicine
				&lt;/td&gt;&lt;td class=&quot;other&quot;&gt;	Defining Addiction: The Politics of An Amorphous Concept	&lt;/td&gt;&lt;/tr&gt;
			&lt;tr&gt;&lt;td&gt;	1/19/12	&lt;/td&gt;&lt;td&gt;	 Gary Humfleet, PhD
			Associate Clinical Professor,                                                                                                                                                 UCSF Dept. of Psychiatry
				&lt;/td&gt;&lt;td&gt;	
			Integrating Smoking Treatment into the HIV Clinical Care Setting
			&lt;/td&gt;&lt;/tr&gt;
			&lt;tr&gt;&lt;td class=&quot;other&quot;&gt;	12/15/11	&lt;/td&gt;&lt;td class=&quot;other&quot;&gt;	Robin Serrahn, MD
			Assistant Clinical Professor,                                                                                                                                                                       UCSF Family &amp; Community Medicine
				&lt;/td&gt;&lt;td class=&quot;other&quot;&gt;	Pain and Cocaine at the PHP: Harm Reduction or Harm Induction?
				&lt;/td&gt;&lt;/tr&gt;
			&lt;tr&gt;&lt;td&gt;	10/20/11	&lt;/td&gt;&lt;td&gt;	Nicholas Bartlett, PhD Candidate                                                                                                                                               Joint Program in Medical Anthropology,                                                                                                            University of California, San Francisco and Berkeley
			&lt;/td&gt;&lt;td&gt;	Habituated Histories: Addiction, Reform and China’s Heroin Generation	&lt;/td&gt;&lt;/tr&gt;
			&lt;tr&gt;&lt;td class=&quot;other&quot;&gt;	9/15/11	&lt;/td&gt;&lt;td class=&quot;other&quot;&gt;	Carol Dawson Rose PhD, RN, MSN
			Associate Professor of Nursing at The Center for AIDS Prevention Studies
			&lt;/td&gt;&lt;td class=&quot;other&quot;&gt;	The Association of Global ASSIST Score and Active Cocaine Use with Low Antiretroviral Adherence in a Public Urban HIV/AIDS Clinic	&lt;/td&gt;&lt;/tr&gt;
			&lt;tr&gt;&lt;td&gt;	6/14/11	&lt;/td&gt;&lt;td&gt;	Alex Kral, PhD
			Director Urban Health Program RTI International and UCSF Associate Adjunct Professor, Department of Family and Community Medicine&lt;br /&gt;
			 
			Kara Lynch, PhD 
			Assistant Clinical Professor, Associate Division Chief, Clinical Chemistry and Toxicology Laboratory, SFGH
			 &lt;br /&gt;
			Brad Shapiro, MD
			Medical Director, Opiate Treatment Outpatient Program and UCSF Associate Clinical Professor, Departments of Family and Community Medicine and Psychiatry
				&lt;/td&gt;&lt;td&gt;	Promethazine Misuse in Opioid Dependent Populations	&lt;/td&gt;&lt;/tr&gt;
			&lt;tr&gt;&lt;td class=&quot;other&quot;&gt;	5/24/11	&lt;/td&gt;&lt;td class=&quot;other&quot;&gt;	David Hersh, MD
			
			Medical Director, SFDPH Opiate Treatment Service
				&lt;/td&gt;&lt;td class=&quot;other&quot;&gt;	Expanding Access to Opiate Agonist Treatment:  The SFDPH Office Based Opiate Treatment (OBOT) Pilot Program	&lt;/td&gt;&lt;/tr&gt;
			&lt;tr&gt;&lt;td&gt;	3/15/11	&lt;/td&gt;&lt;td&gt;	Kelly Ray Knight, PhD 
			 
			 Positive Health Program,                                                                                                                                                                                                               Department of Anthropology, History, and Social Medicine, UCSF
				&lt;/td&gt;&lt;td&gt;	The politics of pain: doctors, addicts, and economies of care	&lt;/td&gt;&lt;/tr&gt;
			&lt;tr&gt;&lt;td class=&quot;other&quot;&gt;	2/1/11	&lt;/td&gt;&lt;td class=&quot;other&quot;&gt;	Adam Carrico, PhD
			Assistant Professor at the Center for AIDS Prevention Studies&quot;	&lt;/td&gt;&lt;td class=&quot;other&quot;&gt;	Substance use and HIV disease progression in the HAART era: Bio&#45;behavioral mechanisms and future research directions	&lt;/td&gt;&lt;/tr&gt;
			&lt;tr&gt;&lt;td&gt;	1/11/12	&lt;/td&gt;&lt;td&gt;	Margot Kushel, MD
			Associate Professor of Medicine in Residence
			Division of General Internal Medicine
			UCSF and San Francisco General Hospital
			&lt;/td&gt;&lt;td&gt;	Pain and the Use and Misuse of Prescription Opioid Analgesics Among Indigent HIV Infected Adults	&lt;/td&gt;&lt;/tr&gt;
			
			
			&lt;/table&gt;
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
UCSF Drug User Research Seminar ./hiv/research/druguserresearch.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/druguserresearch.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;The UCSF Drug User Research Seminar is a city&#45;wide research seminar for faculty, post&#45;doctoral fellows, public health researchers, and graduate students on the broad topic of research with substance&#45;using populations.  Initiated in 2005 after a friendly debate between an epidemiologist and anthropologist on the merits of quantitative versus qualitative research methods, the series provides an opportunity for new and established investigators to present their works&#45;in&#45;progress for peer review, consultation on new or related research questions, and preparation for grant applications, conferences, and publication.  The seminar has been successful in promoting new research collaborations and sustaining an interdisciplinary and inter&#45;professional dialogue between those engaged in basic sciences, epidemiology, clinical research, and qualitative methods.&lt;/p&gt;
			
			&lt;p&gt;If you would like to attend the seminar or present your work for dissemination, collaboration, and/or peer review, please contact Eileen McCormick at &lt;a href=&quot;mccormicke@php.ucsf.edu&quot;&gt;mccormicke@php.ucsf.edu&lt;/a&gt;.&lt;/p&gt;
			
			&lt;h3&gt;Co&#45;Directors:&lt;/h3&gt;
			&lt;ul&gt;&lt;li&gt;Alex Kral, PhD, RTI International
			&lt;/li&gt;&lt;li&gt;Dan Ciccarone, MD MPH, UCSF Departments of Family &amp; Community Medicine and Anthropology, History,&amp; Social Medicine
			&lt;/li&gt;&lt;li&gt;Paula Lum, MD MPH, UCSF Department of Medicine, Division of HIV/AIDS
			&lt;/li&gt;&lt;/ul&gt;
			
			
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Hepatitis &amp; HIV Clinical Trial Group (HCTG) ./hiv/research/hepatitis.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/hepatitis.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;Viral hepatitis has emerged as a leading cause of morbidity and mortality in HIV infected individuals. The field of hepatitis C (HCV) treatment has been revolutionized by the emergence of more potent better tolerated treatments now available that can cure HCV infection in less time. The HCTG partners with industry collaborators to investigate therapeutic strategies for treatment and management of viral hepatitis and HIV infection. The HCTG conducts clinical trials evaluating cutting edge therapies in individuals infected with hepatitis C virus or hepatitis B virus, including individuals both with and without HIV coinfection. The HCTG also investigates new antiretroviral strategies to improve HIV management in treatment naïve and experienced individuals.  &lt;/p&gt; 
			
			&lt;p&gt;Areas of current focus:&lt;/p&gt;
			&lt;ol&gt;&lt;li&gt;
			Use of HCV directly acting agents, including HCV protease inhibitors, polymerase inhibitors, and NS5A inhibitors, to shorten and improve HCV treatment in HIV&#45;coinfection 
			&lt;/li&gt;&lt;li&gt;Interferon&#45;free strategies to cure HCV infection (Genotypes 1&#45;4) in patients with and without HIV coinfection
			&lt;/li&gt;&lt;li&gt;Potent HIV antiretroviral therapy with long term tolerability
			 &lt;/li&gt;&lt;/ol&gt;
			
			&lt;p&gt;Recent publications in which HCTG participated: &lt;/p&gt;
			
			&lt;ol&gt;&lt;li&gt;Luetkemeyer, A.F., et al., Resistance patterns and response to entecavir intensification among HIV&#45;HBV&#45;coinfected adults with persistent HBV viremia. Journal of Acquired Immune Deficiency Syndromes, 2011. 58(3): p. e96&#45;9.
			&lt;/li&gt;&lt;li&gt;Dieterich, D., et al. Telaprevir in Combination with Pegylated Interferon&#45;a&#45;2a+RBV in HCV/HIV&#45;co&#45;infected Patients: A 24&#45;Week Treatment Interim Analysis (Abstract 46) in 19th Conference on Retroviruses and Opportunistic Infections. 2012. Seattle, Washington.
			&lt;/li&gt;&lt;li&gt;Sax, P.E., et al., Co&#45;formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co&#45;formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV&#45;1 infection: a randomised, double&#45;blind, phase 3 trial, analysis of results after 48 weeks. Lancet, 2012. 379(9835): p. 2439&#45;48.
			 &lt;/li&gt;&lt;/ol&gt;
			
			
			&lt;p&gt;A list of current HCTG studies is available &lt;a href=&quot;/research/trials.html&quot;&gt;here&lt;/a&gt;. &lt;/p&gt; 
			
			For more information, please contact our outreach coordinator Jacque Clark at &lt;a href=&quot;mailto:clarkj@php.ucsf.edu&quot;&gt;clarkj@php.ucsf.edu&lt;/a&gt; or (415) 476 4082 ext 352.
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Hepatitis &amp; HIV Clinical Trial Group (HCTG) ./hiv/research/hepatitis.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/hepatitis.html~</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;Viral hepatitis has emerged as a leading cause of morbidity and mortality in HIV infected individuals. The field of hepatitis C (HCV) treatment has been revolutionized by the emergence of more potent better tolerated treatments now available that can cure HCV infection in less time. The HCTG partners with industry collaborators to investigate therapeutic strategies for treatment and management of viral hepatitis and HIV infection. The HCTG conducts clinical trials evaluating cutting edge therapies in individuals infected with hepatitis C virus or hepatitis B virus, including individuals both with and without HIV coinfection. The HCTG also investigates new antiretroviral strategies to improve HIV management in treatment naïve and experienced individuals.  &lt;/p&gt; 
			
			&lt;p&gt;Areas of current focus:&lt;/p&gt;
			&lt;ol&gt;&lt;li&gt;
			Use of HCV directly acting agents, including HCV protease inhibitors, polymerase inhibitors, and NS5A inhibitors, to shorten and improve HCV treatment in HIV&#45;coinfection 
			&lt;/li&gt;&lt;li&gt;Interferon&#45;free strategies to cure HCV infection (Genotypes 1&#45;4) in patients with and without HIV coinfection
			&lt;/li&gt;&lt;li&gt;Potent HIV antiretroviral therapy with long term tolerability
			 &lt;/li&gt;&lt;/ol&gt;
			
			&lt;p&gt;Recent publications in which HCTG participated: &lt;/p&gt;
			
			&lt;ol&gt;&lt;li&gt;Luetkemeyer, A.F., et al., Resistance patterns and response to entecavir intensification among HIV&#45;HBV&#45;coinfected adults with persistent HBV viremia. Journal of Acquired Immune Deficiency Syndromes, 2011. 58(3): p. e96&#45;9.
			&lt;/li&gt;&lt;li&gt;Dieterich, D., et al. Telaprevir in Combination with Pegylated Interferon&#45;a&#45;2a+RBV in HCV/HIV&#45;co&#45;infected Patients: A 24&#45;Week Treatment Interim Analysis (Abstract 46) in 19th Conference on Retroviruses and Opportunistic Infections. 2012. Seattle, Washington.
			&lt;/li&gt;&lt;li&gt;Sax, P.E., et al., Co&#45;formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co&#45;formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV&#45;1 infection: a randomised, double&#45;blind, phase 3 trial, analysis of results after 48 weeks. Lancet, 2012. 379(9835): p. 2439&#45;48.
			 &lt;/li&gt;&lt;/ol&gt;
			
			
			&lt;p&gt;A list of current HCTG studies is available &lt;a href=&quot;/research/trials.html&quot;&gt;here&lt;/a&gt;. &lt;/p&gt; 
			
			For more information, please contact our outreach coordinator Jacque Clark at &lt;a href=&quot;mailto:clarkj@php.ucsf.edu&quot;&gt;clarkj@php.ucsf.edu&lt;/a&gt; or (415) 476 4082 ext 352.
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Research ./hiv/research/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/index.html</Path>
		<FileBody>
			
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/research.jpg&quot; class=&quot;imgRight&quot;&gt;
			&lt;p class=&quot;introduction&quot;&gt;Our research faculty are leading critical studies on new treatments for HIV and its complications, for a cure for HIV and for novel approaches to HIV care delivery in the US and abroad. We have multiple cohort studies, host an implementation science core, and have a global health research program.
			&lt;/p&gt;
			&lt;p&gt;Examples of ongoing research include:    &lt;/p&gt;
			&lt;ul&gt;&lt;li&gt;New drugs to directly treat HIV and new drugs to treat hepatitis C
			&lt;/li&gt;&lt;li&gt;Studies to understand the barriers and path to an HIV cure 
			&lt;/li&gt;&lt;li&gt;Interventions to promote HIV testing and engage and retain patients in care
			&lt;/li&gt;&lt;li&gt;Effect of food insecurity on HIV outcomes
			&lt;/li&gt;&lt;li&gt;HIV and lung disease
			&lt;/li&gt;&lt;li&gt;HIV and aging
			&lt;/li&gt;&lt;/ul&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Research ./hiv/research/index_old.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/index_old.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;The HIV/AIDS Division research faculty is among the most widely published and referenced in the world. Our investigators lead studies on important scientific questions including: new treatments, drug resistance, regimen design, treatment interruptions, long&#45;term non&#45;progression, and therapeutic vaccines. PHP research is local, national and international. Our work includes government&#45;funded network trials and industry&#45;sponsored trials. 
			&lt;/p&gt;
			&lt;p&gt;Current highlights include: &lt;/p&gt;
			&lt;ul&gt;&lt;li&gt;17+ open clinical trials under management 
			&lt;/li&gt;&lt;li&gt;International trials on HIV/TB and HIV/malaria co&#45;infection 
			&lt;/li&gt;&lt;li&gt;Frequent keynotes and poster presentations at major
			conferences 
			&lt;/li&gt;&lt;/ul&gt;
			
			&lt;h3&gt;Faculty&lt;/h3&gt;
			&lt;p&gt;The HIV/AIDS Division is an affliate of the &lt;a target=&quot;_blank&quot; href=&quot;/research/http://ari.ucsf.edu&quot;&gt;AIDS Research Institute at UCSF&lt;/a&gt; and is home to some of the world's leading academic researchers in HIV/AIDS.  &lt;/p&gt;
			&lt;p&gt;Please visit our &lt;a href=&quot;/faculty&quot;&gt;Faculty page&lt;/a&gt; to read their biographies.&lt;/p&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
International Research Programs ./hiv/research/international.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/international.html</Path>
		<FileBody>
			
			 &lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/uganda_3.jpg&quot; class=&quot;imgLeft&quot;&gt;
			&lt;p class=&quot;introduction&quot;&gt;The HIV/AIDS Division at San Francisco General Hospital is globally engaged in research and education around the world. We have established partnerships that lead work to address the most pressing issues of the HIV epidemic in resource limited settings.  We are committed and actively training the next generation of HIV researchers from countries most affected by HIV. Ongoing projects span from understanding disease pathogenesis to epidemiology to treatment to models of care delivery.  We co&#45;direct the Makerere University –UCSF research collaboration which has enrolled over 20,000 patients on clinical studies evaluating HIV, TB, malaria, and nutrition. The SEARCH (Sustainable East Africa Research on Community Health) Collaboration is evaluating the health, education and economic outcomes of novel community based interventions in a “test and treat” approach that includes HIV as well as non&#45;communicable diseases such as hypertension.&lt;/p&gt;
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/inter_team.jpg&quot; class=&quot;imgRight&quot; style=&quot;margin&#45;top:&#45;15px;&quot;&gt;
			&lt;p&gt;Members of our division are active as advisors to the World Health Organization, the STOP TB partnership, and UNAIDS. We are supported by the NIH, CDC, PEPFAR and collaborate with the World Bank in our global programs.&lt;/p&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Options &amp; Scope ./hiv/research/o2.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/o2.html~</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/php_logo.gif&quot; class=&quot;php&quot;&gt;&lt;br clear=all&gt;
			
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/options.jpg&quot; class=&quot;imgRight&quot;&gt;
			&lt;h3&gt;The OPTIONS Project&lt;/h3&gt;
			
			&lt;p&gt; is a multi&#45;study research program at UCSF. Our goal is to learn as much as possible about early HIV infection and to better understand how HIV is being transmitted now. OPTIONS is one of the largest studies of its kind in the world.&lt;/p&gt;
			
			&lt;p&gt;We offer studies for persons with recent HIV infection whether or not participants want to start treatment immediately. Key research questions include assessing the frequency with which drug resistant HIV is being transmitted, factors that may enhance or decrease HIV infectivity, and advancing our understanding of early immune responses in controlling HIV infection. For participants in long&#45;term follow&#45;up, OPTIONS is also part of an overall effort at UCSF and other institutions, the Martin Delaney Collaboratory: Towards an HIV&#45;1 Cure program.  This effort is studying how HIV persists in persons on effective treatment, and is aimed at identifying ways to cure HIV in the future. &lt;/p&gt;
			
			
			&lt;p&gt;OPTIONS also follows people who have been at high risk of getting HIV infected but remain HIV negative.  This work is aimed at understanding what genetic  and immune factors may protect against getting HIV infection.&lt;/p&gt;
			
			
			&lt;h5&gt;Areas of Current Focus&lt;/h5&gt;
			
			OPTIONS has been working with early HIV infection since 1996.  We have recently expanded our research, and are currently enrolling men who have sex with men who are HIV&#45;negative or untested, as we study mechanisms that may protect people from getting HIV. &lt;/p&gt;
			 
			
			&lt;h5&gt;Key Publications&lt;/h5&gt;
			
			&lt;ol&gt;&lt;li&gt;
			Josefsson L, Eriksson S, Sinclair E, Ho T, Killian M, Epling L, Shao W, Lewis 
			B, Bacchetti P, Loeb L, Custer J, Poole L, Hecht FM, Palmer S. Hematopoietic
			Precursor Cells Isolated From Patients on Long&#45;term Suppressive HIV Therapy Did
			Not Contain HIV&#45;1 DNA. J Infect Dis. 2012 Jul;206(1):28&#45;34. Epub 2012 Apr 25.
			PubMed PMID: 22536001.
			
			&lt;/li&gt;&lt;li&gt;Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, Poole L, Loeb L,
			Pilcher CD, Grant RM, Deeks SG, Hecht FM. Transmitted drug resistance in persons 
			with acute/early HIV&#45;1 in San Francisco, 2002&#45;2009. PLoS One. 2010 Dec
			10;5(12):e15510. PubMed PMID: 21170322; PubMed Central PMCID: PMC3000814.
			
			
			&lt;/li&gt;&lt;li&gt;Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Diaz RS, Kallas EG, Janini LM, Liegler T, Pilcher CD, Grant RM, Cortes R, Deeks SG, Hecht FM. Differential Persistence of Transmitted HIV&#45;1 Drug Resistance Mutation Classes. J Infect Dis. 2011,203:1174&#45;1181..
			
			&lt;/li&gt;&lt;li&gt;Hecht FM, Wellman R, Busch MP, Pilcher CD, Norris PJ, Margolick JB, Collier AC, Little SJ, Markowitz M, Routy JP, Holte S. Identifying the early post&#45;HIV antibody seroconversion period. J Infect Dis. 2011;204:526&#45;33 .
			
			&lt;/li&gt;&lt;li&gt;Hecht FM, Hartogensis W, Bragg L, Bacchetti P, Atchison R, Grant R, Barbour J,
			Deeks SG. HIV RNA level in early infection is predicted by viral load in the
			transmission source. AIDS. 2010 Apr 24;24(7):941&#45;5. PubMed PMID: 20168202; PubMed
			Central PMCID: PMC2887742.
			&lt;/li&gt;&lt;/ol&gt;
			
			 
			&lt;p&gt;
			For more information, contact Options Project staff at 415&#45;502&#45;8100, or email us at &lt;a href=&quot;mailto:options@php.ucsf.edu&quot;&gt;options@php.ucsf.edu&lt;/a&gt;, or visit us at &lt;a href&quot;http://labs.ucsf.edu/options/&quot; target=&quot;_blank&quot;&gt;http://labs.ucsf.edu/options/&lt;/a&gt;.&lt;/p&gt;
		</FileBody>
	</node>
	<node>
		<Fname>
The OPTIONS Project ./hiv/research/options.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/options.html</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/php_logo.gif&quot; class=&quot;php&quot;&gt;&lt;br clear=all&gt;
			
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/options.jpg&quot; class=&quot;imgRight&quot;&gt;
			
			&lt;p&gt; The OPTIONS Project is a multi&#45;study research program at UCSF. Our goal is to learn as much as possible about early HIV infection and to better understand how HIV is being transmitted now. OPTIONS is one of the largest studies of its kind in the world.&lt;/p&gt;
			
			&lt;p&gt;We offer studies for persons with recent HIV infection whether or not participants want to start treatment immediately. Key research questions include assessing the frequency with which drug resistant HIV is being transmitted, factors that may enhance or decrease HIV infectivity, and advancing our understanding of early immune responses in controlling HIV infection. For participants in long&#45;term follow&#45;up, OPTIONS is also part of an overall effort at UCSF and other institutions, the Martin Delaney Collaboratory: Towards an HIV&#45;1 Cure program.  This effort is studying how HIV persists in persons on effective treatment, and is aimed at identifying ways to cure HIV in the future. &lt;/p&gt;
			
			
			&lt;p&gt;OPTIONS also follows people who have been at high risk of getting HIV infected but remain HIV negative.  This work is aimed at understanding what genetic  and immune factors may protect against getting HIV infection.&lt;/p&gt;
			
			
			&lt;h5&gt;Areas of Current Focus&lt;/h5&gt;
			
			OPTIONS has been working with early HIV infection since 1996.  We have recently expanded our research, and are currently enrolling men who have sex with men who are HIV&#45;negative or untested, as we study mechanisms that may protect people from getting HIV. &lt;/p&gt;
			 
			
			&lt;h5&gt;Key Publications&lt;/h5&gt;
			
			&lt;ol&gt;&lt;li&gt;
			Josefsson L, Eriksson S, Sinclair E, Ho T, Killian M, Epling L, Shao W, Lewis 
			B, Bacchetti P, Loeb L, Custer J, Poole L, Hecht FM, Palmer S. Hematopoietic
			Precursor Cells Isolated From Patients on Long&#45;term Suppressive HIV Therapy Did
			Not Contain HIV&#45;1 DNA. J Infect Dis. 2012 Jul;206(1):28&#45;34. Epub 2012 Apr 25.
			PubMed PMID: 22536001.
			
			&lt;/li&gt;&lt;li&gt;Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, Poole L, Loeb L,
			Pilcher CD, Grant RM, Deeks SG, Hecht FM. Transmitted drug resistance in persons 
			with acute/early HIV&#45;1 in San Francisco, 2002&#45;2009. PLoS One. 2010 Dec
			10;5(12):e15510. PubMed PMID: 21170322; PubMed Central PMCID: PMC3000814.
			
			
			&lt;/li&gt;&lt;li&gt;Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Diaz RS, Kallas EG, Janini LM, Liegler T, Pilcher CD, Grant RM, Cortes R, Deeks SG, Hecht FM. Differential Persistence of Transmitted HIV&#45;1 Drug Resistance Mutation Classes. J Infect Dis. 2011,203:1174&#45;1181..
			
			&lt;/li&gt;&lt;li&gt;Hecht FM, Wellman R, Busch MP, Pilcher CD, Norris PJ, Margolick JB, Collier AC, Little SJ, Markowitz M, Routy JP, Holte S. Identifying the early post&#45;HIV antibody seroconversion period. J Infect Dis. 2011;204:526&#45;33 .
			
			&lt;/li&gt;&lt;li&gt;Hecht FM, Hartogensis W, Bragg L, Bacchetti P, Atchison R, Grant R, Barbour J,
			Deeks SG. HIV RNA level in early infection is predicted by viral load in the
			transmission source. AIDS. 2010 Apr 24;24(7):941&#45;5. PubMed PMID: 20168202; PubMed
			Central PMCID: PMC2887742.
			&lt;/li&gt;&lt;/ol&gt;
			
			 
			&lt;p&gt;
			For more information, contact Options Project staff at 415&#45;502&#45;8100, or email us at &lt;a href=&quot;mailto:options@php.ucsf.edu&quot;&gt;options@php.ucsf.edu&lt;/a&gt;, or visit us at &lt;a href&quot;http://labs.ucsf.edu/options/&quot; target=&quot;_blank&quot;&gt;http://labs.ucsf.edu/options/&lt;/a&gt;.&lt;/p&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
The OPTIONS Project ./hiv/research/options.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/options.html~</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/php_logo.gif&quot; class=&quot;php&quot;&gt;&lt;br clear=all&gt;
			
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/options.jpg&quot; class=&quot;imgRight&quot;&gt;
			
			&lt;p&gt; is a multi&#45;study research program at UCSF. Our goal is to learn as much as possible about early HIV infection and to better understand how HIV is being transmitted now. OPTIONS is one of the largest studies of its kind in the world.&lt;/p&gt;
			
			&lt;p&gt;We offer studies for persons with recent HIV infection whether or not participants want to start treatment immediately. Key research questions include assessing the frequency with which drug resistant HIV is being transmitted, factors that may enhance or decrease HIV infectivity, and advancing our understanding of early immune responses in controlling HIV infection. For participants in long&#45;term follow&#45;up, OPTIONS is also part of an overall effort at UCSF and other institutions, the Martin Delaney Collaboratory: Towards an HIV&#45;1 Cure program.  This effort is studying how HIV persists in persons on effective treatment, and is aimed at identifying ways to cure HIV in the future. &lt;/p&gt;
			
			
			&lt;p&gt;OPTIONS also follows people who have been at high risk of getting HIV infected but remain HIV negative.  This work is aimed at understanding what genetic  and immune factors may protect against getting HIV infection.&lt;/p&gt;
			
			
			&lt;h5&gt;Areas of Current Focus&lt;/h5&gt;
			
			OPTIONS has been working with early HIV infection since 1996.  We have recently expanded our research, and are currently enrolling men who have sex with men who are HIV&#45;negative or untested, as we study mechanisms that may protect people from getting HIV. &lt;/p&gt;
			 
			
			&lt;h5&gt;Key Publications&lt;/h5&gt;
			
			&lt;ol&gt;&lt;li&gt;
			Josefsson L, Eriksson S, Sinclair E, Ho T, Killian M, Epling L, Shao W, Lewis 
			B, Bacchetti P, Loeb L, Custer J, Poole L, Hecht FM, Palmer S. Hematopoietic
			Precursor Cells Isolated From Patients on Long&#45;term Suppressive HIV Therapy Did
			Not Contain HIV&#45;1 DNA. J Infect Dis. 2012 Jul;206(1):28&#45;34. Epub 2012 Apr 25.
			PubMed PMID: 22536001.
			
			&lt;/li&gt;&lt;li&gt;Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, Poole L, Loeb L,
			Pilcher CD, Grant RM, Deeks SG, Hecht FM. Transmitted drug resistance in persons 
			with acute/early HIV&#45;1 in San Francisco, 2002&#45;2009. PLoS One. 2010 Dec
			10;5(12):e15510. PubMed PMID: 21170322; PubMed Central PMCID: PMC3000814.
			
			
			&lt;/li&gt;&lt;li&gt;Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Diaz RS, Kallas EG, Janini LM, Liegler T, Pilcher CD, Grant RM, Cortes R, Deeks SG, Hecht FM. Differential Persistence of Transmitted HIV&#45;1 Drug Resistance Mutation Classes. J Infect Dis. 2011,203:1174&#45;1181..
			
			&lt;/li&gt;&lt;li&gt;Hecht FM, Wellman R, Busch MP, Pilcher CD, Norris PJ, Margolick JB, Collier AC, Little SJ, Markowitz M, Routy JP, Holte S. Identifying the early post&#45;HIV antibody seroconversion period. J Infect Dis. 2011;204:526&#45;33 .
			
			&lt;/li&gt;&lt;li&gt;Hecht FM, Hartogensis W, Bragg L, Bacchetti P, Atchison R, Grant R, Barbour J,
			Deeks SG. HIV RNA level in early infection is predicted by viral load in the
			transmission source. AIDS. 2010 Apr 24;24(7):941&#45;5. PubMed PMID: 20168202; PubMed
			Central PMCID: PMC2887742.
			&lt;/li&gt;&lt;/ol&gt;
			
			 
			&lt;p&gt;
			For more information, contact Options Project staff at 415&#45;502&#45;8100, or email us at &lt;a href=&quot;mailto:options@php.ucsf.edu&quot;&gt;options@php.ucsf.edu&lt;/a&gt;, or visit us at &lt;a href&quot;http://labs.ucsf.edu/options/&quot; target=&quot;_blank&quot;&gt;http://labs.ucsf.edu/options/&lt;/a&gt;.&lt;/p&gt;
		</FileBody>
	</node>
	<node>
		<Fname>
An SBIRT Training Program at SFGH ./hiv/research/sbirt.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/sbirt.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;Screening, brief intervention, and referral to treatment (SBIRT) is a public health approach to the delivery of early intervention and treatment services for persons with or at risk of developing alcohol and drug use disorders.&lt;/p&gt;
			&lt;ul&gt;&lt;li&gt;&lt;b&gt;Screening&lt;/b&gt; uses evidence&#45;based tools to quickly identify patients with unhealthy alcohol or drug use and assess for substance abuse and dependence.
			&lt;/li&gt;&lt;li&gt;&lt;b&gt;Brief Interventions&lt;/b&gt; with at&#45;risk patients are short, patient&#45;centered conversations to provide feedback, assess readiness for change, and enhance patient motivation.
			&lt;/li&gt;&lt;li&gt;&lt;b&gt;Referral to Treatment&lt;/b&gt; refers to action planning that supports patients ready to make a change.  Action plans may range from self&#45;management strategies (e.g., cutting down), office&#45;based medication&#45;assisted&#45;treatment (e.g., buprenorphine, naltrexone), or referral to specialty care (e.g., detoxification, outpatient or residential treatment).
			&lt;/li&gt;&lt;/ul&gt;
			&lt;p&gt;We offer on&#45;site education and training for resident physicians and their colleagues in team&#45;based care at SFGH to learn practical skills and gain confidence in detecting, diagnosing, and managing patients across a spectrum of substance use disorders.   In doing so, we support SFGH’s mission to provide quality healthcare and trauma services with compassion and respect.&lt;/p&gt;
			
			&lt;p&gt;To date, we have provided didactic and skills&#45;based trainings to physicians, nurses, students, and social workers in the Departments of Medicine, Family &amp; Community Medicine, Obstetrics &amp; Gynecology, Psychiatry and Pediatrics at SFGH.  Curricular content and formats are evidence based and tailored to each learner group’s needs.  For additional information about SBIRT around the country please visit the following &lt;a href=&quot;http://www.nattc.org/regcenters/generalContent.asp?rcid=10&amp;content=STCUSTOM1&quot; target=&quot;_blank&quot;&gt;website&lt;/a&gt;.&lt;/p&gt;
			
			&lt;p&gt;If you are interested in arranging an SBIRT training for your group, please contact project coordinator Eileen McCormick (&lt;a href=&quot;mailto:mccormicke@php.ucsf.edu&quot;&gt;mccormicke@php.ucsf.edu&lt;/a&gt;). &lt;/p&gt;
			
			&lt;h3&gt;Contacts:&lt;/h3&gt;
			&lt;blockquote&gt;&lt;b&gt;Project Coordinator: Eileen McCormick&lt;/b&gt;&lt;br /&gt;
			Address:  995 Potrero Avenue, Building 80, Ward 84, San Francisco, CA  94110&lt;br /&gt;
			Telephone:  (415) 476&#45;4082 ext. 315
			&lt;br /&gt;Fax:  (415) 476&#45;6953
			&lt;br /&gt;E&#45;mail: &lt;a href=&quot;mailto:mccormicke@php.ucsf.edu&quot;&gt;mccormicke@php.ucsf.edu&lt;/a&gt;   &lt;/blockquote&gt;
			&lt;blockquote&gt;&lt;b&gt;Evaluator and Lead Trainer:  Jennifer E. Hettema, Ph.D.&lt;/b&gt;&lt;br /&gt;
			Address:  2821 N. Parham Rd., Suite 203&lt;br /&gt;
			Richmond, VA 23294 &lt;br /&gt;
			Telephone: (804) 527&#45;4268&lt;br /&gt;
			Fax: (804) 527&#45;4215 &lt;br /&gt;
			E&#45;mail: &lt;a href=&quot;mailto:jhettema@virginia.edu&quot;&gt;jhettema@virginia.edu&lt;/a&gt;&lt;/blockquote&gt;
			&lt;blockquote&gt;&lt;b&gt;Project Director:  Paula J. Lum, M.D., M.P.H.&lt;/b&gt;&lt;br /&gt;
			Address:  995 Potrero Avenue, Building 80, Ward 84&lt;br /&gt;San Francisco, CA  94110&lt;br /&gt;
			Telephone:  (415) 476&#45;4082 ext. 411&lt;br /&gt; 
			Fax:  (415) 476&#45;6953&lt;br /&gt;
			E&#45;mail:  &lt;a href=&quot;mailto:plum@php.ucsf.edu&quot;&gt;plum@php.ucsf.edu&lt;/a&gt;&lt;/blockquote&gt;
			
			&lt;h3&gt;Funded by SAMHSA Cooperative Agreement #U79 TI020296&lt;/h3&gt;
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
SFGH Implementation Sciences Working Group ./hiv/research/science.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/science.html</Path>
		<FileBody>
			
			&lt;p class=&quot;introduction&quot;&gt;Despite the tremendous success of biomedical research in the last twenty years, systems, structural, and operational barriers prevent delivery of optimal care to millions of people living with HIV/AIDS. Implementation science is critical to addressing the gap between biomedical research and improved care. The way forward, however, is challenging.  Because implementation science does not belong to any single health sciences area, the practitioners are scattered and often unlinked even within an institution. Furthermore, methodologies for measurement in real word settings and to establish causality in real&#45;world settings are currently the topics of heated debate. At San Francisco General Hospital, Division of HIV/AIDS, we have created a working group to strengthen local efforts to promote interdisciplinary communication and to bring the perspectives of implementation science to bear on the global response to HIV/AIDS.   &lt;/p&gt;
			
			&lt;p&gt;Specifically, we seek to:&lt;/p&gt;
			
			&lt;ol&gt;&lt;li&gt;Strengthen dialogue and alignment of presently scattered intra&#45;institutional efforts to build an implementation and dissemination sciences research agenda by reaching across divisional and departmental boundaries. 
			&lt;/li&gt;&lt;li&gt;Identify gaps in global HIV/AIDS care through systematic reviews and meta&#45;analyses. 
			&lt;/li&gt;&lt;li&gt;Advance the methodological approaches to obtaining causal and actionable inferences from studies conducted in real&#45;world health care delivery settings. 
			&lt;/li&gt;&lt;li&gt;Conduct the next generation of studies to close the gap between evidence and improved health outcomes for people living with HIV/AIDS.
			&lt;/li&gt;&lt;/ol&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
The SCOPE Study ./hiv/research/scope.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/scope.html</Path>
		<FileBody>
			
			
			
			 &lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/scope.jpg&quot; class=&quot;imgRight&quot;&gt;
			&lt;p&gt;The SCOPE study is an ongoing pathogenesis oriented cohort of over 1500 HIV infected and uninfected persons. Our overall goal is to provide a platform for linking the basic laboratory with the clinic. This type of work—which is generally referred to as “translational research”—is often difficult to perform, as basic scientists rarely have the requisite expertise to do clinical research and clinicians often lack the expertise to perform laboratory&#45;based research. The tremendous advances that routinely occur in the laboratory are hence rarely transferred to patient care. To address these concerns, our group has assembled a large cohort of well characterized HIV&#45;infected and uninfected persons of diverse demographic and clinical backgrounds. An extensive biologic specimen repository and clinical data&#45;base have been assembled. These resources are routinely shared with collaboration investigators at UCSF and elsewhere.&lt;/p&gt;
			 
			&lt;p&gt;In the same spirit of insuring that scientific discoveries lead to therapies for patients, the SCOPE cohort has been constructed to support early clinical testing of novel ideas. We have performed several “first&#45;in&#45;human” studies of such approaches, often working closely with the San Francisco community to make sure the study is both relevant and safe. Along these lines, the SCOPE team is now supporting several studies aimed at reducing HIV&#45;associated inflammation during therapy. We are also supporting small clinical trials aimed at reducing the size of the reservoir. Our long&#45;term aim is to help find a cure for HIV infection.&lt;/p&gt;
			 
			&lt;p&gt;The field sites for SCOPE are the HIV/AIDS clinic of the San Francisco General Hospital (SFGH) and the San Francisco Veterans Affairs Medical Center (SFVAMC). As a cohort conceived in the contemporary treatment era, SCOPE is designed as a dynamic cohort to allow recruitment based upon the interests of the collaborating scientists. For example, a concerted effort was made by the study directors to respond to the growing interest in those rare individuals who are able to control HIV replication in the absence of any therapy (“elite” controllers).  We are also enriching our study for those individuals who fail to exhibit robust CD4+ T cell reconstitution despite otherwise effective therapy.  Finally, HIV&#45;uninfected “healthy” subjects have also been enrolled in SCOPE as a valuable comparator to the HIV&#45;infected individuals.&lt;/p&gt;
			 
			&lt;p&gt;Subjects enrolled in SCOPE are seen every 4 months for a confidential questionnaire regarding medications, symptoms, quality of life, and high risk behaviors.  Blood is  collected at every visit.  SCOPE participants are also asked to participate in additional studies assessing the impact of HIV infection on cardiovascular, kidney, neurologic and gastrointestinal function.&lt;/p&gt;
			 
			&lt;p&gt;The SCOPE cohort is directed by Drs. Steven Deeks, Jeffrey Martin, Hiroyou Hatano, Peter Hunt, Priscilla Hsue and Harry Lampiris.&lt;/p&gt;
			 
			&lt;p&gt;For questions or to inquire about enrollment, please call the SCOPE staff at (415) 476&#45;4082 x 140.&lt;/p&gt;
			 
			&lt;h5&gt;Recent Papers&lt;/h5&gt;
			 
			&lt;ol&gt;&lt;li&gt;Deeks SG, McCune JM. Can HIV be cured with stem cell therapy? Nat Biotechnol. 2010 Aug; 28(8):807&#45;10.
			 
			&lt;/li&gt;&lt;li&gt;Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010 Jul 3; 376(9734):49&#45;62.
			 
			&lt;/li&gt;&lt;li&gt;Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, Lampiris H, Hunt PW, Palmer S, McCune JM, Martin JN, Busch MP, Shacklett BL, Deeks SG. A randomized, controlled trial of raltegravir intensification in antiretroviral&#45;treated, HIV&#45;infected patients with a suboptimal CD4+ T cell response. J Infect Dis. 2011 Apr 1; 203(7):960&#45;8.
			 
			&lt;/li&gt;&lt;li&gt;Kulkarni S, Savan R, Qi Y, Gao X, Yuki Y, Bass SE, Martin MP, Hunt P, Deeks SG, Telenti A, Pereyra F, Goldstein D, Wolinsky S, Walker B, Young HA, Carrington M. Differential microRNA regulation of HLA&#45;C expression and its association with HIV control. Nature. 2011 Apr 28; 472(7344):495&#45;8.
			 
			&lt;/li&gt;&lt;li&gt;Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, Tracy RP, Corey L, Deeks SG. Valganciclovir reduces T cell activation in HIV&#45;infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis. 2011 May 15; 203(10):1474&#45;83.
			 
			&lt;/li&gt;&lt;li&gt;Hsue PY, Ordovas K, Lee T, Reddy G, Gotway M, Schnell A, Ho JE, Selby V, Madden E, Martin JN, Deeks SG, Ganz P, Waters DD. Carotid intima&#45;media thickness among human immunodeficiency virus&#45;infected patients without coronary calcium. Am J Cardiol. 2012 Mar 1; 109(5):742&#45;7.
			&lt;/li&gt;&lt;/ol&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Options &amp; Scope ./hiv/research/scope.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/scope.html~</Path>
		<FileBody>
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/php_logo.gif&quot; class=&quot;php&quot;&gt;&lt;br clear=all&gt;
			
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/options.jpg&quot; class=&quot;imgRight&quot;&gt;
			&lt;h3&gt;The OPTIONS Project&lt;/h3&gt;
			
			&lt;p&gt; is a multi&#45;study research program at UCSF. Our goal is to learn as much as possible about early HIV infection and to better understand how HIV is being transmitted now. OPTIONS is one of the largest studies of its kind in the world.&lt;/p&gt;
			
			&lt;p&gt;We offer studies for persons with recent HIV infection whether or not participants want to start treatment immediately. Key research questions include assessing the frequency with which drug resistant HIV is being transmitted, factors that may enhance or decrease HIV infectivity, and advancing our understanding of early immune responses in controlling HIV infection. For participants in long&#45;term follow&#45;up, OPTIONS is also part of an overall effort at UCSF and other institutions, the Martin Delaney Collaboratory: Towards an HIV&#45;1 Cure program.  This effort is studying how HIV persists in persons on effective treatment, and is aimed at identifying ways to cure HIV in the future. &lt;/p&gt;
			
			
			&lt;p&gt;OPTIONS also follows people who have been at high risk of getting HIV infected but remain HIV negative.  This work is aimed at understanding what genetic  and immune factors may protect against getting HIV infection.&lt;/p&gt;
			
			
			&lt;h5&gt;Areas of Current Focus&lt;/h5&gt;
			
			OPTIONS has been working with early HIV infection since 1996.  We have recently expanded our research, and are currently enrolling men who have sex with men who are HIV&#45;negative or untested, as we study mechanisms that may protect people from getting HIV. &lt;/p&gt;
			 
			
			&lt;h5&gt;Key Publications&lt;/h5&gt;
			
			&lt;ol&gt;&lt;li&gt;
			Josefsson L, Eriksson S, Sinclair E, Ho T, Killian M, Epling L, Shao W, Lewis 
			B, Bacchetti P, Loeb L, Custer J, Poole L, Hecht FM, Palmer S. Hematopoietic
			Precursor Cells Isolated From Patients on Long&#45;term Suppressive HIV Therapy Did
			Not Contain HIV&#45;1 DNA. J Infect Dis. 2012 Jul;206(1):28&#45;34. Epub 2012 Apr 25.
			PubMed PMID: 22536001.
			
			&lt;/li&gt;&lt;li&gt;Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, Poole L, Loeb L,
			Pilcher CD, Grant RM, Deeks SG, Hecht FM. Transmitted drug resistance in persons 
			with acute/early HIV&#45;1 in San Francisco, 2002&#45;2009. PLoS One. 2010 Dec
			10;5(12):e15510. PubMed PMID: 21170322; PubMed Central PMCID: PMC3000814.
			
			
			&lt;/li&gt;&lt;li&gt;Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Diaz RS, Kallas EG, Janini LM, Liegler T, Pilcher CD, Grant RM, Cortes R, Deeks SG, Hecht FM. Differential Persistence of Transmitted HIV&#45;1 Drug Resistance Mutation Classes. J Infect Dis. 2011,203:1174&#45;1181..
			
			&lt;/li&gt;&lt;li&gt;Hecht FM, Wellman R, Busch MP, Pilcher CD, Norris PJ, Margolick JB, Collier AC, Little SJ, Markowitz M, Routy JP, Holte S. Identifying the early post&#45;HIV antibody seroconversion period. J Infect Dis. 2011;204:526&#45;33 .
			
			&lt;/li&gt;&lt;li&gt;Hecht FM, Hartogensis W, Bragg L, Bacchetti P, Atchison R, Grant R, Barbour J,
			Deeks SG. HIV RNA level in early infection is predicted by viral load in the
			transmission source. AIDS. 2010 Apr 24;24(7):941&#45;5. PubMed PMID: 20168202; PubMed
			Central PMCID: PMC2887742.
			&lt;/li&gt;&lt;/ol&gt;
			
			 
			&lt;p&gt;
			For more information, contact Options Project staff at 415&#45;502&#45;8100, or email us at &lt;a href=&quot;mailto:options@php.ucsf.edu&quot;&gt;options@php.ucsf.edu&lt;/a&gt;, or visit us at &lt;a href&quot;http://labs.ucsf.edu/options/&quot; target=&quot;_blank&quot;&gt;http://labs.ucsf.edu/options/&lt;/a&gt;.&lt;/p&gt;
			
			&lt;h3&gt;The Scope Study&lt;/h3&gt;
			 &lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/scope.jpg&quot; class=&quot;imgRight&quot;&gt;
			&lt;p&gt;The SCOPE study is an ongoing pathogenesis oriented cohort of over 1500 HIV infected and uninfected persons. Our overall goal is to provide a platform for linking the basic laboratory with the clinic. This type of work—which is generally referred to as “translational research”—is often difficult to perform, as basic scientists rarely have the requisite expertise to do clinical research and clinicians often lack the expertise to perform laboratory&#45;based research. The tremendous advances that routinely occur in the laboratory are hence rarely transferred to patient care. To address these concerns, our group has assembled a large cohort of well characterized HIV&#45;infected and uninfected persons of diverse demographic and clinical backgrounds. An extensive biologic specimen repository and clinical data&#45;base have been assembled. These resources are routinely shared with collaboration investigators at UCSF and elsewhere.&lt;/p&gt;
			 
			&lt;p&gt;In the same spirit of insuring that scientific discoveries lead to therapies for patients, the SCOPE cohort has been constructed to support early clinical testing of novel ideas. We have performed several “first&#45;in&#45;human” studies of such approaches, often working closely with the San Francisco community to make sure the study is both relevant and safe. Along these lines, the SCOPE team is now supporting several studies aimed at reducing HIV&#45;associated inflammation during therapy. We are also supporting small clinical trials aimed at reducing the size of the reservoir. Our long&#45;term aim is to help find a cure for HIV infection.&lt;/p&gt;
			 
			&lt;p&gt;The field sites for SCOPE are the HIV/AIDS clinic of the San Francisco General Hospital (SFGH) and the San Francisco Veterans Affairs Medical Center (SFVAMC). As a cohort conceived in the contemporary treatment era, SCOPE is designed as a dynamic cohort to allow recruitment based upon the interests of the collaborating scientists. For example, a concerted effort was made by the study directors to respond to the growing interest in those rare individuals who are able to control HIV replication in the absence of any therapy (“elite” controllers).  We are also enriching our study for those individuals who fail to exhibit robust CD4+ T cell reconstitution despite otherwise effective therapy.  Finally, HIV&#45;uninfected “healthy” subjects have also been enrolled in SCOPE as a valuable comparator to the HIV&#45;infected individuals.&lt;/p&gt;
			 
			&lt;p&gt;Subjects enrolled in SCOPE are seen every 4 months for a confidential questionnaire regarding medications, symptoms, quality of life, and high risk behaviors.  Blood is  collected at every visit.  SCOPE participants are also asked to participate in additional studies assessing the impact of HIV infection on cardiovascular, kidney, neurologic and gastrointestinal function.&lt;/p&gt;
			 
			&lt;p&gt;The SCOPE cohort is directed by Drs. Steven Deeks, Jeffrey Martin, Hiroyou Hatano, Peter Hunt, Priscilla Hsue and Harry Lampiris.&lt;/p&gt;
			 
			&lt;p&gt;For questions or to inquire about enrollment, please call the SCOPE staff at (415) 476&#45;4082 x 140.&lt;/p&gt;
			 
			&lt;h5&gt;Recent Papers&lt;/h5&gt;
			 
			&lt;ol&gt;&lt;li&gt;Deeks SG, McCune JM. Can HIV be cured with stem cell therapy? Nat Biotechnol. 2010 Aug; 28(8):807&#45;10.
			 
			&lt;/li&gt;&lt;li&gt;Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010 Jul 3; 376(9734):49&#45;62.
			 
			&lt;/li&gt;&lt;li&gt;Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, Lampiris H, Hunt PW, Palmer S, McCune JM, Martin JN, Busch MP, Shacklett BL, Deeks SG. A randomized, controlled trial of raltegravir intensification in antiretroviral&#45;treated, HIV&#45;infected patients with a suboptimal CD4+ T cell response. J Infect Dis. 2011 Apr 1; 203(7):960&#45;8.
			 
			&lt;/li&gt;&lt;li&gt;Kulkarni S, Savan R, Qi Y, Gao X, Yuki Y, Bass SE, Martin MP, Hunt P, Deeks SG, Telenti A, Pereyra F, Goldstein D, Wolinsky S, Walker B, Young HA, Carrington M. Differential microRNA regulation of HLA&#45;C expression and its association with HIV control. Nature. 2011 Apr 28; 472(7344):495&#45;8.
			 
			&lt;/li&gt;&lt;li&gt;Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, Tracy RP, Corey L, Deeks SG. Valganciclovir reduces T cell activation in HIV&#45;infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis. 2011 May 15; 203(10):1474&#45;83.
			 
			&lt;/li&gt;&lt;li&gt;Hsue PY, Ordovas K, Lee T, Reddy G, Gotway M, Schnell A, Ho JE, Selby V, Madden E, Martin JN, Deeks SG, Ganz P, Waters DD. Carotid intima&#45;media thickness among human immunodeficiency virus&#45;infected patients without coronary calcium. Am J Cardiol. 2012 Mar 1; 109(5):742&#45;7.
			&lt;/li&gt;&lt;/ol&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Open Clinical Trials ./hiv/research/trials.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/trials.html</Path>
		<FileBody>
			&lt;p&gt;For more information on our Open Clinical Trials, please download the information &lt;a href=&quot;/sites/hiv.ucsf.edu/files/docs/open_studies_08_2015.pdf&quot; target=&quot;new&quot;&gt;here&lt;/a&gt;.&lt;/p&gt; 
			
			
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Vulnerable Populations ./hiv/research/vulnerable.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/vulnerable.html</Path>
		<FileBody>
			&lt;h3&gt;People Who Are Homeless or Unstably Housed &lt;/h3&gt;
			&lt;p&gt;Our community&#45;based research focuses on the health of homeless and unstably housed adults who are infected or at risk for infection with HIV.  We seek a better understanding of how social and structural factors like housing instability and insurance loss influence health and health services use.  As a T2 (“bedside to community”) translational research group, our goal is to inform health care delivery, drug treatment, trauma interventions and HIV prevention programs targeting impoverished and unstably housed persons.  We emphasize “real&#45;world” strategies that offer the ability to understand complex situations over time.&lt;/p&gt;
			
			&lt;p&gt;Download a newsletter for study participants &lt;a href=&quot;/sites/hiv.ucsf.edu/files/docs/participation_final.pdf&quot;&gt;here&lt;/a&gt;.&lt;/p&gt;
			
			&lt;h5&gt;Recent Publications&lt;/h5&gt;
			&lt;ol&gt;&lt;li&gt;
			Riley ED, Moore KL, Haber S, Neilands TB, Cohen J and Kral AH.  Population&#45;Level Effects of Uninterrupted Health Insurance on Services Use among HIV&#45;Positive Unstably Housed Adults. AIDS Care.  2011; 23(7):822&#45;30.  
			&lt;/li&gt;&lt;li&gt;
			Carrico AW, Bangsberg DR, Weiser SD, Chartier M, Dilworth SE and Riley ED.  Psychiatric Correlates of HAART Utilization and Viral Load among HIV&#45;positive Impoverished Persons.  AIDS.  2011;25(8):1113&#45;8.
			&lt;/li&gt;&lt;li&gt;
			Riley ED, Moore K, Sorensen JL, Tulsky JP, Bangsberg DR and Neilands TB.  Basic Subsistence Needs and Overall Health Among Human Immunodeficiency Virus&#45;infected Homeless and Unstably Housed Women.  Am J Epidemiology.  2011;174(5):515&#45;22.
			&lt;/li&gt;&lt;li&gt;
			Riley ED, Neilands TB, Moore K, Cohen J, Bangsberg DR and Havlir D.  Social, Structural and Behavioral Determinants of Overall Health Status in a Cohort of Homeless and Unstably Housed HIV&#45;Infected Men.  PLoS One.  2012; 7(4):e35207.
			&lt;/li&gt;&lt;/ol&gt;
			
			&lt;p&gt;For additional information contact Elise Riley, PhD at &lt;a href=&quot;mailto:eriley@epi&#45;center.ucsf.edu&quot;&gt;eriley@epi&#45;center.ucsf.edu&lt;/a&gt; and  see also:&lt;/p&gt;
			&lt;ul&gt;&lt;li&gt;
			&lt;a href=&quot;http://nationalaidshousing.org/2008/09/cosponsor&#45;h&#45;con&#45;res&#45;427/&quot; target=&quot;_blank&quot;&gt;National AIDS Housing&lt;/a&gt; 
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;http://www.whitehouse.gov/sites/default/files/microsites/ONAP_rpt.pdf&quot;&gt;White House ONAP&lt;/a&gt; 
			&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;http://www.nlchp.org/content/pubs/2009_National_Town_Hall_Testimony.pdf&quot;&gt;National Town Hall Testimony&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;
			
			
			
			&lt;h3&gt;People Who Use Drugs&lt;/h3&gt;
			&lt;h5&gt;&lt;a href=&quot;/research/sbirt.html&quot;&gt;SBIRT&lt;/a&gt;&lt;/h5&gt;
			&lt;p&gt; Screening, brief intervention, and referral to treatment (SBIRT) is a public health approach to the delivery of early intervention and treatment services for persons with or at risk of developing alcohol and drug use disorders. 
			&lt;p&gt;&lt;a href=&quot;/sites/hiv.ucsf.edu/files/docs/dawson_iac_2012.pdf&quot;&gt;XIX International AIDS Conference 2012 poster&lt;/a&gt;: Screening and Brief Intervention for Unhealthy Substance Use in HIV Primary Care Settings Is Associated with Substance Use Reductions and Viral Suppression among PLWHIV in San Francisco, CA, USA Carol Dawson Rose RN, PhD, FAAN; Emiko Kamitani RN, MS; Shannon Eng MBA &amp; Paula J. Lum MD, MPH&lt;/p&gt;
			&lt;p&gt;Please Visit &lt;a href=&quot;/research/sbirt.html&quot;&gt;SBIRT's Webpage&lt;/a&gt; for more information.
			&lt;h5&gt;&lt;a href=&quot;http://caps.ucsf.edu/uploads/pubs/reports/pdf/UFOPresentsS2C.pdf&quot; target=&quot;_blank&quot;&gt;UFO Presents!&lt;/a&gt;&lt;/h5&gt; 
			&lt;p&gt; UFO Presents! is a Center for Disease Control and Prevention (CDC)&#45;funded program providing much needed hepatitis education, prevention and care services for youth and young adults with injection risk in San Francisco, CA. We aim to meet the broader needs of youth and young adults through comprehensive health and psychosocial support. We are the most experienced group in San Francisco in providing hepatitis, HIV and STI prevention services tailored to young adult IDU, a group with few other health&#45;related resources or programs tailored directly to them.&lt;/p&gt;
			
			UFO Presents! follows from a series of research studies with young IDU, called the UFO Studies. Since 1997, UFO has served over 1200 young IDU in San Francisco. HCV prevention care education resources have been offered to UFO participants. UFO Presents! allows us to apply our years of experience to ALL young IDU, regardless of participation in the UFO Studies.&lt;/p&gt;
			
			&lt;p&gt;Please Visit &lt;a href=&quot;http://caps.ucsf.edu/ufo&#45;study/&quot; target=&quot;_blank&quot;&gt;UFO's Webpage&lt;/a&gt; for more information.
			
			&lt;h5&gt;&lt;a href=&quot;http://journals.lww.com/jaids/toc/2011/03011&quot; target=&quot;_blank&quot;&gt;Buprenorphine Studies&lt;/a&gt;&lt;/h5&gt;
			&lt;p&gt;The Beehive Program provides office&#45;based buprenorphine treatment at the Positive Health Program for patients with heroin or other opioid dependence. An alternative to methadone that can be prescribed by qualified PHP physicians, buprenorphine (or “bupe”) is an effective sublingual medication that can be prescribed for patients that have developed a harmful dependence on prescription opioids. It also can be taken to prevent relapsing back into a heroin or painkiller addiction, making productive living more possible. Please contact Paula Lum, MD, MPH, at (415) 476&#45;4082 ext. 411 for more information.&lt;/p&gt;
			
			
			&lt;h5&gt;Recent Publications&lt;/h5&gt;
			&lt;ol&gt;&lt;li&gt;
			Lum PJ, Little S, Botsko M, Hersh D, Thawley RE, Egan JE, Mitty J, Boverman J, Fiellin DA, BHIVES Collaborative. Opioid Prescribing and Provider Confidence Recognizing Opioid Abuse in HIV Primary Care Settings. J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S91&#45;7. PMID: 21317601
			&lt;/li&gt;&lt;li&gt;
			Lum PJ, Tulsky JP. The medical management of opioid dependence in HIV primary care settings. Curr HIV/AIDS Rep. 2006 Nov;3(4):195&#45;204. Review. PMID: 17089480.
			&lt;/li&gt;&lt;li&gt;
			Rose CD, Courtenay&#45;Quirk C, Knight K, Shade SB, Vittinghoff E, Gomez C, Lum PJ, Bacon O, Colfax G.  HIV intervention for providers study: a randomized controlled trial of a clinician&#45;delivered HIV risk&#45;reduction intervention for HIV&#45;positive people. J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):572&#45;81. PMID: 20827218.
			&lt;/li&gt;&lt;li&gt;
			Evans JL, Tsui JI, Hahn JA, Davidson PJ, Lum PJ, Page K. Mortality among young injection drug users in San Francisco: a 10&#45;year follow&#45;up of the UFO study. Am J Epidemiol. 2012 Feb 15;175(4):302&#45;8.
			&lt;/li&gt;&lt;/ol&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Group Leadership ./hiv/research/implementation/leadership.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/implementation/leadership.html</Path>
		<FileBody>
			
			&lt;h3&gt;Elvin Geng&lt;/h3&gt;
			&lt;p&gt;&lt;a href=&quot;/faculty/?key=dba7282c5b7cf48490744779c1ecdcb2&amp;name=GENG%2CELVIN+H&quot;&gt;Elvin Geng&lt;/a&gt; is Assistant Professor of Medicine at the University of California at San Francisco and based at San Francisco General Hospital in the Division of HIV/AIDS.  He studies effectiveness of routine clinical care for HIV&#45;infected patients in resource limited settings.  Specific topics of interest include antiretroviral initiation, retention in care, loss to follow&#45;up and strategies to facilitate dissemination of evidence in routine clinical practice.  Dr. Geng’s is involved in research in San Francisco as well as in East Africa through East Africa International Epidemiologic Databases to Evaluate AIDS and the Makerere University&#45;University of California San Francisco Collaboration.&lt;/p&gt;
			 
			&lt;h3&gt;Adithya Cattamanchi&lt;/h3&gt;
			&lt;p&gt;&lt;a href=&quot;http://profiles.ucsf.edu/ProfileDetails.aspx?From=SE&amp;Person=5543840&quot;&gt;Dr. Cattamanchi&lt;/a&gt; is an Assistant Professor of Medicine in the Division of Pulmonary and Critical Care Medicine at UCSF. His research is focused on two thematic areas: 1) Development and evaluation of tuberculosis (TB) diagnostics and 2) Implementation and dissemination of evidence&#45;based preventative, diagnostic, and treatment interventions for tuberculosis (TB). He currently has ongoing implementation science&#45;related research projects in Kampala, Uganda and Hanoi, Vietnam.
			&lt;/p&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Meetings ./hiv/research/implementation/meetings.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/implementation/meetings.html</Path>
		<FileBody>
			
			&lt;h3&gt;January 16th 2013&lt;/h3&gt;
			&lt;p&gt;Dr. Thomas Odeny, MBChB, MPH, a Kenyan medical doctor &amp; epidemiologist with an interest in implementation sciences for HIV prevention, care, and treatment. He is a Fellow at the Institute for Health Metrics and Evaluation in the Dept of Global Health at U Washington. As a Fogarty International Clinical Research Fellow he evaluated the use of mobile phone technologies to support HIV prevention interventions. He was PI of “Improving uptake of early infant diagnosis of HIV for PMTCT: a randomized trial of a text messaging intervention.”, and conducted a 1,200&#45;person randomized trial on text messaging to improve outcomes after adult male circumcision for HIV prevention in Kenya &#45; a study nominated for the Top 11 in 2011 mHealth Innovators Challenge by mHealth Alliance and Rockefeller Foundation.&lt;/p&gt;
			
			&lt;h3&gt;October 30, 2012&lt;/h3&gt;
			&lt;p&gt;Harm Reduction Services for People who Inject Drugs in Tanzania: Using Implementation Science to Guide Program Delivery. Dr.Barrot Lambdin, Director of Implementation Science at Pangaea Global AIDS Foundation,  Assistant Professor in  Dept of Global Health at the University of Washington. His research supports and strengthens health systems to more efficiently deliver programs in resource&#45;limited settings, identifying bottlenecks and solutions to the implementation of proven interventions for HIV prevention and treatment. He has been involved in initiatives looking at the impact of integrating HIV services into primary health care, health workforce shortages, mapping patient flow through facilities and strengthening management to support health system integration in Mozambique. Barrot leads efforts to design and implement rigorous operations and implementation research activities for Pangaea and is currently leading initiatives with several programs, including methadone and accompanying risk reduction services for people who inject drugs in Tanzania.&lt;/p&gt;
			
			&lt;h3&gt;September 19, 2012&lt;/h3&gt;
			&lt;p&gt;Dr. George Rutherford and Sarah Royce, from UCSF Global Health, describe the process of evidence synthesis at the World Health Organization and conducting Cochrane Reviews.  They highlight a recent review on TB/HIV service integration.  The discussion illustrated for the group the process by which primary scientific evidence is systematically summarized for policy makers.&lt;/p&gt;
			
			
			&lt;h3&gt;August 14, 2012&lt;/h3&gt;
			&lt;p&gt;Dr. Mead Over, Senior Fellow at the Center for Global Development in Washington DC, was in town to discuss the use of cost “functions” instead of “identities” as a novel approach to modeling the costs of implementation in the global response to HIV/AIDS.&lt;/p&gt;
			
			&lt;h3&gt;July 18, 2012&lt;/h3&gt;
			&lt;p&gt;Dr. Lawrence W. Green, considered by many to be one of the founders of the field of implementation science, discussed the idea of practice&#45;based evidence in his talk “Designing for Dissemination and Implementation:  Making Research More Relevant &amp; Actionable for Translation to Other Populations and Settings.&lt;/p&gt;
			
			&lt;h3&gt;April 25, 2012&lt;/h3&gt;
			&lt;p&gt;Dr. Margret Handley discusses frameworks for implementation science, with a view to frameworks useful for global health settings.&lt;/p&gt;
			 
			&lt;ul&gt;
				&lt;li&gt;&lt;a href=&quot;/sites/hiv.ucsf.edu/files/docs/kenya_cfir.pdf&quot;&gt;Kenya&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;/sites/hiv.ucsf.edu/files/docs/handley_2012.ppt&quot;&gt;Handle&lt;/a&gt;&lt;/li&gt;
				&lt;li&gt;&lt;a href=&quot;/sites/hiv.ucsf.edu/files/docs/damschroeder_2009.pdf&quot;&gt;Damschroeder&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Pulmonary Disease ./hiv/research/international/disease.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/international/disease.html</Path>
		<FileBody>
			
			&lt;h3&gt;Pulmonary Disease Research – Kampala, Uganda&lt;/h3&gt;
			&lt;p style=&quot;margin&#45;top:&#45;10px;&quot;&gt;Contact person: Laurence Huang, MD; &lt;a href=&quot;mailto:lhuang@php.ucsf.edu&quot;&gt;lhuang@php.ucsf.edu&lt;/a&gt;&lt;/p&gt;
			
			&lt;h5&gt;
			International HIV&#45;associated Opportunistic Pneumonias (IHOP) Study&lt;/h5&gt;
			&lt;p&gt;This is an NIH&#45;funded prospective study of HIV&#45;associated pneumonia conducted in 3 cites representing the current HIV/AIDS epidemic in Africa (Kampala, Uganda) and USA (San Francisco, CA and Seattle, WA). IHOP includes clinical sites at San Francisco General Hospital, Harborview Medical Center (Seattle), and Mulago Hospital (Kampala) and involves 6 independent laboratories at the NIH, the University of California San Francisco, the University of Cincinnati, and the University of North Carolina. The IHOP Study is also part of the Lung HIV Study, an NHLBI multi&#45;R01 consortium, with sites in both the US and sub&#45;Saharan Africa. The goals of IHOP are to determine the frequency and mortality of HIV&#45;associated opportunistic pneumonias in an international, multi&#45;center, longitudinal cohort, to investigate non&#45;invasive, molecular diagnosis of tuberculosis (TB) and Pneumocystis pneumonia (PCP), and to explore potential mechanisms for putative trimethoprim&#45;sulfamethoxazole drug resistance in Pneumocystis.&lt;/p&gt;
			
			&lt;h5&gt;Lung Microbiome in Cohorts of HIV&#45;Infected Persons (Lung MicroCHIP)&lt;/h5&gt;
			&lt;p&gt; This is an NIH&#45;funded prospective study examining the lung microbiome in HIV&#45;infected persons over the entire spectrum of HIV disease (acute/recent HIV infection, chronic HIV infection, and acute opportunistic pneumonias). Lung MicroCHIP includes 3 cohorts in San Francisco (Options, SCOPE, and IHOP) and 1 cohort in Kampala, Uganda (MIND&#45;IHOP) and involves 2 independent laboratories at the University of California San Francisco. The Lung MicroCHIP Study is also part of the Lung HIV Microbiome Project, an NHLBI multi&#45;R01 consortium, with sites in both the US and sub&#45;Saharan Africa. The goals of Lung MicroCHIP are to compare the lung microbiome in subjects with and without HIV infection, to determine the effects of opportunistic pneumonia and accompanying pneumonia treatment on the lung microbiome of HIV&#45;infected subjects, and to correlate lung microbiome composition and function with HIV&#45;associated morbidity and mortality.&lt;/p&gt;
			&lt;h5&gt;Key Publications:&lt;/h5&gt;
			&lt;ol&gt;&lt;li&gt;Kyeyune, R, den Boon, S, Cattamanchi, A, Davis, JL, Worodria, W, Yoo, SD, and Huang, L. Causes of early mortality in HIV&#45;infected TB suspects in an East African referral hospital. J Acquir Immune Defic Syndr 2010;55(4):446&#45;450.
			
			&lt;/li&gt;&lt;li&gt;Taylor, SM, Meshnick, SR, Worodria, W, Andama, A, Davis, JL, Cattamanchi, A, den Boon, S, Yoo, SD, Goodman, CD, and Huang, L on behalf of the International HIV&#45;associated Opportunistic Pneumonias (IHOP) Study. Low prevalence of Pneumocystis jirovecii lung colonization in Ugandan HIV&#45;infected patients hospitalized with non&#45;Pneumocystis pneumonia. Diagn Microbiol Infect Dis 2012;72(2):139&#45;143.
			
			&lt;/li&gt;&lt;li&gt;Iwai, S, Fei, MW, Huang, D, Fong, S, Subramanian, A, Grieco, K, Lynch, SV, and Huang, L. Oral and airway microbiota in HIV&#45;infected pneumonia patients. Journal of Clinical Microbiology 2012. In Press.
			
			&lt;/li&gt;&lt;/ol&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Food Security Research ./hiv/research/international/food.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/international/food.html</Path>
		<FileBody>
			
			&lt;h3&gt;The Impact of Food Security on HIV Outcomes and Sexual Risk Behavior in Uganda&lt;/h3&gt;
			&lt;p style=&quot;margin&#45;top:&#45;10px;&quot;&gt;Contact person: Sheri Weiser, MD; &lt;a href=&quot;mailto:sheri.weiser@ucsf.edu&quot;&gt;sheri.weiser@ucsf.edu&lt;/a&gt;&lt;/p&gt;
			
			&lt;p&gt;This NIH&#45;funded study provides the first longitudinal assessment of impacts of food insecurity on HIV health outcomes in a resource&#45;limited setting.  The aims of the study are: (1) To determine the impact of food insecurity on antiretroviral (ART) adherence among HIV&#45;infected individuals in the Uganda Antiretroviral Treatment Outcomes (UARTO) cohort in Mbarara, Uganda; (2) To determine the impact of food insecurity on HIV health outcomes in the UARTO cohort; and (3) To determine the impact of food insecurity on high&#45;risk sexual behaviors in the UARTO cohort and how gender modifies these relationships. This information will be critical in order to develop interventions to address food insecurity among people living with HIV and AIDS.&lt;/p&gt;
			
			&lt;p&gt;Supplemental funding for this study from the Hellman Family Foundation and the Burke Global Health Scholars Award enabled investigators to understand the role of gender and sexual relationship power in mediating negative impacts of food insecurity on HIV health outcomes and risky sexual behaviors.  &lt;/p&gt;
			
			&lt;h3&gt;Shamba Maisha: Pilot agricultural intervention for food security and HIV health outcomes in Kenya&lt;/h3&gt;
			
			&lt;p style=&quot;margin&#45;top:&#45;10px;&quot;&gt;Contact Persons: Sheri Weiser, MD: &lt;a href=&lt;&quot;mailto:sheri.weiser@ucsf.edu&quot;&gt;sheri.weiser@ucsf.edu&lt;/a&gt;
			&lt;br /&gt;Craig Cohen, MD: &lt;a href=&quot;mailto:CCohen@globalhealth.ucsf.edu&quot;&gt;CCohen@globalhealth.ucsf.edu&lt;/a&gt;&lt;/p&gt;
			
			&lt;h5&gt;Project Goals&lt;/h5&gt;
			&lt;p&gt; This NIH&#45;funded project provides a novel approach to addressing the intersecting epidemics of food insecurity and HIV/AIDS by evaluating the impacts of a pilot multi&#45;sectoral agricultural intervention on health and socioeconomic outcomes among people living with HIV/AIDS in Western Kenya.   The study has the following aims: 1) To operationalize and pilot test key design elements of a future cluster randomized control trial (RCT) aimed to improve health outcomes among HIV&#45;infected patients in Western Kenya. The intervention includes: a) a human&#45;powered water pump and other required farm commodities, b) a microfinance loan (~$75) to purchase the pump and agricultural implements, and c) training in financial management and sustainable farming practices. 2) To conduct a pilot study of the agricultural intervention on 140 HIV&#45;infected farmers to determine the preliminary impact of the intervention on mediating outcomes (food security, and household economic indicators), and on primary health outcomes of interest for the planned RCT (HIV treatment outcomes, HIV transmission risk and women’s empowerment).  3) To assess the acceptability and feasibility of intervention and control conditions, and systematically translate lessons learned in the pilot study into the design of a cluster RCT. Our hypothesis is that this intervention will improve food security and income, thereby enhancing HIV treatment adherence, reducing treatment failure, decreasing co&#45;morbidities, improving gender empowerment, and reducing secondary HIV transmission.  &lt;/p&gt;
			
			&lt;p&gt;Supplemental funding from UCGHI and from the World food Programme enables investigators to conduct an in&#45;depth qualitative study and process evaluation to understand impacts of the intervention from the perspective of participants.&lt;/p&gt;
			
			&lt;h5&gt;Publications&lt;/h5&gt;
			
			&lt;ol&gt;&lt;li&gt;Weiser SD, Tuller DM, Frongillo EA, Senkungu J, Mukiibi N, Bangsberg DR. Food insecurity as a barrier to sustained antiretroviral therapy in Uganda. PLoS One. April 2010: 5(4):e10340.
			&lt;/li&gt;&lt;li&gt;Weiser SD, Tsai AC, Gupta R, Frongillo EA, Kawuma A, Senkugu J, Hunt PW, Emenyonu NI, Mattson JE, Martin JN, Bangsberg DR.  Food insecurity is associated with morbidity and patterns of healthcare utilization among HIV&#45;infected individuals in rural Uganda. AIDS. January 2012:26(1):67&#45;75.
			&lt;/li&gt;&lt;li&gt;Weiser SD, Gupta R, Tsai AC, Frongillo EA, Grede N, Kumbakumba E, Kawuma A, Hunt PW, Martin JN, Bangsberg DR.  Changes in food insecurity, nutritional status and physical health status after antiretroviral therapy initiation in rural Uganda.  In Press, JAIDS, June 2012. [Epub Ahead of Print]. 
			&lt;/li&gt;&lt;ol&gt;
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
PROMOTE ./hiv/research/international/promote.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/international/promote.html</Path>
		<FileBody>
			
			&lt;h3&gt;Prevention of Malaria and HIV Disease in Tororo,Uganda&lt;/h3&gt;
			&lt;p style=&quot;margin&#45;top:&#45;10px;&quot;&gt;Contact person: Diane Havlir, MD; &lt;a href=&quot;mailto:dhavlir@php.ucsf.edu&quot;&gt;dhavlir@php.ucsf.edu&lt;/a&gt;&lt;/p&gt;
			
			&lt;p &gt;The PROMOTE program establishes new approaches to reduce HIV and malaria burdens in sub&#45;Saharan Africa, and enhances the public health approach to both diseases. The PROMOTE program is funded by NIH and protease inhibitor (PI) drugs donated by Abbott Labs and consists of 5 projects. Three of the projects are interlinked hypothesis&#45;based intervention cohort trials.  The other 2 projects are linked to all of the clinical trials and utilize data and specimens from each of these trials to characterize nutrition and drug resistance. The PROMOTE program is being conducted in Tororo District, Uganda, a rural area with HIV seroprevalence of 8% and malaria transmission intensity of 562 infective bites per person year, and started accruing participants in October 2009. The five projects of this program are:&lt;/p&gt;
			
			&lt;h5&gt;PROMOTE&#45;Pediatrics&lt;/h5&gt;
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/ugand_5.jpg&quot; class=&quot;imgRight&quot;&gt;
			&lt;p&gt; A randomized open label trial of HIV protease inhibitors for the prevention of malaria in HIV&#45;infected children will enroll 300 HIV&#45;infected children with the aim of determining if the use of PI&#45;based (LPV/r) ART versus NNRTI&#45;based ART among HIV&#45;infected children will reduce the incidence density of malaria in children.&lt;/p&gt;
			&lt;h5&gt;PROMOTE&#45;Pregnant Women and Infants (PIs)&lt;/h5&gt;
			&lt;p&gt;Protease inhibitors to reduce malaria morbidity in HIV&#45;infected pregnant women will enroll 500 HIV&#45;infected pregnant women with the primary objective of determining if the use of PI&#45;based ART versus non&#45;PI ART among HIV&#45;infected pregnant women leads to reduced rates of placental malaria as measured by Giemsa&#45;stained smear or polymerase chain reaction (PCR) of placental blood.&lt;/p&gt;
			&lt;h5&gt;PROMOTE&#45;Chemoprevention&lt;/h5&gt;
			&lt;p&gt;A randomized trial of monthly dihydroartemisinin&#45;piperaquine versus monthly sulfadoxine&#45;pyrimethamine versus daily trimethoprim&#45;sulfamethoxazole versus no therapy for the prevention of malaria will enroll 400 HIV&#45;unexposed infants and 200 HIV&#45;exposed infants with the aim of comparing the incidence of malaria among these infants enrolled at 4&#45;5 months of age and randomized to one of the four arms listed above until they reach the age of 24 months.&lt;/p&gt; 
			
			&lt;h5&gt;PROMOTE&#45;Nutrition&lt;/h5&gt; &lt;p&gt;This project evaluates the nutritional status of PROMOTE program participants, identifying factors which increase the risk of nutritional deficiency and subsequent poor clinical outcomes, correlating levels of malnutrition and ART pharmacokinetic exposure and response, and pilots a nutritional supplementation strategy tailored to routine practice in resource limited settings.&lt;/p&gt; 
			
			&lt;h5&gt;PROMOTE&#45;Drug Resistance&lt;/h5&gt; &lt;p&gt;This program project includes three randomized clinical trials to test whether long&#45;term use of chemopreventive antimalarial therapies in children or of antiretroviral protease inhibitors in children or pregnant women will decrease the incidence of malaria and related malarial morbidity. These interventions offer the opportunity to significantly decrease the incidence and morbidity of malaria, the most important infectious disease in children and pregnant women in Africa. However, repeated or chronic therapy for infectious diseases routinely entails a risk of selection of drug&#45;resistant parasites. This is a particular concern for malaria, as drug resistance already limits treatment options, and control efforts based of intermittent therapy have relied heavily on antifolates, against which resistance is increasing.&lt;/p&gt; 
			
			&lt;h5&gt;Key Publications&lt;/h5&gt;
			&lt;ol&gt;&lt;li&gt;
			A trial of lopinavir/ritonavir&#45;based versus non&#45;nucleoside reverse transcriptase inhibitor&#45;based antiretroviral therapy for the prevention of malaria in HIV&#45;infected Ugandan children.  Achan J, Kakuru A, Ikilezi G, Ruel T, Clark TD, Nsanzabana C, Charlebois ED, Aweeka F, Dorsey G,  Rosenthal PJ, Havlir DV, Kamya MR. In review.
			
			&lt;/li&gt;&lt;li&gt;In vitro activity of antiretroviral drugs against Plasmodium falciparum. Nsanzabana C, Rosenthal PJ. Antimicrob Agents Chemother. 2011 Nov;55(11):5073&#45;7. Epub 2011 Aug 29.
			
			&lt;/li&gt;&lt;li&gt;Maternal nutritional status predicts adverse birth outcomes among HIV&#45;infected rural Ugandan women receiving combination antiretroviral therapy. Young SL, Murray K, Mwesigwa J, Natureeba P, Osterbauer B, Achan J, Arinaitwe E, Clark TD, Ades V, Charlebois ED, Ruel T, Kamya MR, Havlir DV, Cohan DL. PLoS One, In press.
			
			&lt;/li&gt;&lt;/ol&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
PROMOTE ./hiv/research/international/promote_old.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/international/promote_old.html</Path>
		<FileBody>
			
			&lt;h3&gt;Prevention of Malaria and HIV Disease in Tororo,Uganda&lt;/h3&gt;
			&lt;p style=&quot;margin&#45;top:&#45;10px;&quot;&gt;Contact person: Diane Havlir, MD; &lt;a href=&quot;mailto:dhavlir@php.ucsf.edu&quot;&gt;dhavlir@php.ucsf.edu&lt;/a&gt;&lt;/p&gt;
			
			&lt;p &gt;The PROMOTE program establishes new approaches to reduce HIV and malaria burdens in sub&#45;Saharan Africa, and enhances the public health approach to both diseases. The PROMOTE program is funded by NIH and protease inhibitor (PI) drugs donated by Abbott Labs and consists of 5 projects. Three of the projects are interlinked hypothesis&#45;based intervention cohort trials.  The other 2 projects are linked to all of the clinical trials and utilize data and specimens from each of these trials to characterize nutrition and drug resistance. The PROMOTE program is being conducted in Tororo District, Uganda, a rural area with HIV seroprevalence of 8% and malaria transmission intensity of 562 infective bites per person year, and started accruing participants in October 2009. The five projects of this program are:&lt;/p&gt;
			
			&lt;h5&gt;PROMOTE&#45;Pediatrics&lt;/h5&gt;
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/ugand_5.jpg&quot; class=&quot;imgRight&quot;&gt;
			&lt;p&gt; A randomized open label trial of HIV protease inhibitors for the prevention of malaria in HIV&#45;infected children will enroll 300 HIV&#45;infected children with the aim of determining if the use of PI&#45;based (LPV/r) ART versus NNRTI&#45;based ART among HIV&#45;infected children will reduce the incidence density of malaria in children.
			PROMOTE&#45;Pregnant women and Infants (PIs): Protease inhibitors to reduce malaria morbidity in HIV&#45;infected pregnant women will enroll 500 HIV&#45;infected pregnant women with the primary objective of determining if the use of PI&#45;based ART versus non&#45;PI ART among HIV&#45;infected pregnant women leads to reduced rates of placental malaria as measured by Giemsa&#45;stained smear or polymerase chain reaction (PCR) of placental blood.
			PROMOTE&#45;Chemoprevention: A randomized trial of monthly dihydroartemisinin&#45;piperaquine versus monthly sulfadoxine&#45;pyrimethamine versus daily trimethoprim&#45;sulfamethoxazole versus no therapy for the prevention of malaria will enroll 400 HIV&#45;unexposed infants and 200 HIV&#45;exposed infants with the aim of comparing the incidence of malaria among these infants enrolled at 4&#45;5 months of age and randomized to one of the four arms listed above until they reach the age of 24 months.&lt;/p&gt; 
			
			&lt;h5&gt;PROMOTE&#45;Nutrition&lt;/h5&gt; &lt;p&gt;This project evaluates the nutritional status of PROMOTE program participants, identifying factors which increase the risk of nutritional deficiency and subsequent poor clinical outcomes, correlating levels of malnutrition and ART pharmacokinetic exposure and response, and pilots a nutritional supplementation strategy tailored to routine practice in resource limited settings.&lt;/p&gt; 
			
			&lt;h5&gt;PROMOTE&#45;Drug Resistance&lt;/h5&gt; &lt;p&gt;This program project includes three randomized clinical trials to test whether long&#45;term use of chemopreventive antimalarial therapies in children or of antiretroviral protease inhibitors in children or pregnant women will decrease the incidence of malaria and related malarial morbidity. These interventions offer the opportunity to significantly decrease the incidence and morbidity of malaria, the most important infectious disease in children and pregnant women in Africa. However, repeated or chronic therapy for infectious diseases routinely entails a risk of selection of drug&#45;resistant parasites. This is a particular concern for malaria, as drug resistance already limits treatment options, and control efforts based of intermittent therapy have relied heavily on antifolates, against which resistance is increasing.&lt;/p&gt; 
			
			&lt;h5&gt;Key Publications&lt;/h5&gt;
			&lt;ol&gt;&lt;li&gt;
			A trial of lopinavir/ritonavir&#45;based versus non&#45;nucleoside reverse transcriptase inhibitor&#45;based antiretroviral therapy for the prevention of malaria in HIV&#45;infected Ugandan children.  Achan J, Kakuru A, Ikilezi G, Ruel T, Clark TD, Nsanzabana C, Charlebois ED, Aweeka F, Dorsey G,  Rosenthal PJ, Havlir DV, Kamya MR. In review.
			
			&lt;/li&gt;&lt;li&gt;In vitro activity of antiretroviral drugs against Plasmodium falciparum. Nsanzabana C, Rosenthal PJ. Antimicrob Agents Chemother. 2011 Nov;55(11):5073&#45;7. Epub 2011 Aug 29.
			
			&lt;/li&gt;&lt;li&gt;Maternal nutritional status predicts adverse birth outcomes among HIV&#45;infected rural Ugandan women receiving combination antiretroviral therapy. Young SL, Murray K, Mwesigwa J, Natureeba P, Osterbauer B, Achan J, Arinaitwe E, Clark TD, Ades V, Charlebois ED, Ruel T, Kamya MR, Havlir DV, Cohan DL. PLoS One, In press.
			
			&lt;/li&gt;&lt;/ol&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
SEARCH (&lt;a href='http://www.searchendaids.com/'&gt;http://www.searchendaids.com/&lt;/a&gt;) ./hiv/research/international/search.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/international/search.html</Path>
		<FileBody>
			
			&lt;h3&gt;Sustainable East Africa Research of Community Health – Uganda and Kenya &lt;/h3&gt;
			&lt;p style=&quot;margin&#45;top:&#45;10px;&quot;&gt;Contact person: Diane Havlir, MD; &lt;a href=&quot;mailto:dhavlir@php.ucsf.edu&quot;&gt;dhavlir@php.ucsf.edu&lt;/a&gt;&lt;/p&gt;
			
			&lt;p&gt;
			&lt;a target=&quot;_BLANK&quot; href=&quot;http://www.searchendaids.com/&quot;&gt;Sustainable East Africa Research on Community Health (SEARCH)&lt;/a&gt; Collaboration was established in Vienna in 2010 to evaluate health and economic outcomes of bold community based health interventions for communicable and non&#45;communicable diseases (NCD).  The first proposed initiative of the SEARCH collaboration is a community cluster randomized trial in Uganda and Kenya of widespread early community wide antiretroviral therapy (ART), where primary endpoints will include both community health and community economic status. The SEARCH study is designed to inform the current debates on global health investments precipitated by a) mathematical models predicting the HIV epidemic can be halted with widespread ART; and b) the reality of diminishing resources and growing costs of existing programs. The study is designed to leverage investments in HIV to develop sustainable systems for other infectious and NCDs. By examining individual, household, and community level socio&#45;economic outcomes, the SEARCH study will assess whether an integrated approach to addressing health problems serve as an economic development intervention as well. Unique elements of the study a) inclusion of diagnosis and linkage to care of multiple communicable (TB, malaria) and non&#45; communicable disease (hypertension, diabetes) in study design; b) improving and building community health delivery for ART and other diseases using new and efficient care models; c) evaluations that measure the immediate, cumulative and downstream effects of the intervention in the health, education and economic sectors; and d) a focus on sustainability. Pilot studies are underway for the building blocks of SEARCH including:&lt;/p&gt;
			
			&lt;h5&gt;Kakyerere Community Health Campaign&lt;/h5&gt; &lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/uganda_1.jpg&quot; class=&quot;imgRight&quot; style=&quot;margin&#45;top:&#45;5px;&quot;&gt;
			&lt;p&gt;Two high through&#45;put Community Health Campaign in Kakyerere parish, a rural area in southwestern Uganda, took place in May 2011 and May 2012. The primary aim of this activity is to test the feasibility of universal HIV voluntary testing and counseling coupled with early linkage to HIV clinical services within a community&#45;wide public health campaign offering multi&#45;disease care feasibility and assesses the uptake and re&#45;uptake of the community population. Secondary outcomes include the feasibility of estimating multiple community health parameters (the incidence of acute HIV, community HIV viral load, and the prevalence of TB, malaria, diabetes, and hypertension) using a rapid, high through&#45;put campaign, and determining the socioeconomic status of Kakyerere parish residents according to HIV status using a household economic survey among a random selection of community health campaign participants. &lt;/p&gt;
			
			&lt;h5&gt;Early Antiretroviral Therapy in Resource Limited Settings in Patients with HIgh CD4+ Cell Counts (EARLI) study&lt;/h5&gt;
			&lt;p&gt;EARLI is a non&#45;randomized, non&#45;controlled open&#45;label pilot study of ART initiation in 400 ART&#45;naïve patients with CD4+ cell counts ≥250 cells/uL. The purpose of this study will be to assess efficacy and costs associated with delivering ART to these patient populations under a “streamlined” model of care. It is being conducted at a peripherally&#45;located, level IV health center (HC&#45;IV) in Bwizibwera municipality, a town in rural western Uganda located near Mbarara, Uganda and started in August 2011. &lt;/p&gt;
			
			&lt;h5&gt;Recapture study&lt;/h5&gt;
			&lt;p&gt;This is an operational research protocol that describes a sporadic, cohort&#45;based approach to assessing engagement in care for adult patients with high CD4 and not on ART.  In short, the study seeks to identify outcomes in a simple random sample of 15% of patients who enrolled with high CD4 counts and who subsequently became lost to follow&#45;up and took place between May – December 2011 at two clinics in Kampala and Mbarara, Uganda.&lt;/p&gt;
			
			&lt;h5&gt;Pharmacy Only Visits (POV) study&lt;/h5&gt;
			&lt;p&gt;An existing streamlined model of HIV care delivery based on pharmacy only visits (POV) is retrospectively evaluating the Mulago&#45;Mbarara Teaching Hospitals Joint AIDS Program (MJAP) clinics. The standard model of HIV care in Uganda requires clinic visits with a medical officer every 2 months. This study evaluates clinic patients enrolled into and eligible, but not yet enrolled into an ongoing program of a streamlined model of health care delivery in which medical officer visits will occur at 6 month intervals, and pharmacy/nurse only visits will occur at 2 month intervals. Subjects participating in the POV care model are matched by ART status and CD4 nadir to subjects eligible for the POV care model, but not yet enrolled due to available capacity. This study started in February 2012 in Kampala and Mbarara, Uganda&lt;/p&gt;
			
			&lt;h5&gt;Key Publications&lt;/h5&gt;
			
			&lt;ol&gt;
			&lt;li&gt;          Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, Petersen ML, Thirumurthy H, Kamya MR, Havlir DV, Charlebois ED, and the SEARCH Collaboration. Leveraging rapid community&#45;based HIV testing campaigns for non&#45;communicable diseases in rural Uganda. PLoS One 2012;7(8):e43400. Epub 2012 Aug 20. PMID: 22916256
			 
			&lt;li&gt;          Thirumurthy H, Jain V, Chamie G, Geng E, Kabami J, Kwarisiima D, Clark TD, Petersen ML, Kamya M, Charlebois E, Havlir D, and the SEARCH Collaboration. Improved employment, education, and economic outcomes in households of HIV&#45;positive adults with high CD4 counts: evidence from a community&#45;wide health campaign in Uganda. AIDS. 2013 Feb 20;27(4):627&#45;634. PMID: 23169332
			 
			&lt;li&gt;          Jain V, Liegler T, Kabami J, Chamie G, Clark TD, Black D, Geng E, Kwarisiima D, Wong J, Abdel&#45;Mohsen M, Lizak P, Aweeka  F, Thirumurthy H, Petersen ML,  Charlebois ED, Kamya MR, Havlir DV, and the SEARCH Collaboration. Assessment of community viral load in a rural East African setting Using a fingerprick&#45;based blood collection method. Clin Infect Dis. 2013 Feb;56(4):598&#45;605. Epub 2012 Dec 12. PMID: 23243180
			 
			&lt;li&gt;          Namusobya J, Semitala FC, Amanyire G, Kabami J, Chamie G, Bogere J, Jain V, Clark TD, Charlebois E, Havlir DV, Kamya M, Geng EH. High Retention in Care among HIV&#45;infected Patients Entering Care with CD4 Levels &gt; 350/&amp;mu;l under Routine Program Conditions in Uganda. Clin Infect Dis 2013 Aug 23. PMID: 23899683
			 
			&lt;li&gt;          Jain V, Byonanebye D, Liegler, T, Kwarisiima D, Chamie G, Kabami J, Petersen ML, Balzer LB, Clark TD, Black D, Thirumurthy H, Geng E, Charlebois ED, Amanyire G, Kamya MR, Havlir DV, and the SEARCH Collaboration.  Changes in Population HIV RNA Levels in Mbarara, Uganda During Scale&#45;Up of HIV Antiretroviral Therapy Access.  JAIDS.  Epub (ahead of print) 2013 Oct 1. PMID: 24146022
			 
			&lt;li&gt;          Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, Balzer LB, Petersen ML, Thirumurthy H, Charlebois E, Kamya MR, Havlir DV, and the SEARCH Consortium.  Uptake of community&#45;based HIV testing during a multi&#45;disease health campaign in rural Uganda.  PLoS One. 2014 Jan 2: 9(1): e84317. PMID 24392124
			 
			&lt;li&gt;          Kotwani P, Kwarisiima D, Clark TD, Kabami J, Geng E, Jain V, Chamie G, Petersen ML, Thirumurthy H, Kamya MR, Charlebois E, Havlir DV, and the SEARCH Collaboration.  Epidemiology and awareness of hypertension in a rural Ugandan community: a cross&#45;sectional study.  BMC Public Health. 2013 Dec 9: 13(1): 1151. PMID 24321133
			 
			&lt;li&gt;          Kotwani P, Balzer LB, Kwarisiima D, Clark TD, Kabami J, Byonanebye DM, Bainomujuni B, Black D, Chamie G, Jain V, Thirumurthy H, Kamya MR, Geng EH, Petersen ML, Havlir DV, Charlebois ED, and the SEARCH Collaboration. Evaluating a hypertension linkage to care intervention following community&#45;based screening in rural Uganda. Accepted at Tropical Medicine and International Health
			 
			
			&lt;/ol&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
SEARCH ./hiv/research/international/search.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/international/search.html~</Path>
		<FileBody>
			
			&lt;h3&gt;Sustainable East Africa Research of Community Health – Uganda and Kenya &lt;/h3&gt;
			&lt;p style=&quot;margin&#45;top:&#45;10px;&quot;&gt;Contact person: Diane Havlir, MD; &lt;a href=&quot;mailto:dhavlir@php.ucsf.edu&quot;&gt;dhavlir@php.ucsf.edu&lt;/a&gt;&lt;/p&gt;
			
			&lt;p&gt;
			&lt;a target=&quot;_BLANK&quot; href=&quot;http://www.searchendaids.com/&quot;&gt;Sustainable East Africa Research on Community Health (SEARCH)&lt;/a&gt; Collaboration was established in Vienna in 2010 to evaluate health and economic outcomes of bold community based health interventions for communicable and non&#45;communicable diseases (NCD).  The first proposed initiative of the SEARCH collaboration is a community cluster randomized trial in Uganda and Kenya of widespread early community wide antiretroviral therapy (ART), where primary endpoints will include both community health and community economic status. The SEARCH study is designed to inform the current debates on global health investments precipitated by a) mathematical models predicting the HIV epidemic can be halted with widespread ART; and b) the reality of diminishing resources and growing costs of existing programs. The study is designed to leverage investments in HIV to develop sustainable systems for other infectious and NCDs. By examining individual, household, and community level socio&#45;economic outcomes, the SEARCH study will assess whether an integrated approach to addressing health problems serve as an economic development intervention as well. Unique elements of the study a) inclusion of diagnosis and linkage to care of multiple communicable (TB, malaria) and non&#45; communicable disease (hypertension, diabetes) in study design; b) improving and building community health delivery for ART and other diseases using new and efficient care models; c) evaluations that measure the immediate, cumulative and downstream effects of the intervention in the health, education and economic sectors; and d) a focus on sustainability. Pilot studies are underway for the building blocks of SEARCH including:&lt;/p&gt;
			
			&lt;h5&gt;Kakyerere Community Health Campaign&lt;/h5&gt; &lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/uganda_1.jpg&quot; class=&quot;imgRight&quot; style=&quot;margin&#45;top:&#45;5px;&quot;&gt;
			&lt;p&gt;Two high through&#45;put Community Health Campaign in Kakyerere parish, a rural area in southwestern Uganda, took place in May 2011 and May 2012. The primary aim of this activity is to test the feasibility of universal HIV voluntary testing and counseling coupled with early linkage to HIV clinical services within a community&#45;wide public health campaign offering multi&#45;disease care feasibility and assesses the uptake and re&#45;uptake of the community population. Secondary outcomes include the feasibility of estimating multiple community health parameters (the incidence of acute HIV, community HIV viral load, and the prevalence of TB, malaria, diabetes, and hypertension) using a rapid, high through&#45;put campaign, and determining the socioeconomic status of Kakyerere parish residents according to HIV status using a household economic survey among a random selection of community health campaign participants. &lt;/p&gt;
			
			&lt;h5&gt;Early Antiretroviral Therapy in Resource Limited Settings in Patients with HIgh CD4+ Cell Counts (EARLI) study&lt;/h5&gt;
			&lt;p&gt;EARLI is a non&#45;randomized, non&#45;controlled open&#45;label pilot study of ART initiation in 400 ART&#45;naïve patients with CD4+ cell counts ≥250 cells/uL. The purpose of this study will be to assess efficacy and costs associated with delivering ART to these patient populations under a “streamlined” model of care. It is being conducted at a peripherally&#45;located, level IV health center (HC&#45;IV) in Bwizibwera municipality, a town in rural western Uganda located near Mbarara, Uganda and started in August 2011. &lt;/p&gt;
			
			&lt;h5&gt;Recapture study&lt;/h5&gt;
			&lt;p&gt;This is an operational research protocol that describes a sporadic, cohort&#45;based approach to assessing engagement in care for adult patients with high CD4 and not on ART.  In short, the study seeks to identify outcomes in a simple random sample of 15% of patients who enrolled with high CD4 counts and who subsequently became lost to follow&#45;up and took place between May – December 2011 at two clinics in Kampala and Mbarara, Uganda.&lt;/p&gt;
			
			&lt;h5&gt;Pharmacy Only Visits (POV) study&lt;/h5&gt;
			&lt;p&gt;An existing streamlined model of HIV care delivery based on pharmacy only visits (POV) is retrospectively evaluating the Mulago&#45;Mbarara Teaching Hospitals Joint AIDS Program (MJAP) clinics. The standard model of HIV care in Uganda requires clinic visits with a medical officer every 2 months. This study evaluates clinic patients enrolled into and eligible, but not yet enrolled into an ongoing program of a streamlined model of health care delivery in which medical officer visits will occur at 6 month intervals, and pharmacy/nurse only visits will occur at 2 month intervals. Subjects participating in the POV care model are matched by ART status and CD4 nadir to subjects eligible for the POV care model, but not yet enrolled due to available capacity. This study started in February 2012 in Kampala and Mbarara, Uganda&lt;/p&gt;
			
			&lt;h5&gt;Key Publications&lt;/h5&gt;
			
			&lt;ol&gt;
			&lt;li&gt;          Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, Petersen ML, Thirumurthy H, Kamya MR, Havlir DV, Charlebois ED, and the SEARCH Collaboration. Leveraging rapid community&#45;based HIV testing campaigns for non&#45;communicable diseases in rural Uganda. PLoS One 2012;7(8):e43400. Epub 2012 Aug 20. PMID: 22916256
			 
			&lt;li&gt;          Thirumurthy H, Jain V, Chamie G, Geng E, Kabami J, Kwarisiima D, Clark TD, Petersen ML, Kamya M, Charlebois E, Havlir D, and the SEARCH Collaboration. Improved employment, education, and economic outcomes in households of HIV&#45;positive adults with high CD4 counts: evidence from a community&#45;wide health campaign in Uganda. AIDS. 2013 Feb 20;27(4):627&#45;634. PMID: 23169332
			 
			&lt;li&gt;          Jain V, Liegler T, Kabami J, Chamie G, Clark TD, Black D, Geng E, Kwarisiima D, Wong J, Abdel&#45;Mohsen M, Lizak P, Aweeka  F, Thirumurthy H, Petersen ML,  Charlebois ED, Kamya MR, Havlir DV, and the SEARCH Collaboration. Assessment of community viral load in a rural East African setting Using a fingerprick&#45;based blood collection method. Clin Infect Dis. 2013 Feb;56(4):598&#45;605. Epub 2012 Dec 12. PMID: 23243180
			 
			&lt;li&gt;          Namusobya J, Semitala FC, Amanyire G, Kabami J, Chamie G, Bogere J, Jain V, Clark TD, Charlebois E, Havlir DV, Kamya M, Geng EH. High Retention in Care among HIV&#45;infected Patients Entering Care with CD4 Levels &gt; 350/&amp;mu;l under Routine Program Conditions in Uganda. Clin Infect Dis 2013 Aug 23. PMID: 23899683
			 
			&lt;li&gt;          Jain V, Byonanebye D, Liegler, T, Kwarisiima D, Chamie G, Kabami J, Petersen ML, Balzer LB, Clark TD, Black D, Thirumurthy H, Geng E, Charlebois ED, Amanyire G, Kamya MR, Havlir DV, and the SEARCH Collaboration.  Changes in Population HIV RNA Levels in Mbarara, Uganda During Scale&#45;Up of HIV Antiretroviral Therapy Access.  JAIDS.  Epub (ahead of print) 2013 Oct 1. PMID: 24146022
			 
			&lt;li&gt;          Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, Balzer LB, Petersen ML, Thirumurthy H, Charlebois E, Kamya MR, Havlir DV, and the SEARCH Consortium.  Uptake of community&#45;based HIV testing during a multi&#45;disease health campaign in rural Uganda.  PLoS One. 2014 Jan 2: 9(1): e84317. PMID 24392124
			 
			&lt;li&gt;          Kotwani P, Kwarisiima D, Clark TD, Kabami J, Geng E, Jain V, Chamie G, Petersen ML, Thirumurthy H, Kamya MR, Charlebois E, Havlir DV, and the SEARCH Collaboration.  Epidemiology and awareness of hypertension in a rural Ugandan community: a cross&#45;sectional study.  BMC Public Health. 2013 Dec 9: 13(1): 1151. PMID 24321133
			 
			&lt;li&gt;          Kotwani P, Balzer LB, Kwarisiima D, Clark TD, Kabami J, Byonanebye DM, Bainomujuni B, Black D, Chamie G, Jain V, Thirumurthy H, Kamya MR, Geng EH, Petersen ML, Havlir DV, Charlebois ED, and the SEARCH Collaboration. Evaluating a hypertension linkage to care intervention following community&#45;based screening in rural Uganda. Accepted at Tropical Medicine and International Health
			 
			
			&lt;/ol&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
START ./hiv/research/international/start.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/international/start.html</Path>
		<FileBody>
			
			&lt;h3&gt;Streamlined ART Start Strategy – Mbarara and Kampala, Uganda&lt;/h3&gt;
			&lt;p style=&quot;margin&#45;top:&#45;10px;&quot;&gt;Contact person: Elvin Geng, MD, MPH; &lt;a href=&quot;mailto:genge@php.ucsf.edu&quot;&gt;genge@php.ucsf.edu&lt;/a&gt;&lt;/p&gt;
			
			
			&lt;p&gt;
			In the global public health response to the HIV/AIDS epidemic in Africa, optimizing the implementation of evidence&#45;based interventions is a vital to increasing the efficiency and effectiveness of the public health response.  For example, although ART for treatment&#45;eligible HIV&#45;infected patients reduces morbidity, mortality dramatically and mother &#45;to&#45;child transmission (MTCT) practically to zero, up to 20&#45;30% of treatment eligible patients in resource limited settings fail to initiate antiretroviral therapy or encounter significant delays.  Identifying a generalizable intervention that can be used to closing the gap between the known efficacy of antiretroviral therapy (ART) and the sub&#45;optimal delivery in real world settings is the focus of this project and an example of implementation science.    &lt;/p&gt;
			&lt;p&gt;
			We believe failures and delays in ART initiation result from four systems&#45;based drivers in resource limited settings.  First, ART eligibility is determined by CD4 testing results, but testing generally requires overnight processing and therefore results require a second visit to clinic – thus introducing the opportunity for a missed or delayed visit.  Second, diffusion of knowledge from recent randomized trails that demonstrate benefit of fast ART initiation may not have reached all front line health care providers.  Finally, routine requirements for multiple pre&#45;ART adherence counseling sessions are widespread and may limit the pace and completeness of ART initiation in eligible patients.   &lt;/p&gt;
			&lt;p&gt;To address these barriers, we propose a multi&#45;component Streamlined ART Start Strategy (START) based on the “PRECEDE” health planning framework originally developed by Professor Lawrence Green, an early pioneer of implementation sciences.   This model – empirically validated in diverse disease conditions–  states that a combination of three factors are required for effective strategies to improve health care delivery: (1) “enabling factors” are characteristics that facilitate desired change; (2) “predisposing factors” are composed of knowledge, attitudes or beliefs that affect behavior; and (3) “reinforcing factors” are anticipated consequences following a behavior. &lt;/p&gt;
			&lt;p&gt;
			Our START intervention to accelerate ART initiation therefore is composed of:(1) a novel toaster&#45;sized point of care (POC) CD4 platform (PIMA, Alere) which provides real time determination of treatment eligibility and therefore enables ART faster initiation; (2) targeted knowledge transfer to front&#45;line providers in the form of face&#45;to&#45;face teaching by opinion leaders that predisposes them to timely ART initiation and (3) feedback reporting about timing of medication initiation to clinics that reinforces this approach.  We will evaluate the effect of the intervention in a step&#45;wedge cluster randomized trial with outcomes looking at ART initiation, virologic suppression and mortality.  The overall goal of the START is to initiate ART among the greatest number of eligible patients in the shortest amount of time possible while maintaining safety, efficacy and cost effectiveness.   &lt;/p&gt;
			&lt;p&gt;
			We are privileged to carry out this study partnership with Ugandan investigators and colleagues from the  Makerere Joint AIDS Program which is a implementing organization funded by the US Presidents’ Emergency Fund for AIDS Relief and which delivers high quality care and treatment to over 50,000 persons living with HIV/AIDS in Uganda.  &lt;/p&gt;
			
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/start.jpg&quot; class=&quot;image&quot;&gt;
			&lt;p class=&quot;caption&quot;&gt;A hypothetical kernel density histogram of the distribution of ART initiation times under standard of care and the START.   In green the START setting, patients without major socio&#45;structural barriers to ART initiation would start on the first or second visits.  &lt;/p&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
TB Transmission Research ./hiv/research/international/tb.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/international/tb.html</Path>
		<FileBody>
			
			&lt;h3&gt;TB Transmission Research – Uganda&lt;/h3&gt;
			&lt;p style=&quot;margin&#45;top:&#45;10px;&quot;&gt;Contact person: Gabriel Chamie, MD, MPH; &lt;a href=&quot;mailto:Gabriel.Chamie@ucsf.edu&quot;&gt;Gabriel.Chamie@ucsf.edu&lt;/a&gt;&lt;/p&gt;
			
			
			&lt;p&gt;Tuberculosis (TB) is a leading cause of death in HIV&#45;infected persons in sub&#45;Saharan Africa. Incomplete understanding of TB transmission dynamics in rural Africa and in settings with generalized HIV epidemics represents a major gap in knowledge and a significant obstacle to disrupting TB transmission. &lt;/p&gt; 
			
			&lt;h5&gt;Molecular Epidemiology and Geospatial Analysis of TB Transmission in Uganda&lt;/h5&gt;
			&lt;p&gt; This NIH&#45;funded study seeks to characterize recent TB transmission networks, identify sites of ongoing TB transmission using molecular epidemiology, geographic information system (GIS) and social network analysis, and improve our understanding of how HIV influences TB transmission in rural East Africa. The objectives of the study, which began enrolling in 2012, are as follows:&lt;/p&gt;
			&lt;img src=&quot;/sites/hiv.ucsf.edu/files/images/uganda_4.jpg&quot; class=&quot;imgRight&quot; style=&quot;width:300px;&quot;&gt;
			&lt;div style=&quot;margin&#45;left:20px;&quot;&gt;
			&lt;p&gt;&lt;b&gt;Aim 1:&lt;/b&gt; Identify and characterize recent TB transmission networks in an East African rural setting. We are performing molecular epidemiologic analysis of all diagnosed, culture&#45;positive TB cases initiating TB therapy in Tororo Municipality over 3 years in order to identify recent TB transmission networks defined by genotypic clustering of TB isolates.&lt;/p&gt;
			&lt;p&gt;&lt;b&gt;Aim 2:&lt;/b&gt; Locate sites of frequent TB transmission through analysis of the geographic distribution and social networks of genotype&#45;clustered incident TB cases. We will combine molecular epidemiologic, geospatial and social network data to identify TB transmission “hot spots”, characterized by high levels of TB transmission. These “hot spots” may occur in commercial, social (e.g. markets, bars, churches), or health care settings. We will investigate how HIV influences where TB is transmitted at a community level.
			&lt;p&gt;&lt;b&gt;Aim 3:&lt;/b&gt; Pilot test a place&#45;based intensified TB case&#45;finding strategy at two identified locations of high TB transmission risk.&lt;/p&gt;
			
			&lt;/div&gt;
			&lt;p&gt;This project will advance our understanding of how TB is spreading through a rural community with a generalized HIV epidemic in East Africa and serve as the foundation for developing novel ways to disrupt TB transmission and reduce TB mortality through early diagnosis and intensified case finding.&lt;/p&gt;
			
			&lt;h5&gt;The Impact of Household Ventilation on Transmission of Tuberculosis Among Household Contacts of Active Tuberculosis Patients in Uganda&lt;/h5&gt;
			&lt;p&gt; This study’s objective is to better understand determinants of household transmission of TB in both urban (Kampala) and rural (Tororo) Uganda. The specific aims of the study are: &lt;/p&gt;
			&lt;div style=&quot;margin&#45;left:20px;&quot;&gt;
			&lt;p&gt;&lt;b&gt;Aim 1:&lt;/b&gt; Describe the determinants of ventilation in homes of TB index patients in Uganda with a standardized household survey tool.&lt;/p&gt;
			&lt;p&gt;&lt;b&gt;Aim 2:&lt;/b&gt; Correlate the determinants of ventilation to quantitative measures of household air exchange rate (AER) using an innovative carbon dioxide (CO2) tracer decay technique.&lt;/p&gt;
			&lt;p&gt;&lt;b&gt;Aim 3: &lt;/b&gt;Compare air exchange rates in homes with and without demonstrated TB transmission to determine the impact of ventilation on household TB transmission.&lt;/p&gt;
			&lt;/div&gt;
			&lt;p&gt;
					</FileBody>
	</node>
	<node>
		<Fname>
Translational HIV Research ./hiv/research/international/translational.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./hiv/research/international/translational.html</Path>
		<FileBody>
			
			&lt;h3&gt;Translational HIV Research – Mbarara, Uganda&lt;/h3&gt;
			&lt;p style=&quot;margin&#45;top:&#45;10px;&quot;&gt;Contact person: Peter Hunt, MD; &lt;a href=&quot;mailto:phunt@php.ucsf.edu&quot;&gt;phunt@php.ucsf.edu&lt;/a&gt;&lt;/p&gt;
			
			&lt;p&gt;Dr. Peter Hunt, in collaboration with Drs. Jeffrey Martin (UCSF) and David Bangsberg (Harvard), has helped develop a translational HIV research program in southwestern Uganda.&lt;/p&gt;
			&lt;p&gt;  The Uganda AIDS Rural Treatment Outcomes (UARTO) study, is a cohort of 750 HIV&#45;infected individuals starting their first ART regimen in Mbarara, Uganda.  Participants are followed every 3&#45;4 months with intensive adherence monitoring and biologic specimen archiving.  Dr. Hunt has led the translational immunology studies affiliated with this cohort.  His primary research interest is in the immunologic determinants of CD4+ T cell recovery, morbidity, and mortality during ART&#45;mediated viral suppression.  He and his colleagues established that pre&#45;therapy CD8+ T cell activation predicts poor long&#45;term CD4+ T cell recovery and that persistent T cell activation despite treatment&#45;mediated viral suppression predicts earlier mortality, the first study in the world to link T cell activation during viral suppression and clinical outcomes.  His recent work with the UARTO cohort also established the indolamine 2,3&#45;dioxygenase (IDO)&#45;mediated tryptophan catabolism pathway as an even more important predictor of mortality in this setting.  While this pathway had been linked to HIV pathogenesis in small cross&#45;sectional studies, these data were the first in the world to link this pathway to subsequent mortality during treatment&#45;mediated viral suppression. In more recent work presented at CROI 2012, Dr. Hunt and his colleagues have demonstrated that the IDO&#45;mediated tryptophan catabolism pathway might also contribute to the increased risk of depression in HIV infection (and its improvement during ART), given the role of IDO&#45;induced tryptophan catabolism in depleting serotonin stores.  His ongoing work with the UARTO cohort seeks to understand how prevalent co&#45;infections contribute to IDO induction and other immune activation pathways during ART&#45;mediated viral suppression, and to better characterize the immunologic mechanisms that mediate the relationship between IDO induction and mortality in this setting (including microbial translocation and T cell proliferative defects).&lt;/p&gt;
			
			&lt;h5&gt;Publications&lt;/h5&gt;
			
			
			&lt;ol&gt;&lt;li&gt;Hunt, P.W., H.L. Cao, C. Muzoora, I. Ssewanyana, J. Bennett, N. Emenyonu, A. Kembabazi, T.B. Neilands, D.R. Bangsberg, S.G. Deeks, and J.N. Martin, Impact of CD8+ T&#45;cell activation on CD4+ T&#45;cell recovery and mortality in HIV&#45;infected Ugandans initiating antiretroviral therapy. AIDS, 2011. 25(17): p. 2123&#45;31.
			
			&lt;/li&gt;&lt;li&gt;Hunt, P.W., S. Weiser, Y. Huang, C. Muzoora, A. Kembabazi, K. Ragland, J. Bennett, S.G. Deeks, D.R. Bangsberg, J.N. Martin, and J.M. McCune. Impact of Tryptophan Catabolism on CD4+ T Cell Recovery and Mortality in HIV&#45;infected Ugandans Initiating Antiretroviral Therapy. in Program and Abstracts from the 6th IAS Conference on HIV Pathogenesis, Treatment, and Prevention; Rome; July 17&#45;20; 2011; Abstract MOAA0105. 2011.
			
			&lt;/li&gt;&lt;li&gt;Martinez, P., A. Tsai, C. Muzoora, A. Kembabazi, S. Weiser, Y. Huang, J. Haberer, J. Martin, D. Bangsberg, and P. Hunt. Reversal of IDO&#45;induced Tryptophan Catabolism May Mediate Antiretroviral Therapy&#45;related Improvements in  Depression in HIV&#45;infected Ugandans. in in the Program and Abstracts of the 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, Abstract #462. 2012.
			&lt;/li&gt;&lt;/ol&gt;
			
			
			
					</FileBody>
	</node>
</nodes>